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Metabolomics studies the collection of small molecules (metabolites) involved in 
enzymatically catalyzed reactions, cell signaling and cellular structure. Perturbations in 
metabolite concentrations have been used to reflect the activity of corresponding 
enzymes or proteins. Nuclear magnetic resonance (NMR) spectroscopy is a well-known 
approach for the structure determination of biological macromolecules. Alternatively, 
NMR has recently been established as a valuable tool of metabolomics, in which NMR 
spectral signals correlate small molecules with cellular activities. This has been 
accomplished through the chemometric analysis of high-throughput one dimensional 
1
H 
spectra (metabolic fingerprinting) and quantitative metabolite identification based on two 
dimensional 
1
H, 
13
C HSQC spectra (metabolic profiling).  
Staphylococcus aureus and Staphylococcus epidermidis are the leading pathogens 
that contribute to a large portion of fatal infections in the USA because of their virulence 
factors, abilities to survive and thrive on various hosts, and enhanced drug-resistance 
through biofilm formation. The ability of pathogens to “sense” environmental conditions 
and to mediate an adaptation of its metabolism to various conditions was studied using 
NMR-based metabolomics. My research projects included: the correlation between TCA 
cycle inactivation and biofilm formation related stressors in S. epidermidis; investigating 
 
 
the metabolic details contributing to biofilm formation in S. epidermidis under conditions 
that repress TCA cycle activity; establishing a correlations between iron depletion and 
oxygen limitation in S. aureus metabolism; and evaluation of CcpE as a positive TCA 
cycle regulator in S. aureus.  
Ribose phosphate isomerase R (RpiR) is a transcriptional regulatory protein 
involved in the pentose phosphate pathway. Inactivation of the TCA cycle increases 
carbon flow into the pentose phosphate pathway where the RpiR protein family may be 
involved. In S. aureus, mutations of intracellular ribose sensing regulators (members of 
the RpiR family) resulted in changes in the synthesis of virulence factors. The inducer for 
ribose phosphate isomerase A, B and the mechanism by which RpiRa regulates rpiA, 
rpiB gene expression remain to be elucidated. The C-terminal domain of RpiRa was 
predicted to be a sugar isomerase binding protein domain using homology modeling and 
it was overexpressed and purified using an E. coli pET overrexpression system as a first 
step towards the structural determination of this protein. 
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“If I were doing a PhD, I’d be doing it in Metabolomics.” 
                                                       - James Watson (2013)
1 
 
CHAPTER 1 
INTRODUCTION 
1.1 A brief history of metabolomics  
Metabolomics is a new member of the “omics” community and focuses on the 
analysis of a collection of small molecules in a biological system.
1
 In the past decade, it 
has gained great attention in fundamental science and has been applied in clinical practice 
and in the pharmaceutical industry.
2
 The number of papers with the keyword 
“metabolomics” has grown exponentially in the past decade (Figure 1). As a 
methodology, metabolomics has made a fundamental impact on analytical techniques 
such as NMR, mass spectroscopy and chromatography.
3,4
 
 
                   
Figure 1.1 PubMed search result of the number of publications with “metabolomics” as a 
keyword.  
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     Metabolites can be defined as all the small molecules with a molecular weight 
less than 1 kDa subject to enzymatic transformation in all metabolic pathways.
5
 They can 
be categorized into intracellular/intercellular metabolites based on the location of their 
inception. The roles that metabolites play in a biological system vary greatly. First, they 
are small molecules that can be used as building blocks by numerous metabolic pathways 
to synthesize biological macromolecules. Second, they can be used by organism-
dependent respiration processes to provide energy in order to maintain regular cellular 
functions. Furthermore, because of their high turnover rate, they are ideal molecules for 
cells to produce and consume so as to counterbalance the environmental stimuli and keep 
a homeostasis within the cells.
6
 A growing amount of evidence has shown that the 
mediation of gene transcription and protein expression by metabolites is not rare, but 
more likely to be a universal phenomenon.
7,8
 As metabolites participate in many cellular 
activities, they can be used to evaluate the activity of proteins. Similarly, all of the 
metabolites within a cell, a tissue, an organ, or even an organism can be used to represent 
the biological state of the system.  
The complete collection of metabolites is termed as the metabolome. The concept 
of studying a large set of metabolites simultaneously under a certain set of conditions is 
called “metabonomics” or “metabolomics”, representing two viewpoints of “how” to 
interpret the metabolome.
9
 Professor Jeremy Nicholson, a pioneer of the field, suggested 
the term “metabonomics” to be used during measurement of the multivariate metabolic 
responses to various environmental and toxic stimuli.
9
 The metabolome can be therefore 
used for biomarker identification
10
 and drug toxicity evaluation
11
 among other 
3 
 
examples.
12,13
 NMR is mainly used for such applications in “metabonomics” and is ideal 
for the detection of amino acids, organic acids, amines, carbohydrates and lipids. Another 
camp uses the term “metabolomics”, which was first coined by Professor Oliver Fiehn.14 
The information obtained using “metabolomics” places a greater emphasis on metabolic 
profiling at a cellular or organ level and is primarily concerned with normal endogenous 
metabolism. Genomics and proteomics data are routinely combined and used as a tool to 
study functional genomics.
15,16
 Mass spectrometry (MS) has been heavily employed in 
this camp to detect the metabolome.
17
 MS has to be coupled with gas chromatography, 
liquid chromatography or capillary electrophoresis because of the low molecular-weight 
dispersion of the metabolome and because biologically irrelevant information introduced 
from ion suppression, matrix effect, and analyte fragmentation can otherwise prevent the 
results from representing the true metabolome in vivo.
18,19
 Liquid Chromatography (LC)-
MS can be used to identify amino acids, amines, fatty acids, nucleosides, lipids, 
carbohydrates. Gas Chromatography (GC)-MS can be used for organic acids, aldehydes, 
ketones, volatiles, fatty acids, amino acids, and steroids. In practice, the difference 
between “metabolomics” and “metabonomics” has become too obscure, so the terms are 
used interchangeably in the literature, and as a matter of personal preference.  
Different instruments have their own strengths and weaknesses and, 
correspondingly, different coverage of the metabolome, so the correct choice of 
instrumentation is critical to successfully address the specific metabolic question. The 
selection of proper instrumentation is dependent on the availability of these platforms, as 
well as the ability to combine different instruments to obtain a comprehensive metabolic 
4 
 
profile. NMR is known for its simple sample preparation, high reproducibility and ease of 
quantification so it is popular in detecting primary metabolites and metabolic fingerprints. 
MS is well-established for detecting secondary or low abundant metabolites with its high 
sensitivity in conjunction with a chromatography system. Currently, both instruments 
have been widely used as standalone systems, or in combination, to analyze tissues,
20
 
biofluids,
21
 mammalian cell culture,
22
 and plants.
23
 As an illustration, a recently 
completed study identified a total of 445 metabolites in human urine samples using a 
multi-platform analysis: 209 metabolites by NMR, 179 metabolites by GC-MS, 127 
metabolites by DFI/LC-MS/MS, 40 metabolites by ICP-MS and 10 by HPLC.
24
 Thus, 
platforms that combine multiple analytical techniques are likely to become a standard 
approach in metabolomics. About 50 metabolites were regarded as the “cellular 
metabolome” for E. coli in 1972. In 2013, a metabolomics database contains more than 
2600 metabolites for the basic K-12 strain of E.coli.
25
 Thus, advancements in 
instrumentation and the development of new methodologies are currently benefiting 
metabolomics and are key factors to continued progress in the field. 
 
1.2 Experimental protocols for NMR-based metabolomics  
Metabolome samples can be generated from bacterial strains, human cell lines, 
animal tissues, and various biofluids (urine, serum, etc.). The preparation protocols for 
these different sources are rather diverse due to sample variability in pH, salt 
concentration, and protein content, among numerous other factors. An efficient 
metabolome sampling procedure also needs to consider the properties of the metabolites 
5 
 
of interest: size, structure, solubility, concentration and stability. In addition, the response 
of the metabolome to environmental or experimental changes can be extremely rapid. 
Therefore, accurately analyzing the metabolome to obtain biologically relevant 
information is technically very difficult and requires extensive methodology development. 
In our efforts to establish a successful metabolomics sample preparation workflow, three 
standards were considered.  
The first standard considered was efficiency because of the relatively low 
sensitivity of NMR. It is particularly challenging to completely extract the entire 
metabolome from a cell, tissue, organ or organism. So a series of “trial and error” 
experiments are required to optimize cell lysis, extraction buffer, and instrumental 
parameters. A second critical criterion of metabolomics is the need to ensure that the 
sample represents the “true” state of the cell or system being studied. The key is to 
process all of the samples as quickly as possible while also stopping or slowing down all 
cellular activities by quenching the sample. Achieving these goals makes it likely that an 
accurate “snapshot” of the metabolome has been obtained. Consequently, quenching 
cellular activities is a critical step of properly preparing metabolomics samples, where 
evaluating different extraction and quenching procedures are discussed in Chapter 3. 
Consistency was the third standard considered. The primary goal is to avoid the 
introduction of biologically irrelevant variations in the metabolome by the investigator or 
by any step of the protocol. While the introduction of irrelevant variations in 
metabolomics samples is unavoidable, the goal is to optimize experimental protocols in 
order to drastically reduce their occurrence and negative impact. An advantage of NMR 
6 
 
is its easy sample preparation that does not require any chromatography or sample 
separation step, which effectively removes variations attributed to sample handling and 
preparation. Similarly, it is also critical to include proper experimental design in regards 
to data collection and data process to reduce unwanted variation or bias and to ensure that 
the variations detected are limited to the factors being modified (eg. untreated vs. 
treatment). Besides these general standards, each research projects required further 
optimization of sample preparation, metabolome extraction, data collection and data 
analysis procedures. Improving the reproducibility and the quality of NMR-based 
metabolomics data were important components of each project. Thus, additional 
advancements in our metabolomics protocols and experimental details that led to 
improved metabolomics datasets are described throughout the thesis.   
The identification and quantification of metabolites is an important component of 
metabolomics, where there are two general strategies – targeted and untargeted 
metabolomics. In targeted metabolomics, the goal is to quantify changes to a specific set 
of metabolites that have been previously associated with a particular biological process or 
function.
26
 In untargeted metabolomics (also referred to as metabolic profiling, metabolic 
fingerprinting (intracellular metabolites) or footprinting (intercellular metabolites), it is 
not necessarily required to identify the metabolites. Instead, the goal is to identify global 
similarities or differences in the metabolomes from two or more groups or classes (wild-
type vs. mutant, untreated vs. drug treated, etc.)  In untargeted metabolomics, the NMR 
or MS spectra are often subjected to chemometric analysis, such as Principal Component 
Analysis (PCA) and Orthogonal Projection Latent Structure for Discriminant Analysis 
7 
 
(OPLS-DA).
27,28
 The resulting scores plot (Figure 3) identifies the relative class 
differentiation based on the clustering pattern. Spectra that cluster together in the scores 
plot have a similar metabolome. Conversely, the further two clusters are separated in the 
scores plot indicates a relative difference in the metabolomes. Figure 3 illustrates 
theoretical PCA scores plots demonstrating how cluster analysis can be used to determine 
in vivo efficacy and selectivity of a drug candidate.
29
  
 
 
Figure 1.2 Illustration of hypothetical PCA scores plot for the following scenarios a) 
inactive compound, b) active and selective inhibitor, c) active, nonselective inhibition of 
target and secondary protein, and d) active, nonselective preferential inhibition of 
secondary protein. Reprinted with permission from reference. 29 
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In the current application, the metabolome is perturbed by chemicals (i.e. drugs), 
by biology (i.e. mutations), by phenotype (i.e. disease), or by the environment (i.e. 
nutrients). The corresponding changes in the metabolome are used to investigate the 
system’s response to the perturbation and identify the underlying molecular mechanisms. 
For example, pathogenicity related stressors can reveal which normal metabolic 
processes are connected with virulence biosynthesis. Alternatively, genes with unknown 
function can be annotated by comparing changes in the metabolome between wild-type 
and mutant cell lines. Specifically, I applied “differential metabolomics” or “comparable 
metabolomics” to investigate biological process associated with the survivability and 
adaptability of staphylococcus bacteria. The quantitative and qualitative analysis of 
metabolites from intracellular extracts can be extremely valuable when investigating the 
mechanism of drugs, diseases or environmental stimuli.
30-32
  
NMR based metabolomics can also be used to study the gene functions besides 
the global monitoring of metabolic perturbations under a stress. Enzymes are the driving 
force of metabolic reactions and they make up to 25% of genes in microbes and 10% in 
humans.
33,34
 An in silico genome-scale reconstruction of the metabolic network of 
Staphylococcus aureus listed 774 reactions, representing 23% of its open reading frame.
35
 
Unfortunately, our understanding of the metabolism on the system level is far from 
complete because a large portion of genes encode proteins of unknown function (also 
known as hypothetical proteins).
36-39
 There are two ways of studying gene functions in 
terms of metabolomics data: forward genetics and reverse genetics.
14
 The forward 
genetics approach has a defined biological state but unknown perturbation in genes, 
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proteins and metabolites. The goal is to identify which genes, proteins or metabolites are 
affected. Reversed genetics refers to the process where a target gene or protein is up- or 
down-regulated, but its influence has not been explored.
40
 Nevertheless, there is no 
consensus on how metabolomics data can be used to interpret how a biological systems 
response to a perturbation. The challenge arises from the fact that individual metabolites 
can be involved in many known or unknown metabolic pathways. Based on a single 
concentration change, it is difficult to accurately distribution this change through multiple 
pathways.  
Another system-level approach to understand metabolomics data is computational 
modeling.
41
 Flux analysis has been performed by using metabolic control analysis (MCA), 
flux balance analysis (FBA) and other techniques.
42-45
 To date, all flux analysis studies 
have concluded that it is not a trivial task to understand the “function” of individual 
metabolite. In other words, there is no definite destination for a metabolite given a 
complex array of highly-interrelated metabolic pathways. In effect, any solution is strictly 
case-dependent. This is also a challenge in biomarker discovery.
46
  Thus, taking full-
advantage of the power of metabolomics is highly dependent on establishing a restricted 
and determinant state, where genomics, transcriptomics, and proteomics data can provide 
a biological context to the metabolomics data. In effect, the “omics” data complement 
each other.    
 
1.3 Optimization of NMR-based metabolomics methods  
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Statistical methods, especially multivariate regression methods that include PCA 
and OPLS, are routinely used in the analysis of one dimensional (1D) NMR spectra. 
Therefore, a large portion of my research efforts were dedicated to the optimization of 
PCA analysis of NMR datasets. In a PCA scores plot generated from NMR metabolomics 
data, the analysis mainly lies in the determination of the relative distances between 
multiple “clusters”. The presence of different class clusters is due to the fact that within-
group variability is smaller than the between-group variability. Multiple sample replicates 
are required to statistically define a class cluster, which are dependent on the 
reproducibility of the replicates. In practice, within-group variability is defined by a 
combination of experimental conditions and the inherent variability of the biological 
sample. Thus, a larger data set is always desirable because of the statistical power it 
possesses in defining statistically relevant class separation.
47
 To address the need to 
determine the statistical significance of class differentiation in a scores plot, a tree-
diagram based on a matrix of center-averaged distances between each cluster was 
generated. The significance of each node is based on traditional boot-strapping 
approaches. The tree-diagram provides a  quantitative alternative to the direct inspection 
of  a PCA scores plot.
48
 
Heteroscedasticity is a commonly neglected property of chemometric data and it 
has a negative impact on the multivariate classification. Simply, the variance of a variable 
increases as the value of a correlated variable increases. This leads to biased standard 
errors and biased inferences. Biological variability is one source of heteroscedasticity. 
For example, more metabolic pathways are active during exponential growth when 
11 
 
reproduction is taking place compared to post-exponential growth when metabolism is 
focused on survival due to limited carbon sources. Therefore, the dynamics and 
composition of the metabolome is completely different between the two phases. As a 
result, metabolomes extracted from cells during the post-exponential phase resulted in 
tighter clusters in a scores plot. Currently, there are few applications that explore such 
information and Dr. Daniel Raftery is a leading researcher in this area. Ratio Analysis of 
NMR Spectroscopy (RANSY) and Raito Analysis of Mass Spectrometry (RAMSY) have 
been developed based on the assumption that individual peaks can be correlated by their 
relative standard deviation.
49,50
 For each individual metabolite in a sample set, there can 
only be one relative standard deviation in the metabolites concentration and, therefore, a 
correlation between relative standard deviations can be used to assign all the NMR peaks 
originating from the same metabolite. This assumes a small likelihood that peaks 
originating from different metabolites having the same relative standard deviation. This 
method is a complementary to their statistical total correlation spectroscopy (STOCSY) 
method. STOCSY is based on a correlation of peak intensity that assumes coupling 
patterns and peak overlap does not mask the correlated peaks.
51
 We have also taken 
advantage of heteroscedasticity in our methodology development, albeit from a different 
direction. The random, low intensity peaks in a 1D 
1
H NMR spectrum are considered 
noise. It was previously shown that the inclusion of noise in a multivariate analysis can 
negatively impact clustering in a scores plot and lead to erroneous interpretations.
52
 But, 
the complete removal of noise regions, while leaving real signals intact, is particularly 
challenging for complex NMR spectra of biological samples. To resolve this issue, a 
12 
 
novel noise removal method was developed based on the relative standard deviation of 
noise instead of the traditional cutoff based on arbitrary minimum signal intensity. A 
region absent of peaks (spectral edge) is used to define the “noise” parameters, which is 
then used to remove all noise from the remainder of the spectrum. The removal of noise 
ensures that our PCA analysis does not unintentionally mask any biologically relevant 
trends.   
Two-dimension (2D) 
1
H, 
13
C Heteronuclear Single Quantum Coherence (HSQC) 
correlates protons attached directly to a carbon, which is a very basic component of 
organic structures. Thus, the 2D 
1
H, 
13
C HSQC experiment is a valuable approach to 
improve the accuracy in metabolite identification. Although the analysis of 2D NMR 
datasets takes considerable more time and effort, 2D NMR experiments are increasingly 
being used by the metabolomics community because of several distinct advantages. The 
two chemical shifts (
1
H and 
13
C) from a C-H pair must both match the chemical shift 
values in a NMR metabolomics database to make a metabolite assignment. Also, peak 
overlap and chemical shift ambiguity is significantly reduced by dispersing the chemical 
shift information into two-dimensions. The 2D 
1
H, 
13
C HSQC experiment has been 
recently improved and optimized for metabolomics to directly measure concentrations 
(Figure 3).
53,54
 To enhance the detection of metabolites,
55
 the culture media is 
supplemented with a 
13
C-labeled compound  to boost the sensitivity of the 2D 
1
H, 
13
C 
HSQC experiment due to the low natural abundance (1.1%) of 
13
C.
56,57
 More importantly, 
only metabolites that are derived from the 
13
C-labeled compound are observable in the 
2D 
1
H, 
13
C HSQC spectrum. It allows for monitoring carbon flow from the 
13
C-labeled 
13 
 
compound throughout the metabolome. This also simplifies the analysis by restricting the 
metabolome to a select sub-set of the metabolites. The judicious choice of the 
13
C-labeled 
compound will only emphasizes the region of the metabolome that is particularly relevant 
to the biological system under investigation. The application of 2D 
1
H, 
13
C HSQC 
spectroscopy has been largely incorporated into our NMR-based metabolomics, which 
includes a method to automate peak alignment, peak-picking, absolute concentration 
determination, and multiple ways of representing metabolome changes.  
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Figure 1.3 The principle of Time-0 HSQC experiment. A series of HSQC spectra 
acquired with incremented repetition times (the time between the end of the first 
1
H 
excitation pulse to the beginning of data acquisition) can be extrapolated back to zero 
time to yield a time-zero 2D 
1
H, 
13
C HSQC spectrum (HSQC0) in which signal intensities 
are proportional to concentrations of individual metabolites. Reprinted with permission 
from reference 53,54 
 
1.4 Metabolism-dependent biofilm formation in S. epidermidis and S. aureus  
Biofilms are a ubiquitous microbial phenomenon that has been observed for 
bacteria, fungi, algae, yeasts, protozoa, and other organisms.
58-60
 Biofilms were first 
observed in 1923 during the fouling of ships’ hulls by marine microorganisms.61 In 1933, 
Henrici wrote “it is quite evident that for the most part water bacteria are not free floating 
organisms, but grow upon submerged surfaces”.62 In 1940, Heukelekian and Heller added 
"development takes place either as bacterial slime or colonial growth attached to 
15 
 
surfaces".
63
 It is worth noting that the extensive interest in biofilms are not merely a 
result of scientific curiosity, but are also derived from practical concerns related to a 
broad spectrum of areas such as medical science,
64
 material engineering,
65
 civil 
engineering,
66
 and others.
67
 In particular, biofilm-related bacterial infections are a serious 
health concern. A 2000 US government report identified infectious diseases as a leading 
cause of death worldwide and the third leading cause of death in the United States.
68
 It 
has been estimated that 60%-80% of human microbial infections are caused by bacteria 
growing as a biofilm.
69
 Certain pathogenic biofilms are particularly concerning because 
of the added issue of drug-resistance.
70
 As methicillin-resistant Staphylococcus aureus 
(MRSA) and other resistant pathogens capable of biofilm formation continue to emerge 
and propagate, understanding and circumventing biofilm resistance to antibiotics is a 
paramount necessity.
71
  
Bacteria can respond to a universal signal of nutrient exhaustion by 1) swimming 
to new locations; 2) synthesizing enzymes that degrade macromolecules and use the 
products; 3) secreting antibiotics that kill competitor bacteria in the local environment. A 
biofilm is likely to form if these strategies are not successful in promoting normal culture 
growth in a harsh environment.
72
 The biofilm phenotype is not exclusively caused by this 
mechanism.
73
  In a biofilm, the metabolism of the bacteria is dramatically lowered so that 
a minimal amount of nutrients are required for survival. Thus, a biofilm may provide 
further protection against antibiotics that typically target cell growth-related processes. 
Also, the biofilm matrix may provide a further layer of antibiotics resistance by acting as 
a physical barrier and hindering drug delivery to the bacteria.
74
 Intercellular 
16 
 
communications within a biofilm and between planktonic cells is important to our 
understanding of bacterial behavior.
75
 Quorum sensing,
76
 programed cell death
 
or 
population-wide drug resistance may be regulated by or are established examples of 
intercellular communications.
65,66
 These observations raise some questions about the 
validity of research into bacterial behavior that is based solely on highly homogenous 
cultures. At a minimum, it suggests the need for studies that involve both planktonic and 
biofilm forms in order to obtain a complete picture of bacterial cellular biology. In this 
sense, the study of bacterial biofilms is still in its infancy.   
As with most pathogens, the survival of staphylococcal bacteria is largely 
dependent on host-pathogen interactions or on the environment. The host environment 
provides the necessary nutrients and energy for the bacteria to grow and reproduce. These 
cellular activities are accomplished through a series of metabolic pathways. In 
staphylococci, the central metabolic pathways that include glycolysis, pentose phosphate 
pathway and the tricarboxylic acid cycle (TCA cycle) can produce all the intermediate 
building blocks for macromolecular production.
77
 To be more specific, the TCA cycle is 
a major source of the metabolites and energy for the bacteria. Biofilm formation, as a 
survival strategy, is also largely mediated by environmental stimuli and nutrient 
availability (Figure 4). Thus, bacteria respond to a multitude of stressors to induce a 
biofilm. Thus, based on its major role in central metabolism, the TCA could translate 
environmental stressors into the metabolic signals and subsequently control the 
metabolism and pathological activities of the cells.
7
 An accumulating amount of evidence 
has demonstrated that cell sensoring and regulation, detoxification, repair and protection, 
17 
 
and a variety of other important cellular activities are coordinated through 
metabolites.
78,79
 An ultimate goal of our research is to examine global patterns of 
metabolic control and the corresponding regulatory proteins and pathways under various 
genetic model systems.  
 
 
Figure 1.4 Summary of metabolic pathways that are associated with the TCA cycle’s 
response to environmental stress.
77
 
 
1.5 The RpiRa protein expression system and structural determination   
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Studying metabolism is challenging because it is one of the most flexible and 
complex systems of a living organisms in terms of regulation. Metabolism connects all of 
the components (e.g., proteins, genes) of a cell with the external environment. As the 
number of metabolites identified continues to increase, an obvious question arises - what 
are the biological functions of these metabolites? Determining the structure of a protein 
may be important to addressing these questions. The availability of a protein structure 
may assist in our understanding of the protein’s biological function, which may include 
interactions with small molecules like metabolites. Conversely, identifying metabolites 
that interact with a protein may establish the biological importance of a specific 
metabolite.  
TCA cycle stress alters the intracellular ribose concentration in S. epidermidis and 
also alters the temporal expression of virulence factors in S. epidermidis and S. aureus. 
One metabolic change associated with TCA cycle repression is an increased 
concentration of intracellular ribose. It indicates the presence of a pentose phosphate 
pathway (PPP)-responsive regulator that can partially mediate TCA cycle-dependent 
regulatory effects.
77
 In biofilm formation, the replication and production of nucleotides 
requires overproduction of ribose. As a result, a PPP-responsive regulator may mediate 
some of the TCA cycle-dependent regulatory effects.  
Ribose Phosphate Isomerase (Rpi) is a family of protein hypothetically mediating 
the regulation of PPP. A search of the S. aureus strain Mu50 genome returned three open 
reading frames (ORFs) with significant amino acid homology to RpiR (21 to 23% amino 
acid identity and 45 to 46% amino acid similarity): SAV0317, SAV0193, and SAV2315. 
19 
 
For simplicity, these homologues were designated RpiRa (SAV0317), RpiRb (SAV0193), 
and RpiRc (SAV2315).
80
 Two of these three homologues of Rpi (RpiRb and RpiRc) have 
been found to positively influence the transcription of the PPP genes rpiA and zwf, while 
the third homologue (RpiRa) is slightly antagonistic.
80,81
 In addition, inactivation of 
RpiRc altered the temporal transcription of RNAIII, the effector molecule of the agr 
quorum-sensing system.
80
 Thus, these data reveal the close linkage of central metabolism 
and virulence determinant synthesis in terms of protein and metabolism regulation.  
These observations led us to hypothesize that an RpiR homologue may link the 
PPP to virulence factor regulation in staphylococci. The structure determination is a 
direct way to understand protein functions in detail. Currently there is only one X-ray 
crystal structure of RpiR C-terminal domain (CTD) from Sphaerobacter thermophilus 
deposited in the Protein Data Bank (PDB) (unpublished data, PDB ID: 3SHO). It has a 
sequence identity of 22% and similarity of 44% with RpiRa from S. aureus. A homology 
model for the sugar isomerase-like CTD of S. aureus RpiRa was built up and examined 
based on the Vibrio vulnificus NanR protein (PDB ID: 4IVN) using sequence alignment 
tools of FASTA
82
 and BLAST
®
; domain prediction software packages of DomPred
83
 and 
InterProScan
84
; secondary structure prediction tools of PredictProtein
85
 and PSIPRED
86
. 
The CTD of RpiRa, a hypothetical sugar isomerase domain, was proposed to be a ligand 
binding domain that can sense the perturbation of metabolites. Therefore, it can be used 
as a metabolite regulatory mechanism in pathogenesis development. The purification of 
various constructs of RpiRa CTD and analysis of NMR sample conditions to identify a 
suitable sample for NMR structure determination. 
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Figure 1.5 Predicted model of RpiRa structure. a) front, b) top, and c) side views of the 
predicted model of the entire RpiRa structure. The RpiRa homology model was 
determined using PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/) based on the Vibrio 
vulnificus NanR protein (PDB ID: 4IVN).
87
 
 
1.6 Overview of thesis 
The study of metabolomics is making an increasingly beneficial impact on basic 
and applied biology. The challenge of metabolomics is to combine well-established 
instrumentation with novel biological experimental design. The desirable outcome of this 
effort is to yield a meaningful and reliable dataset to support a hypothesis or to inspire a 
new hypothesis.
88,89
 This dissertation describes my efforts to improve methodology 
critical to the successful application of NMR-based metabolomics and the application of 
these techniques to investigate the metabolome S. epidermidis and S. aureus.  
In Chapter 2, a literature review summarizes the current progress in NMR-based 
metabolomics methodologies as applied to biofilm formation. This review demonstrates 
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the value and impact that NMR-metabolomics has had on the study of biofilms and 
exemplifies how metabolomics can assist in solving real-world problems. This review 
includes a detailed description of the history and current understanding of biofilm 
formation, the mechanism of molecular regulations under harsh environmental stressors, 
and many methods utilized to explore biofilms in a systems biology approach. In 
summary, it provides a practical and broad view of how to incorporate metabolomics into 
a biochemical research program.  
The questions we asked ourselves everyday are how NMR spectroscopy is useful 
in metabolomics and how can we modify the current 1D and 2D NMR spectroscopic 
protocols so that they can provide more biologically relevant information. Thus, one 
important focus of my dissertation, which has had a significant impact on the field, is the 
establishment of protocols for NMR-based metabolomics. Dr. Steve Halouska made 
significant contributions to this project. A detailed description of our NMR-based 
metabolomics methodology is presented in Chapter 3. In Chapter 4, an in-house designed, 
high-throughput NMR tube washer is discussed. The NMR tube washer is used on 
routine and daily basis by a number of colleagues and undergraduate students.  
Chapter 5-8 include two first- and two second-authored papers, showing the 
contribution of our NMR metabolomics method to investigate the metabolome from 
staphylococcal bacteria with our collaborator Dr. Somerville. The bacteria of S. aureus 
may cause a multitude of serious and acute infections, while infections with S. 
epidermidis are usually chronic and often involve the colonization and infection of 
indwelling medical devices.
90
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 In Chapter 5, a series of conditions that induce biofilm formation are examined 
and their effects on the TCA cycle are evaluated using NMR metabolomics. A 
relationship between biofilm formation and TCA cycle metabolism is established and 
well-characterized. Furthermore in Chapter 6, several environmental stressors are shown 
to depress the TCA cycle activity in S. epidermidis and cause the up-regulation of 
polysaccharide intracellular adhesion (PIA) biosynthesis. In Chapter 7, another 
metabolomics study is focused on the redox status of S. aureus. Iron limitation and 
aeration limitation are linked by oxidative stress and can lead to cell death. Fe or O2 
limitation can also trigger biofilm formation. Therefore, the impact of Fe and O2 
limitation on the S. aureus metabolome was investigated by NMR. A specific set of 
metabolites and metabolic pathways were identified that explain the physiological 
response of S. aureus to Fe and O2 limitation. In Chapter 8, an S. aureus carbon catabolite 
repression (CcpE) deletion mutant, a postulated regulator of the TCA cycle, was 
constructed, and its metabolome was analyzed by NMR. Taken together, these studies 
strengthen our long-term hypothesis, originally postulated by Dr. Somerville, that the 
TCA cycle functions as a global regulator of many pathological processes in S. 
epidermidis and S. aureus. PIA, an important precursor of biofilm formation, is regulated 
by the TCA cycle. 
In Chapter 9, one of the hypothetical regulatory proteins in the pentose phosphate 
pathway, the overexpression and multiple isotope labeling strategies for RpiRa is 
performed. The domain structure of this protein was predicted by bioinformatics, and the 
CTD is expected to be a ligand binding domain. The ligand-binding domain is predicted 
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to sense, an as yet, undefined metabolite to regulated PPP. RpiRa has been shown to be a 
PPP activator and can direct carbon flow away from the TCA cycle. Because of the size 
of the protein and NMR size-limitations, only a CTD plasmid was constructed and over-
expressed in E. coli. The optimal condition and procedures for protein expression and 
purification is discussed. Preliminary studies in the structural determination are also 
addressed. Chapter 10 is a concluding chapter containing the summary of the work and 
future directions.   
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Introduction 
Biofilms are a natural part of the ecology of the earth, and correspond to a “social 
structure” of microorganisms compared to a planktonic state.1-3 Biofilms are a ubiquitous 
microbial phenomenon that has been observed for bacteria, fungi, algae, yeasts, protozoa, 
and other organisms. In a biofilm composed of multiple diverse organisms, the 
interspecies interaction can range from neutral, to cooperative, to competitive, and finally 
to antagonistic.
4
 The diversity of organisms able to self-organize and form biofilms is 
quite astounding and may provide clues to the evolution of multicellular organisms.
5
 Are 
biofilms a transitional state of evolution and the basis for multicellular organisms? Or are 
biofilms simply a highly organized state of single cell organisms? The fact that biofilms 
provide a significant survival advantage for adapting to the harsh and distinct 
environmental conditions probably explains its broad adaptation.  
Biofilms have been studied for almost a century. The fouling of ships’ hulls by 
marine microorganisms was documented in 1923.
6
 In 1933, Henrici observed “it is quite 
evident that for the most part water bacteria are not free floating organisms, but grow 
upon submerged surfaces”.7 In 1940, Heukelekian and Heller added "development takes 
place either as bacterial slime or colonial growth attached to surfaces".
8
 However, it was 
not until the last decade of the last century that significant progress was made to 
effectively study microbial communities. It was then that we began to appreciate the 
significant implications of biofilms. Nevertheless, there are still many gaps in our 
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understanding of the biological processes related to this phenomenon.
1,9-11
  
The interest in biofilm is not merely a result of scientific curiosity, but is also 
derived from practical concerns related to medical science,
12
 material engineering,
13
 civil 
engineering,
14
 and others.
15
 In the area of medicine, research on biofilms has focused on 
its relationship to bacterial infections and drug resistance. Bacterial infections are a 
serious disease and major source of world-wide deaths. Especially concerning is the 
growing resistance to antibiotics that has become a major medical issue in developing 
countries. Between 1980 and 1992, infectious disease deaths increased by 58%; the major 
contributors were HIV infections and AIDS, respiratory disease, and bloodstream 
infection.
16
 A 2000 US government report identified infectious diseases as a leading 
cause of death worldwide and the third leading cause of death in the United States.
17
 It 
has been estimated that 60%-80% of human microbial infections are caused by bacteria 
growing as a biofilm.
18
 Certain pathogenic biofilms are particularly concerning because 
of the added issue of drug-resistance.
19
 Multidrug resistant pathogens, such as 
Enterococcus faecium, Klebsiella pneumonia, Acinetobacter baumanii, Pseudomonas 
aeruginosa, and Enterobacter species are infecting the majority of US hospitals.
20
 As 
methicillin-resistant Staphylococcus aureus (MRSA) and other resistant pathogens 
capable of biofilm formation continue to emerge and propagate, understanding and 
circumventing biofilm resistance to antibiotics is a paramount necessity.
21
 
Pathogens can be introduced into the human body through trauma, medical 
operations, dental procedures, or by other means.
22-24
 Many surfaces of organs are 
heavily colonized by microbes that have the potential to cause an infection, especially 
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during any invasive medical procedure. In fact, the ratio of bacteria to mammalian cells 
living within the human body is ten to one, providing ample opportunity for inducing a 
bacterial infection from medical procedures or trauma.
25
 For example, there are over 500 
species of microorganisms identified in typical dental plaque.
26
 Correspondingly, dental 
cavities (caries) are commonly a result of bacterial biofilm infections.
27
 Biofilms are also 
formed on our tongues, cheeks, in our intestines, nasal passages, sinuses, and on our 
skin.
26
 These human microbial communities are largely unstudied and their role in 
infections is largely unknown. But biofilms protect the organisms from both 
antimicrobials and the host immune response, making infectious biofilms extremely 
difficult to treat.
28
 For instance, staphylococcal biofilm infections have a 10 to 1000 fold 
increase in antibiotic resistance.
29-31
 
A serious source of biofilm infections is heart disease, which is also a major cause 
of mortality in the US.
32
 Invasive surgical techniques are inevitably required to treat the 
resulting symptoms of heart disease, which may lead to fatal staphylococcal infective 
endocarditis (IE). S. aureus and S. epidermidis
33
 infections stemming from implantable 
medical devices (e.g., pace makers,
34,35
 indwelling vascular catheters,
36-38
 grafts,
39
 and 
left ventricular assist devices
40-44
) are common causes of IE. Biofilms have also been 
identified on various other medical devices
18,45
 such as contact lenses, endotracheal tubes, 
central venous catheters, pacemakers, and voice prostheses that account for over 80% of 
microbial infections in the body. Catheter-associated urinary tract infection is also a 
common source of biofilm infections. It has also been suggested that autoimmune 
disorders like arthritis, chronic fatigue syndrome, fibromyalgia, Crohn's disease, and 
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ulcerative colitis are caused by biofilm infections.
46
 In summary, bacterial biofilms pose a 
serious threat to human health because of the added protection biofilms provide from an 
immune response and antibiotic treatments, because of the ease of acquiring an infection 
from trauma and medical procedures, and because of the rapid emergence of drug 
resistance among bacteria that form biofilms. 
 
2.2 Biofilm Structure 
Initial scientific studies on bacterial biofilms have focused on understanding the 
structure and composition of biofilms (Figure 2.1). Confocal scanning laser microscopy 
(CSLM) combined with fluorescent molecular probes and antibody labeling has been 
used to provide invaluable information on biofilm cell morphology, cellular metabolism, 
and cell phylogeny.
47,48
 These studies revealed heterogeneous features for both pure-
cultured and mix-cultured biofilms, and the adaptability of unicellular organisms to a 
diverse range of physical, chemical and communal circumstances.
49,50
 Basically, a 
biofilm is comprised of three parts: (1) a living or non-living substance that provides a 
moist surface for attachment of the highly-organized microbial structure,
51-53
 (2) a slim-
like matrix made of extracellular DNA, proteins, and polysaccharides (β (1-6)-linked N-
acetylglucosamine polymer)
54,55
 that embeds the microorganism,
56
 and (3) an aggregate 
of microorganisms in a community that exchange fluids, nutrients and chemical signals.
57
 
Biofilms are viewed as layers of bacteria encapsulated within different 
microenvironments due to variations in nutrient availability
58
 and differing cell 
densities.
50,59
 Bacteria within the biofilm core exist in a stationary or dormant growth 
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phase
58
 and are physiologically distinct from planktonic bacteria.
60-63
 Antibiotics that 
target cellular mechanisms associated with growing bacteria have diminished activity 
against biofilms.
64,65
 Presumably, the antibiotic is only affective against the fast growing 
bacteria on the biofilm’s surface. The dormant bacteria in the interior can replenish a 
biofilm’s outer layers after the antibiotic has been withdrawn. In order for these dormant 
bacteria to enter a growth phase, it is necessary that they respond to a change in nutrient 
and cell density resulting from the death of the fast growing bacteria on the surface.
36 
 
 
Figure 2.1 Horizontal optical thin sections (0 to 2.6 µm) of the P. aeruginosa biofilm 
obtained by SCLM. The biofilm was negatively stained with 0.1% fluorescein. The 
horizontal sections show the removal of out-of-focus information and reveal aspects of 
the internal structure of the biofilm. Bar=5 µm. Reprinted with permission from 
reference.
50
  
 
Bacterial cells have also been shown to adopt various functions critical to the 
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biofilm structure, such as forming the initial attachment point with the surface, producing 
the slime matrix, forming water channels to deliver oxygen and other nutrients, or 
comprising the simple building blocks of the biofilm.
2
 Bacterial cells within a micro-
colony can maintain homeostasis, achieve flexible spatial relationships with cooperative 
organisms, and create an effective way of exchanging nutrients and metabolites with the 
environment. The realization that biofilms consist of such a complex structure raised 
intriguing scientific questions: how do bacteria create such an elaborate architecture and 
what stimulates biofilm formation? 
The life cycle of the biofilm turns out to be even more complicated and can be 
divided into roughly three steps: attachment, growth and propagation (Figure 2.2). First, a 
few colonies reversibly adhere to the surface via van der Waals forces to create an 
initiation site. Attachment involves lipoteichoic acid anchored to the cell membrane.
57
 
This is followed by an irreversible attachment of the cells through the production of the 
exopolysaccaride (EPS) matrix and cell growth.
52
 The cell growth is not uniform and 
results in the formation of channels.
9
 A combination of cell division and recruitment 
occurs during the maturation stage and only biofilm shape and size are changed.
9,53,66
 
Other organisms may be recruited to the biofilm depending on the microenvironments 
created by on-going metabolic activity. Finally, detachment of individual cells and 
dispersion enables the biofilm to spread and colonize new surfaces or to join another 
biofilm.
67,68
 Biofilms form irregular spatial structures, which are affected by many 
different ecological, biological, chemical, and physical factors. The effect of these factors 
on biofilm formations have been investigated using a variety of computer simulations.
69-
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73
  
 
 
Figure 2.2 a) The four-step process involved in the formation of biofilms. b) The 
lipoteichoic acid is anchored to the cell membrane and extends out past the edge of the 
cell wall being the initial molecular contact between the bacterium and other materials. c) 
The chemical structure of lipoteichoic acid. Reprinted with permission from reference.
57
  
 
Biofilm models have been reported in the literature for different organisms and 
biofilms composed of multispecies, for different nutritional conditions, and for different 
environments. These mathematical models have been used to investigate the 
interrelationship of various biofilm factors, especially for parameters that can be difficult 
to vary experimentally.
74
 There are three primary biofilm mechanisms: (i) substrate 
transport, (ii) growth, and (iii) necrosis and loss, which are applied to any computational 
model.
75,76
 Biofilm models can be grouped into four different categories:
77
 (1) one-
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dimensional continuum models, (2) diffusion limited aggregation models, (3) cellular 
automaton models, and (4) fully coupled biofilm-fluid models. One-dimensional 
continuum models assume gradients are orders of magnitude higher in the direction 
perpendicular to the attachment surface. Diffusion limited aggregation models have an 
immobile seed located on a square lattice. One particle after another is released from a 
random location from the seed and is allowed to diffuse through a random walk to form 
an aggregate when it contacts the seed particle.
78
 Cellular automaton models consist of a 
regular grid of cells where each cell is in one of a finite number of states. Rules determine 
cell movement, replication, death, etc. as a function of micro-environmental changes. As 
an example, different morphologies from dense layers to open, mushroom-like forms can 
be simulated. Effectively, small changes in nutrient concentration can have a dramatic 
effect on biofilm development.
79
 Fully coupled biofilm-fluid models are more complex 
simulations and also take into account the hydrodynamics of the bulk fluid and the non-
uniform distribution of cells and polymers.
77
 
 
2.3 Biofilm formation at the molecular level 
There are some general principals regarding biofilm formation that include the 
need for metabolically active bacteria for surface adhesion, the need for an adequate 
nutrient supply for cell replication and exopolysaccharide production, and the fact that 
surfaces coated with organic nutrients stimulate biofilm formation.
2,3
 Correspondingly, 
bacteria biofilms readily form on the surfaces of plastic or metal medical devices in body 
fluids. Some common bacterial biofilm infections include Pseudomonas aeruginosa in 
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the lung, Escherichia coli in the urinary tract, Vibrio cholera in the gastrointestinal tract, 
S. epidermidis in the heart, S. aureus in arteries, Enterococcus species in the urinary tract, 
and fungi such as Candida species in gastrointestinal tract.
80
 The identification of 
biochemical pathways critical to biofilm formation is an important first-step to being able 
to prevent these bacterial biofilm infections. Even with our general understanding of the 
basic structure and development of bacterial biofilms, comprehending the underlying 
processes responsible for inducing the transition from planktonic cells to a biofilm is still 
unclear. Correspondingly, the planktonic to biofilm transition is a complex and highly 
regulated process that results in a phenotypic change. Thus, the differential expression 
and regulation of specific genes are associated with biofilm formation.  
Genomics analysis of biofilm formation started in the 1990s by first screening for 
biofilm-defective mutants.
81,82
 Such efforts identified a diverse number of genes required 
for biofilm formation.
83-89
 More recently, DNA microarray technology has been used to 
identify genes up- or down-regulated in bacterial biofilms.
90
 Unfortunately, there does 
not appear to be a clear trend in biofilm related genes. Instead, multiple pathways to 
biofilm formation that depend on media, growth conditions, and specific organism is 
likely.
91
 Nevertheless, some broad, common features have been observed, such as the up-
regulation of genes for polysaccharide production, for various stress-induced pathways, 
for stationary-phase induced genes, for a prevalence of genes of unknown function, and 
new regulatory pathways.
90
 For example, Quoc et al. (2007) identified nineteen genes in 
S. aureus associated with biofilm formation that were not previously observed.
87
 Again, 
this highlights the difficulty encountered with identifying a uniform set of biofilm-related 
41 
 
genes. Besides genes involved in polysaccharide intercellular adhesion (PIA) or unknown 
function, the authors observe mutations in guanosine-dependent regulation and formation 
of wall teichoic acid. The complexity of biofilm formation may be attributed to the fact 
that the transition from planktonic cells to a biofilm is influenced by various and diverse 
environmental factors such as ethanol,
92
 oleic acid,
93
 glucose,
94
 UDP-N-
acetylglucosamine,
95
 sub-inhibitory concentrations of some antibiotics,
96
 anaerobic 
conditions,
97
 Fe limitation,
98-100
 high osmolarity,
101
 and high temperature.
101
 The diversity 
of these external stimuli suggests a versatile regulation system.  
After two decades of research, multiple mechanisms of biofilm regulation have 
been proposed: sigma factors, two-component systems, or quorum sensing. Sigma factors 
control the expression of various genes including virulence factors and global regulators 
that are related to biofilm formation.
102-104
 Sigma factors are activated when bacteria 
sense environmental conditions that induce stress (heat shock, nitrogen-limitation, 
starvation, high osmolarity, etc.).
105
 Two-component systems are an alternative stimulus-
response coupling mechanism that have been shown to regulate diverse metabolic 
processes such as the bacterial cell cycle, cell-cell communication, and virulence factors 
in biofilm formation.
106
 In a two-component system, a ligand or a signal molecule can 
stimulate a histidine kinase sensor protein, which undergoes autophosphorylation at a 
conserved histidine residue. The phosphoryl group is then transferred to the cognate 
response regulator, which can activate or repress transcription of the target genes.
106,107
 
Conversely, quorum sensing uses signal molecules for bacterial intercellular 
communication. Quorum sensing enable bacteria to “sense” cell density and coordinate 
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behavior in response to nutrient availability, toxic compounds, host-immune response, 
and defense.
108,109
 In gram-negative bacteria, N-acyl homoserine lactones (autoinducer-1, 
AI-1) have been identified as the signal molecules.
110
 AI-1 is synthesized and sensed by 
analogous LuxI and LuxR regulatory proteins. The specific AI-1 molecule varies between 
gram-negative organisms. For gram-positive bacteria, autoinducer peptides (with no 
conserved sequence) have been identified as a signal molecule that involves a two-
component signal transduction system.
111
 Furanosyl borate diester (AI-2) has been 
identified as a universal interspecies signal molecule that regulates biofilm formation in 
over 55 gram-positive and gram-negative species.
112
 Figure 2.3 illustrates some common 
regulatory mechanisms of the planktonic to biofilm transition.  
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
 
Figure 2.3 Regulatory networks controlling transition between planktonic and biofilm 
lifestyle. The external frames illustrate the bacterial envelope with one or two membranes 
(OM: outer membrane, IM: inner membrane) according to Gram-positive (c) and Gram-
negative bacteria (a, b, and d), respectively. a) Control of biofilm formation in P. 
aeruginosa through the TCS GacS (HK)/GacA (RR) mediated by sRNA rsmY and rsmZ 
gene transcription and modulated by RetS and LadS, two additional HK in P. aeruginosa. 
b) Control of EPS alginate in P. aeruginosa, which further impacts biofilm architecture 
by the system ECF sigma factor AlgU - anti-sigma MucA - AlgP (IM)-AlgW 
(periplasmic) complex: 1) activation of AlgW/AlgP, 2) cleavage of MucA, 3) release of 
AlgU, 4) activation of the alg UmucABCD operon. c) Control of S. aureus biofilm 
formation through the Agr QS system: 1) AgrD autoinducer production, 2) AgrD 
autoinducer accumulation in the extracellular medium where it reaches a threshold, 3) 
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activation of the TCS AgrCA by AgrD at the threshold concentration, 4) AgrA-dependent 
activation of the sRNA RNA III expression repressing expression of genes involved in 
biofilm formation together with amplification loop of agrABCD. d) Control of P. 
aeruginosa biofilm formation through the intracellular second messenger c-di-GMP level 
controlled by the FimX protein having DGC and PDE domains, a RR domain, and a PAS 
domain. Note that in FimX protein only PDE activity is detectable (continuous arrow), 
whereas DGC activity is undetectable (dotted arrow). Reprinted with permission from 
reference.
113
 
 
Two-component systems (TCS) and autoinducers are promising drug targets for 
biofilms because of the essential role in cell growth regulation and the unique 
mechanisms of action compared to conventional antibiotics.
114-117
 Importantly, proteins 
from TCS and quorum sensing are absent in humans, minimizing toxicity concerns. Also, 
both biological processes are based on ligand-receptor interactions, which are typical 
targets for drug discovery and have a reasonable likelihood of success. Histidine kinases 
and response regulators, such as WalK/WalR, YhcS/YhcR81, HP165/HP166, and 
MtrB/MtrA are potential drug targets for bacteria pathogens.
117
 Targeting the kinase 
domain appears to suffer from poor selectivity, but targeting the sensor domain may 
prove more successful. Also, targeting non-essential TCS proteins that regulate virulence 
such as GacS/GacA, PhoQ/PhoP, and CorS/CorR, has demonstrated some initial positive 
results.
117
  
Alternatively, quorum sensing may be interrupted by targeting the LuxI, LuxR, or 
LuxS transcriptional regulators,
118,119
 AIP receptors,
116
 or Lsr transporters.
112
 A common 
approach is to use the three classes of autoinducers as chemical templates to design 
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agonists or antagonists as a starting-point for drug design (Figure 2.4).
120,121
 For instance, 
TCS proteins QseC/QseB from Escherichiacoli (EHEC) O157:H7 that responds to AI-3, 
epinephrine, and norepinephrine, are inhibited by LED209 (N-phenyl-4-
[[(phenylamino)thioxomethyl]amino]-benzenesulfonamide).
122
 Additionally, the RNAIII-
inhibiting peptide (RIP; YSPWTNF-NH2) is an inhibitor of the staphylococcal TRAP/agr 
system, which is regulated by autoinducer RNAIII-activating protein.
123
 RIP was shown 
to be active against methicillin-resistant Staphylococcus aureus graft infections. There 
has also been significant effort in the design of AI-2 analogs as novel antibiotics because 
of AI-2’s broad activity against multiple species.124,125 For instance Roy et al. (2010) 
explored the activity C-1 alkyl analogs of AI-2 against multiple bacterial species. Ethyl-
DPD (DPD; 4,5-dihydroxy-2,3-pentanedione) was found to inhibit quorum-sensing in 
both Escherichia coli and Salmonella typhimurium. In addition, Rui et al. (2012) 
explored DPD analogs with a new stereocenter at C-5 (4S, 5R)-DHD.
126
 The compound 
was also shown to be active against both E. coli and Vibrio harveyi. Conversely, 
Tsuchikama et al. (2011) synthesized carbocyclic analogues of DPD that were inactive 
against S. typhimurium and V. harveyi, suggesting the importance of the linear form of 
DPD and the heterocyclic oxygen atom.
127
 Similarly, Lowery et al. (2005) explored a 
variety of DPD analogs that resulted in a uniform lower activity that highlights the 
general challenge in evolving a small chemical template into a drug.
128
 Nevertheless, the 
unique mechanism of action for TCS and autoinducer targets holds the promise of a 
valuable new class of drugs that may circumvent biofilm resistance to antibiotics (Figure 
2.4). 
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Figure 2.4 Structures of autoinducers and analogs. (top) AI-1 chemical structure and its 
analogs a) homocysteine derivative 
120
; b) 3-oxopentanoyl HSL 
121
. (bottom) AI-2 
chemical structure, its precursor DPD and its analogs c) ethyl-DPD 
129
; d) DHD (4S, 5R)-
4.
130
 
 
2.4 An Overview of Metabolomics 
Metabolomics is the study of metabolites, such as amino acids, carbohydrates and 
lipids that are the end products of cellular regulatory processes, as well as intermediates 
and other signaling molecules.
131,132
 The metabolome is the complete collection of all 
metabolites within a biological cell compartment, cell, tissue, organ or organism 
examined in the form of a cellular extract or biofluids.
133,134
 In general, a molecular 
weight of 1 kDa is the typical limit that separates metabolites from macromolecules.
135
  
There are many differences between conventional metabolite measurements and 
metabolomics. First, metabolomics focuses on a global or broad-based analysis of 
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metabolites through a high-throughput detection methodology compared to a limited and 
directed analysis of a specific number of individual metabolites.
132
 In general, 
metabolomics does not require the complete separation of individual metabolites. Instead, 
it captures a “snap-shot” or “fingerprint” of the state of the metabolome. Thus, 
metabolomics simplifies metabolite detection by using a single analytical technique to 
characterize the state of the metabolome. In this manner, metabolomics also provides an 
unbiased view of changes in metabolism by covering all major pathways. Thus, the 
systematic analysis of the ultimate response of  a biological system has a better chance of 
describing pleiotropic effects.
132
 Second, metabolomics uses a combination of multiple 
methodologies, such as cellular biology, instrumental analysis, chemometrics, and 
bioinformatics to analyze the biological system. This combination of techniques provides 
a better view of the global role that metabolism plays in cellular functions. Again the 
analysis of a select set of metabolites does not provide this sort of global picture of 
cellular activity. Yet in theory, it should be possible to correlate metabolic changes in a 
biochemical pathway with the enzymes involved, and then to the underlying genetic 
alterations or changes in gene expression or regulation.
132
 A computational simulation 
could also integrate the experimental data to create a systematic view of the effected 
biochemical pathways, and potentially, the relevant proteins. The identification of 
specific proteins that are disease-related, or in this case related to biofilm formation, is a 
fundamental and critical step of the drug discovery process.  
Autoinducers are an excellent example of the significant roles that small 
molecules can play in bacterial biofilms, where mimicking or inhibiting the mode of 
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action of autoinducers is a potential drug discovery target. Other inter- or intracellular 
small molecular-weight molecules may have similar roles in the initiation, progression 
and survivability of bacterial biofilms. Specifically, biofilms are a spatial distribution of 
heterogeneous cells, where cells exists in different metabolic states to maximize survival. 
Thus, understanding biofilms requires a comprehensive characterization of the various 
metabolic states within a complex cellular community. Correspondingly, metabolomics 
provides a systematic approach to explain this complex system.
136,137
 
Compared to genes and proteins, primary metabolites are highly conserved 
between various cells and organisms.
138
 In a similar manner to gene expression, some of 
the key metabolites, nutrients, and signal molecules (autoinducers) have been shown to 
significantly influence biofilm formation.
139
 Thus, metabolite quantification and the 
pathway modeling of complex biological systems is useful for exploring cell behavior in 
establishing a biofilm community. Furthermore, metabolomics is an invaluable approach 
for investigating antibiotic resistance in biofilms. By generating a network of metabolites 
affected by the drug treatment, it is possible to predict the antibiotic’s mechanism of 
action.
140
 Additionally, the phenotype of antibiotic resistance strains and biofilm strains 
can be characterized through their relative metabolome differences. Similarly, monitoring 
metabolic changes can be used to investigate the effects of other environmental stimuli 
on biofilm formation.
141
 Metabolomics can also be used for detecting disease 
biomarkers,
142
 and as a supplementary tool for proteomics and transcriptomics. The 
linkage between metabolomics, mRNA and protein expression makes it possible to 
visualize the biological state of an organism.
143
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Metabolomics is the bridge between genotype and phenotype.
132
 Correspondingly, 
metabolomics provides a better understanding of a disease since it links the pathology to 
actual changes in the activity of biological processes. Metabolomics provides an 
approach to diagnose a disease, monitor its progression, evaluate a response to therapy, 
and identify potential novel drug targets. Thus, metabolomics has a wide range of 
applications in drug discovery,
144
 including toxicology
145
 and functional genomics.
143
 
The biofilm study can be categorized into either biological science or medical 
engineering. However, so far, the main focus of our research is on the stage of 
mechanism exploration. Therefore, metabolomics is mainly used for such purpose. A 
series of examples addressed below demonstrated how metabolomics can be used to 
answer fundamental science problems with some extension of future perspectives of how 
metabolomics can be applied to engineering areas.  
NMR metabolomics has been applied to identify biomarkers for cardiac disease, 
146,147
 liver disease,
148
 respiratory disease,
149,150
 cancer,
151-154
 and central nervous system 
disorders,
155-158
 among others. Simply, NMR metabolomics provides a means to 
differentiate between a disease and healthy state or between drug-treated and untreated. 
Drug discovery or chemical-lead identification is then based on observing the 
metabolome change from a disease-state to a healthy state or by simply observing that a 
compound changes the metabolome. For example, Tizianni et al. (2011) describes using 
NMR metabolomics in a high-throughput screening platform (96 well plates) to identify 
kinase inhibitors.
159
 They demonstrate that changes in the lactate/pyruvate ratio in human 
leukaemia cells (CCRF-CEM) and  human ovarian cancer cells (SKOV-3) was successful 
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in identifying inhibitors to eEF-2, NF-kB, MK2, PKA, PKC and PKG kinases. Similarly, 
Halouska et al. (2012) demonstrate that the in vivo mechanism of action of a chemical 
lead can be inferred by comparing the metabolome changes to a known drug.
140
 If two or 
more drugs have a similar impact on the metabolome then the compounds share a similar 
target. Additionally, NMR metabolomics is also widely-used for drug development and 
personalized medicine.
160-162
 The consortium for metabonomic toxicology (COMET), an 
organization of major pharmaceutical companies, was formed to share metabolomics data 
from drug studies to characterize metabolites associated with kidney or liver toxicity. The 
overall protocol for toxicity analysis is comparable to drug discovery and lead 
identification. Specifically, biofluid (urine, serum, saliva, etc.) metabolites from animals 
or patients undergoing drug treatment are analyzed by NMR to identify metabolites 
known to be associated with drug toxicity or disease biomarkers. If the biofluid 
metabolites reveal the presence of drug toxicity or the lack of drug efficacy, then an 
alternative treatment can be prescribed.  
Metabolomics is routinely combined with alternative strategies to resolve a 
biological problem and to generate a comprehensive analysis. Although different 
strategies may require alternative experiments and data analysis, targeted metabolite 
analysis, metabolic profiling, and metabolic fingerprinting share the same general 
workflow from sample preparation to data collection and analysis. Targeted metabolite 
analysis is the exclusive study of the direct product of a corresponding enzyme or 
protein.
132
 Metabolic profiling is the identification and quantification of a set of pre-
defined metabolites in a biological sample.
163
 The metabolites may belong to a specific 
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class of compounds or a particular metabolic pathway. As an illustration, metabolic 
fingerprinting can be used to probe different metabolic phenotypes. Metabolic profiling 
can then be used to provide a detailed analysis of specific metabolite changes between the 
two phenotypes. Metabolomics can also be referred to as “metabolic fingerprinting”,164 
and is generally meant to rapidly classify biological samples. The combination of 
different strategies makes metabolomics a flexible and versatile technique for the analysis 
of various biological systems, such as bacterial biofilms.
165,166
 The NMR metabolomics 
methodologies described for drug discovery are equally applicable to investigating 
bacterial biofilms, for identifying new drug targets and chemical leads, and evolving lead 
candidates into new drugs. Again, characterizing and comparing the metabolomic 
differences between planktonic cells and biofilms provides a means to identify active and 
relevant biological processes associated with biofilm formation. Correspondingly, 
proteins involved in these pathways are potential drug targets. Identifying and validating 
drug leads can then be accomplished by observing chemical-induced changes in the 
metabolome related to biofilm formation.  
NMR-based metabolomics generally refers to a comprehensive approach to the 
analysis of metabolomic samples that include specific NMR experiments, sample 
preparation protocols, and multivariate statistical analysis.
167-169
 NMR spectroscopy is 
used to characterize the metabolic samples by providing both qualitative and quantitative 
data.
134
 NMR-based metabolomics of bacterial biofilms consist of the general procedures 
outlined in figure 2.5: 1) prepare the metabolic samples by culturing the desired bacterial 
strains under identical conditions, the only variable should be the specific environmental 
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or genetic factor being investigated; 2) prepare the NMR samples by lysing the cells, 
extracting the metabolites, and removing cell debris; 3) detecting the metabolites through 
various NMR techniques; and 4) spectral processing, data normalization, statistical 
analysis, and metabolite identification. The success of metabolomics largely depends on 
accomplishing each step in a highly controlled and uniform manner. Variation in the 
NMR metabolomics data should result from relevant biological differences between the 
samples as opposed to artifacts introduced from sample or data handling. For example, 
extracting the metabolites from the lysed cells should occur quickly and at low 
temperatures to avoid changes to the metabolome that result from the process of 
harvesting the cells. In effect, all potential variables such as: the number of cells, growth 
phase, culture media, experimental conditions, bacterial strain, time, etc. need to remain 
constant between all bacterial samples.
170
 Again, the only difference between the various 
bacterial cultures should be the specific environmental or genetic factor being 
investigated. Uniformity is the key to a successful metabolomics experiment. It is 
impractical to investigate a heterogeneous sample composed of multiple bacterial 
organisms since there is no mechanism to associate the majority of the commonly 
observed metabolites to a specific organism. Alternatively, using flow cytometry or other 
techniques to separate the cells prior to investigating the metabolome does not solve the 
problem.
171
 The results would be invalid because the time required and the process of 
separating the cells would perturb the state of the cells and, correspondingly, the 
metabolome.  
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Figure 2.5 A flowchart illustrating the general protocols for an NMR metabolomics 
study. 
 
Fundamental to a metabolomics study is the identification of the “classes” or 
“groups” of bacterial cells that will be compared. A straightforward application is the 
comparison between two groups, a bacterial strain in its planktonic state (class one) and 
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its biofilm state (class two). Models of higher complexity include even more classes. For 
example, Figure 2.6 illustrates the application of metabolomics to monitor in vivo drug 
activity. The diagram illustrates the general analysis of clustering patterns in a principle 
component analysis (PCA) scores plot. Simply, the metabolome of four different classes 
are compared: 1) wild-type cells, 2) mutant cells where the drug-target has been 
genetically knocked-out, 3) wild-type cells treated with the drug, and 4) mutant cells 
treated with the drug. The activity and selectivity of the drug is determined by the relative 
similarity of the four different metabolomes as described in Figure 2.6. As an illustration, 
a drug is selective and active if the metabolome of the wild-type cells treated with the 
drug clusters together with the metabolome obtained from the mutant cells with and 
without drug treatment, where this cluster forms a separate cluster from the wild-type 
cells without the drug treatment (Figure 2.6, top-right). Simply, these results indicate the 
protein target in the wild-type cells was chemically inactivated since the metabolome is 
identical to the mutant cells where the protein was genetically inactivated. It also differs 
from the wild-type cells without the drug treatment where the protein is still active. The 
drug is selective because there is no difference between the metabolomes for the mutant 
cells with or without drug treatment. This analysis can be easily generalized. The “drug” 
in this scenario can also be taken as any environmental condition, while the “mutant” can 
be taken as the drug target or any knockout, repressed or over-expressed gene.  
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Figure 2.6 Cartoon illustrations of hypothetical PCA scores plot for the following 
scenarios: inactive compound, active and selective inhibitor, active, nonselective 
inhibition of target and secondary protein, and active, nonselective preferential inhibition 
of secondary protein. Reprinted with permission from reference.
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2.5 Metabolomics Sample Preparation 
Metabolite sample preparation includes cell quenching, cell harvesting, cell 
disruption and metabolite extraction. An important advantage of NMR-based 
metabolomics is the minimal and relatively simple sample preparation protocol. 
Nevertheless, the details of the procedure influence the accuracy, reliability, and 
reproducibility of the metabolomics data.
134
 Different approaches to sample preparation 
have various advantages in terms of speed, capability, consistency, efficiency and 
metabolite recovery yield.
173-175
 Since biofilms can form on a wide range of surfaces or 
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habitats, the experimental conditions for growing and harvesting cells can be highly 
variable. Thus, this review will focus on a general discussion of sampling methods for 
biofilm-related planktonic cells. 
A very critical issue in sample preparation is the need to rapidly and efficiently 
quench all enzymatic and biological activities in order to capture an accurate “snap-shot” 
of the metabolome. This is because metabolites such as pyruvate, fumarate, oxoglutarate, 
phosphoenolpyruvate, fructose-6-phosphate, and others have a rapid turnover rate.
176
 
Also, it is important to avoid inducing a stress response or cell death that would 
completely invalidate the study. Thus, a quick quenching step that involves reducing the 
cell temperature has been shown to be a useful approach to slow down enzyme activity 
within a cell.
173
 Methanol is commonly used because of its low melting point and 
minimal toxicity relative to other organic solvents.
174
 However, methanol may only be 
suitable for gram-positive bacteria or fungi due to the possibility of cell leakage and the 
loss of metabolites during the quenching and washing steps.
176
 Choosing the proper 
metabolite extraction protocol is extremely critical since it influences the efficiency and 
accuracy of the entire metabolomics experiment. 
Improperly removing the cell-growth medium and washing the cells is an easy 
way to contaminate the metabolomic samples and generate unreliable data. Filtration and 
centrifugation are the two main methods of removing the culture medium before 
collecting the metabolome. Centrifugation takes longer so there are concerns regarding 
induced stress and metabolome changes, but it has a higher consistency in sample 
preparation. Conversely, filtration is significantly faster, and it is also easier to quench 
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cells on a filter membrane. But, there are also practical concerns with uniformly and 
consistently retrieving all the frozen cells from the filter paper. Nevertheless filtration-
quenching was demonstrated to have the highest yield for an S. aureus metabolomics 
study.
177
 Also, an NMR-based metabolomics study of P. pastoris applied a single 
centrifugation step and demonstrated that there was no benefit to including an additional 
washing step in the quenching process.
178
 Directly growing E. coli cells on filter paper 
may provide an efficient and fast approach to quench cells and extract the metabolome.
179
 
To date, the choice of technique to separate and wash cells is still very flexible, which 
implies a necessary optimization step for any metabolomics study. An inability to 
efficiently arrest all cell processes and purify the cells without inducing leakage or lysis 
will inadvertently lead to undesirable changes in the state of the system and the 
metabolome. Thus, choosing system appropriate washing, quenching and cell separation 
protocols is the first and most critical step of a metabolomic project and will determine 
the validity of the entire study.  
Cell lysis and metabolite extraction can sometimes be done simultaneously. Both 
mechanical disruptions, such as the Fast-Prep system or organic solvent-based methods 
are widely used.
175,180
 Trichloroacetic acid (TCA) is a traditional approach for lysing cells 
from filter paper, but TCA causes a significant background for metabolomics data 
because it also degrades the filter paper.
176
 The optimal extraction buffer should: 1) 
extract the largest number of metabolites, 2) be nonselective and not exclude molecules 
with particular physical or chemical properties, and 3) be nondestructive and not modify 
metabolites through chemical or physical means.
181
 Since metabolites are normally 
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dissolved in a D2O buffer or CDCl3 for NMR, choosing alternative extraction solvents is 
not particularly beneficial. A common extraction solvent is a (5:2:2) v/v mixture of 
methanol, chloroform, and water.
182
 Others extraction mixtures include a (1:1) v/v 
mixture of methanol and chloroform, or water and chloroform for metabolite extractions 
that include lipids.
183
  
 
2.6 NMR Experiments for Metabolomics 
There are many practical challenges encountered when studying the bacterial 
metabolome. A cellular metabolome can contain upwards of thousands of metabolites, 
with a 7 to 9 order of magnitude range in concentrations (picomoles to millimoles).
184
 
Therefore, it is generally not possible to analyze all cellular metabolites in a single 
experiment. Also, cellular metabolism is very sensitive to environmental changes, where 
the measurement and sampling process can influence the metabolome. Thus, 
metabolomic measurements are also perturbed by including separation techniques. 
Correspondingly, each biological system requires experimental optimization to accurately 
study its metabolome.  
Mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy 
are the primary analytical techniques used for metabolite detection. Mass spectrometry 
measures the mass-to-charge ratio of charged molecules that can be used to determine the 
elemental composition and elucidate the chemical structure of molecules. While an exact 
mass is determined by MS, the limited molecular-weight dispersion of the metabolome 
generally requires using chromatography.
185
 Gas chromatography, high performance 
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liquid chromatography (HPLC) and capillary electrophoresis are common separation 
techniques used by MS-based metabolomics.
186,187
 Unfortunately, the use of 
chromatography to separate metabolites inevitably leads to changes in the metabolome. 
The amount that is recovered from the chromatography step will vary for each metabolite, 
where some metabolites will be lost or chemically modified. MS also requires ionization 
of the molecule for detection with the corresponding uncertainty that a specific 
metabolite will ionize. Also, determining a concentration for each metabolite by MS is 
particularly challenging. 
Conversely, NMR determines a molecular structure by measuring nuclear 
chemical shifts within a magnetic field.
188
 Three valuable pieces of information are 
obtainable from a single peak in an NMR spectrum (Figure 2.7). The chemical shift is 
related to the local chemical environment of that specific nucleus (
1
H, 
13
C, 
15
N, etc.), and 
the peak-splitting (J-coupling) identifies chemically bonded nuclei, which are both used 
to identify the chemical structure of the metabolite.
188
 Importantly, the peak intensity is 
directly proportional to the metabolite’s concentration. Typically, multiple distinct NMR 
resonances are observed per molecule that eliminates the need for chromatographic 
separation and increases the accuracy of metabolite identification.  
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Figure 2.7 
1
H NMR spectra of the intracellular metabolic profiles of aqueous extract of 
MCF-7 cells. The sample used for spectrum contained ~6x10
5
 cells. The inserted spectra 
were also plotted using the same expanded x scale. Reprinted with permission from 
reference.
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MS is significantly more sensitive than NMR and covers a wider diversity of the 
metabolome, even though the use of cryogenic probes has significantly increased the 
sensitivity of NMR by a factor of four.
190
 In effect, NMR only detects the most abundant 
metabolites that are present at concentrations greater than 1 to 5 µM. 
1
H NMR is 
typically used for metabolomics since 
1
H NMR is 64 times more sensitive than 
13
C NMR. 
Nevertheless, NMR cryoprobes can still be used to detect metabolites using naturally 
occurring 
13
C, which has an abundance of only 1.1% (
12
C is not detectable by 
NMR).
191,192
 MS is a destructive technique, but it requires a significantly lower sample 
amount (< 100 L) compared to NMR (600 L). Correspondingly, both approaches are 
complementary to each other and contribute inherently distinct information to the 
analysis of a metabolome.
193
 The complementary nature of MS and NMR has been 
61 
 
demonstrated by a number of metabolomic studies using both techniques.
194-198
 In effect, 
the MS and the NMR data can be combined to create a three-dimensional scores plot. The 
added dimensionality from complementary data may provide the additional resolution 
necessary to differentiate between multiple classes or groups. 
The application of NMR spectroscopy for metabolomics can be categorized into 
one of three groups, one dimensional (1D) NMR, two dimensional (2D) NMR 
experiments and solid state NMR.
188
 1D and 2D solution-state 
1
H NMR experiments are 
commonly used for global metabolomics analysis of bacterial cell extracts.
199
 Conversely, 
solid state NMR can be used to analyze intact cells.
200-202
 In addition to 
1
H, other nuclei 
are also used in 1D NMR-based metabolomics, such as the metabolic profiling of the 
carbohydrate cycle using 1D 
13
C NMR,
203,204
 or tissue metabolism using 1D 
31
P NMR.
205
  
A typical 1D 
1
H NMR spectrum of a bacterial cell lysate may contain thousands 
of sharp lines from low molecular weight metabolites (Figure 2.7).
134
 The entire 1D 
1
H 
NMR spectrum is used as a “fingerprint” to characterize the state of the bacterial cell. A 
global investigation of the metabolome is simply based on a comparative analysis of the 
features present or absent in each 1D 
1
H NMR spectrum. Effectively, a global 
metabolomic analysis is based on how similar or how different the 1D 
1
H NMR spectra 
are between each class or group. It is not necessary to assign each 1D 
1
H NMR spectrum 
to identify and quantify all the metabolites present in each sample. Overlapping these 
relevant NMR resonances and interfering with the analysis may be broad bands from 
proteins or other biomolecules, which can be readily removed by using a Carr–Purcell–
Meiboom–Gill (CPMG) spin-echo sequence.206 The CPMG pulse sequence takes 
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advantage of the large difference in T2 relaxation times between small molecular-weight 
metabolites and large MW biomolecules. Effectively, the NMR resonances from the 
biomolecules rapidly decay during the CPMG pulse. Alternatively, proteins and other 
biomolecules can be removed by an appropriate choice of extraction solvents.
207,208
 The 
large interfering signal from water or other buffer components is also eliminated by the 
use of appropriate NMR solvent suppression methods and 100% deuterated buffer.
209
 
Basically, the water NMR resonance is set in the center of the spectrum where selective 
irradiation and gradient pulses suppress the solvent peak while leaving all other peaks 
unaffected. In effect, any resonance in the 1D 
1
H NMR spectrum that does not originate 
from the bacterial metabolome will generate a “false feature” that needs to be removed. 
NMR resonances originating from proteins or solvents are likely to be variable and 
dominate the spectra relative to metabolite signals.  This will lead to an erroneous 
interpretation of the 1D 
1
H NMR spectra and incorrect sample classification. For instance, 
replicate samples may not cluster together because of a significant variation in the peak 
height and peak shape of the water resonance despite the overall similarity in all the 
metabolite NMR peaks. 
High resolution magic angular spinning (HR-MAS) is used to generate in vivo 1D 
1
H spectra of solids comparable to solution-state NMR.
210
 Thus, small, intact, and 
untreated cells or tissues can be directly analyzed by HR-MAS by spinning samples at 
speeds between 4 and 12 kHz at the “magic” angle of 54.7° relative to the external 
magnetic field. Spinning the sample significantly reduces NMR line widths by averaging 
out chemical shift anisotropy, magnetic susceptibility, and dipolar coupling that are 
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prominent in solid samples.
188
  
Assigning a 1D 
1
H NMR spectrum to identify the metabolites present in a 
metabolomics sample is challenging because of the large number of peaks, the significant 
overlap in peaks, the high chemical shift degeneracy (multiple metabolites have some 
chemical shifts in common), and an incomplete database of NMR reference spectra for 
metabolites. Again, assigning a 1D 
1
H NMR spectrum is not necessary for a global 
analysis of the metabolome, but identifying the specific metabolites that are changing and 
are the main contributors to class distinction is extremely valuable for understanding the 
underlying biological differences. Statistical total correlation spectroscopy (STOCSY) 
can be used to associate multiple NMR peaks from the same molecule in a complex 
mixture.
211
 This significantly simplifies the assignment problem since most, if not all, of 
the NMR resonances for a given metabolite can be used together in a database search. A 
positive identification only occurs when all of the observed chemical shifts match the 
metabolite’s known chemical shifts in a database. In STOCSY, a series of 1D 1H NMR 
spectra is converted into a pseudo-2D spectrum that is based on a correlation of peak 
intensities. NMR peaks from the same metabolite will change together as the metabolite’s 
concentration varies across multiple distinct classes. The statistical heterospectroscopy 
(SHY) is similar in concept to STOCSY.
212
 Instead of correlating NMR peak intensities, 
SHY correlates chemical shifts from NMR with mass-charge (m/z) data from mass 
spectroscopy. Thus, SHY can improve molecular identification by directly cross-
correlating NMR chemical shifts with molecular weight. 
More commonly, 2D NMR spectroscopy improves the accuracy of metabolite 
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assignments by significantly increasing spectral resolution by extending chemical shift 
information into a second frequency dimension. Additionally, 2D NMR experiments can 
identify the network of resonances associated with a specific metabolite through J-
coupling. Two-dimensional correlation spectroscopy (COSY) and total correlation 
spectroscopy (TOCSY) experiments identify spin–spin coupling connectivities that 
identify chemically bonded pairs of hydrogens, carbons or nitrogens.
213,214
 To a lesser 
extent, 2D J-resolved NMR experiments are also used for metabolomics studies.
215
 In a 
2D J-resolved NMR experiment, the data is dispersed into two-dimensions based on 
chemical shifts and the J-coupling pattern.
216
 While it is possible to match coupling 
patterns to identify bonded resonances, this is generally not practical for complex 
metabolomics data set. So, a 2D J-resolved NMR experiment has significantly less 
information then a 2D COSY or TOCSY experiment while requiring the same amount of 
experimental time. Alternatively, a 1D projection of the 2D J-resolved NMR experiment 
can be used to simplify the NMR spectra by removing peak multiplicity due to J-
coupling.
217
 This dramatically reduces the number of peaks and correspondingly reduces 
peak overlap. Removing peak splitting improves the accuracy of metabolite identification 
and quantification. Of course, a single 2D NMR experiment may require an hour or 
longer to acquire compared to a few minutes for a 1D NMR experiment.     
The 2D
 1
H, 
13
C HSQC (Heteronuclear Single-Quantum Correlation) experiment 
correlates the 
1
H and 
13
C chemical shifts for each C-H pair in a molecule.
218
 This 
provides unique information relative to the COSY, TOCSY or J-resolved experiments. 
Also, metabolite assignments are easier with a 2D 
1
H, 
13
C HSQC experiment because of 
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two correlated and distinct chemical shift assignments, the large 
13
C chemical shift 
dispersion, and the simplified spectrum without splitting from J-coupling. However, due 
to the low natural abundance (1.1%) of 
13
C, 
13
C-labeled compounds, such as 
13
C-
methanol, 
13
C-CO2
219
, 
13
C-glycerol
220
 and 
13
C-glucose
221
 are required as a bacterial 
carbon source to enhanced the sensitivity of the NMR spectrum.
222
 This significantly 
simplifies and focuses the analysis of the metabolome. Only metabolic intermediates and 
products of the 
13
C-labeled materials will be partially or completely enriched with 
13
C. 
Correspondingly, only these metabolites will be observed in a 2D 
1
H, 
13
C HSQC 
spectrum, which provides a means to follow carbon-flow through the metabolome and 
identify the perturbed metabolic pathways. Standard HSQC experiments are not 
quantitative because of significant variability in coupling-constant and relaxation times 
(T1 and T2) between metabolites. Nevertheless, the newly developed 2D extrapolated 
time-zero 
1
H, 
13
C HSQC (HSQC0) experiment allows for the calculation of metabolite 
concentrations.
223
 Basically, a series of 2D HSQC spectra are collected with an increasing 
number of the core HSQC experiment. The peak intensity will decrease linearly with the 
number of HSQC blocks, where a linear fit and extrapolation back to zero HSQC blocks 
will determine the true peak intensity and metabolite concentration. Examples of 2D 
NMR spectra used to identify metabolites from biological samples are shown in Figure 
2.8. 
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Figure 2.8 a) Overlay of 2D 
1
H, 
13
C HSQC spectra comparing wild-type S. epidermidis 
strain 1457 (red) and aconitase mutant strain 1457-acnA::tetM (black) grown for 6 h in 
standard TSB media augmented with 0.25% 
13
C-glucose. NMR resonances 
corresponding to specific metabolites are labeled, where citrate is circled. b) Overlay of 
2D 
1
H, 
1
H TOCSY spectra comparing wild-type S. epidermidis strain 1457 (red) and 
aconitase mutant strain 1457-acnA::tetM (black) grown for 6 h in standard TSB media. 
Reprinted with permission from reference.
141
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
68 
 
For chemometrics (please see the Chemometrics and Bioinformatics Analysis of 
Metabolomics Data section), the 1D 
1
H NMR spectra are transformed into a data matrix 
of integrated peak intensities and corresponding chemical shift values. This data is used 
to define the classes and to identify NMR spectral features that differentiate the classes. 
Unfortunately, subtle instrument, temperature, and sample condition variability (pH, 
ionic strength, etc.) can result in chemical shift differences between replicate samples. 
Correspondingly, misalignments will occur in the NMR data matrix between these 
replicate samples that will lead to clustering errors independent of any biological 
differences. One approach to normalize NMR metabolomics samples is the inclusion of a 
known concentration of chemical shift reference compound such as the sodium salt of 3-
trimethylsilylpropionic acid (TSP). The TSP peak intensity can also be used to calibrate 
the concentrations of the metabolites in the biological sample.  Unfortunately, an internal 
reference only corrects for global differences. It does not correct for individual peak 
position and shape variability due to subtle experimental differences. Instead, binning or 
bucketing is commonly used to correct for peak variability between replicate 
samples.
224,225
  
In its simplest implementation, bucketing divides the NMR spectrum into equal 
sized, non-overlapping sub-spectral regions with a width or bin size of 0.025 ppm. So, a 
typical 1D 
1
H NMR spectrum with a width that ranges from 0 to 10 ppm will have 400 
buckets. Bin sizes typically range from 0.01 to 0.04 ppm. The peak intensity within each 
bucket is integrated, where these resulting integrals are then used as input to the 
chemometrics analysis. In this manner, the buckets or bins smooth-out small peak 
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variability with the expectation that the same peaks occur in the same bucket. 
Unfortunately, bin edges create a second problem; the undesirable splitting of a peak 
between buckets. Thus, “intelligent” or “adaptive” bucketing techniques have been 
developed that vary the individual bin size to avoid dividing peaks between multiple 
buckets.
226-229
 These methods use a Gaussian function, a recursive algorithm, optimize an 
objective function using a dynamic programming strategy, or use underestimated wavelet 
transforms to automatically identify bin edges. In all cases, intelligent bucketing performs 
significantly better than uniform bucketing, where dynamic adaptive binning was 
recently shown to perform the best.
229
 The use of intelligent bucketing results in a 
significant improvement in replicate clustering in scores plots since it minimizes spectral 
differences that are biologically irrelevant. Correspondingly, noise regions of the NMR 
spectra are typically zeroed or removed from the bucketing.
230
 Similarly, buckets 
resulting from solvent or buffer peaks that are unrelated to the bacterial metabolome are 
also excluded. Again, this eliminates class distinction that results from biologically 
irrelevant data. In essence, the variables used in the chemometrics analysis should be 
relevant to real variations in the metabolome between the classes.
170
     
Peak alignment is a more robust and complex alternative to NMR binning.
231-234
 
The goal is to remove the chemical shift variability between the replicate 1D 
1
H NMR 
spectra by individually aligning each NMR peak to a representative spectrum from each 
class. The approaches used include fuzzy warping, genetic algorithms, a generalized 
fuzzy Hough transform approach, a reduced set mapping (PARS) algorithm, or a 
recursive segment-wise peak alignment. Each approach demonstrated acceptable results 
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on test metabolomic samples and was shown to improve upon the results obtained from 
bucketing.
234
 Nevertheless, intelligent bucketing is still the predominate methodology 
used in NMR metabolomics. 
An NMR spectrum is experimentally collected as a free induction decay (FID) 
that requires further processing to convert the time-domain data into a frequency-domain 
spectrum through a Fourier transform. This process can be accomplished using a variety 
of software packages (Table 2.1). All of the software packages can import popular NMR 
data formats such as: Bruker, Varian, Jeol Delta, JCAMP-DX, and others. Some NMR 
software can process both 1D and 2D data, where others only focus on processing 1D 
(most popular) or 2D data sets. In addition to the Fourier transform step, the processing 
of NMR data may include zero-filling, phase correction, baseline correction, applying a 
window function, and removal of solvent peaks. The inclusion of any of these steps 
induces changes in the resulting NMR spectrum that is not biologically relevant. Thus, 
uniformity in the NMR processing protocol is essential, where minimizing all spectral 
manipulation is ideal. In general, phase correction is essential in order to obtain purely 
absorption peak shapes. Uniform zero-filling of the NMR spectra is typically acceptable 
since it provides a constant improvement in the digital resolution. Similarly, removing 
residual solvent peaks by simply zeroing the corresponding region of the NMR spectrum 
does not have any detrimental effect because these solvent regions are not included in the 
binning process. Conversely, applying a window function or incorporating baseline 
correction should be avoided, if possible, since these processes induce significant 
variable changes in the NMR spectrum. The goal of a window function is to either 
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increase the spectral resolution or the signal-to-noise by multiplying the FID with a 
mathematical function. As a result, each NMR peak shape is artificially changed. Instead, 
the signal-to-noise and spectral resolution should be improved experimentally. A baseline 
correction is required if the baseline for the NMR spectrum is not flat. A flat baseline is 
necessary for reliable chemometrics analysis. Distorted baselines may result from intense 
solvent or buffer peaks, from phasing problems, errors in the first data points of the FID, 
large range of T1 values (short recycle times), or short acquisition times. Again, baseline 
problems should be experimentally minimized. Nevertheless, numerous computational 
approaches to obtain a flat baseline are available and include a linear or polynomial (up 
to 6 orders) fit of the baseline, FID reconstruction and spectrum averaging. The choice of 
a baseline correction method depends on the specifics of the baseline distortion, which is 
typically determined by trial-and-error. Importantly, a single baseline correction method 
most be used for an entire metabolomics dataset in order to avoid inducing class 
distinctions that are primarily a result of the NMR processing protocol. 
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Table 2.1 NMR software packages. 
 
Ideally, the overall concentration of the metabolites and the corresponding signal-
to-noise of each replicate 1D 
1
H NMR spectrum will be essentially identical. 
Unfortunately, in practice, there may be a significant variability in the signal-to-noise 
between replicate NMR spectra due to random errors in cell lysing, metabolite extraction, 
or the number of bacterial cells per sample. Correspondingly, the 1D 
1
H NMR spectra 
needs to be normalized.
241
 Center averaging is a common normalization technique: 
iX XZ


       (1) 
where X is the average signal intensity, σ is the standard deviation in the signal intensity, 
Software OS Source Reference 
ACDLab Win Commercial 1D, 2D Advanced Chemistry Development, Inc. 
CCPNmr Win/Mac/Unix Academic 2D 235 
Felix Win/Unix Commercial 2D Felix NMR, Inc. 
FERCH Win Commercial 1D PERCH Solutions Ltd. 
Gifa Unix Academic 1D, 2D 236 
iNMR Mac Commercial 1D, 2D Nucleomatica, Inc. 
matNMR Win/Mac/Unix Academic 1D, 2D 237 
MestreNova Win/Mac/Unix Commercial 1D, 2D Mestrelab research 
NMRPipe Win/Mac/Unix Academic 2D 238 
NMRViewJ Win/Mac/Unix Commercial 2D One Moon Scientific, Inc. 
NUTS Win Commercial 1D, 2D Acorn NMR Inc. 
RMN Mac Academic 1D, 2D 
P. J. Grandinetti, Ohio State University, 
Columbus, OH, U.S.A. 
rNMR Win/Mac/Unix Academic 2D 239 
Sparky Win/Mac/Unix Academic 2D 
T. D. Goddard and D. G. Kneller, SPARKY 3, 
University of California, San Francisco, CA, 
U.S.A. 
SpinWorks Win/Mac/Unix Academic 1D, 2D 
K.Marat, University of Manitoba, Winnipeg, 
Manitoba, Canada 
TARQUIN Win/Mac/Unix Academic Solid state 240 
WIN-NMR Win Commercial 1D Bruker Instruments, Inc. 
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and Xi is the signal intensity within a bin. Other normalization techniques include: 
normalization to a constant sum, Pareto scaling, mean-centering, logarithmic scaling, 
probabilistic quotient normalization, etc. A recent analysis of NMR processing 
procedures by De Meyer et al. (2010), suggests that a combination of intelligent 
bucketing with probabilistic quotient normalization yields the best results.
242
 Of course, it 
was not practical to explore all the possible combinations of the various processing 
techniques and, as a result, the analysis did not include center averaging. This highlights 
a particular challenge with processing NMR metabolomics data; there is no clear 
consensus of an optimal protocol because of all the possible combinations of parameters 
that need to be evaluated. 
 
2.7 Chemometrics and Bioinformatics Analysis of Metabolomics Data  
 For a detailed understanding of a complex biological system, it is essential to 
follow the response of an organism to a conditional perturbation at the transcriptome, 
proteome or metabolome level.
143
 Metabolic products are dependent on genotype, 
environment, time, and location.
243
 Perturbations in any of these factors may lead to a 
variety of biological changes that inadvertently effect the metabolome.
143
 The primary 
goal of chemometrics is to reduce the complexity of the NMR-based metabolomics data 
to understand these global correlations. In essence, chemometrics identifies the major 
features within an NMR spectrum, the presence or absence of peaks, the change in peak 
intensity, shape, or the change in chemical shifts that differ between the various classes. 
A class definition can be based on any variable that affects or changes the bacterial cell 
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culture, such as different bacterial strains (including wild-type and mutant cells) and 
different experimental conditions (growth phase, drug dosage, media composition, pH, 
etc.). Bioinformatics is used to uncover and characterize all the associated variables and 
to reveal the underlying relationships. Essentially, bioinformatics is used to identify the 
metabolites that correlate with the major changes in the NMR spectra and to associate 
these metabolites with specific proteins and enzymes, with metabolic pathways, and other 
biological processes.   
For statistical modeling, principle component analysis (PCA) is the most common 
multivariate technique for the comparison of metabolomic data.
244
 Basically, each 
multivariable (chemical shift and intensity) NMR spectrum is converted into a single-
point in multidimensional Cartesian space (Figure 2.9). Each axis (V1, V2, V3 … Vn) 
corresponds to a specific chemical shift where the peak intensity is the value along each 
axis. PCA determines the vector ( 1PC ) corresponding to the largest variation in the data 
and fits each NMR spectra to this vector. Each NMR spectrum is assigned a value (PC1-
principal component one) based on its distance to the vector ( 1PC ). The process is 
repeated for the next largest variation ( 2PC ) orthogonal to the first vector. Plotting the 
resulting principal components (PC1, PC2) corresponds to a scores plot, where similar 
spectra (and metabolomes) cluster together in a scores plot. Spectra (and metabolomes) 
obtained from different classes are expected to form separate clusters in the scores plot.  
Figure 2.9 illustrates the hypothetical separation of class 1 (♦) from class 2 (●) and the 
relatively tight clustering of the class replicates. The class separation is based on 
differences in the 1D 
1
H NMR spectra.    
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Figure 2.9 Conceptual illustration of the principal component analysis of NMR spectral 
data. Each 1D 
1
H NMR spectrum is converted into a single point in multidimensional 
space. Each axis (V1, V2, V3, etc.) corresponds to a chemical shift (ppm) and the value 
along the axis is the peak intensity or bin integral. A vector (PC1) corresponds to the 
largest variation in the data. The second vector (PC2) is orthogonal to the first vector and 
corresponds to the second largest variation in the data. The scores corresponds to the fit 
of each point (spectrum) to each principal component vector, where the resulting 2D 
scores plot identifies the relative similarities and differences between the NMR spectra 
based on the clustering pattern.  
 
Orthogonal partial least squares discriminant analysis (OPLS-DA) is a related, but 
alternative approach to PCA. Unlike PCA, OPLS-DA is a supervised method. This is an 
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important and significant difference. In PCA, the different classes are not identified and 
each 1D 
1
H NMR spectrum follows the protocol described above. Thus, the clustering of 
each NMR spectrum in the scores plot is solely determined by the intrinsic differences 
and similarities in the features of its NMR spectrum relative to all the other NMR spectra. 
Conversely, in OPLS-DA each 1D 
1
H NMR spectrum is assigned to one of two classes, 
(biofilm vs. planktonic, healthy vs. diseased, treated vs. untreated, wild-type vs. mutant, 
etc.). More than two class definitions can be used, but it is generally not recommended. 
As a result, OPLS-DA determines the clustering patterns in the scores plot based on the 
NMR spectral features and the class definition. OPLS-DA tries to maximize the 
separation between the classes based on these manual class assignments, while 
minimizing the within class variation. This results in tighter class clustering in the OPLS-
DA scores plot relative to PCA. Fundamentally, if two classes are defined in OPLS-DA 
then two clusters corresponding to the two assigned classes will be generated in the 
resulting scores plot. OPLS-DA assesses a relationship between an X matrix (NMR data) 
and Y matrix (the 0 or 1 class designation). Thus, OPLS-DA will only identify all the 
spectral features that can be used to distinguish the two classes regardless of any real 
significance (i.e., noise, small random variability in peak height, etc.). Conversely, the 
class separation in a PCA scores plot depends on a combination of all principal 
component variables. Since OPLS-DA is a supervised method or biased by the class 
assignment, it is essential that the model is validated.
170
 Is the class separation due to 
relevant changes in the 1D 
1
H NMR spectra resulting from changes in metabolite 
concentrations? 
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The quality of the OPLS-DA model can be evaluated by multiple statistical 
factors and cross-validation, the goodness of fit (R
2
) and the quality assessment score 
(Q
2
).
245
 A good OPLS-DA model has R
2
 values ≥ 0.5 (range of 0 to 1) that is 
conceptually similar to simple linear regressions. Similarly, a typical value for Q
2
 for a 
biological model is ≥ 0.4. The leave-one-out cross-correlation technique is commonly 
used to calculate Q
2
, where a sub-set of the NMR spectra are left out to calculate a model 
that is then used to predict the left out data.
246,247
 Q
2
 is the consistency between the 
predicted and original data. Importantly, Q
2
 and R
2
 values should only be used as a figure 
of merit and not validation of the model. A permutation tests is one approach to validate 
the model.
246,247
 Simply, the NMR spectra classifications are randomly assigned creating, 
in principal, a random data set that should have poor class separation and low Q
2
 scores. 
The process is repeated numerous times (> 1000 permutations) until a Gaussian 
distribution of Q
2
 scores are obtained for the random data set. The statistical significance 
of the model with the correct NMR spectra classification can then be obtained by 
comparing the model Q
2
 with the random Q
2
 scores and calculating a P-value. In addition 
to Q
2
, a similar validation can be achieved by using the area under a receiver operating 
characteristic (ROC) curve or the number of misclassifications. 
Further validation of the OPLS-DA model can be assessed by determining if the 
NMR features that determine the class separation are biologically relevant. S-plots and 
loading plots are additional outcomes of an OPLS-DA model. An S-plot identifies the 
relative contribution of each bin (chemical shift, metabolite) to the clustering in the 
corresponding scores plot, each bin with a covariance of greater than 0.10 or less than -
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0.10 are identified as major contributors to the class separation.
248
 Similarly, a loadings 
plot displays the relative contribution of each bin to the principal components. Thus, a 
valid OPLS-DA model is supported by being able to assign metabolites to the bins that 
are associated with the class separation. The model is further validated if multiple bins 
assigned to the same metabolite are all major contributors to the class separation. 
Additionally, the identification of multiple correlated metabolites, members of the same 
metabolic pathway for instance, that are all major contributors to the class separation 
would further strengthen the reliability of the OPLS-DA model. Again, the overall goal 
of NMR-based metabolomics is to identify major changes in the NMR spectra that can be 
associated to a specific set of metabolites with a relationship to a biological process, such 
as bacterial biofilm formation.    
A number of metabolomics software packages have been developed to automate 
the chemometrics analysis by combining data normalization, data reduction, model 
prediction and validation, and even metabolite identification, into a single work-flow. 
These programs include: Automics,
249
  HiRes,
250
 MetaboAnalyst,
251
 and the R-package 
Metabonomic.
252
 Among these, Automics is the most versatile and extensive package and 
includes nine different statistical methods applicable to metabolomics data: feature 
selection (Fisher's criterion), data reduction (PCA, LDA, ULDA), unsupervised 
clustering (K-Mean) and supervised regression and classification (PLS/PLS-DA, KNN, 
SIMCA, SVM). Automics also incorporates processing tools to generate a STOCSY 
spectrum.  
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 Interpreting a PCA or OPLS-DA scores plot is fundamentally a cluster analysis. If 
two or more classes cluster together in the scores plot, then the NMR spectra and the 
corresponding metabolome are considered statistically similar. Conversely, two or more 
classes that form distinct clusters indicate the samples are significantly different 
metabolomes. For a simple metabolomics study that involves only two or three different 
types of samples, the cluster analysis is generally straightforward. An ellipse that 
corresponds to the 95% confidence limits from a normal distribution for each cluster can 
be used to define each class in the 2D scores plot to visually determine class separation. 
Alternatively, Werth et al. (2010) recently demonstrated the application of metabolomic 
tree diagrams combined with standard boot-strapping techniques as a more robust 
statistical analysis of clustering patterns in scores plots.
253,254
 Simply, each PC value (PC1, 
PC2) is treated as an axis in a Cartesian coordinate system. An average position is 
calculated for each class cluster, which is then used to calculate a Euclidean distance 
between each class to create a distance matrix. The cluster centers and distances between 
clusters are re-calculated by randomly selecting data points from each class. The process 
is repeated until 100 different distance matrices are generated, which are then used to 
generate 100 tree diagrams using Phylip 3.68b.
255
 A consensus tree is created, where the 
bootstrap number is simply the number of times each node appears in all 100 trees. 
Bootstrap values below 50% imply a statistically insignificant separation. Further 
analysis to identify the metabolic processes that led to class separation may require 
bioinformatics.
256
 An Example 2D OPLS-DA scores plot and associated metabolomics 
tree diagram is shown in Figure 2.10. 
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Figure 2.10 2D OPLS-DA comparing wild-type S. epidermidis 1457 cells grown 6 h in 
standard TSB media ( ), with S. epidermidis 1457 cells grown 6 h in iron-depleted media 
(DTSB) ( ), with the addition of 4% ethanol ( ),with the addition of 2% glucose ( ), 
with the addition of 0.06 µg/mL tetracycline ( ), with the addition of 5% NaCl ( ), and 6 
h growth of aconitase mutant strain 1457-acnA::tetM in standard TSB media ( ). The 
ellipses correspond to the 95% confidence limits from a normal distribution for each 
cluster. For the OPLS-DA scores plot, the 6 h growth of wild-type S. epidermidis 1457 (
) was designated the control class and the remainder of the cells were designated as 
treated. The OPLS-DA used 1 predictive component and 4 orthogonal components to 
yield a R
2
X of 0.637, R
2
Y of 0.966 and Q
2
 of 0.941. (b) Metabolomic tree diagram 
generated from the the 2D OPLS-DA scores plot depicted in (a). The label colors match 
the symbol colors from the 2D scores plot. Each node is labeled with the boot-strap 
number, where a value above 50 indicates a statistically significant separation. Reprinted 
with permission from reference.
141
  
 
Metabolic pathway reconstructions has been widely employed with five major 
goals: 1) contextualization of high-throughput data, 2) guidance of metabolic engineering, 
3) directing hypothesis-driven discovery, 4) interrogation of multi-species relationships, 
and 5) network property discovery.
257
 NMR-based metabolomics are routinely used to 
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generate these metabolic networks for a particular biological system (Figure 2.11). The 
first step of the process is to deconvolute and decode the NMR spectra. This is a difficult 
and time-consuming process because the high-degeneracy of NMR chemical shifts makes 
unambiguously assigning an NMR resonance to a specific metabolite extremely 
challenging. This is further complicated by the incompleteness of metabolomics data and 
by several technical problems that include proper peak assignment,
199
 peak 
alignment,
258,259
 absolute concentration determination,
223,260
 and intensity 
normalization.
261
 A number of metabolomics databases that contain NMR and MS 
spectra with the associated assignments are available: Metabominer,
262
 Madison 
Metabolomics Consortium Database (MMCD),
263
 BioMagResBank,
264
 and Human 
Metabolome Database.
265
 Some efforts to automate the process have also been 
made.
199,249
   
 
 
 
 
82 
 
 
Figure 2.11 Cytoscape network depicting the metabolite concentration changes caused 
by the inactivation of the TCA cycle. Nodes colored red correspond to metabolites with 
an increase in concentration due to TCA inactivated. Nodes colored green correspond to 
metabolites with a decrease in concentration due to TCA inactivated. Nodes colored grey 
correspond to metabolites that are not observed in the NMR spectra, do not have a 
reference NMR spectrum (or assignment), or did not exhibit a significant concentration 
change. Metabolic pathways are labeled on the network. The metabolite names were 
abbreviated as follows: ACA (Acetaldehyde), ACE (Acetate), ACP (Acetyl-P), AKG (α-
ketoglutarate), ALAAc (Acetyl-alanine), AMI (4-Aminobutanoate), ARG (Arginine), 
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ASN (Asparagine), ASP (Aspartate), CIR (Citrulline), CIT (Citrate), ETH (Ethanol), F6P 
(Fruc-6P), G1P (Gluc-1P), G6P (Gluc-6P), GAL (Galacturonic-acid), GAL1P (R-D-
Gala-1P), GLN (Glutamine), GLR (Glucuronate), GLS (D-glucosamine), GLS6P 
(Glucosamine-6P), GLSAc (N-Ac-D-glucosamine), GLSAc6P (Acetyl-glucosamine-6P), 
GLU (Glutamate), GLUAc (Acetyl-glutamate), GLY (Glyceraldehyde), HIS (Histidine), 
ICI (Isocitrate), INO (Ino, Ade, Xan), LAC (Lactate), ALA (alanine), LEU (Leucine), 
LYS (Lysine), MANAc (N-acetyl-D-mannosamine), MET (Methionine), MIN (myo 
inositol), MSE (selenomethionine), NEUAc (N-Ac-neuraminate), ORN (Ornithine), 
ORNAc (Acetyl-ornithine), PEP (Phosphoenolpyruvic acid), PRO (Proline), RIB (D-
ribose), SAM (S-adenosyl-methionine), SER (Homoserine), SUCSER (O-Succinyl-L-
homoserine), UDPGLR (UDP-glucoronate), UDPGLSAc (UDP-NAc-D-glucosamine), 
VAL (Valine). Reprinted with permission from reference.
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The next critical step is to analyze the identified metabolites and find all possible 
correlations. The presence of metabolites and metabolic pathways in a particular 
organism can be verified by the KEGG
266
 and MetaCyc databases.
267
 A metabolic 
network map can then be generated using Cytoscape.
268
 Also, there are many 
metabolome simulators that are useful for predicting the networks involving hundreds of 
metabolites.
269
 Additionally, Cell Designer is a valuable diagram editor for drawing 
biochemical networks.
270
  
 
2.8 Analysis of Biofilms with NMR-based Metabolomics 
An obvious application of NMR-based metabolomics has been used to 
characterize the difference in the metabolome between planktonic and biofilm cells. 
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Gjersing et al. (2007) applied 
1
H HRMAS to study the metabolome difference between 
Pseudomonas aeruginosa chemostat planktonic and biofilm cells.
166
 There was no 
apparent difference in the extracellular metabolite composition when planktonic and 
biofilm cells were grown under continually feed chemostat mode. Conversely, the 2D 
PCA scores plot of the intracellular metabolome indicated a clear distinction between the 
batch and chemostat planktonic and biofilm cells (Figure 2.12 (top)). The corresponding 
loadings plot suggests major and complex differences between the two metabolomes 
(Figure 2.12 (bottom)). The metabolite differences were not analyzed in detail, but it was 
noted that biofilm metabolites were generally lower in concentration, possibly due to the 
cells closer to the substrate operating at a lower metabolic rate. Similarly, Workentine et 
al. (2010) used 
1
H NMR to characterize the phenotype of different biofilm colonies of 
Pseudomonas fluorescens.
271
 PCA of the 1D 
1
H NMR spectra yielded a 3D PCA scores 
plot with distinct clustering for the four different P. fluorescens colonies (Figure 2.13 
(left)). The class distinction was attributed to changes in amino acids (Asp, Glu, Gly, Met, 
Phe, Pro, Trp, Val) and central metabolites (Acetate, Glutathione, Pyruvate). This is 
suggestive of changes in exopolysaccharide production, response to oxidative stress, and 
an impaired amino acid metabolism. Interestingly, the four different P. fluorescens 
phenotypes exhibited distinctly different metal sensitivity (Figure 2.13 (right)). 
Unfortunately, it was not possible to determine if the metabolome differences were a 
result of the different metal sensitivity. Booth et al. (2011) also analyzed P. fluorescens 
cells under metal stress, but compared planktonic to biofilms cells.
165
 1D 
1
H NMR was 
combined with GC-MS to obtain a detailed analysis of metabolite changes caused by the 
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addition of copper (Figure 2.14). Planktonic cells responded differently to copper stress 
compared to biofilms. Planktonic cells experienced an oxidative stress response as 
indicated by changes in the TCA cycle, glycolysis, pyruvate and nicotinate and 
niacotinamide metabolism. Conversely, biofilms exhibited changes in exopolysaccharide 
related metabolism suggestive of a protective response instead of the reactive changes 
that occurred in planktonic cells.  
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Figure 2.12 (top) PCA score plot for chemostat planktonic and biofilm cell samples for 
Pseudomonas aeruginosa. (bottom) Loading plot of the first principal component. 
Reprinted with permission from reference.
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Figure 2.13 (above) Partial least squares discriminate analysis (PLS-DA) scores plot of 
the metabolite concentrations of P. fluorescence CHA0 (black), CHA19 (red), SCV 
(green) and WS (blue). Each data point represents a single extract and the position 
determined as a linear combination of 32 metabolite concentrations obtained from the 
1
H 
NMR spectra. The four strains could be separated along three components. (below) 
Killing curves of P. fluorescens CHA0 (open squares), CHA19 (filled squares), SCV 
(closed circles) and WS (open circles). Biofilms of each of the strains were exposed to a 
series of metal concentrations for 4 h followed by viable cell counting. Shown are the 
log-killing values, which are the number of cells killed following the exposure to metal. 
Error bars represent standard deviation calculated from four replicates. Average cell 
counts for the initial unexposed controls were 5.38 ± 0.47, 4.89 ± 0.45, 5.23 ± 0.39, 5.17 
± 0.47 log10 cfu peg
-1
 for CHA0, CHA19, SCV and WS respectively. Reprinted with 
permission from reference.
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Figure 2.14 Hierarchical clustering analysis of control and copper exposed biofilm and 
planktonic culture metabolite concentrations. Identified metabolites were analyzed for 
any apparent patterns. Clustering was performed using Pearson correlation as the distance 
metric. The cluster tree shows how the samples and metabolites divide. Across the top are 
the samples, labeled by their class and along the side are the metabolites. These were 
colored according to the grouping pattern that they showed: green metabolites were only 
changing in the planktonic cultures, red only in biofilms and blue were changing in both 
cultures in response to copper exposure. Reprinted with permission from reference.
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Demonstrating a difference between planktonic cells and biofilms by NMR is an 
important step towards an application in drug discovery. Does a chemical lead inhibit 
metabolic pathways associated with biofilm formation? Does drug treatment result in a 
metabolome more similar to planktonic cells despite conditions that induce biofilm 
formation? Comparing the metabolome of planktonic cells with and without drug 
treatment may provide an answer to these key questions. Furthermore, the comparative 
analysis of planktonic cells and biofilms has already identified changes in the activity of 
specific cellular process correlated with biofilm formation. Thus, proteins essential to 
exopolysaccharide production and the response to oxidative stress may be novel targets 
for disrupting biofilm formation. Additionally, the metabolome differences between 
planktonic cells and biofilms can be used as a diagnostic tool and to design treatments. 
As an illustration, Hall-Stoodley et al. (2006) describe the application of microbiological 
culture, polymerase chain reaction (PCR)-based diagnostics, direct microscopic 
examination, fluorescence in situ hybridization, and immunostaining to characterize 
middle-ear mucosa biopsy specimens for biofilm morphology.
272
 The authors concluded 
that chronic otitis media in children that require tympanostomy tube placement is biofilm 
related. NMR metabolomics could provide a similar analysis of biopsy samples. The 
treatment of biofilm infections that have colonized on medical implants often requires the 
removal of the infected device.
166
 Investigating changes in bacterial metabolomes in 
response to the different surfaces (metals, polymers, etc.) may contribute to the 
development of novel materials resistant to biofilm formation.
273,274
 Coating or 
embedding medical devices with antibiotics is a common approach to prevent biofilm 
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infections, but the over-use of antibiotics incurs the risk of inducing the rapid 
development of resistance.
275,276
  
Besides characterizing cellular differences through metabolomics, NMR can also 
be used to explore the overall structure and function of biofilms. Vogt et al. (2000) used 
NMR to describe differences in metabolite diffusion within a biofilm.
277
 PFG-NMR was 
used to measure diffusion coefficients for slowly moving water and other components in 
a P. aeruginosa biofilm. Five groups of components including water, glycerol, and 
polysaccharides, were observed with diffusion coefficients ranging from 1.8x10
-9
 to 
5x10
-13 
(m
2
 s
-1
) that indicate locations in the biofilm pores or the extracellular polymeric 
substance (EPS). Correspondingly, the complicated structure of a biofilm is a major 
obstacle to a successful treatment with antibiotics. As the above NMR experiment infers, 
a biofilm is a diffusion barrier that hinders the infusion and dispersion of antibiotics 
within a biofilm.
278
 This also infers that the in vivo activity of a chemical lead is 
determined by both its efficient dispersion throughout the biofilm in addition to its 
intrinsic inhibitor activity. 
A recent study by Rogers et al. (2010) analyzed the synergistic activity of 2-
aminoimidazole-derived compounds, a new class of anti-biofilm agents that disperse 
biofilms.
279
 Combining a 2-aminoimidazole-derived compound with known antibiotics 
resulted in a 2- to 8-fold reduction in MICs against biofilms of P. aeruginosa, 
Acinetobacter baumannii, Bordetella bronchiseptica, and S. aureus. Importantly, the anti-
biofilm agent actually resensitized a multi-drug resistant strain of S. aureus (MRSA). 
Similarly, Walencka et al. (2007) observed a synergy between salvipisone and 
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aethiopinone from Salvia sclarea Hairy Roots with β-lactam antibiotics. An improved 
activity was observed against MRSA and multi-resistant S. epidermis (MRSE).
280
 
Salvipisone and aethiopinone are postulated to function by altering cell surface 
hydrophobicity and cell wall/membrane permeability. 
NMR metabolomics has also been used to investigate the mechanism by which 
Staphylococcus epidermidis and S. aureus respond to a diverse set of environmental 
signals to induce the planktonic to biofilm transition. Bacteria have been shown to form 
biofilms in response to variations in ethanol, oleic acid, glucose, UDP-N-
acetylglucosamine, sub-inhibitory concentrations of some antibiotics, anaerobic 
conditions, Fe limitation, high osmolarity, and high temperature. Instead of numerous 
distinct signaling pathways, a series of detailed NMR and molecular biology experiments 
have demonstrated the presence of a single flexible metabolic signaling pathway centered 
on the tricarboxylic acid (TCA) cycle.
141,221,281
 1D 
1
H NMR combined with OPLS-DA 
was used to compare the metabolome of wild-type S. epidermidis 1457 and an aconitase 
mutant strain 1457-acnA::tetM under various environmental stressors known to induce 
biofilm formation (Figure 2.10). The change in the metabolome of wild-type S. 
epidermidis 1457 in the presence of 4% ethanol, 2% glucose, Fe-limitation and 0.06 
 of tetracycline was shown to be essentially identical to the aconitase mutant with 
an inactive TCA cycle. No change in the metabolome was observed for the aconitase 
mutant with or without the addition of environmental stress factors. 2D 
1
H, 
13
C HSQC 
experiments combined with bacteria grown in the presence of 
13
C-glucose were used to 
generate a detailed analysis of the changes in the S. epidermidis metabolome (Figure 
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2.11). Consistent with the global changes in the metabolome, wild-type S. epidermidis in 
the presence of the environmental stressors induced the down-regulation of metabolites 
associated with the TCA cycle and the up-regulation of metabolites related to PIA 
production. These results suggest that biofilm formation is regulated by the activity of the 
TCA cycle. Inactivating the TCA cycle allows the shuttling of key metabolites into PIA 
production, which is generally necessary for biofilm formation. Similarly, White et al. 
(2011) compared the metabolome of wild-type Salmonella and a CsgD deletion mutant 
that prevents production of an extracellular matrix.
282
 GC-MS and NMR were used to 
analyze the metabolome along with an analysis of gene expression. Metabolites 
associated with glucogenesis and major osmoprotectants were up-regulated in wild-type 
Salmonella, whereas; metabolites associated with the TCA cycle were up-regulated in the 
mutant. Again, this is consistent with the TCA cycle activity regulating biofilm formation. 
These results suggest that agonists of the TCA cycle would interfere with biofilm 
formation. Diets or drugs that modulate the nutrient environment may be an approach to 
prevent bacterial biofilm. As an example, iron-limitation down-regulates the TCA cycle 
and induces biofilm formation.
283
 The major source of morbidity and mortality in cystic 
fibrosis patients is P. aeruginosa biofilms formed in the lung. High iron concentrations 
inhibit P. aeruginosa biofilms, where chelated sources of iron combined with antibiotics 
hold promise as a treatment for cystic fibrosis.
284,285
 
Metabolomics can also be used to construct metabolic pathways, with 
contributions from proteomics and genomics information. Liebeke et al. (2011) provided 
a time-resolved analysis of S. aureus during the transition from exponential growth to 
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glucose starvation. The activity of more than 500 proteins and the concentration of 94 
metabolites were followed. 
1
H NMR was used for the quantification of compounds in the 
media before inoculation, and at defined time points during cell growth. Intracellular 
metabolites were measured by gas/liquid chromatography–mass spectrometry. In general, 
changes in the metabolome correlated with changes in the proteome, where the 
metabolome displayed a larger dynamic range. The most dramatic changes were observed 
for amino acids. During initial cell growth, glycolysis and protein-synthesis were highly 
active, but as glucose was exhausted gluconeogenesis and the TCA cycle were activated. 
Again, this is consistent with the TCA cycle activity regulating biofilm formation due to 
variations in glucose concentrations.
94
 Metabolomics is a valuable approach to 
characterize the state of a system. Nevertheless, incorporating additional complementary 
data, such as proteomics, significantly enhances the reliability of the information. 
Observing a correlation between a metabolite’s concentration and a protein’s expression 
level further substantiates the importance and relevance of the protein to the system, such 
as biofilm formation. From a drug discovery perspective, this provides substantial 
corroboration of a potentially new drug discovery target.  
 
2.9 Conclusion and future perspective 
NMR metabolomics can be used to characterize different cell phenotypes, to 
investigate the underlying biology of biofilm formation, to explore the impact of various 
environmental stress factors on cell biology, to analyze the effect of gene mutations, to 
the investigate the spatial and temporal structure of a biofilm, and even generate a three-
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dimensional image. Notably, the NMR metabolomics methodologies used to study the 
biochemistry of bacterial biofilms are directly applicable to a drug discovery effort. NMR 
metabolomics has been used to identify disease biomarkers and diagnose a disease, to 
screen for drugs, to evaluate drug activity and toxicity, to identify new therapeutic targets 
and design new treatments. While the application of NMR for the analysis of changes in 
the metabolomics is a relatively new endeavor, the technique has already made some 
significant contributions to our understanding of bacterial biofilms. More importantly, 
NMR metabolomics holds great promise to significantly contribute to the diagnosis and 
treatment of biofilm related diseases, where it may play an important role in personalized 
medicine.  
NMR-based metabolomics is a relatively new technology for systems biology and, 
correspondingly, has only had a limited use in the investigation of bacterial biofilms. This 
review summarized the majority of these studies. Nevertheless, the application of NMR-
based metabolomics to the investigation of bacterial biofilms is only limited by the 
creativity of the scientific community. For the near future, the further development of the 
technology will be a primary focus. While NMR-based metabolomics is straight-forward 
in concept, there are numerous practical considerations that can severely complicate the 
routine application of the technique. A primary issue is our incomplete knowledge of the 
metabolome; extensive effort is still required to characterize the metabolome from all 
organisms and populate databases with reference NMR and MS spectra. Similarly, while 
some progress has been made, a metabolomics software package is still needed that 
automates and standardizes the processing of metabolomics data, chemometric analysis 
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and model validation, and metabolite identification. Also, the efficient and accurate 
extraction of metabolites from cell lysates requires continued optimization, and varies 
depending on the organism under investigation. Developing these protocols is extremely 
critical to the future success of metabolomics. Additional methodology advancements 
that will benefit metabolomics include the routine integration of MS and NMR data, and 
the efficient quantitation of metabolite concentrations from MS and 2D NMR 
experiments.            
Our understanding of bacteria cell biology is far from complete, where NMR-
based metabolomics will be an invaluable addition to the study of biofilms and related 
processes such as programed cell death, inter-/intra-species communication, and 
pathogenesis. The systematic analysis of the bacterial genome, transcriptome, proteome 
and metabolome will enable the construction of a detailed network to describe the 
regulatory and metabolic pathways associated with biofilm formation, progression, 
evolution and survivability. In addition to enhancing our basic understanding of bacterial 
biofilms, NMR-based metabolomics will be an invaluable tool for drug discovery, 
disease diagnosis and personalized medicine. NMR-based metabolomics can be used as 
part of a drug discovery screening protocol. Observing an induced change in the bacterial 
metabolome due to a drug treatment would further validate a chemical lead identified 
from standard high-throughput screens.
286,287
 In fact, Halouska et al. (2012) recently 
demonstrated how NMR-based metabolomics can be used to identify the in vivo 
mechanism of action of a chemical lead.
140
 This addresses a major challenge with drug 
discovery, identifying new drugs with activity against novel therapeutic targets that also 
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avoid common mechanisms of resistance or toxicity. Similarly, characterizing the 
metabolome of various pathogenic bacterial strains with a correlation to drug 
susceptibility provides a means to personalize patient treatments. In essence, the 
identification of characteristic metabolites from the biofluids of infected patients would 
identify the bacterial strain and preferred form of treatment.           
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CHAPTER 3 
REVISITING PROTOCOLS FOR THE NMR ANALYSIS OF BACTERIAL 
CENTRAL METABOLOMES 
3.1 Introduction 
Metabolomics is the study of small molecules in a biological system that 
participates in the metabolic reactions responsible for cell growth, survival, and other 
normal cellular functions.
1-3
 Additionally, the metabolome responds to transcriptional and 
translational alterations associated with genotypical, epigenetic, or environmental 
perturbations.
4-7
 Thus, metabolomics provides an assessment of global perturbations with 
respect to an altered genome, proteome, or environment.
2,8,9
 The simultaneous integration 
of genomic, transcriptomic and proteomic data has enabled an in-depth analysis of the 
interplay, interaction, and regulation of DNA, RNA and proteins.
10-12
 Along this line, 
monitoring the bacterial metabolome and integrating the results with other “omics” data 
has provided valuable insights into bacterial adaptability,
13
 biofilms,
14
 evolution,
15
 
pathogenesis,
16
 and drug resistance.
17
  
Depending on the organism and growth state, the total number of metabolites 
within a cell varies between several hundred to a few thousand, with a corresponding 
diversity in physical and chemical properties, such as size, stability, and concentration.
18
 
In addition to the challenge of the simultaneous study of all the metabolites within a 
given biological system,
19
 the selection of an analytical technique will influence which 
metabolites are observed. NMR and MS are commonly employed for metabolomics, 
where both instruments can be interfaced with LC, GC, and CE systems to select and 
121 
 
emphasize specific components of the metabolome.
20-24
 NMR has a number of 
advantages in analyzing the metabolome that includes minimal sample handling and that 
it is not reliant on chromatography to purify or separate metabolites. In addition, multiple 
resonances from a single molecule increase the accuracy of metabolite identification and 
quantitation. This accuracy can be further enhanced by the application of 
13
C- and 
15
N-
isotope labeling to enhance specific regions of the metabolome.
25,26
 Importantly, the 
choice of 
13
C- or 
15
N-labeled metabolite determines the region of the metabolome 
observed by NMR, providing significant flexibility in experimental design. In contrast to 
MS, NMR is a relatively insensitive technique and only observes the most abundant (≥ 1 
to 5 µM) metabolites. In addition, MS has the advantage of detecting a wider-range of the 
metabolome. However, because of the relatively low molecular-weight range of the 
metabolome, MS methods generally require chromatography to separate metabolites 
before analysis.
27
 Additionally, variations in ionization and the occurrence of ion 
suppression in a complex mixture add uncertainty in detecting specific metabolites by 
MS.
28
 Finally, quantitation by MS is typically more challenging than NMR. Taken 
together, NMR and MS each have strengths and weaknesses but should be viewed as 
complementary techniques.
29
  
NMR-based metabolomics have been used to study a wide range of biological 
systems such as tissues,
30
 biofluids,
31
 mammalian cell cultures,
32
 plants
33
 and bacteria.
34-
36
 The overall procedure for an NMR-based metabolomics study includes the following 
general steps: cell growth and harvesting, metabolite extraction, NMR data collection and 
analysis, multivariate statistical analysis, metabolite identification and quantification.
37
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Typically, one-dimensional (1D) 
1
H NMR spectra are used for a multivariate analysis 
such as principal component analysis (PCA) or orthogonal partial least squares 
projections discriminant analysis (OPLS-DA).
38,39
 Both PCA and OPLS-DA provide 
global profiles of metabolome changes.
40,41
 Two-dimensional (2D) 
1
H,
13
C Heteronuclear 
Single Quantum Coherence (HSQC) or 
1
H,
1
H TOtal Correlated SpectroscopY (TOCSY) 
NMR experiments are used for the quantitative assessment of metabolite changes 
resulting from genetic modification or external stimuli.
5,14
 The ability to generate global 
profiles and quantitative differences coupled with the ease of applying NMR-based 
metabolomics has contributed to the rapid growth of the NMR metabolomics field. While 
NMR data acquisition and analysis methods are improving, care must be taken to ensure 
that the methods are appropriate to the task at hand and generate biologically relevant 
information. As an example, protocols to efficiently extract metabolites without inducing 
cellular changes are essential for success.
32,42
 In brief, the observed changes in the 
metabolome should reflect a change in the state of the system instead of how the cells are 
handled and processed. Similarly, variations in instrument performance, choice of 
procedures for data collection and processing, and invalidated models from multivariate 
analysis may induce unintended biases or incorrect interpretation of metabolomics 
data.
43-46
  
Since NMR-based metabolomics is a relatively new and still developing 
technology, improving and enhancing the experimental protocols is necessary to advance 
the field and ensure continued success. Toward this end, we describe our recently 
developed and optimized protocols for the application of NMR metabolomics to 
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microbial samples. We present our current methodology and also discuss the challenges 
associated with each major step of the process: (i) sample preparation, (ii) NMR data 
collection and processing, (iii) multivariate statistical analysis, (vi) metabolite 
identification and network generation. Specifically, the overall methodology will be 
discussed in detail, where a number of key features will also be highlighted, such as 
automation, bioinformatics, experimental design, and harvesting the metabolome. The 
focus of our efforts has been to identify and minimize procedural steps that negatively 
influence the outcome of an NMR-based metabolomics experiment. 
 
3.2 Experimental design 
A general protocol for the analysis of bacterial metabolomes using NMR is shown 
in Figure 3.1. The flow diagram illustrates procedures for both a global analysis of 
metabolome changes (metabolomics fingerprinting); and the identification and 
quantitation of specific metabolites correlated with the biological process (metabolomics 
profiling). The overall process consists of the following key steps: bacterial cultivation 
and harvesting, metabolite extraction, NMR data collection and analysis, multivariate 
statistical analysis, metabolite identification and quantification. Successful metabolomics 
sample preparation involves three steps: The first step is the simultaneous growth of all of 
the bacterial cultures or as many as is practical at a time. The bacteria are grown in a 
standard medium for fingerprint analysis, whereas the medium is supplemented with a 
13
C-labeled metabolite for metabolomics profiling.
47,48
 After the bacteria are grown for a 
defined time or they have achieved a specified cell density, bacteria are harvested and 
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quenched to halt all enzymatic processes and washed to remove the medium. The third 
sample preparation step involves lysing the cells and extracting the metabolome. A 
variety of solvents are routinely employed depending on the solubility of the targeted 
metabolites (cytosolic metabolites, lipids, etc.). The metabolomics samples are then used 
to generate a series of NMR spectra, which are used for the multivariate statistical 
analysis, metabolite identification and quantification. The individual steps of the NMR-
based metabolomics protocol will be discussed in detail highlighting challenges 
associated with each step.  
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Figure 3.1 A flow chart of our protocol used for the NMR analysis of bacterial 
metabolomes.  
 
3.2.1 Identify the appropriate biological system for a metabolomics study  
NMR-based metabolomics is an important tool in systems biology research. The 
quantitative and qualitative measurement of metabolites from cytosolic extracts can be 
extremely valuable for investigating cellular processes, pathogenesis, and the effects of 
drugs or the environment on bacteria. Unfortunately, the bacterial metabolome is a 
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complex mixture of metabolites and numerous interconnected metabolic and signaling 
pathways. This high interconnectivity may result in significant metabolite concentrations 
changes far from the origin of the perturbation (inhibited, inactivated or down-regulated 
protein). Correspondingly, it is easier to observe changes to the metabolome than deduce 
the primary source of the perturbation after its impact has rippled throughout the 
metabolome. As an illustration, treating a bacterial culture with a particular drug would 
be expected to lead to a global change in the metabolome, but interpreting these changes 
to identify the therapeutic target is extremely challenging. To address this challenge, the 
in vivo mechanism of action of a potential drug lead may be determined by comparing 
these metabolome changes to other drugs with known biological targets
49
 or to a mutant 
bacteria where a specific protein target is ablated or modified by genetic inactivation.
50,51
 
This example illustrates that the comparative analysis between two or more metabolomes 
is an effective application of metabolomics. In order to obtain reliable insights into the 
physiology of bacteria or any other organism, it is essential to identify and establish at 
least two reference metabolomes (wild-type vs. mutant, drug-resistant vs. drug 
susceptible, nutrient-rich vs. nutrient-limited, etc.) for a comparative analysis. Once the 
reference conditions are established, bacteria can be exposed to any range of 
experimental variables such as a drug treatment, environmental stimuli (pH, temperature, 
nutrient change), or gene knockout (mutants, RNAi, inhibitor) to determine if similarities 
exists with the reference metabolome. The similarity between metabolomes infers an 
overlap in the underlying physiological processes or responses that gave rise to the 
metabolome changes. We have used this approach to demonstrate the similarity of 
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Staphylococcus epidermidis metabolomes resulting from exposure to divergent 
environmental stressors that are known to facilitate biofilm formation.
5,14
 Our results 
suggested that the tricarboxylic acid (TCA) cycle acts as a metabolic signaling network to 
transduce external stresses into internal metabolic signals. This conclusion was only 
possible because the experimental design was based on comparing the metabolomes of 
the S. epidermidis wild-type strain 1457 and an aconitase mutant strain 1457-acnA::tetM 
with and without the treatment of biofilm stressors. In summary, the successful outcome 
of a metabolomics study hinges on the experimental design and the proper choice of the 
cellular metabolomes to be compared. 
 
3.2.2 Minimize unintended bias and biologically irrelevant variations 
In addition to the proper choice of bacterial strains to compare in a metabolomics 
study, the experimental protocols must be optimized to reduce unwanted variation or bias 
in the collection of cell-free lysates. It is essential to ensure that any metabolome changes 
are limited to biologically relevant factors and are not caused by the handling or 
processing of the samples. Thus, the key to metabolomics is establishing an efficient 
methodology that closely captures the true state of the metabolome.
52
 Fundamental to a 
successful metabolomics experiment is maximizing the uniformity of the preparation, 
handling, processing, and analysis of each replicate sample.
35,45,53-56
 In instances where 
cultivation and/or processing variation is unavoidable (e.g., if multiple incubators are 
required to accommodate all the replicates), then the cultures should be randomly 
distributed between the incubators to minimize bias. Ideally, all of the metabolomics 
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samples should be handled by the same person because subtle differences in individual 
techniques may influence the outcome. If multiple investigators are required to efficiently 
handle the samples, each researcher should be assigned a specific set of tasks that are 
consistently applied to each sample. For example, one investigator lyses all the bacterial 
cells while another performs the metabolome extraction procedure on every sample. 
As with sample cultivation and preparation methods, the NMR spectra generated 
from metabolomics samples need to accurately represent the state of the system. In other 
words, the NMR spectra must reflect the actual concentrations and identity of the 
metabolites present in the biological sample at the time of harvest. If the sample 
preparation and data acquisition represent the metabolic status at the time of harvest, then  
multivariate statistical techniques, such as PCA and OPLS-DA, will enhance the 
identification of similarities or differences in the NMR spectra, and, correspondingly, 
between the bacterial metabolomes.
39
 These multivariate statistical techniques typically 
involve multiple replicates of 1D 
1
H NMR or 2D 
1
H, 
13
C HSQC spectra for each bacterial 
class or group (e.g. wild-type, mutant, drug treated, etc.). The exact number of replicates 
is dependent on a number of factors: (i) the variance within a group, (ii) the variance 
between groups, (iii) the number of variables, and (iv) type of statistical analysis 
performed.
57,58
  
In most metabolomics experiments, the number of biological samples is 
significantly smaller than the number of variables; in this case, the variables correspond 
to peaks in the NMR spectra or the detectable metabolites.
58
 For this reason, a larger 
number of replicates (≥ 6) per class are required to obtain a statistically significant PCA 
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or OPLS-DA model. While greater numbers of replicates are desirable, there are practical 
considerations to increasing the number of replicates, including increased experimental 
time, availability of incubator space, and practical limits on the number of samples that 
can be simultaneously prepared and processed within a reasonable time frame. The 
increased time, larger number of samples, and added complexity may be detrimental to 
maintaining consistency between samples, where metabolite stability may become more 
of an issue.
59
 So the potential benefit in improving the reliability of the PCA or OPLS-
DA models may be negated by too large of a sample size if sample consistency is 
sacrificed. In general, 6 to 10 replicates per class can be routinely handled while 
providing a statistically significant PCA or OPLS-DA model. Lastly, to increase the 
sample consistency, the application of an automated sample changer or flow-probe can 
minimize variability by eliminating human involvement and providing a uniform and 
consistent protocol for NMR data collection. Nevertheless, instrument drift may still 
occur during the high-throughput experiment so it is also important to randomize the 
samples during data collection.  
 
3.3 Sample Preparation 
3.3.1 Bacterial cultivation 
Consistency is critical to metabolomics, where variations in a bacterial 
metabolome may be introduced by cultivation protocols. To achieve the reproducible 
cultivation of bacteria requires consideration of three variables: bacterial strain, culture 
medium, and cultivation conditions. Strain selection is often driven by investigator 
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preference, availability, or cultivability. The choice of culture medium will largely 
depend on which, if any, isotopically-labeled metabolite is being followed. For example, 
when using 
15
N-arginine, it is impractical to add labeled arginine to a complex medium 
containing an unknown concentration of unlabeled arginine. In this example, to achieve 
maximal labeling of the bacteria, it would be best to use a chemically defined medium 
lacking arginine. Importantly, the culture medium has to be consistently employed 
throughout the metabolomics study. A different culture medium cannot be used for 
metabolomics fingerprinting and profiling, it cannot vary based on the requirements of 
the bacterial strain or to accommodate an experimental variable. Different culture media 
will induce changes in the metabolome that will mask or complicate any analysis. 
Bacterial cultures also need to be properly handled in order to avoid inducing biologically 
irrelevant changes. For example, pre-warming the culture medium prevents temperature 
shock and minimizes variation between biological replicates. Similarly, randomizing the 
samples from each group and class also minimizes bias that may occur if all the samples 
are processed in a predefined order. Importantly, different cell types may require special 
care or different handling protocols. Cultivation conditions will also vary depending upon 
the experiment; however, consideration must be given to each of the following: 
temperature, pH buffering (if used), % CO2 (if used), the flask-to-medium ratio, the 
revolutions per minute of agitation (if used), the use of baffled or non-baffled flasks, and 
the inoculum dose. In effect, one protocol does not necessarily “fit all” and a general 
metabolomics protocol needs to be optimized for each experiment and cell type.  
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Deciding on the number of bacterial cultures needed for a metabolomics study and 
identifying the optimal culture size are important next steps. The volume of the bacterial 
culture should be large enough to provide a sufficient number of cells to maximize the 
NMR signal-to-noise, but small enough to simplify the handling of numerous replicate 
samples. An appropriate cell density must be determined empirically for each species and 
bacterial strain, which will also limit the culture size. Similarly, the growth phase chosen 
for harvesting bacteria will also contribute to defining the optimal culture size since cell 
density changes drastically between the lag, exponential and post-exponential phases. In 
our experience with staphylococcal and mycobacteria cultures, media volumes between 
15 to 50 mL are used to grow cells to an optical density at 600 nm (O.D.600) of 1-2 for 
bacterial cultures collected during the exponential phase. Conversely, media volumes of 
between 3 to 5 mL are used to grow cells to an O.D.600 of 3 to 7 for bacterial cultures 
collected during the post-exponential phase (e.g., 6 to 7 for Staphylococcus epidermidis, 
and 3 to 4 for Mycobacterium smegmatis). The overall goal is to have an O.D.600 of 10 to 
20 after the bacterial cells have been concentrated to a final volume of 1 mL. This will 
ensure metabolite concentrations sufficient for detection by NMR. These culture volumes 
and O.D.600 values should be viewed as guidelines and targeted goals that may require 
further optimization for different bacterial strains or species. As previously stated, the 
number of bacterial cultures determines the statistical significance of class differentiation 
or metabolite changes. In our experience, ten replicates are an optimal choice for 
metabolomics fingerprinting and only three replicates are needed for metabolomics 
profiling.    
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Metabolomics profiling requires 
13
C- or 
15
N-labeled metabolites and defines the 
choice of culture media. In our laboratories, we typically label staphylococci using 
13
C-
glucose in the complex medium tryptic soy broth (TSB) that is devoid of unlabeled 
glucose.
6,7
 This medium allows for maximal biomass generation, while assuring that 
nearly all (~99%; 1.1% is due to naturally occurring 
13
C) of the 
13
C-labeled metabolites 
in the metabolome were derived from glucose. Similarly, we have labeled mycobacteria 
using 
13
C-glucose or 
13
C-glycerol in Middlebrook 7H9 Albumin Dextrose Complex 
(MADC; Becton-Dickinson) media. We have also supplemented culture media with 
13
C-
alanine, 
13
C-aspartate, 
13
C-glutamate, 
13
C-proline and 
13
C-pyruvate as a more targeted 
approach to the analysis of the metabolome. These metabolites are associated with a 
limited number of metabolic pathways. The analysis of the metabolome can be further 
focused by using a targeted metabolite where only one or a few specific carbons in the 
metabolite are 
13
C labeled. Only the metabolic pathways involving the specific 
13
C-
labeled carbon will be observable by NMR. The concentration of the 
15
N-, or 
13
C-labeled 
experience with staphylococcal and mycobacterial cultures, the volumes range from 25 
mL to 100 mL and the culture media should be supplemented with approximately 2.5 to 4 
g/L of 
13
C6-glucose or ~10-15 mg/L of a targeted metabolite like 
13
C-D-alanine in order 
to acquire a 2D 
1
H, 
13
C HSQC spectrum with acceptable signal-to-noise.  
Ideally, each bacterial culture should contain the same number of cells and be at 
the same growth phase when harvested. In reality, differences in cultivation conditions, 
media, and/or bacterial strains may substantially affect growth rates and/or growth yields. 
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The two more common approaches to compensate for different bacterial growth rates are: 
collect the bacteria when they have reached the same cell density, but at different times to 
account for the different growth rates; and harvest the bacteria at the same time but 
harvest equivalent cell numbers. As examples, in staphylococci, the exponential and post-
exponential growth phases were typically analyzed at the 2 h and 6 h time points, 
respectively.
5
 For our mycobacterial experiments, a consistent growth phase was 
achieved by harvesting bacteria at a uniform O.D.600 of 1.2. In practice, it is extremely 
difficult to harvest every bacterial culture with an identical O.D.600 value. To correct for 
this variability, all the bacterial cultures are normalized to the same number of cells. 
Simply, the cultures are suspended into a phosphate buffer until the O.D.600 values are 
equal. Typically the cultures are concentrated to an O.D.600 of 10 to 20 into a final 
volume of 1 mL prior to lysis. Alternatively, the bacterial cell cultures can be normalized 
based on colony-forming units (CFU) or total protein concentration.  
To ensure consistency, the experimental variable such as a drug treatment, 
environmental stimuli, or gene knockout needs to be uniformly applied to the “treatment” 
class. An additional consideration for treatment of cultures, is that the impact on the 
metabolome should be strong enough to detect.
49
 In other words, a particular drug dosage 
needs to be large enough to affect the cellular metabolome relative to untreated cells, but 
should not induce cell death. In our experience, a drug concentration that inhibits 
bacterial growth by 50% relative to untreated cultures is a desirable target.
49,50
 The 
availability from the literature of a minimal inhibitory concentration for the strain (MIC), 
or otherwise for the population isolates (MIC50), provides a good starting point for 
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optimizing a drug dosage, but the actual dosage must be determined empirically for each 
set of cultivation conditions. In our experience, literature MIC or MIC50 values tend to be 
too low for cultivation conditions used for metabolomics. We typically test drug 
concentration ranges at between 1 to 24 times the reported MIC or MIC50 values in order 
to identify an optimal drug dosage. Importantly, this also implies that drugs with a range 
of biological activity will require different drug concentrations in a metabolomics study; 
hence, the use of the 50% inhibition of growth is used as a metric as opposed to drug 
concentration. Typically, in our experiments the drug treatments are normally 
administered during the exponential phase and the bacteria are allowed to grow for at 
least one generation before harvesting. In our experience, this provides a sufficient 
amount of time for the drug to affect cell physiology and induce a perturbation in the 
metabolome. Administering a drug at an earlier time point can be problematic because of 
the inability to harvest enough bacteria.   
 
3.3.2 Quenching, washing and harvesting the bacterial cells 
Speed is critical to harvesting bacteria without inducing a change to the 
metabolome. Changes occur quickly because of different metabolite turnover-rates, 
varying stabilities, and the induction of stress responses, among other factors.
59-61
  As 
bacteria are being harvested, the environment is changing dramatically: (i) the bacteria 
are either adhered to the surface of filter paper or at the bottom of a centrifuge tube under 
anaerobic conditions, (ii) the temperature is changed from 37
o
C to ~ 0
o
 C, and (iii) the 
growth media is replaced with either double distilled water or a phosphate buffer. To 
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prevent perturbations to the metabolome caused by handling of the cell samples, the 
bacteria need to be rapidly quenched in order to stop all cellular processes from 
responding to these changes. Quenching efficiency has been widely discussed in the 
literature.
42,62-64
 Importantly, the quenching technique employed also defines the washing 
protocol and the order that quenching, washing and cell separation takes place. Our 
quenching techniques consist of a filtered cells being quickly submerged into liquid 
nitrogen or the cells and media being directly added to -60
o
C cold ethanol or methanol 
solution while being vortexed. The media and ethanol/methanol volumes are at an equal 
1:1 ratio. After centrifugation, the supernatant is decanted and disposed of, and the cell 
pellet is ready for washing. Unfortunately, there is a possibility of cell leakage and loss of 
metabolites when the cells are directly added to the cold ethanol or methanol solution.  
Before intracellular metabolites can be analyzed, the bacteria need to be rapidly 
separated from the culture media. Filtration and centrifugation are both routinely used in 
our laboratory to separate bacterial cells from the media. Filtration has a definitive 
advantage because it is significantly faster than centrifugation, but challenges in 
removing and collecting intact cells from filter paper may lead to sample variability. 
Conversely, the variability between metabolome replicates is expected to be reduced with 
centrifugation because of the ease in handling the cells. Nevertheless, our experience with 
washing bacterial cells using either filtration or centrifugation has resulted in essentially 
identical metabolomics fingerprints (Figure 3.2a); thus, any undesirable variation within a 
group likely occurs during sample preparation. Metabolome differences between replicate 
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bacterial cultures likely arises from a combination of subtle variations in the number of 
cells, culture conditions, length of bacterial cultivation time, and sample handling.  
The use of centrifugation or filtration also determines the quenching protocol.
36
 
Harvesting bacteria using centrifugation requires quenching the bacteria using the direct 
addition to -60
o
C cold ethanol or methanol. The bacteria, culture media, and quenching 
solution are in a properly sized conical centrifuge tube that is centrifuged for 8 minutes at 
4,284 g (bucket rotor). Following centrifugation, the culture media and quenching 
solution are decanted and the bacteria are suspended in 30 mL of an ice cold wash. We 
routinely wash bacteria with ice cold double distilled water, phosphate buffer (20 mM, 
pH 7.2), or phosphate buffered saline (PBS; 6 mM phosphate buffer, pH 7.4, 137 mM 
NaCl and 2.7 mM KCl) to remove residual media and avoid contamination of the 
metabolome. The bacteria are centrifuged again, the wash is decanted off and the process 
is repeated. After two washes, the cell pellet is suspended in 1 mL of the ice cold wash 
and transferred to a 2 mL vial for cell lysing. Additional washings provide an 
insignificant benefit in removing media contaminates, but results in an undesirable 
increase in time. Also, the buffered wash eliminates any impact on the cells from a pH 
change, but double distilled water eliminates the possibility of “salting-out” any 
metabolites that may occur from concentrating the buffer in subsequent steps.
65
 The cells 
are kept on ice throughout this entire process. 
Harvesting bacteria by vacuum filtration collects the bacteria on sterile filter paper 
(0.45 µm pore size; Millipore), while simultaneously removing the media. The number of 
bacteria that can be harvested onto a filter must be empirically determined to prevent a 
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filter blockage. Under proper conditions, removing the media should take less than a 
minute, and should never exceed two minutes. If this cannot be achieved, then the 
bacteria need to be harvested using centrifugation. After filtration, the filter paper 
containing the cells is then quickly placed into a 50 mL conical centrifuge tube and 
submerged into liquid nitrogen to freeze and quench the cells. The conical vial is then 
warmed by placing it into a bucket of ice for ~1 to 2 minutes. This prevents freezing of 
the 1 mL of wash that is added to the conical vial. The cells are gently removed from the 
filter paper with the wash and then transferred to a 1.5 mL microcentrifuge tube. The 
cells are centrifuged and washed twice (1 mL) as before. 
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Figure 3.2 Illustrations of the impact of a) filtration and centrifugation, b) number of 
extraction steps, c) type of wash buffer, and d) lyophilization on the composition of the 
metabolome. 
 
3.3.3 Cell lysing and metabolite extraction 
The cells need to be lysed in order to extract the cellular metabolome. Cells can be 
lysed by chemical or physical means, but the use of chemicals runs the added risk of 
contaminating the metabolome. Thus, the FAST-Prep bead beating method of lysing cells 
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is our preferred approach. Before lysing, the samples are normalized to an O.D.600 value 
of between 10 to 20 units. This insures an equivalent number of cells, comparable 
metabolite concentrations, and a detectable NMR spectrum. Each sample is placed into a 
2 mL micro-centrifuge tube with small glass beads (Lysinf Matrix B; MP Biomedical) 
and 1 mL of extraction buffer. The cells are crushed by bead beating for 40 to 60 seconds 
in the FAST-Prep instrument at a speed of 6.0 m/s. The sample is then centrifuged for 2 
minutes at 17,000 g to pellet the cell debris. The supernatant with the extracted 
metabolites is collected. The cell debris is washed 1 to 3 times with 1 mL of the 
extraction buffer to maximize the metabolome yield (Figure 3.2b). Also, double distilled 
water or a phosphate buffer are routinely used as the extraction buffer, since both 
approaches provide similar results (Figure 3.2c). All extracts per sample are combined for 
lyophilization, where the sample is then dissolved in 700 L of a phosphate buffer in D2O 
at pH 7.2 (uncorrected). Lyophilization may negatively impact some volatile metabolites, 
but, in general, no effect is observed (Figure 3.2d). A major concern during the extraction 
step is maximizing the overall yield while minimizing any perturbation to the 
metabolome. In our experience, the cell lysing and metabolite extraction process will 
require approximately 45 minutes for 30 cultures. The metabolomics samples can be 
stored in a -80
o
C freezer or directly lyophilized over-night. 
 
3.3.4 Isotopic labeling of metabolites 
Uniform or selective isotopic labeling with 
13
C/
15
N has often been used to boost 
the sensitivity of carbon or nitrogen due to their low natural abundance in protein 
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structural determination by NMR.
66,67
 The use of stable isotope tracing in metabolic 
pathway studies is dated back to 1935.
68
 And there is no evidence that 
13
C/
15
N isotopic 
labelling has an observable effect on the physiology of bacteria.
69
 Hence, stable isotope 
labeling combines the analytical development and biological requirement and 
demonstrates large potentials in the metabolomic study by handful applications.
70-73
 The 
uniform labeling by 
13
C glucose is a common strategy in NMR-based metabolomics.
74
 It 
often employs chemical defined medium (CDM) in which glucose as the sole carbon 
source is used to completely label the metabolome. CDM is not ideal for many 
physiological studies in bacteria because it has the drawbacks of less reproducibility and 
less association with the growth conditions in the host.
75
 Therefore random labeling of 
13
C isotope using 
13
C glucose within a complex medium can also be performed with a 
good signal-to-noise ratio (Figure 3.3a). 
13
C glucose should be added to the medium 
which is free of dextrose. However, there is a concern that if the 
13
C glucose should be 
used in the overnight culture, or in another word, if the labeling of overnight culture 
makes a difference on the labeling efficiency. In Figure 3.3b and 3.3d, there was no 
significant difference between the two overnight cultures. In Figure 3.3a and 3.3c, as a 
negative control experiment, 
12
C glucose was used for the post-exponential growth using 
the overnight cultures. And very little difference was found. In conclusion, the small 
amount of overnight culture has no significant effect on the labeling efficiency.    
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Figure 3.3  Illustrations of isotope carry-over effects in the overnight culture using 
1
H, 
13
C HSQC experiments of the metabolomes from: (a) overnight culture using 
12
C glucose 
medium, post-exponential phase growth using 
12
C glucose, (b) overnight culture using 
12
C glucose medium, post-exponential phase growth using 
13
C glucose, (c) overnight 
culture using 
13
C glucose medium, post-exponential phase growth using 
12
C glucose, and 
(d) overnight culture using 
13
C glucose medium, post-exponential phase growth using 
13
C 
glucose. 
 
3.3.5 Storage of metabolite samples 
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 The metabolite samples should be lyophilized and kept in -80
o
C freezer for long-
term storage. Once the sample is prepared in NMR tubes, only short term storage in 4
o
C 
for 1-2 days is allowed, as a short term in the room temperature can lead to observable 
changes (Figure 3.4). This is important to notice when running multiple samples for long 
experiments such as 
1
H, 
13
C HSQC experiments. The samples still in the queue should be 
kept in 4
o
C refrigerator. It is also advisable to add 0.5 mM NaN3 to inhibit trace bacterial 
activities.
76
 
  
Figure 3.4 Metabolic changes dependent on the time of storage. 
1
H, 
13
C HSQC spectra of 
the same sample: S. aureus wild-type Newman strain metabolome in post-exponential 
phase.
77
   
 
3.4 NMR Spectroscopy 
3.4.1 One-dimensional 
1
H NMR methodology 
One-dimensional (1D) 
1
H (proton) NMR is an unbiased, nonselective, and 
nondestructive approach that requires no modification of the samples, where the data can 
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be collected in a high-throughput manner. A 1D 
1
H NMR spectrum contains numerous 
proton signals generated from a complex metabolomics mixture, where the chemical shift 
of each signal describes the structural characteristic of a specific metabolite. Moreover, 
the peak intensities or volumes are directly proportional to the concentration of each 
metabolite. Quantification of metabolites can be achieved by using an internal standard 
with a known concentration, where we routinely use 50 µM 3-(trimethylsilyl) propionic 
acid-2,2,3,3-d4 (TMSP-d4, Sigma). Thus, 1D 
1
H NMR experiments combined with 
multivariate statistics are commonly used for the global analysis of the metabolome. 
Collecting 1D 
1
H NMR data for metabolomics is fast and simple, and provides 
highly reproducible and accurate results. Importantly, the NMR experimental parameters 
need to be identical for each metabolomics sample in order to collect reliable 
metabolomics data. Any per sample variation will erroneously bias the resulting 
clustering patterns in the PCA and OPLS-DA scores plot. To avoid this and maintain 
sample consistency, we use a BACS-120 sample changer, Bruker ICON-NMR, an 
automatic tuning and matching (ATM) unit, and autoshim to automate the NMR data 
collection. Nevertheless, instrument drift may still occur during the high-throughput 
metabolomics screen, so it is also important to randomize the samples during NMR data 
collection. If an NMR spectrum is collected first for all the control samples followed 
subsequently by each treatment class, there is a significant potential of inducing a 
biologically irrelevant bias into the analysis. The clustering pattern in the PCA and 
OPLS-DA scores plot may be dominated by the order of data collection instead of the 
expected biological differences.      
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In our laboratory, a typical 1D 
1
H NMR spectrum is collected using 128 scans and 
32k data points on a Bruker 500 MHz Avance DRX NMR spectrometer equipped with a 
triple-resonance, Z-axis gradient cryoprobe. The acquisition time is approximately 10 
minutes per sample. The goal is to obtain optimal signal to noise while minimizing the 
total experimental time. We previously demonstrated that spectral noise is detrimental to 
the resulting PCA and OPLS-DA scores plot.
53
 Random noise fluctuations results in large 
and irrelevant variations in the scores clustering. To avoid this problem, spectral noise 
needs to be removed prior to PCA and OPLS-DA. Correspondingly, the quality of the 
within class clustering in PCA and OPLS-DA scores plot is directly dependent on the 
spectral signal-to-noise (Figure 3.5). The within class variance decreases dramatically as 
the number of scans (signal-to-noise) is increased from right to left in the scores plot.  
Importantly, the spectral noise was still removed prior to PCA. Thus, the accuracy of 
identifying similarities or differences between multiple classes is dramatically improved 
by reducing within class variance, which is achieved by improving spectral sensitivity. 
Also, correctly identifying class differences improves with the number of replicates 
(Figure 3.6). The statistical significance of cluster separation as measured by p-values is 
shown to decrease as both a function of group variance and the number of replicates.
78
 As 
a result, we prefer to use ten replicates per class and strive to achieve an average signal-
to-noise ratio of > 100 to 200. This is achieved by simply increasing the number of scans 
or the number of cells, whichever is more practical. While signal-to-noise has a dramatic 
impact on scores clustering, PCA and OPLS-DA is indifferent to changes in spectral 
resolution unless the number of data points is ≤ 2K.  
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Figure 3.5 Illustration of the impact of the NMR signal-to-noise on within class variation 
in a PCA scores plot. From right to left, the 1D 
1
H NMR spectra were collected with an 
increasing number of scans (1, 2, 4, 8, 16, and 32) resulting in a proportional increase in 
signal-to-noise. All other experimental parameters were kept constant. 
 
 
 
 
 
 
 
Figure 3.6 Illustration of the impact of within group variation and the number of 
replicates on the p values calculated between clusters in a simulated PCA scores plot. 
From top to bottom, p values from the simulated PCA scores plot were calculated with an 
increasing number of replicates (6, 8, 10) resulting in a proportional decrease in p values. 
Similarly, increasing the group variation by increasing the standard deviation (σ) per 
cluster resulted in a significant increase in p values.   
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A D2O phosphate buffer is the typical solvent of choice for aqueous metabolomics 
samples in order to efficiently remove residual water signals and avoid interference from 
buffer signals. Water and buffer signals are problematic since they can distort the NMR 
spectrum and may overlap and obscure important metabolite signals. Most NMR 
processing software can automatically remove the residual water peak, but extra data 
processing is required to correct for baseline distortions induced by the solvent.  
Unfortunately, simply applying a baseline correction changes the PCA and OPLS-DA 
clustering patterns.
79
 Furthermore, different baseline correction protocols will induce 
variable changes into the scores plot. Also, removing the residual water peak may result 
in a potential loss of information by also removing metabolite peaks near the water 
signal. Instead, a water suppression technique that experimentally removes the water 
peak without inducing baseline distortions is the preferred alternative.  
There are a variety of NMR pulse sequences for water suppression that are 
available to the metabolomics community, such as WATERGATE, water pre-saturation, 
WET, and PURGE.
80-84
 Our preferred choice for a water suppression pulse sequence is 
Solvent-Optimized Gradient-Gradient Spectroscopy (SOGGY). SOGGY does an 
outstanding job in eliminating the water signal without inducing any base line distortions 
(Figure 3.2).
84
 SOGGY is a variant of excitation sculpting that employs a pulsed field 
gradient with a simple phase-alternating composite pulse. SOGGY offers the flexibility to 
optimize the 180 degree hard pulse to achieve optimal excitation of the water signal, and 
adjusting the 180 degree soft pulse to optimize the range of the water frequency to be 
suppressed.
84,85
 As a result, SOGGY efficiently suppresses the water signal while 
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removing any phase cycle artifacts. A flat baseline is obtained while also maintaining 
metabolite signals near the water signal.
84
 SOGGY completely eliminates the need to 
apply any baseline correction. 
 
3.4.2 Two-dimensional 
1
H, 
13
C HSQC NMR methodology 
The severe overlap of signals in a 1D 
1
H NMR spectrum is a challenge for 
metabolite identification. The difficulty arises because hundreds to thousands of peaks 
occupy a small chemical shift range (~10 ppm), where multiple metabolites share similar 
chemical shifts. Thus, we typically do not use 1D 
1
H NMR spectra to assign metabolites. 
Instead, we routinely use 2D 
1
H, 
13
C HSQC experiments for metabolite assignments. The 
2D 
1
H, 
13
C HSQC experiment is a more reliable approach for metabolite identification 
because of the significantly higher resolution and the correlation between 
1
H and 
13
C 
chemical shifts for each C-H pair in a molecule.
86,87
 Also, the 2D 
1
H, 
13
C HSQC 
experiment simplifies the analysis of the metabolome because only compounds 
containing a 
13
C-carbon derived from the 
13
C-labeled metabolite added to the media will 
be detected.  
In our laboratory, we use a standard 2D 
1
H, 
13
C HSQC pulse sequence on Bruker 
500 MHz Avance DRX NMR spectrometer equipped with a triple-resonance, Z-axis 
gradient cryoprobe. An acceptable signal-to-noise is achievable using 64 scans. Similarly, 
a reasonable digital resolution is achieved by collecting 2K and 128 data points in the 
direct and indirect direction, respectively, with a corresponding spectral width of 10 ppm 
and 140 ppm along the 
1
H and 
13
C axis, respectively. Since some aromatic C-H pairs 
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have a 
13
C chemical shift greater than 140 ppm, the spectrum will contain folded peaks, 
but the folded peaks will not interfere with or overlap with other metabolite peaks due to 
their unique position along the 
1
H axis (~ 7.0 ppm). In general, the 2D 
1
H, 
13
C HSQC 
experiment requires approximately 4 hours per sample on our system. 
A conventional 2D 
1
H, 
13
C HSQC spectrum is useful for detecting metabolite 
changes by overlaying multiple spectra to identify missing peaks or peaks with 
significant intensity changes. Unlike 1D 
1
H NMR spectra, obtaining metabolite 
concentrations is more difficult because peak intensities are dependent on J-couplings, 
dynamics and relaxation, in addition to metabolite concentrations.
88,89
 To quantify 
absolute metabolite concentrations, we use the Time-Zero HSQC (HSQC0) experiment.
88
 
This approach requires collecting a series of three HSQCs spectra (HSQC1, HSQC2, 
HSQC3) with an increased number of pulse sequence repetitions. A natural log plot of 
peak areas or intensities versus the increment number (1,2,3) allows for an extrapolation 
back to increment 0 or zero-time. The experimental parameters used in the HSQC0 
experiment is similar to the conventional method, but with some minor variations. The 
number of scans is increased to 128 due to the decrease in signal-to-noise in HSQC2 and 
HSQC3. To partially compensate for the increase in experimental time, the number of 
data points in the indirect dimension is reduced to 64. In general, the HSQC0 set of 
experiment requires approximately 6 hours per sample on our system. 
 
3.5 Data analysis 
3.5.1 Preprocessing of 1D 
1
H NMR data 
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The 1D 
1
H NMR spectra are minimally processed (Fourier transformed and phase 
corrected) using ACD/1D NMR Manager (Advanced Chemistry Development). Each 
NMR metabolomics sample contains 50 µM of TMSP-d4 as an internal standard, where 
each NMR spectrum is referenced to the TMSP-d4 peak and uniformly aligned to 0.00 
ppm. Also, all peak heights are normalized to the intensity of the TMSP-d4 peak. 
Intelligent bucketing within the ACD/1D NMR Manager is then used to integrate each 
spectral region with a bin size of 0.025 ppm. The spectra are normalized; noise regions 
and residual solvent and buffer resonances are removed, and then the remaining bins are 
scaled prior to PCA and OPLS-DA using SIMCA12.0+ (UMETRICS).  
The need for data normalization and scaling prior to multivariate statistical 
analysis has been extensively discussed in the literature.
90,91
 Normalization adjusts for 
experimental variations between replicates, different number of cells, varying signal-to-
noise, etc., and minimizes these contributions to the clustering patterns in PCA and 
OPLS-DA scores plot. We have encountered significant success in using a Z-score or 
center averaging the spectrum:    
                                      i
X X
Z


                               (1) 
where X is the average signal intensity in a given spectrum, is the standard deviation in 
the signal intensity, and iX is the signal intensity within bin i  (Figure 3.7a). After 
normalization, all the noise bins are uniformly removed. This was initially accomplished 
by manually identifying a “reference” noise region above 10 ppm and below 0 ppm; and 
calculating an average noise value. If a bin across all replicates had an integral value of 
less than twice the average noise, it was also identified as noise and removed (Figure 
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3.7b). The protocol for identifying noise regions has been recently improved upon and 
results in smaller within class variations (Figure 3.7c). This also results in an improved 
separation between truly distinct classes and removed erroneous separations. For 
example, the statistical significance between clusters 6hwt and 6hacna improved from a 
p-value of 3.1x10
-13
 to 8.1x10
-15
, while the small, but biologically irrelevant, separation 
between clusters 2hwt and 2hacna (p-value 2.5x10
-3
) was removed (Figure 3.7). Instead 
of using an average minimal signal intensity to define noise, we now define noise based 
on a relative standard deviation. This is based on the expectation that real NMR peaks 
from metabolites will have a higher intrinsic variability compared to the noise because of 
biological variations that naturally occur even between within class replicates. 
Conversely, the variability of the noise should be effectively constant for a given 
spectrometer operating within normal parameters. Simply, the standard deviation and 
average is calculated for each bin, where the standard deviation is normalized by the 
average peak intensity. This avoids eliminating weak peaks with a relatively small 
standard deviation. The same is done for the reference noise region, which is then used to 
define noise: 
Noise:  σi’≤σ0’                                                  (2) 
 Cutoff: σ0’=avg(σn’)+2* sd(σn’)                                         (3)       
where σi’,σn’ are the relative standard deviations (absolute standard deviation divided by 
the mean) for the ith bin in the spectral region and nth bin in the reference noise region, 
respectively, and avg(σn’) and sd(σn’) are the mean and standard deviation of σn’ 
respectively. In effect, any peak that falls within the normal distribution of the reference 
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noise region is defined as a noise bin. This approach is better at defining noise peaks in 
crowded and overlapping regions of the NMR spectra. 
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Figure 3.7 Illustration of the impact of NMR preprocessing on within and between class 
variations in a PCA scores plot. a) The 1D 
1
H NMR spectra was not properly 
preprocessed. The spectra were not normalized and the noise was not removed. The 
spectra were only Fourier transformed, phased corrected, and the residual H2O resonance 
was removed. b) The 1D 
1
H NMR spectra were processed as in a) with the addition of 
normalization using center averaging, but without noise removal. c) The 1D 
1
H NMR 
spectra were processed as in b) with the addition of noise removal. Each spectrum was 
binned using intelligent bucketing with a bin size of 0.025 ppm. The ellipses correspond 
to the 95% confidence limits from a normal distribution for each cluster. The PCA scores 
plots compare the metabolomes of S. aureus wild-type (wt) strain SA564 with an 
aconitase mutant (acnA) strain SA564-acnA::tetM at either two hours (2h) or six hours 
(6h) of cell growth. Below each PCA scores plot is a corresponding dendrogram 
generated from the scores using Mahalanobis distances, with p values for the null 
hypothesis reported at each branch.      
 
In addition to normalization, each bin or column in the data matrix also needs to 
be scaled to account for the large dynamic range in peak intensities. PCA and OPLS-DA 
emphasizes the absolute variation in bins between classes. Correspondingly, the relative 
variation of an intense peak may be insignificant compared to a weak peak, but the 
absolute changes in its intensity may completely mask biologically relevant changes in a 
small peak. Scaling increases the weight of the low intensity peaks so strong peaks do not 
dominate in PCA and OPLS-DA.
90,91
 In our experience, unit variance scaling, also known 
as auto-scaling or a Z-score (see eqn. 1), has been shown to be effective in generating 
reliable clusters with the correct separation based on biologically relevant class 
distinctions. Also, within class variance is reduced using auto-scaling, which is our 
default scaling method. 
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3.5.2 Multivariate statistical analysis of 1D 
1
H NMR data 
We routinely apply PCA, a non-supervised technique, to determine if the 1D 
1
H 
NMR data can easily distinguish between the various test classes. PCA provides an 
unbiased view of group clustering in the resulting 2D scores plot. We only use a three-
dimensional (3D) scores plot if class separation in a 2D scores plot is insufficient and the 
PC3 contribution is significant (> 5 to 10%). OPLS-DA is only used if class separation is 
observed in the PCA scores plot. OPLS-DA is a supervised technique and assesses a 
relationship between the NMR data class designations. We limit OPLS-DA to only two 
class designations that differentiate between the single control group (0) and the entire 
treatment group (1). As a supervised technique, OPLS-DA maximizes a separation 
between these two classified groups, while minimizing within class variations.
39
 Thus, 
OPLS-DA identifies the important spectral features (metabolites) that primarily 
contribute to class separation. We routinely use an OPLS-DA S-plot or loading plot to 
readily identify the key metabolites that contribute to class separation. Since OPLS-DA is 
a supervised technique and can generate a class separation even for random data,
92
 it is 
essential to verify the model.
46
 But this is also an advantage of OPLS-DA over PCA; the 
statistical significance of the model is quantified. We cross-validate OPLS-DA models 
using a modified leave-one-out method
93,94
 and CV-ANOVA.
95
 The modified leave-one-
out method provides a quality assessment score (Q
2
) and R
2
 values, where CV-ANOVA 
provides a standard p-value. The theoretical maximum for Q
2
 is 1, where a value of ≥ 0.4 
is an empirically acceptable value for biological samples,
96
 but Q
2
 does not have a critical 
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value for inferring significance. It is still possible for an invalid model to produce a large 
Q
2
 value. Similarly, the R
2
 values only provide a measure of the fit of the data to the 
model. But large differences between Q
2
 and R
2
 (R
2
 >> Q
2
) does suggest an over-fit 
model. Conversely, a p-value << 0.05 from CV-ANOVA provides clear validation of the 
OPLS-DA model.    
In addition to validating the OPLS-DA model, it is also extremely important to 
verify the statistical significance of the clustering patterns in the PCA and OPLS-DA 
scores plot. Is the between group difference larger than the within group variations? One 
key factor is the number of replicate samples. We have previously shown that increasing 
the number of replicates improves the statistical significance of cluster separation.
97
 This 
finding is also supported by the increase in p-values seen with an increase in within class 
variations (Figure 3.6). Again, increasing the number of replicates improves the statistical 
significance of the class separation (lower p-value) even when within class variation 
increases. Correspondingly, we routinely use 10 replicates per group in our metabolomics 
study to improve the likelihood of observing statistical significant class separations.  
It is also important to visually define each group or class within the PCA and 
OPLS-DA scores plot and to classify the statistical significance of the class separation. 
We developed a PCA and OPLS-DA utilities software package
78
 that draws ellipses or 
ellipsoids around each group cluster in a scores plot, where the ellipse corresponds to the 
95% confidence limits from a normal distribution for each cluster. Visual separation of 
the ellipses infers a class separation. The same software package is also used to generate 
a metabolomics tree diagram based on the group clusters in the scores plot.
78,97
 Simply, a 
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centroid from each cluster is used to calculate a Mahalanobis distance between clusters, 
where dendrograms are then generated from the resulting distance metric. The 
significance of each node (cluster separation) is determined by using standard 
bootstrapping techniques and returning a bootstrap number,
98
 where a value above 50 
infers a significant separation; or from Hotelling’s T2 and F-distributions that returns a p-
value, where a number << 0.05 infers a statistically significant separation. 
Observing a statistically significant difference in the global metabolome between 
two or more bacterial samples is typically the first objective of a metabolomics 
investigation. While this difference may infer some biological significance, the ultimate 
goal is to identify the underlying metabolites and associated pathways that are the 
primary contributors to the observed class separation in the PCA and OPLS-DA scores 
plot. One approach is to generate an S-plot (Figure 3.1) from the resulting OPLS-DA 
analysis. The S-plot identifies the key bins or 
1
H chemical shifts that are correlated or 
anti-correlated with the separation between the two classes in an OPLS-DA scores plot. 
The 
1
H chemical shifts can then be compared against a number of online NMR 
metabolomics databases to assign the metabolites.
99-103
 Unfortunately, an unambiguous 
assignment is rarely possible because of the low chemical shift dispersion and the large 
number of potential metabolites. Instead, 2D NMR experiments combined with the 
biological knowledge of the system under investigation are required to improve the 
accuracy of metabolite identification.      
 
3.5.3 Metabolite Identification 
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3.5.3.1 Automated peak picking of 2D NMR data  
2D 
1
H, 
13
C HSQC and 
1
H, 
1
H TOCSY spectra are commonly used for metabolite 
identification because of the increase in chemical shift resolution achieved by spreading 
the information out into two-dimensions. Also, the correlation between 
1
H chemical 
shifts for each J-coupled H pair; and the correlation between 
1
H and 
13
C chemical shifts 
for each C-H pair significantly reduces the assignment ambiguity. This occurs because 
now both chemical shifts have to match a single metabolite in the database to make an 
assignment. Despite the advantages, peak picking and organizing a table of intensities 
from a 2D NMR experiment is a time consuming process, especially when multiple 
spectra are involved. Numerous software packages are available to automate the peak 
picking of 2D NMR spectra, however; it is extremely difficult, if not impossible, to align 
and match multiple sets of spectra with different peak patterns due to unique 
metabolomes.  
For example, three different sets of cell cultures (different cell types, treatments or 
environmental conditions, etc.) will each exhibit a distinct set of peaks in the NMR 
spectrum due to the presence of unique metabolites. These unique peaks will be mixed 
with other peaks common to all three groups, but the relative peak intensities are likely to 
vary due to different metabolite concentrations. Thus, if the control group is designated 
as the reference spectrum for automated peak picking, a peak list will be generated that 
only contains peaks observed in the control spectrum that are above the designated noise 
threshold. Correspondingly, peaks unique to the other two groups will be missed when 
this peak list is used to peak pick their spectrum. In addition, weak peaks may also be 
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missed due to different noise levels between the spectra and a corresponding difference in 
the threshold setting for peak picking. Instead, a composite reference spectrum for 
automated peak picking needs to be generated that captures all the peaks present in the 
three separate groups. We accomplish this task by using the addNMR function in the 
NMRpipe software package.
104
 As the name implies, addNMR mathematically sums all 
spectra together from the three groups to make a single spectrum. This resulting “master 
spectrum” contains all the peaks observed throughout the set of 2D experiments and is 
used to generate a peak list for automated peak picking of each individual spectrum. 
Critically, the 2D NMR spectra need to be collected and processed using identical 
experimental parameters (spectral width, data points, zero-filling, etc.) and needs to be 
aligned to an internal reference (TMSP-d4). In our experience, all the peaks from the 
complete set of NMR spectra are routinely matched to the reference list by using a 
chemical shift error-tolerance of 0.04 ppm and 0.25 ppm in the 
1
H and 
13
C dimensions, 
respectively. This approach has greatly simplified and increased the efficiency of a 
previously laborious procedure. The addNMR command can also be used to generate a 
difference spectrum that clearly highlights the major spectral changes between two 
classes (Figure 3.8).  
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Figure 3.8 (a-c) Illustration of the procedure to generate a “master spectrum” and 
facilitate automated peak picking by creating a complete peak list. (a-b) Representative 
2D 
1
H, 
13
C HSQC spectra obtained from two distinct bacterial cultures, where some 
major spectral differences are highlighted. c) The two 2D 
1
H, 
13
C HSQC spectra from (a-
b) were added to yield a master spectrum that contains all the observed NMR peaks. (d-f) 
Illustration of the procedure to generate a “difference spectrum” to facilitate metabolite 
identification by creating a signed (+, -, null) peak list. (d-e) Representative 2D 
1
H, 
13
C 
HSQC spectra obtained from two distinct bacterial cultures. f) The two 2D 
1
H, 
13
C HSQC 
spectra from (d-e) were subtracted to yield a difference spectrum that identifies the NMR 
peaks, and correspondingly metabolites, that differ between the two bacterial cell 
cultures. Positive peaks, increased metabolite concentration, are colored green and 
negative peaks, decreased metabolite concentration, are colored red. 
 
3.5.3.2 Assignment of an NMR peak to a metabolite  
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Metabolite identification is an extremely important component of the 
metabolomics process because it enables the determination of the key metabolites 
perturbed by the treatment or the metabolites primarily contributing to class distinction. 
This includes the discovery of important biomarkers associated with drug efficacy or 
drug resistance. Also, metabolite identification is important to the drug discovery process 
by either identifying metabolic pathways affected by a drug to evaluate efficacy or 
potential toxicity; or by identifying potentially new therapeutic targets. Nevertheless, 
accurate metabolite identification is very difficult and labor-intensive. The success of 
metabolite spectral assignment relies largely on the completeness of metabolomics 
databases. We routinely use a combination of the following databases: Human 
Metabolome Database,
99
 Madison Metabolomics Consortium Database,
100
 Platform for 
RIKEN Metabolomics,
101
 BioMagResBank,
102
 and Metabominer,
103
 which provide both 
redundant and complementary NMR spectral data. Importantly, the reference NMR 
spectra in the various databases were obtained under different buffer condition and use 
different internal standards. This results in a range of potential chemical shifts for a given 
metabolite. Thus, the database with sample conditions that closely match our 
experimental conditions are used for chemical shift matching. The overall goal is to 
identify a complete set of metabolites as quickly and accurately as possible without any 
bias, by matching the experimental chemical shifts from the 2D NMR spectra with the 
values in the database.  
For a 2D 
1
H, 
13
C HSQC experiment, it is important to realize that metabolites may 
be heterogeneously labeled by the carbon-13 source present in the growth media. 
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Correspondingly, all the peaks for a specific metabolite may not be detectable in the 2D 
1
H, 
13
C HSQC experiment. Also, a reference spectrum for the metabolite may not be 
present in any of the available databases. The assignment of a particular peak might still 
be ambiguous because multiple metabolites may contain the same chemical shift or 
contain an identical substructure (i.e., ATP, ADP, AMP or NAD, NADPH). Therefore, a 
few automated filters are applied to overcome some of these ambiguities during the peak 
assignment process.  
The first filter is to verify that the bacteria can actually produce the proposed 
metabolite. This is routinely accomplished by searching the Biocyc
105
 and KEGG
106
 
database for metabolites known to exist in the bacteria under investigation. The second 
filter is based on a differential peak list. All the NMR peaks potentially assigned to a 
specific metabolite should have the same trend relative to the control. Obviously, the 
metabolite can only have one concentration and all the NMR peaks need to be consistent 
with this single concentration. Correspondingly, all the peaks have to be increased, 
decreased or the same relative to the same peaks in the control spectrum. This is easily 
and quickly visualized by subtracting the two sets of spectra and generating a signed (+, -
, null) peak list. Peaks assigned to the same metabolite have to have the same sign. The 
third filter is based on a biological relationship with other metabolites. Simply, the 
likelihood of a correct assignment increases if other metabolites in a specific metabolic 
pathway have also been assigned. It is more likely to observe multiple metabolites from 
the same pathway than various metabolites from unrelated pathways. Similarly, if there is 
a direct metabolic path between two or more metabolites, then their assignments are more 
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likely to be correct. The final filter is the application of our biological knowledge of the 
bacterial system under investigation. The pathways or metabolites that are expected to be 
perturbed by the treatment would be given precedent in the assignment process. As a 
simple example, a comparison between wild-type and mutant bacterial strains where 
aconitase has been inactivated would reasonably be expected to lead to changes in 
metabolites associate with the TCA cycle. Likewise, a comparison between untreated and 
drug-treated cells would be expected to lead to changes in metabolic pathways inhibited 
by the drug.  
 
3.5.3.3 Statistical analysis of the 2D 
1
H, 
13
C HSQC data. 
After assigning the 2D 
1
H, 
13
C HSQC spectra to a set of metabolites, the next goal 
is to determine metabolite concentration differences between the various bacterial culture 
conditions under investigation. Unfortunately, peak intensities in a standard 2D 
1
H, 
13
C 
HSQC experiment are dependent on metabolite concentrations and J-couplings, 
dynamics, and relaxation properties.
88
 Therefore, only a relative percent change in a 
metabolite concentration can be determined.
5
 Alternatively, an absolute concentration can 
be determined using HSQC0, which requires a set of three HSQC experiments per 
sample. We routinely employ both approaches.
88
 
A relative difference in peak intensities is determined by using a triplicate set of a 
conventional 2D 
1
H, 
13
C HSQC experiment for each bacterial culture condition. Prior to 
calculating a relative percent change in peak intensities, a detailed normalization process 
is required, which was previously described in detail.
5
 First, the peak intensities within 
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each spectrum are normalized by dividing each peak by the internal standard, the 
intensity of the TMSP-d4 peak. Each peak pertaining to a specific chemical shift across 
each triplicate data set is then normalized by the most intense peak in the set of three 
peaks. Specifically, the maximal intensity for each peak across all data sets would be set 
to 100 and all other intensities are scaled relative to this peak intensity. Then all the 
normalized intensity for a given metabolite for each triplicate set is averaged together, 
and a relative percent error can be calculated between different cultures. A Student’s t-
test or ANOVA is then used to determine if the relative change in peak intensities is 
statistically significant at the 95% confidence limit. Calculating a relative difference in 
metabolite concentrations can be beneficial to understanding broader changes to the 
system, especially when a cluster of metabolites in a specific pathway exhibit a similar 
trend in concentration changes inferring an important role for the metabolic pathway. 
Nevertheless, this approach is rather cumbersome and does not allow for a direct 
comparison between different metabolites.  
Alternatively, we routinely use the HSQC0 experiment to determine absolute 
metabolite concentrations. The overall protocol for the extrapolation of peak intensities to 
time-zero and the determination of the associated concentration has been previously 
described in detail.
88,89
 A distinct advantage of this method is that a single calibration 
curve can be made using multiple compounds with known concentrations to correlate the 
time-zero peak intensity with a concentration. Figure 3.9 illustrates such a calibration 
curve using 5 different mixtures, each consisting of 9 different 
13
C-labeled metabolites 
ranging in concentrations from 5 to 300 µM. Also, the concentration for each metabolite 
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was randomized in each mixture. For example the concentration of 
13
C-D-alanine in the 5 
mixtures is 300, 10, 25, 5, and 100 µM, respectively. The data was fitted using a 
weighted linear least squares calculation. Notably, the best-fit line (R
2
 0.997) has a y-
intercept close to zero as expected for a concentration of zero. Also, the correlation 
between peak volume and concentration is independent of the metabolite. Importantly, 
the accurate application of the calibration curve requires collecting and processing 
HSQC0 spectra identical to the parameters used to obtain the original calibration curve. 
Critically, the receiver gain must be the same for all samples, because any change in the 
receiver gain influences the slope of the calibration curve. Also, the addition of 500 µM 
TMSP-d4 as an internal standard is crucial, because both the calibration samples and 
experimental samples must both be similarly normalized to the TMSP-d4 peak. As an 
example, if the TMSP-d4 peak volumes for the calibration mixtures are 1000, 500, and 
250 for each HSQCi (i = 1,2,3) spectrum, respectively, then the experimental results for 
all in vivo metabolite extracts must be normalized so that the internal standard (TMSP-d4) 
peak volumes are also 1000, 500, and 250. The concentrations are measured in triplicate, 
where a Student’s t-test or ANOVA is used to determine if the concentration changes are 
statistically significant at the 95% confidence limit. 
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Figure 3.9 A strong correlation between NMR peak volumes and metabolite 
concentrations (R
2
 0.997) is demonstrated by linear regression plot generated from 
HSQC0 data. HSQC0 NMR spectra were collected for five different metabolite mixtures 
containing nine 
13
C-labeled compounds with concentrations ranging from 5 µM to 300 
µM.  The relationship between peak volume and metabolite concentration is independent 
of the metabolite. 
 
3.5.4 Metabolomics Network Map 
Metabolites are highly interconnected through numerous metabolic pathways that 
form an extremely complex network.
107
 Correspondingly, it is not uncommon to observe 
correlated changes between distantly connected metabolites. In effect, metabolomics 
depends on these complex interactions to understand the phenotype of a bacterial cell. 
Thus, a metabolomics network map provides an efficient approach to visualize and 
summarize the overall changes to the metabolome, to validate metabolite assignments 
based on clear connections to other metabolites, and the identification of key metabolic 
pathways.  
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 We have routinely used Cytoscape to easily and quickly generate metabolomics 
network maps. Cytoscape is a user-friendly software package with plug-ins related to 
metabolomics.
108-111
 Cytoscape simply requires a list of the metabolites and their 
associated concentration changes as input. The connections between nodes (metabolites) 
in the map are based on metabolic pathways from the MetaCyc database.
112
 An example 
of a typical Cytoscape map summarizing the observed changes in the S. epidermidis 
metabolome caused by environmental stimuli associated with biofilm formation is shown 
in Figure 3.1. The metabolomics network map can be easily modified to highlight 
specific features of the metabolome. Edges can be broadened to highlight specific 
pathways; and the color and size of nodes can be adjusted to reflect the direction and 
magnitude of the concentration changes, respectively.
113
 Cytoscape also provides a range 
of map design choices. Unfortunately, the resulting network maps (Figure 3.1) do not 
resemble standard metabolic pathways. Thus, Cytoscape maps are simply used as a 
template to manually draw more traditional looking metabolic pathways. Since 
Cytoscape maps are so easily generated, we also use the software to assist in metabolite 
assignments. Potential lists of metabolite assignments are input into Cytoscape to identify 
metabolites that are isolated nodes excluded from the main network map. These 
metabolites are likely misassigned and are reevaluated. In addition to Cytoscape, we also 
use the R statistics package to create heat maps from absolute metabolite concentrations 
or percent relative concentration changes. The structure is made of nodes and edges. 
Metabolites are small molecules that are involved in the metabolism which is the overall 
chemical reactions in the biological system. Therefore, in terms of choosing metabolites, 
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the intermediates from glycolysis pathways, TCA cycle and pentose phosphate pathways 
were taken as the major contributions since they are essential to synthesis all the 
macromolecules for S. aureus, although for pentose phosphate pathway, only a portion of 
it was selected because there are many metabolites that are not detectable by our 
technique so far. Other metabolites, especially the common amino acids that can be 
derived from these three pathways directly were also included. The goal is to maximize 
the efficiency of the usage of the network so that it should represent the status of the cells 
and provide systematic information on the perturbed cellular metabolome. For each 
project, it can be modified as needed. The connections between different nodes are based 
on S. aureus pathway stored in the MetaCyc database. The direct and indirect reactions 
were all represented by edges without discrimination because multiple pathways can 
happen. Therefore only the shortest one was shown. If a metabolite increases its 
concentration, red color is assigned. If a metabolite decreases its color, green color is 
assigned. If there is no change between the comparison pair, then a grey color is assigned. 
The size of the node representing the metabolite is increased or decreased in proportion to 
the relative change. For example, if metabolite A is 2 times increased in its concentration, 
the node is 2 times larger than the ones with no change and vice versa. The exact number 
of times is normalized from 1 to 2 in order to keep the basic shape of the map, without 
being perturbed by some huge nodes that may be made. A student’s t-test is used to 
determine that if a concentration is significantly changed or not, only p value smaller than 
0.05 are taken to be changed in concentration. Under other conditions, if a change has a p 
value larger than 0.05 but smaller than 0.1, a pink or light green was coded. The layout 
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was designed based on traditional flowchart. The glycolysis and TCA cycle are 
highlighted by broadening the width of the edges.  
 
3.6 Conclusion 
 NMR metabolomics is an invaluable tool for systems biology and its application 
is rapidly expanding. Global changes in the metabolic state of bacterial cells occur as a 
result of environmental stressors, genetic modifications, drug treatments, or numerous 
other factors. A detailed analysis of the differences in the NMR spectra is commonly 
used to identify the key metabolite changes that differentiate between these bacterial 
classes (i.e., controls versus treated). In addition, metabolite identification by NMR 
allows for the subsequent identification of the important metabolic pathways that are 
affected by the treatment, providing further insight into the underlying biological process. 
The appeal of NMR metabolomics is its simplicity, but unfortunately it is also easy to 
obtain unreliable results. The observed changes in the metabolome should be biologically 
relevant, but because the metabolome is so sensitive to any environmental change; it is 
also easily perturbed by the experimental protocol. This is clearly an undesirable 
outcome. To address this issue, we described in detail our optimized protocols for the 
NMR analysis of bacterial metabolomes. We also highlighted common problems and 
potential sources of mistakes. We discuss the entire process that includes growing and 
harvesting bacterial cells, extracting the metabolome, NMR data collection, processing 
and analysis, statistical analysis, metabolite and network identification. The protocols 
described have been successfully applied to a number of systems biology projects.   
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CHAPTER 4 
AN INEXPENSIVE HIGH-THROUGHPUT NMR TUBE CLEANING 
APPARATUS 
4.1 Introduction 
High-throughput screening (HTS) is widely used in the biotechnology and 
pharmaceutical industries 
1-3
 with an expanding interest in academia.
4,5
  HTS is an 
efficient approach for the experimental testing of large sample sets for the discovery of 
new drugs. Multiple reviews on HTS automation have discussed robotic systems 
employed to transport samples, add reagents, mix samples or detect signals.
6-8
 These 
steps are clearly essential components to a successful screen and are understandably a 
focal-point of any assay design. Conversely, there is a complete lack of reports discussing 
the automation of recycling devices. For the majority of high-throughput screens, a 
reliance on disposable labware (assay plates, pipette tips, etc) simplifies the execution of 
the assay while being reasonably cost-effective. 
Fragment-based NMR screens complement traditional HTS and have evolved to 
become an important and common component of drug discovery.
9,10
 Fragment-based 
screens utilize a chemical library of low molecule-weight ligands (≤ 200 – 300 Da)11 that 
correspond to fragments of known drugs or have drug-like characteristics.
12
 NMR is used 
to identify binders, to identify the ligand binding site, and to assist in “growing” the 
fragments to improve binding affinity. There are several advantages to fragment-based 
NMR screens over HTS that include maximizing ligand efficiency, improving coverage 
of chemical space, higher hit rates and higher quality of leads, direct observation of 
biologically relevant interactions, and a universal assay design. Conversely, NMR ligand 
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affinity screens are typically limited to assaying only hundreds to thousands of 
compounds. Another practical disadvantage is the hundreds of NMR tubes that quickly 
accumulate and require cleaning.  
High quality NMR tubes are generally used for ligand affinity screens and 
because of cost ($2 to $8 per tube) are typically not limited to a single use. A standard 
NMR tube cleaner (Sigma-Aldrich, St. Louis, MO) can handle from one to five tubes. 
The NMR tube sits inverted on a glass adapter for washing, which is very fragile since it 
has a small diameter (<5 mm) and long length (8 in.). Thus, the routine cleaning of 
thousands of NMR tubes rapidly results in broken NMR tube cleaners at a cost of $90 to 
$420 per cleaner. Besides manually cleaning, there are commercial devices available 
such as the Bruker BioSpin Autoclean system (Billerica, MA) that is capable of cleaning 
60 tubes per hour, but generates a significant amount of waste and has a cost of $15K. 
Alternatively, NMR tubes can be completely discarded from the NMR screen by using a 
flow-probe.
13
 The NMR probe contains a fixed cell with active volumes ranging from 30 
liquid handling system. After data acquisition, the sample is either transferred to waste or 
collected. Challenges with flow probes may include cross-contamination between 
samples, clogging of the system by solid particulates that may also result in lost samples, 
and problems with properly positioning the sample in the probe. There is also the initial 
cost of $75K for a flow-probe system. 
A cost effective and efficient means of cleaning thousands of NMR tubes is an 
annoying problem and a routine challenge currently faced by NMR screening groups. To 
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solve this problem, an inexpensive (~$300) and highly effective apparatus for cleaning 
NMR tubes has been designed and successfully employed in our laboratory. It is 
extremely efficient compared to existing tube cleaners since 180 tubes are cleaned in an 
hour. Obviously, the use of large amounts of solvent increases the cost of cleaning and 
diminishes the value of recycling NMR tubes. There are also safety and health concerns. 
As a result, the design of the NMR tube cleaner apparatus and the development of the 
protocol focused on minimizing solvent usage. Only 200 to 300 mL of solvent is used to 
clean the 180 NMR tubes. The amount of solvent waste will increase proportionally if 
multiple solvents are used. Similarly, an apparatus that routinely cracks, chips or 
scratches the NMR tubes defeats the cost-effectiveness of recycling. More concerning is 
the possibility of unnoticed tube damage that may result in a broken tube in an NMR 
probe. Unlike the manual cleaning of a large batch of NMR tubes where damage is 
common, we have not observed any damage to the hundreds of NMR tubes cleaned using 
our apparatus. This is primarily a result of minimal handling of the NMR tubes during 
cleaning and the fact that the tubes are simply placed inverted into a glass vessel.  
 
4.2 Methods and Materials 
Diagrams and pictures of our NMR tube cleaning apparatus are shown in Figure 
4.1. The apparatus can be easily constructed in any laboratory with access to a glass 
blower. The cleaner consists of three major components: (i) a specially designed glass 
valve assembly (switch), (ii) a 750 mL Labconco® vacuum bottle, cap and adaptor, (iii) 
and a standard pump system (not shown). The NMR tubes are simply placed inverted into 
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the 750 mL Labconco® vacuum bottle. The cap is placed onto the vacuum bottle, which 
is then partially filled with solvent. Our glass switch is attached to the cap and the 
apparatus is connected to a vacuum pump. A flexibly attached glass tube extends from 
the glass switch to the base of the vacuum bottle. A pressure differential is used to push 
solvent into and out of the NMR tubes or to completely remove the solvent from the 
apparatus. This occurs by manipulating the two Teflon valves on our glass switch while 
the apparatus is attached to a vacuum pump. Basically, with the left valve closed, slowly 
and briefly opening the T-valve to the vacuum position evacuates the air from the 
Labconco® vacuum bottle and places it under a slight vacuum without removing the 
solvent. Turning the T-valve to the vent position opens the vacuum bottle to atmosphere 
breaking the vacuum and forcing solvent into the NMR tubes. Switching the T-valve 
back to the vacuum position places the NMR tubes back under vacuum and removes the 
solvent from the NMR tubes. Repeating the process two or three times effectively washes 
the NMR tubes with solvent. Switching the T-valve to the vent position and opening the 
left valve rapidly removes the solvent from the NMR tube cleaner into the filter flask. 
The process can be repeated with other solvents. 
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Figure 4.1 Schematic drawing a) and picture b) of our NMR tube cleaning apparatus. 
Schematic drawing c) and picture d) of an expanded view of the glass switch. Important 
features and dimensions are labeled. 
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The general protocol for cleaning NMR tubes (Figure 4.2) corresponds to the 
following steps: (1) empty the NMR tubes that need to be cleaned and remove any labels, 
(2) load tubes into the NMR tube cleaner along with solvent, (3) install the valve 
assembly and hook up the filter flask and vacuum system, (4) rinse multiple times with 
solvents of choice, (5) remove tubes and dry in an oven at 100 ºC for an hour. For heavily 
soiled NMR tubes that contain solid films or stains, a simple solvent wash may not be 
sufficient. Instead, the NMR tubes are typically soaked overnight in a concentrated 
(<70%) nitric acid bath. The tubes are then quickly rinsed with tap water before placing 
in the NMR tube washer. The wash solvent is a saturated sodium bicarbonate solution in 
deionized water. Various solvents can be used in the NMR tube cleaner depending on 
need and the chemical composition of the original NMR samples.  
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Figure 4.2 Flow diagram of the NMR tube cleaning process. 
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4.3 Conclusion 
For a typical fragment-based NMR screen, deionized water is the first wash 
solvent since it will effectively remove a majority of the aqueous-based samples. A 
second wash using a polar organic solvent such as methanol, tetrahydrofuran or 
dichloromethane may also be used to remove any compound residue and promote tube 
drying. If necessary, a third and final wash with a non-polar solvent such as chloroform 
could be employed. To ensure the effectiveness of our NMR tube cleaner, there are a few 
general rules that need to be followed.  It is important to avoid having the wash solvent 
sit in the NMR tubes for an extended period of time. The rapid insertion and removal of 
the wash solvent provides efficient agitation that assists in the cleaning process. 
Conversely, prolonged exposure to a wash solvent may result in compound precipitation 
and the formation of a difficult to remove film. For a similar reason, it is highly 
undesirable to allow an NMR sample to evaporate to dryness. Effectively, NMR tubes 
should be cleaned immediately after use to obtain optimal performance from our NMR 
tube cleaner. 
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CHAPTER 5 
NMR ANALYSIS OF A STRESS RESPONSE METABOLIC SIGNALING 
NETWORK 
5.1 Introduction 
In eukaryotic organisms, signaling pathways are essential to the life-cycle of cells 
and are ubiquitous processes that regulate a variety of functions in response to both 
extracellular and intracellular environmental changes.
1-4
 These signaling systems are 
spatially and temporarily organized, where the kinetic properties of these cycles depends 
on the cellular distribution of the activator and deactivator proteins. Protein activity is 
usually controlled through a variety of post-translational modifications (phosphorylation, 
acetylation, ubiquitylation, etc.), through protein complex formation, through 
transcription regulation, or any combination of these factors. A prototypical signaling 
cascade includes a membrane-bound receptor that binds a signal molecule which in turn 
activates a kinase proximal to the membrane. This activated kinase phosphorylates a 
second kinase, where the cascade continues and perpetuates the signal away from the 
membrane to the final target. Typically, the impact of a signaling network is the up- and 
down-regulation of a set of genes or proteins associated with a specific response 
(apoptosis, metabolic process, proliferation, stress responses, etc.). Correspondingly, the 
cell commits a significant amount of energy and resources to undergo such a phenotype 
change.  
In prokaryotes, signal transduction frequently involves two-component regulatory 
systems that consist of a membrane-bound sensor histidine protein kinase and a response 
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regulator.
5
 These two-component signal transduction systems are activated when an 
external signaling molecule, peptide, metal ion, etc., is bound by the sensor kinase, which 
undergoes autophosphorylation at a conserved histidine. Transfer of the phosphoryl 
group to the receiver domain of a response regulator in the cytoplasm of a bacterium 
completes the activation and the response regulator is then competent to activate 
transcription of a limited set of genes. In staphylococci, there are numerous two-
component regulatory systems,
6
 with the best studied being the agr quorum sensing 
system.
7
 In addition to two-component systems, bacteria use sigma factors as a means to 
detect environmental conditions that induce heat stress, envelope stress, nitrogen stress, 
etc.
8
  In staphylococci, σB is activated during stress conditions, growth phase transitions, 
and morphological changes.
9,10
 Most recently, the hypothesis that central metabolism can 
act as a signal transduction pathway to transduce external environmental signals (e.g., 
iron-limitation) into intracellular metabolic signals by altering the activity of the enzymes 
of central metabolism has been proposed.
11
 
The tricarboxylic acid (TCA) cycle is part of central metabolism and provides 
reducing potential, energy and biosynthetic intermediates necessary for other 
macromolecular synthesis.
12
 Several studies have also shown that the TCA cycle is 
involved in regulating or affecting virulence or virulent determinant biosynthesis.
13-15
 
One specific example is the production of the exopolysaccharide, polysaccharide 
intercellular adhesion (PIA),
16
 which is associated with virulence and biofilm 
formation.
17-20
 PIA synthesis is regulated by nutrient availability and external stress 
conditions.
21,22
 Importantly, TCA cycle activity has also been shown to be affected by 
190 
 
 
 
changes in environmental stress factors.
16,22,23
 A number of environmental stress factors 
have also been shown to influence biofilm formation: ethanol,
24
 oleic acid,
25
 glucose,
26
 
UDP-N-acetylglucosamine,
27
 sub-inhibitory concentrations of some antibiotics,
28
 
anaerobic conditions,
29
 Fe limitation,
30-32
 high osmolarity,
33
 and high temperature.
33
 The 
diversity of these external stimuli suggests a versatile regulation system. Recently, we 
used NMR metabolomics to demonstrate that Fe limitation and ethanol decrease TCA 
activity.
23
 These stressors cause a common metabolic change that can be sensed by 
metabolite responsive-regulators (e.g., catabolite control protein A; CcpA) that affect PIA 
production. We proposed that the TCA cycle plays a central role in a metabolic signaling 
network that senses disparate environmental stress conditions and regulates PIA 
biosynthesis, virulence determinants and biofilm formation (Figure 5.1). Herein, we 
report a further NMR analysis of the impact on the metabolome of S. epidermidis 
resulting from a diverse range of environmental stress factors associated with biofilm 
formation that include 5% NaCl,
33
 2% glucose,
26
 0.06 µg/mL tetracycline,
28
 and  400 nM 
autoinducer-2 (AI-2, furanosyl borate diester),
34
 in addition to our prior study
23
 with 4% 
ethanol,
24
 and Fe limitation.
30-32
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Figure 5.1 An illustration of the interrelationship of metabolic pathways associated with 
the TCA cycle and biofilm formation.  
 
Our differential NMR metabolomics methodology has been applied to the study 
of in vivo drug activity in Aspergillus nidulans
35
 and Mycobacterium smegmatis
36
 and is 
ideally suited to a systems biology analysis of the impact of environmental stress factors 
on the S. epidermidis metabolome and the corresponding role of the TCA cycle.
23
 In the 
latter study, NMR was used to detect metabolic perturbations by following changes to S. 
epidermidis (strain 1457) cultured under environmental stress conditions that induce 
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biofilm formation. These results were then compared to the metabolome of a S. 
epidermidis mutant (aconitase mutant strain SE1457-acnA::tetM) with an inactivated 
TCA cycle. If S. epidermidis senses environmental stress conditions by affecting TCA 
cycle activity as previously observed, then the impact on the metabolome caused by the 
aconitase mutant and the disparate external signals were expected to be equivalent. The 
overlapping clusters in principal component analysis (PCA) and orthogonal partial least 
squares discriminant analysis (OPLS-DA) two dimensional (2D) scores plot and the 
branch similarity on a metabolic tree diagram
37
 indicate that external biofilm signals 
inactivate the TCA cycle. Furthermore, a detailed analysis of the relative concentration 
changes of 55 different metabolites from 2D 
1
H, 
1
H TOCSY and 2D 
1
H, 
13
C HSQC 
spectra implies the TCA cycle plays a central role in a metabolic signaling 
network.
35,36,38,39
 A metabolic network created with Cytoscape
40
 illustrates this metabolic 
signaling network and the interrelationship of the TCA cycle activity with alanine 
metabolism, amino sugar metabolism, glycolysis/gluconeogenesis and the urea cycle.  
 
5.2 Methods and Materials 
5.2.1 Bacterial growth and NMR sample preparation  
Staphylococcus epidermidis wild-type strain 1457 and the isogenic aconitase 
mutant strain 1457-acnA::tetM were grown in tryptic soy broth (TSB; BD Biosciences) 
without dextrose and supplemented with 0.25% glucose (Sigma Chemical) or 0.25% 
13
C6-glucose (Cambridge Isotope Laboratories).  
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All bacterial cultures were inoculated to an optical density at 600 nm (O.D.600) of 
0.06 and were grown for 2 hours or 6 hours at 37
o
C with 225 rpm aeration in TSB or TSB 
supplemented with a stressor know to induce biofilm formation. Either 10 or 12 replicate 
bacterial cultures were grown for each bacterial strain or environmental condition for the 
one-dimensional (1D) 
1
H NMR experiments. 3 replicate bacterial cultures were grown for 
each bacterial strain or environmental condition for both the two-dimensional (2D) 
1
H, 
13
C HSQC and the 2D 
1
H, 
1
H TOCSY experiments.  
In general, four different bacterial cultures were harvested per experiment: (1) 
wild-type S. epidermidis in TSB media, (2) wild-type S. epidermidis in TSB media with 
an environmental stress condition, (3) aconitase mutant of S. epidermidis in TSB, and (4) 
aconitase mutant of S. epidermidis in TSB with an environmental stress condition. The 
environmental stress conditions used in this study were 5% NaCl,
33
 2% glucose,
26
 0.06 
µg/mL tetracycline,
28
 400 nM autoinducer-2 (AI-2, furanosyl borate diester)
34
 in TSB 
media. To facilitate integrating this current work with our recent study,
23
 control cultures 
containing 4% ethanol
24
 in TSB or TSB medium depleted of iron (DTSB, defferated 
TSB)
30-32
 were included for comparison. DTSB was prepared as described.
23
 AI-2, 
furanosyl borate diester, was synthesized as previously described.
41,42
     
For the 1D 
1
H NMR experiments, 2.74 O.D.600 units were harvested for analysis 
and for both the 2D 
1
H, 
13
C HSQC and 2D 
1
H, 
1
H TOCSY experiments 5.48 O.D.600 units 
were harvested. Following harvest, the culture medium was removed and the bacteria 
were suspended in 1 mL portions of 50 mM phosphate buffer (PBS) in 99.8% D2O 
(Isotec) at pH 7.2 (uncorrected). The bacteria were lysed using a FAST-Prep instrument 
194 
 
 
 
(MP Biomedicals) for 40 seconds, centrifuged for 5 min to remove the bacterial debris 
and glass beads, and frozen in liquid nitrogen.  
 
5.2.2 NMR Data Collection 
  The NMR spectra were collected on a Bruker 500 MHz Avance spectrometer 
equipped with a triple-resonance, Z-axis gradient cryoprobe. A BACS-120 sample 
changer with Bruker Icon software was used to automate the NMR data collection. 1D 
1
H 
NMR spectra were collected using excitation sculpting
43
 to efficiently remove the solvent 
and maintain a flat baseline, eliminating any need for baseline collection that may induce 
artifacts in the PCA or OPLS-DA 2D or three-dimensional (3D) scores plot. 1D 
1
H NMR 
spectra were collected at 298K with a spectrum width of 5482.5 Hz and 32K data points. 
A total of 16 dummy scans and 64 scans were used to obtain each spectrum.  
2D 
1
H, 
13
C HSQC spectra were collected with solvent pre-saturation and 
relaxation delay of 0.5 seconds.
44,45
 A total of 1024 data points with a spectrum width of 
4734.85 Hz, and 64 data points with a spectrum width of 13834.26 Hz were collected in 
the 
1
H and 
13
C dimensions, respectively. A total of 8 dummy scans and 128 scans were 
used to obtain each of the 2D 
1
H, 
13
C HSQC NMR spectra. 2D 
1
H, 
1
H TOCSY spectra 
were collected with WATERGATE solvent pre-saturation, and a relaxation delay of 2 
seconds.
46, 47
 A total of 1024 data points with a spectrum width of 5000 Hz, and 256 data 
points with a spectrum width of 5001.324 Hz were collected in the direct and indirect 
1
H 
dimensions, respectively. A total of 16 dummy scans and 8 acquisition scans were used to 
obtain each of the 2D 
1
H, 
1
H TOCSY NMR spectra. 
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5.2.3 NMR Data Analysis  
1D 
1
H NMR spectra were processed in the ACD/1D NMR manager version 12.0 
(Advanced Chemistry Development, Inc). The residual H2O NMR resonance was 
removed. Intelligent bucketing was used to integrate each region with a bin size of 0.025 
ppm. Each NMR spectrum was center averaged to minimize any experimental variations 
between bacterial cultures as follows: 
  
    ̅
 
       (1) 
where  ̅ is the average signal intensity, σ is the standard deviation in the signal intensity, 
and Xi is the signal intensity within a bin. Noise regions of the spectra were omitted from 
the PCA analysis by setting the corresponding bins to zero.
48
 The table of integrals was 
imported into SIMCA11.0+ (UMETRICS) for PCA and OPLS-DA analysis using the 
program’s standard parameters. The identification of the control group and treated group 
or groups for the OPLS-DA analysis was based on the PCA clustering pattern. 
2D NMR Spectra were analyzed using NMRView
49
 and Sparky (T. D. Goddard 
and D. G. Kneller, SPARKY 3, University of California, San Francisco) to identify 
chemical shifts and assign peak intensities. Peak intensities were normalized for each 2D 
NMR spectrum by dividing by the average peak intensity for a given spectrum. Each 
peak for each metabolite from each specific triplicate data set was averaged and the 
intensity for each peak was further normalized across all data sets (i.e., wild-type, 
aconitase mutant, and each bacterial growth condition). Specifically, the maximal 
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intensity for each peak across all data sets was set to 100. The peak intensities in the 
remaining data sets were all scaled relative to this peak intensity. Then, a normalized 
intensity for the metabolite within each data set was calculated by averaging the 
normalized intensity for each of the metabolite’s assigned peaks. In this manner, the 
relative percent difference in metabolite intensity (concentration) can be reported 
between different bacterial strains or bacterial growth conditions. As an illustrative 
example, consider a metabolite with thee assigned peaks (A, B, C) in a 2D 
1
H, 
13
C HSQC 
spectrum. The 2D 
1
H, 
13
C HSQC spectrum is collected in triplicate under three different 
bacterial growth conditions for a total of 9 spectra and 27 peak intensities, 3 peaks in 
each spectrum for the metabolite. Peak A has average intensities of 0.05, 0.10, and 0.20 in 
the three different bacterial growth conditions, respectively. The values would be 
normalized to 25, 50, and 100. Similarly, peaks B and C are normalized against their 
maximal peak intensities for values of 20, 60, 100 and 30, 65, 100, respectively. Thus, the 
average relative concentrations of the metabolite under the three bacterial growth 
conditions would be the average of the three normalized peaks, yielding values of 25, 
58.3 and 100, respectively. The bacterial growth condition with the highest relative 
metabolite concentration (100) would have a corresponding concentration increase of 75 
and 41.7 relative to the two other bacterial growth conditions.  
The observed NMR peaks in the 2D 
1
H, 
13
C HSQC and 2D 
1
H, 
1
H TOCSY 
spectra were assigned to specific metabolites using 
1
H and 
13
C chemical shift tolerances 
of 0.05 ppm and 0.50 ppm, respectively. Metabominer,
50
 Madison Metabolomics 
Consortium Database (MMCD)
51
, the BioMagResBank,
52
 and Human Metabolome 
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Database
53
 were used to identify metabolites. The presence of metabolites and metabolic 
pathways were verified with the KEGG
54
 and Metacyc
55
 databases. A metabolic network 
map was generated using Cytoscape using a force directed layout.
40
 Metabolites 
identified with a percent concentration difference of ≥ ±10% relative to wild-type S. 
epidermidis were manually color-coded to indicate either an up- or down-regulated 
concentration change. 
 
5.3 Results and Discussion 
5.3.1 NMR metabolomics and principal component analysis  
The elimination of experimental factors that may inadvertently influence PCA or 
OPLS-DA metabolomic data interpretation is essential. The observed variability in the 
PCA or OPLS-DA data should result from differences in the biological samples as 
opposed to changes in sample preparation, sample handling, data acquisitions, data 
processing or any number of experimental parameters (temperature, pH, time, 
concentration, etc.). In order to obtain accurate and reproducible metabolomic data, the 
following general protocols were employed: (i) bacterial cultures of wild-type S. 
epidermidis were used as a reference metabolome and were prepared with all sets of 
bacterial cultures, (ii) equivalent bacterial numbers were used, so metabolite 
concentrations were independent of any bacterial growth variability, (iii) all NMR spectra 
were normalized using center averaging,
56
 so variability in sample concentration was 
minimized, (iv) noise regions
48
 and solvents were removed from NMR spectra prior to 
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PCA or OPLS-DA, and (v) minimal processing (no baseline correction or apodization 
functions) of the NMR spectra.  
 
5.3.2 Harvesting of S. epidermidis cultures    
Bacteria grown in vitro undergo four different growth phases: (i) lag, (ii), 
exponential, (iii) stationary, and (iv) death. Throughout a typical growth cycle, the state 
of the bacteria and the environment are constantly changing. Clearly, there is a 
fundamental difference between the exponential phase, when cell density is relatively 
low, cells are rapidly dividing and the required nutrients are abundant; and the stationary 
phase when these characteristics are effectively reversed. Correspondingly, the 
metabolome is expected to reflect these differences. Therefore, exploring a biological 
system by monitoring changes in the metabolome necessitates the appropriate choice of 
the state of the system. In the case of S. epidermidis biofilm formation and the proposed 
role of the TCA cycle in a metabolic signaling network, the proper choice of the state of 
the system requires endogenous TCA cycle activity.     
The TCA cycle is minimally active during the exponential phase (2 h growth) 
when nutrients (i.e., glucose or other rapidly catabolizable carbohydrates) are sufficient 
for bacteria to grow quickly.
16,57
 Overflow metabolism results in an incomplete oxidation 
of glucose, leading to the accumulation of acetate, lactate, and other incompletely 
oxidized metabolites in the culture medium (Figure 5.1.2a). During the transition to the 
post-exponential growth phase (6 hours), the TCA cycle is de-repressed as the 
carbohydrate(s) are depleted from the culture medium. Concomitantly, the incompletely 
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oxidized metabolites that accumulated in the medium are catabolized through the TCA 
cycle resulting in the depletion of secondary metabolites from the culture medium. 
 
 
Figure 5.2 a) Typical S. epidermidis growth curve superimposed on the cellular 
production of acetic acid. b) 2D PCA scores plot and c) 2D OPLS-DA scores plot 
comparing 2 h growth of wild-type S. epidermidis 1457 (grey ●), 2 h growth of aconitase 
mutant strain 1457-acnA::tetM (grey ▲), 6 h growth of wild-type S. epidermidis 1457 
(black ●), and 6 h growth of aconitase mutant strain 1457-acnA::tetM (black ▲). The 
ellipses correspond to the 95% confidence limits from a normal distribution for each 
cluster. For the OPLS-DA scores plot, the 6 h growth of wild-type S. epidermidis 1457 
(black ●) was designated the control class and the remainder of the cells were designated 
as treated. The OPLS-DA used 1 predictive component and 3 orthogonal components to 
yield a R
2
X of 0.788, R
2
Y of 0.992 and Q
2
 of 0.992. 
 
The growth phase-dependent activity of the TCA cycle in S. epidermidis is also 
apparent from the PCA 2D scores plot generated from 1D 
1
H NMR spectra of S. 
epidermidis cell lysate (Figure 5.2b). The 2D PCA scores plot indicates that PC1 and PC2 
account for 20.6% and 10.7% of the variations in the NMR spectra, respectively. A 3D 
PCA scores plot (Figure 5.3) did not improve cluster separations. Each 1D 
1
H NMR 
spectrum obtained for each cell lysate is represented as a single point in the PCA 2D 
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scores plot, where the 10 replicates form four distinct clusters for the wild-type and 
aconitase mutant strains grown for 2 hours and 6 hours, respectively. As expected and 
consistent with our prior study,
23
 the metabolomes of the S. epidermidis wild-type and 
aconitase mutant cells from the exponential growth phase (2 hours) were more similar to 
each other than the 6 hour cultures. This is apparent from the close clustering in the 2D 
scores plot for the 2 hour wild-type and aconitase mutant. This is consistent with the 
minimal activity of the TCA cycle at 2 hours and the loss of TCA cycle activity for the 
aconitase mutant. Conversely, there is a large separation in the 2D scores plot along the 
PC1 axis between the 6 hour wild-type and aconitase mutant. In fact, the 6 hour aconitase 
mutant cluster is closer to the 2 hour wild-type cluster. Again, this is consistent with an 
increase in TCA activity at 6 hours and the loss of TCA activity in the aconitase mutant. 
Correspondingly, the separation along PC1 reflects TCA cycle activity. Since the TCA 
cycle is minimally active during the exponential phase, the 2 hour wild-type cluster is 
slightly closer to the 6 hour wild-type cluster along PC1, compared to the aconitase 
mutants.      
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Figure 5.3. Three dimensional versions of the 2D PCA scores presented in Figure 5.2b, 
Figure 5.5b, and Figure 5.7b, respectively. a) 3D PCA scores plot comparing S. 
epidermis 1457 strain (circles) and aconitase mutant (triangles) grown for 2 hours (grey) 
and 6 hours (black). The PCA model consists of 3 significant components where the 
contribution (R
2
) for each successive component is 20.6%, 10.7%, and 6.8%. The overall 
cross validation (Q
2
) is 15.9%, 7.58%, and 2.7%, respectively. b) 3D PCA scores plot 
comparing wild-type S. epidermidis 1457 cells grown 6 h in standard TSB media ( ), 
with S. epidermidis 1457 cells grown 6 h in iron-depleted media (DTSB) ( ), with the 
addition of 4% ethanol ( ),with the addition of 2% glucose ( ), with the addition of 0.06 
µg/mL tetracycline ( ), with the addition of 5% NaCl ( ), and 6 h growth of aconitase 
mutant strain 1457-acnA::tetM in standard TSB media ( ). The PCA model consists of 5 
significant components where the contribution (R
2
) for each successive component is 
12.5%, 7.5%, 6.0%, 3.8%, and 3.3%. The overall cross validation (Q
2
) is 15.9%, 7.58%, 
and 2.7%, respectively. c) 3D PCA scores plot comparing wild-type S. epidermidis 1457 
cells grown 6 h in standard TSB media ( ), 6 h growth of aconitase mutant strain 1457-
acnA::tetM in standard TSB media ( ), aconitase mutant strain 1457-acnA::tetM in iron-
depleted media (DTSB) ( ), with the addition of 4% ethanol ( ), with the addition of 
2% glucose ( ), with the addition of 0.06 µg/mL tetracycline ( ), and with the addition 
of 5% NaCl ( ). The PCA model consists of 5 significant components where the 
contribution (R
2
) for each successive component is 12.3%, 8.1%, 6.7%, 3.8%, and 3.4%. 
The overall cross validation (Q
2
) is 10.1%, 6.8%, 6.0, 1.6%, and 2.3%, respectively. 
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Alternatively, the separation along PC2 axis may reflect the variability in 
nutrients available to the cells. Glucose is still present after 2 hours of bacterial growth, 
but is being depleted while acetate is being accumulated. After 6 hours of growth, the 
depletion of acetate is dependent on TCA cycle activity, resulting in the largest separation 
along PC2 between the 6 hour aconitase mutant and the 2 hour wild-type samples. These 
two samples correspond to the largest expected variation in glucose and acetate 
concentrations. From the detailed 2D NMR analysis (please see below), acetate is 
approximately twice as concentrated in the 6 hour wild-type sample compared to the 2 
hour aconitase mutant. The glucose concentration is effectively reversed. Glucose is 
twice as concentrated in the 2 hour aconitase mutant compared to the 6 hour wild type 
sample.   
The PCA results were used to guide a subsequent analysis using OPLS-DA 
(Figure 5.2c). The OPLS-DA yielded a reliable model (R
2
X 0.788, R
2
Y 0.992, Q
2
 0.992). 
The R
2
 and Q
2
 values represent the goodness of fit and predictability of the model, 
respectively. The OPLS-DA scores plot is similar to the PCA scores plot, except for the 
limited separation between the 2 hour wild-type and aconitase mutant clusters. Again, 
this is consistent with the minimal TCA activity expected for the 2 hour wild-type and 
aconitase mutant. Also, OPLS-DA emphasizes the difference between the control group 
(6 hour wild-type) and the treated classes, while minimizing contributions from within 
group variations. Thus, OPLS-DA generates significantly tighter clusters than PCA. 
More importantly, the S-plot (Figure 5.4) generated from the OPLS-DA provides 
unambiguous identification of the major contributors to the class separation (i.e., 
1
H 
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NMR bins and associated metabolites). Specifically, comparing the 6 hour aconitase 
mutant and the 6 hour wild-type samples, which had the largest separation along PC1 in 
the PCA 2D scores plot, identified citrate, isocitrate, and other TCA related metabolites. 
Similarly, comparing the 2 hour aconitase mutant and the 2 hour wild-type samples, 
which had the largest separation along PC2 in the PCA 2D scores plot, identified glucose, 
acetate and other nutrients required for cell growth. These results provide strong support 
for our subjective analysis of the trends in the 2D PCA scores plot and demonstrate that 
not only does PCA and OPLS-DA differentiate between metabolic profiles, but they also 
provide information about specific enzymatic activity and environmental conditions. 
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Figure 5.4 a) OPLS-DA S-plots comparing the S. epidermidis 1457 and aconitase mutant 
strain 1457-acnA::tetM where both cell cultures were grown for 6 hours. The two cell 
cultures were shown be separated along the PC1 axis in Figure 5.2a. Each point in the S-
plot represents a specific bin containing a chemical shift range of 0.025 ppm, where the 
points at the extreme ends of the S-plot are the major contributors to the class distinction. 
Each point was identified to a specific metabolite using the Human Metabolomics 
Database and Madison Metabolomics Database. All the identified metabolites are 
associated with TCA cycle inactivation. b) OPLS-DA S-plot comparing the mutant strain 
1457-acnA::tetM grown for 2 hours and 6 hours. The two conditions are shown to be 
separated along the PC2 axis in Figure 5.2a. The metabolites identified are associated 
with variations in the utilization of glucose for cell growth. c) OPLS-DA loading plot 
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comparing S. epidermidis 1457 and aconitase mutant strain 1457-acnA::tetM where both 
cell cultures were grown for 6 hours. Negative values indicate a decrease in peak 
intensity when comparing the wild type to the mutant, while positive values indicate an 
increase in peak intensity. These results are comparable to the bar graphs depicted in 
Figure 5.10 from the analysis of 2D NMR data.  d) OPLS-DA loading plot comparing the 
mutant strain 1457-acnA::tetM grown for 2 hours and 6 hours. 
 
5.3.3 Impact of environmental stress conditions on the S. epidermidis metabolome 
 Numerous genes and protein complexes are involved in the transformation of 
planktonic cells to a biofilm.
58
 This process requires that S. epidermidis “sense” changes 
in its environment and the availability of nutrients, such as changes in temperature, O2 
levels, osmorality, ethanol, glucose and iron.
29,31,33,59-63
 It is reasonable to expect that 
different external factors would trigger distinct signaling pathways and mechanisms of 
biofilm regulation. Correspondingly, different biofilm formation pathways would 
presumably induce dissimilar metabolomic profiles. Alternatively, a versatile regulation 
system responsive to disparate signals would be significantly more efficient. A metabolic 
signaling pathway is one potential mechanism of rapidly responding to changing 
environmental stress conditions. Conceptually, the environmental flux of essential 
nutrients and metabolites would direct the up- or down- regulation of specific metabolic 
pathways in response to concentration changes (Le Chatelier’s principle) to initially 
reestablish equilibrium without affecting protein activity. Effectively, a limited or 
abundant metabolite would direct the metabolic flow through a specific pathway causing 
a cascade affect due to the high interrelationship of the metabolome. Eventually, gene 
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and protein regulation processes would respond to the perturbed metabolic activity 
leading to the up- or down- regulation of specific genes and proteins.    
We have previously demonstrated that both Fe limitation and 4% ethanol decrease 
TCA cycle activity.
23
 These environmental stress factors are known to induce S. 
epidermidis biofilm formation.
24,30-32
 We have also demonstrated that Fe limitation and 
4% ethanol had a similar impact on the S. epidermidis metabolome and altered the 
activity of CcpA, a metabolite-responsive regulator. An important role for the TCA cycle 
in a staphylococcal biofilm metabolic signaling pathway seems apparent, especially since 
the TCA cycle is a central metabolic pathway that interacts with numerous other 
pathways (Figure 5.1). Thus, we proposed that the TCA cycle senses environmental 
stressors and transduces this signal through the metabolome to activate or repress the 
activity of metabolite-responsive regulators, which, in turn, modulates PIA production, 
virulence factor synthesis, and biofilm formation.
23
 To further support our hypothesis that 
the TCA cycle senses disparate environmental signals to regulate PIA synthesis and 
biofilm formation, we analyzed changes in the S. epidermidis metabolome caused by 
additional environmental stress factors also known to induce an S. epidermidis biofilm.
26
 
28,33,64
   
S. epidermidis cultures were treated with 5% NaCl, 2% glucose, 0.06 µg/mL 
tetracycline, and 400 nM of autoinducer-2 (AI-2, furanosyl borate diester). Glucose and 
NaCl were reported to induce biofilm formation by the regulation of the rbf gene,
65
 which 
has been shown to be  a regulator of icaR,
66
 a negative regulator of the icaADBC operon 
that is required for PIA synthesis and biofilm formation.
67
 Subinhibitory concentrations 
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of antibiotics enhance icaADBC gene expression
28,68
 by potentially inhibiting TcaR, a 
weak negative regulator of icaADBC gene expression.
69
 AI-2 is an intercellular signaling 
molecule that has a modest effect on staphylococcal biofilms.
64
 Conversely, if these 
additional environmental stress factors impact the S. epidermidis metabolome in a 
manner similar to Fe limitation and 4% ethanol, which is also correlated with TCA cycle 
inactivation, then these results would further support the hypothesis that the TCA cycle 
acts as a signal transducer as a part of a metabolic signaling network.  
 The PCA 2D scores plot (Figure 5.5a) and the associated metabolic tree (Figure 
5.5c) indicates that S. epidermidis wild-type cultures grown with the addition of the 
environmental stressors 4% ethanol, 0.06 µg/mL tetracycline or iron-limitation exhibited 
essentially identical metabolomes as the aconitase mutant. Both the aconitase mutant and 
wild-type cultures under these stress conditions formed a large cluster distinct from the 
cluster of wild-type cells in standard growth media. These results further support our 
hypothesis that environmental stress factors influence biofilm formation by inactivating 
the TCA cycle and re-directing key metabolites into PIA synthesis. Conversely, growing 
S. epidermidis wild-type cells in the presence of 5% NaCl showed no significant effect on 
the metabolome since the wild-type cells in the presence and absence of 5% NaCl cluster 
together. Similarly, AI-2 did not affect the S. epidermidis metabolome since both the 
wild-type and aconitase mutant cells in the presence and absence of 400 nM AI-2 cluster 
together (Figure 5.12). Interestingly, S. epidermidis cells treated with 2% glucose were 
separated from both the wild-type and aconitase mutant clusters, implying a different 
impact on the metabolome and a unique mechanism of regulating biofilm formation. 
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Alternatively, the addition of 2% glucose may be viewed as an intermediary effect, where 
the metabolome of the S. epidermidis cells grown with 2% glucose is moving toward the 
aconitase mutant cells. Effectively, the amount of glucose added to the bacterial culture 
was insufficient to completely inactivate the TCA cycle. It has been previously shown 
that different strains have different glucose uptake rates and different sensitivities to 
glucose-induced biofilm formation.
70,71
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Figure 5.5 (a) 2D PCA scores plot and (b) 2D OPLS-DA comparing wild-type S. 
epidermidis 1457 cells grown 6 h in standard TSB media (black ●), with S. epidermidis 
1457 cells grown 6 h in iron-depleted media (DTSB) (red ●), with the addition of 4% 
ethanol (green ●),with the addition of 2% glucose (blue ●), with the addition of 0.06 
μg/mL tetracycline (pink ●), with the addition of 5% NaCl (orange ●), and 6 h growth of 
aconitase mutant strain 1457-acnA::tetM in standard TSB media (black ▲). The ellipses 
correspond to the 95% confidence limits from a normal distribution for each cluster. For 
the OPLS-DA scores plot, the 6 h growth of wild-type S. epidermidis 1457 (black ●) was 
designated the control class and the remainder of the cells were designated as treated. The 
OPLS-DA used 1 predictive component and 4 orthogonal components to yield a R2X of 
0.637, R2Y of 0.966 and Q2 of 0.941. Metabolomic tree diagram generated from the (c) 
2D PCA scores plot depicted in (a) and (d) 2D OPLS-DA scores plot depicted in (b). The 
label colors match the symbol colors from the 2D scores plot. Each node is labeled with 
the boot-strap number, where a value above 50 indicates a statistically significant 
separation. 
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The PCA results were used to guide a subsequent analysis using OPLS-DA 
(Figure 5.5b) and the corresponding metabolomics tree diagram (Figure 5.5d). The 
OPLS-DA analysis yielded a reliable model (R
2
X 0.637, R
2
Y 0.966, Q
2
 0.941), and 
results identical to PCA. The wild-type cells in the presence and absence of 5% NaCl 
were defined as the controls and, as expected, formed a single cluster in the 2D scores 
plot. S. epidermidis wild-type cultures grown with the addition of the environmental 
stressors 4% ethanol, 0.06 µg/mL tetracycline or iron-limitation again formed a single 
cluster with the aconitase mutant in the 2D OPLS-DA scores plot. Also similar to the 
PCA results, the S. epidermidis cells grown with 2% glucose formed a unique cluster. 
Thus, the corresponding metabolomics tree diagram identified three distinct clusters with 
bootstrap values of 100. The OPLS-DA results further support our hypothesis that 
environmental stress factors influence biofilm formation by inactivating the TCA cycle 
and re-directing key metabolites into PIA synthesis.   
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Figure 5.6 a) OPLS-DA S-plots comparing wild-type S. epidermidis 1457 and S. 
epidermidis cultured under the different stress conditions described in Figure 5.5. b) 
OPLS-DA loading plot showing the contribution of the identified metabolites from the S-
plot. These results are comparable to the bar graphs depicted in Figure 5.10 from the 
analysis of 2D NMR data.  
 
To verify the observed effect on the S. epidermidis metabolome is due to 
inactivating the TCA cycle as opposed to other potential factors, the S. epidermidis 
aconitase mutant strain was also grown with the addition of  4% ethanol, 0.06 µg/mL 
tetracycline, 2% glucose, 5% NaCl or under iron-limitation conditions. If the impact of 
these stress conditions is primarily through the inactivation of the TCA cycle, then the 
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metabolome of the aconitase mutant strain should be unperturbed. Otherwise, if the stress 
conditions induce additional or alternative responses, then changes in the metabolome 
should be observed. The 2D PCA scores plot (Figure 5.7a) and metabolomic tree (Figure 
5.7c) indicate the stress conditions did not affect the metabolome of the aconitase mutant. 
The aconitase mutant with and without the stress conditions forms a large cluster distinct 
from the wild-type cluster. Importantly, this includes the addition of 2% glucose. This 
implies the addition of 2% glucose to wild-type S. epidermidis resulted in an incomplete 
inactivation of the TCA cycle instead of a novel mechanism of biofilm regulation. Again, 
the PCA results were used to guide a subsequent analysis using OPLS-DA (Figure 5.7b) 
and the corresponding metabolomics tree diagram (Figure 5.7d). The OPLS-DA analysis 
yielded an acceptable model (R
2
X 0.488, R
2
Y 0.976, Q
2
 0.961), and results very similar 
to PCA. The lower R
2
X is consistent with the larger spread observed within the two 
primary clusters. The wild-type cells were defined as the controls and, as expected, the 
aconitase mutant with and without the stress conditions formed a single large cluster. 
Consistent with the PCA analysis, the single cluster also contained the addition of 2% 
glucose. The OPLS-DA scores plot, along with the metabolomics tree diagram, suggests 
sub-clusters are present within the large aconitase mutant cluster. But, the aconitase 
mutant data is spread throughout this cluster, such that an ellipse that corresponds to the 
95% confidence limit for the aconitase mutant data encompasses the two other apparent 
sub-clusters. This result indicates that within the resolution of the PCA and OPLS-DA 
model, no statistical difference is observed between the metabolomes of the aconitase 
mutant with and without the stress conditions. Critically, the S-plot obtained from the 
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comparison between the wild-type cells and the aconitase mutant treated with the stress 
conditions was identical to the S-plot generated from the comparison between the wild-
type cells and the untreated aconitase mutant cells. Again, this supports the conclusion 
that the addition of the stressors did not perturb the metabolome of the aconitase mutant 
cells.     
 
 
Figure 5.7 (a) 2D PCA scores plot and (b) 2D OPLS-DA comparing wild-type S. 
epidermidis 1457 cells grown 6 h in standard TSB media (black ●), 6 h growth of 
aconitase mutant strain 1457-acnA::tetM in standard TSB media (black ▲), aconitase 
mutant strain 1457-acnA::tetM in iron-depleted media (DTSB) (red ▲), with the addition 
of 4% ethanol (green ▲), with the addition of 2% glucose (blue ▲), with the addition of 
0.06 μg/mL tetracycline (pink ▲), and with the addition of 5% NaCl (orange ▲). The 
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ellipses correspond to the 95% confidence limits from a normal distribution for each 
cluster. The four ellipses correspond to clusters formed by (i) wild-type S. epidermidis 
1457 cells, (ii) aconitase mutant strain 1457-acnA::tetM in standard TSB media, (iii) 
aconitase mutant strain 1457-acnA::tetM in DTSB or with the addition of 4% ethanol, 
and (iv), aconitase mutant strain 1457-acnA::tetM with the addition of 2% glucose, 0.06 
μg/mL tetracycline, or 5% NaCl. For the OPLS-DA scores plot, the 6 h growth of wild-
type S. epidermidis 1457 (black ●) was designated the control class and the remainder of 
the cells were designated as treated. The OPLS-DA used 1 predictive component and 2 
orthogonal components to yield a R
2
X of 0.488, R
2
Y of 0.976 and Q
2
 of 0.961. 
Metabolomic tree diagram generated from the (c) 2D PCA scores plot depicted in (a) and 
(d) 2D OPLS-DA scores plot depicted in (b). The label colors match the symbol colors 
from the 2D scores plot. Each node is labeled with the boot-strap number, where a value 
above 50 indicates a statistically significant separation. 
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Figure 5.8 a) OPLS-DA S-plots comparing the S.epidermidis 1457 and the aconitase 
mutant 1457-acnA::tetM under the different stress conditions described in Figure 5.7b. b) 
OPLS-DA loading plot showing the contribution of the identified metabolites from the S-
plot. These results are comparable to the bar graphs depicted in Figure 5.10 from the 
analysis of 2D NMR data.  
 
5.3.4 Detailed analysis of changes to the S. epidermidis metabolome caused by 
environmental stress    
An overall correlation between the metabolomes of S. epidermidis under stress 
and TCA cycle inactivation provides further support for our hypothesis that 
environmental conditions induce biofilm formation though the regulation of the TCA 
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cycle.
23
 Specifically, the disparate signals of 2% glucose, 4% ethanol, 0.06 µg/mL 
tetracycline and iron-limitation are all sensed by the TCA cycle. To further support our 
hypothesis, a detailed analysis of changes to the S. epidermidis metabolome caused by 
these environmental stress factors was necessary. We previously reported an analysis of 
changes in the metabolome of S. epidermidis caused by TCA cycle inactivation that 
resulted in an increase in PIA production.
16
 Among other observed changes, amino-acids 
derived from TCA cycle intermediates (Asn, Asp, Gln, and Glu) exhibited a decrease in 
concentration. Correspondingly, an increase in concentrations was observed for the PIA 
biosynthetic precursors UDP-N-acetyl-glucosamine and fructose-6-phosphate. A similar 
approach using 2D 
1
H, 
13
C HSQC and 2D 
1
H, 
1
H TOCSY NMR spectra was applied to 
quantitate metabolite changes in the S. epidermidis metabolome caused by Fe-limitation 
and 4% ethanol (Figure 5.9).
23
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Figure 5.9 Overlay of (a) 2D 
1
H, 
13
C HSQC spectra and (b) 2D 
1
H, 
1
H TOCSY spectra 
comparing wild-type S. epidermidis strain 1457 (red) and aconitase mutant strain 1457-
acnA::tetM (black) grown for 6 h in standard TSB media augmented with 0.25% 13C-
glucose. NMR resonances corresponding to specific metabolites are labeled, where citrate 
is circled. 
 
2D NMR spectra improve metabolite identification by reducing the complexity 
and congestion of 1D 
1
H NMR spectrum by spreading the information into two-
dimensions. Additionally, the 2D 
1
H, 
13
C HSQC experiment allows for monitoring the 
flow of carbon-13 through the metabolome from a specifically 
13
C-labeled metabolite. 
Alternatively, the 2D 
1
H, 
1
H TOCSY spectrum monitors all detectable metabolites with a 
bias to metabolites with the highest concentration. This may include the carbon-13 
labeled metabolites observed in the 2D 
1
H, 
13
C HSQC spectrum in addition to non-
isotope labeled metabolites produced from other carbon sources. Therefore, the 2D 
1
H, 
13
C HSQC and 2D 
1
H, 
1
H TOCSY NMR spectra are complementary experiments for 
metabolomics and allow for a more complete analysis of metabolite concentration 
changes. Specifically, S. epidermidis wild-type cells and the aconitase mutant cells were 
grown with and without stress factors and harvested during either the exponential or post-
exponential phase with and without the addition of 
13
C-glucose. A total of 12 different 
bacterial culture conditions were prepared in triplicate for both the 2D 
1
H, 
13
C HSQC and 
2D 
1
H, 
1
H TOCSY NMR experiments for a minimum of 72 bacterial cultures or NMR 
experiments. To maintain consistency, S. epidermidis wild-type cells were used as a 
reference and prepared with each bacterial culture set.  
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Differences in metabolite concentrations between the stresses, the bacterial 
growth phases, the aconitase mutant cells, and the wild-type cells was based strictly on 
detecting changes in peak intensities in the 2D 
1
H, 
13
C HSQC and 2D 
1
H, 
1
H TOCSY 
NMR experiments. To minimize contributions from experimental variability, three levels 
of normalization were used. First, metabolite concentrations were normalized based on 
the total number of cells grown for each culture. Second, the peak intensities in each 
NMR spectrum were normalized by the spectrum’s average peak intensity. Third, each 
individual peak was normalized by scaling by the largest intensity observed for that peak 
across the set of NMR spectra. The intensity of peaks assigned to each metabolite within 
a spectrum were averaged and then averaged across the triplicate NMR data set. Relative 
changes in peak intensities (metabolite concentrations) were compared to the S. 
epidermidis wild type metabolome and are displayed as bar graphs in Figure 5.10. 
Importantly, the metabolites identified from the 2D NMR experiments were also 
consistent with the metabolites identified as the major contributors to class distinction in 
the 2D OPLS-DA plots (Figures 3, 4). The OPLS-DA S-plots (Figure 5.8) identifies the 
relative contribution of each bin (
1
H NMR chemical shift) to the clustering in the 
corresponding 2D scores plot. Each NMR bin with a high reliability (p(corr)[1] ~ 1 or -1) 
and a high magnitude (p[1] > 0.1 or < -0.1) was assigned to a metabolite that was also 
found to be present in the Figure 5.10 bar graph.    
An inactivated TCA cycle caused concentration changes for 55 metabolites 
involved in the amino sugar pathway, glycolytic pathway, several amino acid pathways, 
and the TCA cycle. The NMR data shows the amount of cellular glucose in the 6 hour 
222 
 
 
 
post-exponential wild-type strain was reduced by 80% compared to the 2 hour 
exponential phase. The amount of cellular acetate was increased by 25%. As expected, 
the inactivation of the TCA cycle in the aconitase mutant resulted in the accumulation of 
a large concentration of acetate. Acetate was the most intense peak in the 6 hour cultures 
for the wild-type and aconitase mutant strains shown in Figure 5.9. There were also 
noticeable differences in the aconitase mutant metabolome. Peaks corresponding to the 
amino acids derived from the TCA cycle intermediates such as Asn, Asp, Gln, and Glu 
were not present. Not surprisingly, a large amount of citrate was also seen, since the 
inactivated aconitase prevents the conversion of citrate to isocitrate. Other metabolites 
associated with the glycolytic pathway were up-regulated. Similarly, some amino sugar 
and aromatic metabolites were up-regulated except for the significant down-regulation of 
UDP-glucuronate.  
As expected from the clustering pattern in the 2D PCA scores plot, the direction 
of carbon flow in cells under stress were similar to the aconitase mutant cells, but 
dramatically different from wild-type cells during post exponential growth. A decrease in 
the concentration of amino acids derived from TCA cycle intermediates such as Asp, 
Asn, Glu, and Gln shows that the TCA cycle is still repressed when the cells are under 
stress. Instead the carbon flow is redirected back into the glycolytic pathway as indicated 
by an increase in concentrations for phosphoenolpyruvate (PEP), acetaldehyde, and 
fructose 6-phosphate. The carbon flow was also directed into the amino sugar pathway 
with an increase in concentrations for UDP-N-acetylglucosamine, N-acetyl-neuraminate, 
and N-acetyl-D-mannosamine. UDP-N-acetylglucosamine is an important precursor to 
223 
 
 
 
PIA formation. Again, the detailed analysis of changes in the metabolome of S. 
epidermidis provides additional support for the role of TCA cycle activity in a metabolic 
signaling pathway that transduces disparate external stimuli into internal metabolic 
signals that facilitate biofilm formation. Effectively, the observed changes in the 
metabolome caused by disparate external stimuli are consistently suppressing TCA cycle 
activity and inducing PIA synthesis required for biofilms.  
Conversely, the change of the carbon flow in the 2 hour growth is minimal. 
Again, this is consistent with the low TCA activity and the similar clustering in the 2D 
PCA scores plot between the aconitase mutant and wild-type 2 hour growth (Figure 
5.2b). Obviously, stress factors cannot suppress an already inactive TCA cycle. Instead, 
the catabolic conversion of glucose into intermediates throughout the glycolytic pathway 
proceeds as expected with a slight change since pyruvate is also produced. Much of the 
carbon-13 from glucose was still directed to the production of acetate. The NMR data 
indicates cellular acetate concentrations were similar across the 2 hour bacterial cultures, 
but an increased amount of acetyl-phosphate was accumulated under stress conditions. 
This confirms that when an abundant amount of glucose is present, it is processed by 
glycolysis and pyruvate dehydrogenase into acetyl-CoA and converted into acetyl-
phosphate for use in substrate level phosphorylation. The excretion of acetate into the 
culture medium helps pH homeostasis due to the large flux of acetate.
72
 Aside from the 
glycolytic pathway, the NMR data indicates that wild-type bacteria tend to utilize glucose 
more efficiency based on small decreases in amino sugar and aromatic metabolites. 
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Figure 5.10 Bar graphs showing the percent change in metabolite concentrations relative 
to wild-type S. epidermidis strain 1457 grown in standard TSB media. Metabolite 
concentration changes were measured after 2 and 6 h bacterial growths for the aconitase 
mutant strain 1457-acnA::tetM in TSB media (light yellow), aconitase mutant strain 
1457-acnA::tetM with iron-depletion (dark yellow), aconitase mutant strain 1457-
acnA::tetM with the addition of 4% ethanol (orange), wild-type S. epidermidis strain 
1457 with iron-depletion (dark purple), and wild-type S. epidermidis strain 1457 with the 
addition of 4% ethanol (light purple). Positive values represent increased concentrations 
while negative values represent decreased concentrations with respect to S. epidermidis 
strain 1457 grown in standard TSB media. The metabolite names were abbreviated as 
follows: ACA (Acetaldehyde), ACE (Acetate), ACP (Acetyl-P), AKG (α-ketoglutarate), 
ALAAc (Acetyl-alanine), AMI (4-Aminobutanoate), ARG (Arginine), ASN 
(Asparagine), ASP (Aspartate), CIR (Citrulline), CIT (Citrate), ETH (Ethanol), F6P 
(Fruc-6P), G1P (Gluc-1P), G6P (Gluc-6P), GAL (Galacturonic-acid), GAL1P (α-d-Gala-
1P), GLN (Glutamine), GLR (Glucuronate), GLS (d-glucosamine), GLS6P 
(Glucosamine-6P), GLSAc (N-Ac-d-glucosamine), GLSAc6P (Acetyl-glucosamine-6P), 
GLU (Glutamate), GLUAc (Acetyl-glutamate), GLY (Glyceraldehyde), HIS (Histidine), 
ICI (Isocitrate), INO (Ino, Ade, Xan), LAC (Lactate), ALA (alanine), LEU (Leucine), 
LYS (Lysine), MANAc (N-acetyl-d-mannosamine), MET (Methionine), MIN (myo 
inositol), MSE (selenomethionine), NEUAc (N-Ac-neuraminate), ORN (Ornithine), 
ORNAc (Acetyl-ornithine), PEP (Phosphoenolpyruvic acid), PRO (Proline), RIB (d-
ribose), SAM (S-adenosyl-methionine), SER (Homoserine), SUCSER (O-Succinyl-l-
homoserine), UDPGLR (UDP-glucoronate), UDPGLSAc (UDP-NAc-d-glucosamine), 
VAL (Valine). 
 
 
 
 
226 
 
 
 
5.3.5 Metabolic rearrangements during TCA cycle stress  
The metabolome of S. epidermidis is not a series of independent isolated 
metabolic pathways, but instead is a complex inter-connected network. Thus, metabolic 
pathways connected to the TCA cycle are also affected by changes in TCA cycle activity. 
In order to visualize the cascade effect of inactivating the TCA cycle, a metabolic 
network was constructed using Cytoscape.
40
 The metabolic network (Figure 5.11) was 
generated by manually associating each metabolite to its corresponding pathway from the 
KEGG
54
 database and then using the automated biological network modules integrated 
into Cytoscape.
73,74
 The network connects the 37 metabolites identified by NMR whose 
concentrations are either increased (red) or decreased (green) by an inactivated TCA 
cycle. Only metabolites affected by a minimally active TCA cycle under all 
circumstances (aconitase mutant and stress factors) are highlighted on the network map. 
It is important to note that NMR is not able to identify every metabolite affected by 
perturbing the metabolome. The concentrations or stabilities of some metabolites are 
simply below the NMR detection limit. These intervening and undetected metabolites are 
colored grey in the metabolic network. The network shows the TCA cycle as the central 
pathway where common metabolites connect the urea cycle, alanine metabolism, and 
glycolysis/gluconeogenesis that then leads to amino sugar metabolism and other 
metabolites associated with PIA synthesis. 
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Figure 5.11 Cytoscape network depicting the metabolite concentration changes caused 
by the inactivation of the TCA cycle. Nodes colored red correspond to metabolites with 
an increase in concentration due to TCA inactivation. Nodes colored green correspond to 
metabolites with a decrease in concentration due to TCA inactivation. Nodes colored 
gray correspond to metabolites that are not observed in the NMR spectra, do not have a 
reference NMR spectrum (or assignment), or did not exhibit a significant concentration 
change. Metabolic pathways are labelled on the network. The metabolite names were 
abbreviated as described in the legend to Figure 5.10. 
 
228 
 
 
 
5.4 Conclusion 
The systematic analysis of the S. epidermidis metabolome using NMR provides 
further evidence for a metabolic signaling network for biofilm formation that involves the 
TCA cycle. Inactivation of the TCA cycle enables metabolic precursors to flow into 
pathways associated with PIA synthesis, an important component of S. epidermidis 
biofilm formation. Disparate environmental stress conditions known to induce biofilm 
formation were shown to perturb the metabolome of S. epidermidis in a manner similar to 
an aconitase mutant. Effectively, iron-depletion, and the addition of ethanol, tetracycline, 
and glucose resulted in the inactivation of the TCA cycle. Furthermore, a detailed 
analysis of the specific changes to the S. epidermidis metabolome indicates that 
essentially the same set of metabolites affected by TCA cycle inactivation are also 
affected by environmental stress conditions. A network map identified the TCA cycle as 
playing a central role in the proposed signaling pathway that also involves the urea cycle, 
alanine metabolism, glycolysis/gluconeogenesis, amino sugar metabolism and other 
metabolites associated with PIA synthesis. Interestingly, the addition of NaCl or 
autoinducer-2 did not induce any effect on the S. epidermidis metabolome or effect TCA 
cycle activity. Suggesting these factors must act through a distinct process from the other 
environmental factors.  
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APPENDIX A: EFFECT OF AUTOINDUCER-2 (AI-2) ON THE S. EPIDERMIDIS 
METABOLOME  
Autoinducer 2 (AI-2) is believed to be an intercellular signaling molecule used in 
quorum sensing by both gram-negative and gram-positive bacteria.
64
 AI-2 minimally 
represses biofilm formation in S. epidermidis where it has been reported that AI-2 
indirectly effects the transcription of metabolic genes.
75
 This raises the possibility that 
AI-2 may also function by affecting TCA cycle activity. To investigate the impact of AI-
2 on the TCA cycle, bacterial cultures of wild-type S. epidermidis and the corresponding 
aconitase mutant strain were treated with AI-2. Zhao et al.
34
 recently demonstrated that S. 
aureus cultures supplemented with 390 nM of 4,5-dihydroxy-2,3-pentanedione (DPD), 
the AI-2 precursor molecule, restored a luxS deletion mutant. Thus, 400 nM of AI-2 was 
used for our NMR metabolomics studies since this concentration of AI-2 was identified 
as physiologically relevant. The 2D PCA and 2D OPLS-DA scores plots comparing AI-2 
treated and untreated bacterial cultures indicates AI-2 did not change the typical 
clustering pattern (Figure 5.12). In other words, the NMR metabolomics data suggests 
AI-2 does not affect TCA activity or cause a corresponding perturbation in the S. 
epidermidis metabolome. This observation is in contrast to the data reported by Li et al., 
where AI-2 was shown to effect the transcription of numerous metabolic genes.
75
 The 
apparent discrepancy highlights the benefits of NMR metabolomics, where changes in the 
metabolome reflect actual changes in protein activity. Conversely, a change in a 
transcriptional profile does not necessarily correlate with a difference in protein 
activity.
76
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Figure 5.12 2D PCA scores plot comparing wild-type S. epidermidis strain 1457 and 
aconitase mutant strain 1457-acnA::tetM with and without the addition of 400 nM of AI-
2. Cells were grown for 2 h or 6 h in standard TSB media, 2 h growth of wild-type S. 
epidermidis strain 1457 with AI-2 ( ) and without AI-2 ( ); aconitase mutant strain 
1457-acnA::tetM with AI-2 ( ) and without AI-2 ( ); 6 h growth of wild-type S. 
epidermidis strain 1457 with AI-2 ( ) and without AI-2. ( ); and aconitase mutant strain 
1457-acnA::tetM with AI-2 ( ) and without AI-2 ( ). b) Metabolomic tree diagram 
generated from the 2D PCA scores plot depicted in (a). The label colors match the 
symbol colors from the 2D PCA scores plot. Each node is labeled with the boot-strap 
number, where a value above 50 indicates a statistically significant separation. c) 2D 
OPLS-DA scores plot comparing wild-type S. epidermidis strain 1457 and aconitase 
mutant strain 1457-acnA::tetM with and without the addition of 400 nM of AI-2. Each 
pair of cell cultures treated with and without AI-2 were defined as a separate class for a 
total of four separate classes. The model consists of 1 predictive component and 3 
orthogonal components that yielded an R
2
X of 0.774, R
2
Y of 0.970, and a Q
2
 of 0.954
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CHAPTER 6 
USING NMR METABOLOMICS TO INVESTIGATE TRICARBOXYLIC ACID 
CYCLE DEPENDENT SIGNAL TRANSDUCTION IN STAPHYLOCOCCUS 
EPIDERMIDIS 
6.1 Introduction 
Staphylococcus epidermidis is a skin-resident, opportunistic pathogen that is the 
leading cause of hospital-associated infections.
1
 Although the type and severity of 
diseases produced by this bacterium varies, its most common infectious manifestation is 
associated with implanted biomaterials. The dramatic environmental changes that occur 
during the transition from being skin-resident to residing on implanted biomaterials 
necessitates the need for changes in the expression of genes coding for enzymes required 
for growth in the new environment. This environmental adaptation often includes 
activating transcription of virulence genes; hence, most virulence genes are regulated by 
environmental and nutritional signals.
2
 Accordingly, a major area of interest in 
microbiology is determining how bacteria “sense” and respond to environmental signals. 
Given the tremendous diversity of microbial life it is not surprising that the mechanisms 
bacteria employ are equally diverse. These mechanisms include two-component 
regulatory systems, alternative sigma factors, mechanosensors, small RNAs, 
riboswitches, and many others. Although remarkable advances have been made in 
identifying the response regulators, our knowledge of signaling mechanisms has lagged 
behind; the exception being cell-density signaling.  
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The tricarboxylic acid (TCA) cycle has been implicated as regulating or affecting 
staphylococcal virulence and/or virulence determinant biosynthesis.
3-9
 The TCA cycle 
has three primary functions: i.) provide biosynthetic intermediates, ii.) generate reducing 
potential, and iii.) directly produce a small amount of ATP. The availability of 
biosynthetic intermediates affects the availability of amino acids and nucleic acids. 
Increasing the reducing potential alters the bacterial redox balance, necessitating 
oxidation reactions via the electron transfer chain. The small amount of ATP produced 
directly by the TCA cycle is amplified many times when the ATP generated by oxidative 
phosphorylation is considered. In short, the TCA cycle has a central function in 
maintaining the bacterial metabolic status. Importantly, the activity of TCA cycle 
enzymes is affected by the availability of nutrients and a variety of stress-inducing 
stimuli;
9-12
 thus, the availability of biosynthetic intermediates, the redox status, and the 
energy status can be altered by nutritional and environmental stimuli. These observations 
led us to propose a fourth function for the TCA cycle, the transduction of external signals 
into intracellular metabolic signals that can be “sensed” by metabolite-responsive 
regulatory proteins.
2
 Fundamental to this hypothesis are the predictions that disparate 
environmental stimuli will cause common metabolic changes and that these metabolic 
changes will precede regulatory changes.  
Two of the more extensively studied environmental stimuli that influence S. 
epidermidis virulence determinant biosynthesis are iron-limitation
13,14
 and ethanol 
stress.
15,16
 The effect of iron-limitation on bacterial growth is primarily through 
preventing the activity of enzymes that require iron as a cofactor and altering 
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transcription of iron-regulated genes.
2
 As S. epidermidis has many iron-requiring 
enzymes (e.g., aconitase, serine dehydratase, peptide deformylase, iron-containing 
alcohol dehydrogenase, nitrate reductase, etc.), it is reasonable to expect that the 
metabolic effects of iron-limited growth are diverse and not restricted to the TCA cycle. 
Ethanol denatures proteins in the cytoplasmic membrane causing changes in membrane 
permeability, which can lead to the loss of membrane integrity.
17
 With the exception of 
the succinate dehydrogenase complex, most TCA cycle enzymes are not membrane 
associated; hence, it is reasonable to predict that the deleterious effects of ethanol stress 
are largely independent of the TCA cycle. Taken together, these observations suggest that 
disparate environmental conditions will cause divergent metabolomic changes. In 
contrast to this suggestion, our central hypothesis predicts that different stresses will 
cause common metabolomic changes that are dependent on the TCA cycle. To test our 
central hypothesis, we chose to induce environmental stress by growing bacteria in an 
iron-limited medium or in a medium containing ethanol and assessing the metabolic 
changes using NMR metabolomics. 
 
6.2 Methods and Materials 
6.2.1 Bacterial strains, media, and growth conditions 
S. epidermidis wild-type strain 1457
18
 and the isogenic aconitase mutant strain 
1457-acnA::tetM (tetM cassette inserted into position 856 of the 2,702-bp acnA gene) and 
σB mutant strain 1457-sigB::dhfr 7,19 have been described. Strains 1457-codY, 1457-ccpA, 
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1457-acnA-codY, and 1457-acnA-ccpA were constructed  using the gene splicing by 
overlap extension (gene SOEing) technique
20
 to replace the gene of interest with an 
antibiotic resistance marker (i.e., ermB or tetM). Primers were designed to amplify 
approximately 1 kb regions upstream and downstream of the gene of interest based on the 
genome sequence of S. epidermidis strain RP62A. Gene knockouts were confirmed by 
PCR and Southern blot hybridization. In addition, strains containing mutations in the 
single S. epidermidis aconitase gene were assayed to ensure that no aconitase activity was 
detected (data not shown). All strains were grown in tryptic soy broth without dextrose 
(TSB; BD Biosciences) supplemented with 0.25% glucose (Sigma Chemical) or 0.25% 
13
C6-glucose (Cambridge Isotope Laboratories). Defferated TSB (DTSB) was prepared 
by adding 50 g of Chelex 100 (Sigma Chemical) to approximately 1 L of TSB and 
stirring at 4°C for 20 h. After 20 h, the Chelex resin was removed, 1 mM MgSO4 was 
added, the volume was adjusted to 1 L, and the medium was filter sterilized. To induce 
ethanol stress and minimize growth defects, ethanol or deuterated ethanol (Isotec) was 
added to the medium at a final concentration of 4% (v/v). All cultures were inoculated 
1:200 from overnight cultures (normalized for growth) into glucose supplemented TSB, 
incubated at 37°C, and aerated at 225 rpm with a flask-to-medium ratio of 7:1. Bacterial 
growth was assessed by measuring the optical density at 600 nm (OD600). Antibiotics, 
when used, were purchased from Fisher Scientific or Sigma Chemical and used at the 
following concentrations: chloramphenicol (8 μg/mL), trimethoprim (10 g/mL), and 
erythromycin (8 μg/mL).  
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6.2.2 Aconitase activity assay  
Cell-free lysates of S. epidermidis were prepared as follows. Aliquots (3 mL) 
were harvested by centrifugation (1 min at 20,800 x g) at the indicated times, suspended 
in 1.5 mL of lysis buffer containing 90 mM Tris (pH 8.0) and 100 M fluorocitrate. The 
samples were lysed in 2 mL screw cap tubes containing lysing matrix B using a FastPrep 
instrument (MP Biomedical). The lysate was centrifuged for 5 min at 20,800 x g at 4ºC. 
Aconitase activity in the resulting cell-free lysate was assayed by the method described 
by Kennedy et al.
21
 One unit of aconitase activity is defined as the amount of enzyme 
necessary to give a A240 min
-1
 of 0.0033.
22
 Protein concentrations were determined by the 
Lowry method.
23
  
 
6.2.3 Northern blot analysis  
Northern blot analysis of transcripts was performed as described.
7
 
Oligonucleotide primers used in making DNA probes were designed using the S. 
epidermidis RP62A genome sequence. Probes for northern blotting were generated by 
PCR amplification of unique internal regions of RNAIII and glnA (femC) genes using 
primers:  
femC- forward, 5’-GATGTTTGATGGTTCATCTATTGAAGGTTTCG-3’;  
femC-reverse, 5’-GCAGTATCAGTCAATTGTAAATCACCTTCAG-3’;  
RNAIII-forward, 5’-TGAAAAATTTGCTTAATCTAGTCGAGTG-3’;  
RNAIII-reverse, 5’- CATGATAAATTGAATGTTGTTTACGATAGC-3’. 
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DNA probes were labeled using the North2South random prime labeling kit 
(Pierce). Electrophoresis, transfer of the RNA to the Nytran SPC nylon membrane 
(Whatman), and hybridization were done using the NorthernMax Kit (Ambion). 
Detection was performed using the Chemiluminescent Nucleic Acid Detection Module 
(Pierce).  
 
6.2.4 PIA immunoblot assay  
PIA accumulation was determined as described.
24
 
 
6.2.5 NMR sample preparation  
NMR samples for one-dimensional (1D) 
1
H spectra were prepared from 10 
independent, 25 mL S. epidermidis cultures. Two-dimensional (2D) 
1
H, 
13
C HSQC
25,26
 
and 2D 
1
H, 
1
H TOCSY
27
 spectra were prepared from 3 independent 50 mL cultures. The 
TSB medium used in the 2D 
1
H, 
13
C HSQC analysis contained 0.25% 
13
C6-glucose 
(Cambridge Isotope Laboratories). For 2D 
1
H, 
13
C HSQC and 2D 
1
H, 
1
H TOCSY
 
involving ethanol stress, deuterated ethanol (Isotec) was used to minimize the 
contribution of exogenous ethanol to the NMR spectra. For 1D 
1
H NMR experiments, 
2.74 OD600 units were harvested at each time point and for the 2D 
1
H, 
13
C HSQC and 2D 
1
H, 
1
H TOCSY experiments, 5.48 OD600 units were collected. Bacteria were harvested by 
centrifugation (4000 rpm for 5 min), suspended in 50 mM phosphate buffer in 100% D2O 
at pH 7.2 (uncorrected), and lysed using lysing matrix B tubes and a FastPrep instrument. 
The lysates were centrifuged to remove cell debris and glass beads and then frozen in 
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liquid nitrogen. All samples were kept at -80°C until ready for analysis. At the time of 
use, a 600 L aliquot of the cell-free lysate was transferred to each NMR tube.  
 
6.2.6 NMR Analysis  
The NMR spectra were collected on a Bruker 500 MHz Avance spectrometer 
equipped with a triple-resonance, Z-axis gradient cryoprobe. A BACS-120 sample 
changer with Bruker Icon software was used to automate the NMR data collection. The 
1D 
1
H NMR spectra collection and principal component analysis (PCA) were performed 
as described with minor modifications.
28-30
 Briefly, each multidimensional NMR 
spectrum (chemical shifts and peak intensities) was converted to a single point in a 
multidimensional Cartesian space. Conceptually, each axis corresponds to a specific 
chemical shift, where the peak intensity is the value along the axis. PCA identifies a 
principal component vector ( )P1

 corresponding to the largest variation in the data set 
within this multidimensional space. The second vector ( )P2

 is orthogonal to the first and 
represents the next largest variation in the data set. Each successive vector describes a 
diminishing amount of the data set’s variability, where most of the variability is described 
by the first two principal components. The PC1 and PC2 scores (unitless values) are 
effectively the individual fit of each NMR spectrum to 1P

 and 2P

. The PC1 and PC2 
scores are usually presented in a 2D plot, where similar NMR spectra cluster together. 
Solvent presaturation used excitation sculpting to efficiently remove the solvent 
and maintain a flat baseline, eliminating any need for baseline collection that may induce 
246 
 
 
 
artifacts in the 2D scores plot.
31
 Each NMR spectrum was center averaged for PCA 
analysis to minimize any experimental variations between cultures.
32
 
2D 
1
H, 
13
C HSQC spectra were collected and processed as previously described.
7
 
2D 
1
H, 
1
H TOCSY spectra were collected with watergate solvent presaturation,
33
 and a 
relaxation delay of 2 seconds.  A total of 1024 data points with a sweep width of 5000 
Hz, and 256 data points with a sweep width of 5001.324 Hz were collected in the direct 
and indirect 
1
H dimensions, respectively. A total of 16 dummy scans and 8 acquisition 
scans were used to obtain each of the 2D 
1
H, 
1
H TOCSY NMR spectra. The 2D 
1
H, 
1
H 
TOCSY NMR spectra were processed similar to the 2D 
1
H, 
13
C HSQC spectra and both 
spectra were analyzed using NMRView
34
(One Moon Scientific) and Sparky (T. D. 
Goddard and D. G. Kneller, SPARKY 3, University of California, San Francisco) to 
identify chemical shifts and assign peak intensities.  
The observed NMR peaks in the 2D 
1
H, 
13
C HSQC and 
1
H, 
1
H TOCSY spectra 
were assigned to specific metabolites using 
1
H and 
13
C chemical shift tolerances of 0.05 
ppm and 0.50 ppm, respectively, and the Madison Metabolomics Consortium Database 
(MMCD),
35
 the BioMagResBank,
36
 and the Human Metabolome Database.
37
 The 
presence of metabolites and metabolic pathways were verified with the KEGG
38
 and 
Metacyc
39
 databases.  
Peak intensities were normalized for each 2D NMR spectrum by dividing by the 
average peak intensity. The triplicate data sets were then used to calculate average 
intensities for each peak observed in the 2D spectra for strain 1457, 1457-acnA, ethanol 
stress and iron-limitation. A percent error was calculated for each peak by dividing the 
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standard deviation by the average peak intensity. The average peak intensities were then 
used to calculate a percent difference relative to the wild-type bacteria in TSB medium. 
Peaks with calculated percent differences greater than 5 times the average percent error 
were considered to have either decreased or increased concentrations relative to the wild-
type strain 1457. Peaks with less than a 5-fold deviation were considered similar. 
Secondary peaks assigned to the same metabolite were required to have the same relative 
change in intensity in order to be classified as a metabolite with an increase or decrease in 
concentration. 
 
6.2.7 Metabolomic dendrogram  
The relative clustering patterns in the PCA 2D scores plots were quantitatively 
analyzed using a tree diagram and bootstrapping technique.
40
 The PC1 and PC2 scores 
for each set of 10 duplicate NMR spectra representing a specific metabolic state (iron-
limitation, ethanol treatment, etc.) are used to calculate an average PC score and standard 
deviation. Any PC score outside 2 standard deviations were removed and a new average 
was calculated. The average PC scores represent the center of a cluster of NMR spectra 
(metabolic state) in the 2D scores plot. The process is repeated for each set of 10 
duplicate NMR spectra. Distances between the average PC positions for each metabolic 
state are then calculated using the standard equation for a Euclidean distance to create a 
distance matrix. 
To assess the significance of the similarity (overlap) or difference (separation) 
observed between pairs of clusters in the 2D scores plot, standard bootstrapping methods 
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were also applied.
41,42
 Briefly, the average PC scores are recalculated by randomly 
selecting points from the data set. Distances are recalculated between the clusters using 
the new average PC scores to create a new distance matrix. The process is repeated until 
100 different distance matrices are created and transferred to version 3.68 of the 
PHYLIP
43
 suite of software programs (http://www.phylip.com). PHYLIP calculates a tree 
for each distance matrix and then determines a consensus tree. The program calculates a 
bootstrap value for each node, which is simply the number of times the node appears in 
all 100 trees. Bootstrap values below 50% imply a statistically insignificant separation. 
Conversely, as the bootstrap number increases above 50% the confidence in the tree 
branch or separation increases. 
 
6.3 Results 
6.3.1 Disparate environmental stresses create a metabolic block in the TCA cycle  
To determine if ethanol stress and iron-limitation alter TCA cycle activity, the 
specific activity of aconitase in S. epidermidis strain 1457 at 2 hours (exponential growth) 
and 6 hours (post-exponential growth) post-inoculation was assessed (Figure 6.1). As 
expected, iron-limited growth and ethanol stress prevented the post-exponential growth 
phase increase in the specific activity of the iron-requiring enzyme aconitase, creating a 
metabolic block in the TCA cycle (Figure 6.1). Although ethanol stressed bacteria are in 
the post-exponential growth phase at 6 h post-inoculation, their growth is slower, which 
slows the consumption of glucose and excess glucose can repress transcription of TCA 
cycle genes. Irrespective of the mechanism by which ethanol repressed aconitase specific 
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activity, the normal post-exponential growth phase increase in TCA cycle activity did not 
occur. These data demonstrate that environmental stresses whose deleterious effects are 
substantially different from one another have a similar effect on TCA cycle function. 
 
     
Figure 6.1 The temporal induction of aconitase specific activity is inhibited by dissimilar 
stressors. Aconitase activity was assessed during the exponential (2 and 4 h) and post-
exponential (6 h) growth phases during growth in DTSB or TSB containing 4% ethanol. 
The data are presented as the mean and SEM of 2 independent experiments each 
determined in triplicate.  
 
6.3.2 Environmental stimuli elicit TCA cycle-dependent metabolic changes  
The TCA cycle provides biosynthetic intermediates, ATP, and reducing potential; 
therefore, alteration of TCA cycle activity will alter the metabolic status of a bacterium. 
To determine the metabolic changes associated with iron-limitation, ethanol stress, and 
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TCA cycle inactivation, NMR metabolomic analysis
28,29
 was used to assess the stressed 
and non-stressed metabolomes of strains 1457 and the TCA cycle inactive strain 1457-
acnA. Specifically, S. epidermidis strains 1457 and 1457-acnA were grown for two or six 
hours in TSB, TSB with 4% ethanol, or DTSB. Following acquisition of the NMR 
spectra, the σ of integrals was used for PCA (Figure 6.3a). As expected, during the 
exponential growth phase, PCA revealed that the effects of ethanol stress and iron-
limitation on the metabolome were largely independent of the TCA cycle (Figure 6.2). 
This was expected due to the normal repression of TCA cycle activity during nutrient rich 
growth (Figure 6.1
8,44
). Despite the TCA cycle being repressed during the exponential 
growth phase, the different stresses induced common metabolomic changes (Table 6.1). 
In contrast to the exponential growth phase, PCA of post-exponential growth phase 
metabolomes revealed that ethanol stress and iron-limitation induced metabolomic 
changes very similar to TCA cycle inactivation (Figure 6.3a and Table 6.2). In addition, 
these data highlight the relative insensitivity of the metabolome of strain 1457-acnA to 
ethanol stress and iron-limited growth, confirming that the major effect of these stressors 
is dependent upon the TCA cycle. That being said, the more diffuse clustering of ethanol 
stressed metabolomes of both the wild-type and aconitase mutant strains, suggest that 
ethanol stress had TCA cycle-independent metabolomic effects (Figure 6.3a). The TCA 
cycle-independent effects are likely due to the denaturation of membrane proteins not 
related to electron transport or the TCA cycle. Taken together, these data demonstrate 
that diverse environmental stimuli elicit common metabolic changes that require the TCA 
cycle.  
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Figure 6.2 PCA 2D scores plot comparing non-stressed, or iron-limited cultures of 
strains 1457, 1457-acnA, and 1457-sigB::dhfr grown for 2h. Symbols and colors are 
defined in the figure.  
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Figure 6.3 Environmental stressors cause metabolomic perturbations similar to TCA 
cycle inactivation. (A) PCA 2D scores plot comparing non-stressed, ethanol stressed, or 
iron-limited cultures of strains 1457, 1457-acnA, and 1457-sigB::dhfr grown for 6 h. 
Symbols and colors are defined in the figure. The ovals are manually drawn to identify 
clusters of related samples and to guide the reader. They are not statistically relevant. The 
relative contribution of each principal component is indicated in the parenthesis.  (B) 
Metabolic tree generated using the PCA scores plot data demonstrating the relationship 
between stresses and strains. Bootstrap values are indicated on the dendrogram branches. 
Bootstrap values below 50% imply a statistically insignificant separation; conversely, as 
the bootstrap number increases above 50% the confidence in the tree branch or separation 
increases. 
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The common metabolomic response to environmental stimuli can be more easily 
observed by a recently developed method to visualize PCA data.
40
 By calculating an 
average position for each data set, such that each PC value (PC1, PC2, etc.) is treated as 
an axis in a Cartesian coordinate system, a distance matrix can be generated. 
Correspondingly, methods developed for representing genetic distances in phylogenetic 
trees can be used to create a metabolomic dendrogram (Figure 6.3b).
43
  Using this 
approach, it becomes clear that stress induced metabolomic responses are very similar to 
the metabolome of the aconitase deficient strain 1457-acnA. As with the 2D scores plot 
(Figure 6.3a), the higher bootstrap values in the dendrogram for ethanol stressed cultures 
also indicate that ethanol has TCA cycle-independent effects on the metabolome.  
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Table 6.1 Metabolites that have increased or decreased concentrations relative to the 
wild-type strain 1457 at 2 h post-inoculation. 
 
Strain 1457
a
 
(DTSB) 
Iron-limitation 
Strain 1457
a
 
(4% Ethanol) 
Ethanol stress 
Strain 1457-acnA
a
 
(TSB) 
TCA cycle inactivation 
Metabolites whose concentration is increased relative to strain 1457 grown in TSB medium. 
  Acetaldehyde  
Acetyl-phosphate Acetyl-phosphate Acetyl-phosphate 
  Citrate 
  Glyceraldehyde  
Metabolites whose concentration is decreased relative to strain 1457 grown in TSB 
medium. 
  Acetyl-glutamate
b
  
  Asparagine  
  Glutamate  
 Lactate  Lactate 
Glutamine  Glutamine Glutamine 
Succinate  Succinate  Succinate  
 
 
a
 The intracellular concentration was considered to be increased or decreased when the 
percent difference in the NMR peak intensities was 5-fold greater than the percent error 
observed in the peak intensities between triplicate NMR spectra. 
b
 Due to peak overlap, we are unable to determine if the metabolite is acetyl-glutamine or 
acetyl-glutamate; however, we note that acetyl-glutamine is uncommon in prokaryotes.   
Metabolites whose concentrations were changed under all stress conditions relative to the 
wild-type strain grown in TSB are shaded in grey. 
  
255 
 
 
 
Table 6.2 Metabolites that have increased or decreased concentrations relative to the 
wild-type strain 1457 at 6 h post-inoculation. 
 
Strain 1457
a
 
(DTSB) 
Iron-limitation 
Strain 1457
a
 
(4% Ethanol) 
Ethanol stress 
Strain 1457-acnA
a
 
(TSB) 
TCA cycle inactivation 
Metabolites whose concentration is increased relative to strain 1457 grown in TSB 
medium. 
Acetaldehyde  Acetaldehyde  Acetaldehyde 
Acetate  Acetate  Acetate  
Acetylalanine    
N-Acetyl-glucosamine N-Acetyl-glucosamine   
 Acetyl-glucosamine 6-phosphate   
N-Acetyl-mannosamine N-Acetyl-mannosamine  N-Acetyl-mannosamine  
N-Acetyl-neuraminate N-Acetyl-neuraminate  N-Acetyl-neuraminate  
Acetyl-phosphate Acetyl-phosphate  Acetyl-phosphate 
  Arginine  
  Citrate  
Ethanol   
Glucosamine  Glucosamine
c
 Glucosamine  
  Galactose-1-phosphate  
GDP  GDP   
Glucose  Glucose  Glucose  
Glucose-1-phosphate   
Glucose-6-phosphate Glucose-6-phosphate  Glucose-6-phosphate 
Glyceraldehyde  Glyceraldehyde  Glyceraldehyde  
Lactate  Lactate  Lactate  
 myo-Inositol   
   Proline  
Ribose
c
 Ribose  Ribose  
 UDP-N-acetyl-glucosamine  
Metabolites whose concentration is decreased relative to strain 1457 grown in TSB 
medium. 
α -Ketoglutarate α -Ketoglutarate α-Ketoglutarate 
ɣ -Aminobutyrate ɣ -Aminobutyrate ɣ-Aminobutyrate 
Acetyl-glutamate
b
 Acetyl-glutamate
b
 Acetyl-glutamate
b
 
  Acetyl-ornithine 
  Alanine 
Arginine    
Asparagine Asparagine Asparagine 
  Aspartate 
β-Alanine β-Alanine β-Alanine 
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Citrulline Citrulline Citrulline 
 Ethanol Ethanol 
Fructose-6-Phosphate Fructose-6-Phosphate Fructose-6-phosphate 
Glutamate Glutamate Glutamate 
Glutamine Glutamine Glutamine 
 
Isocitrate Isocitrate Isocitrate 
Methionine Methionine Methionine 
NAD
+
  NAD
+ 
  
Ornithine Ornithine Ornithine 
O-Succinyl-L-homoserine O-Succinyl-L-homoserine O-Succinyl-L-
homoserine 
Proline Proline  
S-Adenosyl-L-methionine S-Adenosyl-L-methionine S-Adenosyl-L-
methionine 
Sedheptulose   
Selenomethionine Selenomethionine Selenomethionine 
UDP-N-acetyl-
glucosamine  
  
 
 
a
 The intracellular concentration was considered to be increased or decreased when the 
percent difference in the NMR peak intensities was 5-fold greater than the percent 
error observed in the peak intensities between triplicate NMR spectra. 
b
 Due to peak overlap, we are unable to determine if the metabolite is acetyl-glutamine or 
acetyl-glutamate; however, we note that acetyl-glutamine is uncommon in prokaryotes.       
c
 The percentage difference in the NMR peak intensities of these metabolites fell just 
below the 5-fold cutoff in the percent error observed in the peak intensities between 
the triplicate NMR spectra. 
Metabolites whose concentrations were changed under all stress conditions relative to the 
wild-type strain grown in TSB are shaded in grey. 
 
S. epidermidis grown in TSB under aerobic conditions have two distinct 
metabolic states: the nutrient-rich exponential phase and the nutrient-limited post-
exponential phase. The transition from nutrient-rich conditions to nutrient-limited growth 
coincides with the transition from generating ATP by substrate-level phosphorylation to 
using oxidative phosphorylation. The reduced dinucleotides that drive oxidative 
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phosphorylation are primarily derived from the TCA cycle; thus, inhibiting TCA cycle 
activity (Figure 6.1) hinders the transition to oxidative phosphorylation and the post-
exponential growth phase.
8,44
 Iron-limited growth of strain 1457 or aconitase inactivation 
did not significantly alter the growth rate; although, aconitase inactivation did increase 
the lag phase (data not shown). Both aconitase inactivation and iron-limited growth 
caused an early entry into the stationary phase; as such, the growth yield was decreased. 
As stated, the addition of 4% ethanol decreased the growth rate; therefore, it slowed the 
consumption of glucose. Based on these observations, it was reasonable to hypothesize 
that post-exponential growth phase (6 h) stressed metabolomes will be more similar to an 
un-stressed exponential growth phase (2 h) metabolome than to the unstressed 
metabolome of post-exponential growth phase of cultures. As expected, PCA of 
unstressed strain 1457 cultures, grown for 2 or 6 hours, form separate subsets in a 3D 
scores plot (Figure 6.4). Consistent with our hypothesis, PCA of post-exponential growth 
phase stressed and acnA mutant cultures were more closely associated with the unstressed 
exponential growth phase metabolome of strain 1457 than with the strain 1457 post-
exponential growth phase metabolome (Figure 6.4). These data suggest that any stress 
which interferes with TCA cycle function results in a metabolome similar to an 
unstressed exponential phase culture. 
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Figure 6.4 PCA 3D scores plot comparing non-stressed, ethanol stressed, or iron-limited 
cultures of strains 1457 grown for 6 h to that of strain 1457 grown for 2 h. Symbols and 
colors are defined in the figure. The ovals are manually drawn to identify clusters of 
related samples and to guide the reader. They are not statistically relevant. The relative 
contribution of each principal component is indicated within the parenthesis. 
 
6.3.3 Metabolomic changes are largely independent of the σB-mediated general stress 
response  
In staphylococci, σB controls the general stress response and as such is activated 
during stress conditions, growth phase transitions, and morphological changes.
45,46
 As 
stated previously, the regulation of many virulence determinants is affected by 
environmental stresses; therefore, the stress-dependent activation of σB has been an 
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important area of research into the environmental regulation of staphylococcal virulence 
determinants.
47-49
 Interestingly, σB does not directly respond to most environmental 
signals, suggesting another path to transduce stress signals that is independent of σB. To 
test this possibility, an S. epidermidis sigB mutant strain (1457-sigB::dhfr)
19
 was grown 
for two or six hours in TSB, TSB with 4% ethanol, or DTSB and the metabolomes were 
analyzed by NMR spectroscopy. The PCA scores plot demonstrates that the majority of 
metabolomic changes associated with iron-limitation and ethanol stress occur largely 
independent of σB (Figure 6.3a). Additionally, the metabolomic dendrogram confirms the 
stressor induced metabolic changes observed in strain 1457-sigB::dhfr are most closely 
associated with those in the TCA cycle mutant strain 1457-acnA (Figure 6.3b). Taken 
together, these data demonstrate that environmental stresses can alter the staphylococcal 
metabolome by a largely σB-independent mechanism that requires the TCA cycle. 
 
6.3.4 Metabolomic changes precede genetic changes  
Metabolomic data demonstrate that ethanol stress, iron-limitation, and TCA cycle 
inactivation decrease the intracellular concentration of Gln relative to the wild-type strain 
grown in TSB medium (Tables 6.1 and 6.2). The two more likely explanations for the 
decreased intracellular concentration of Gln: i.) the stressors alter enzymatic activity 
causing a decrease in the concentration of Gln; or ii.) the stressors decrease transcription 
of genes involved in the biosynthesis of Gln, resulting in a decreased concentration of 
Gln. If the first possibility is correct, then stressors will cause an increase in the 
transcription of Gln biosynthetic genes, as bacteria attempt to compensate for the 
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decreased availability of Gln. If the second possibility is correct, then stressors will cause 
a decrease in the transcription of Gln biosynthetic genes.  To determine which of these 
two possibilities was correct, we performed northern blot analysis on glutamine 
synthetase (femC; a.k.a. glnA) (Figure 6.5). The data suggest the first possibility is the 
more correct one; specifically, bacteria are responding to metabolomic changes by 
increasing transcription of genes necessary to counterbalance those changes. 
Interestingly, in untreated wild-type cultures, the post-exponential growth phase 
concentration of Glu and Gln increased between 2 and 5 times that of the exponential 
growth phase concentration (data not shown) and this increase correlated with a post-
exponential growth phase decrease in glnA mRNA levels (Figure 6.5). Similarly, Gln and 
Glu were not detected in the NMR spectra of the aconitase mutant strain and this 
correlated with a high level of glnA mRNA in both the exponential and post-exponential 
growth phases. The correlation between Gln and Glu concentrations and glnA mRNA 
levels are consistent with a GlnR-dependent regulation of glnA transcription.
2
 This 
correlation was maintained for Gln/Glu sufficient or insufficient conditions; however, the 
intermediate concentrations of Gln and Glu found during ethanol stress and iron-limited 
growth (data not shown) produce mixed glnA mRNA levels (Figure 6.5). These data 
suggest that for the concentrations of Gln and Glu to affect glnA transcription, the stress-
induced concentration change must be sufficiently large.     
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Figure 6.5 Northern blot analysis of RNAIII and glnA mRNA levels in the exponential (2 
h) and post-exponential (6 h) phases of growth. To ensure that equivalent quantities of 
RNA were loaded in the gel, 23S and 16S rRNA were visualized by ethidium bromide 
staining and used as loading controls (bottom panel). The results are representative of at 
least two independent experiments. 
 
6.3.5 CcpA responds to TCA cycle-associated metabolomic changes  
Ethanol stress, iron-limitation, and TCA cycle inactivation increased the post-
exponential growth phase concentration of glucose-6-phosphate (Table 6.2). Glycolytic 
intermediates such as glucose-6-phosphate and fructose-1,6-bisphosphate increase the 
ATP-dependent phosphorylation of the histidine-containing protein (HPr) by enhancing 
the activity of the HPr kinase.
50
 The increase in phosphorylated HPr enhances its 
interaction with the catabolite control protein A (CcpA).
51-53
 CcpA primarily functions as 
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a repressor; however, it also activates transcription of genes involved in fermentation and 
overflow metabolism.
52,54
 In addition to the concentration of glucose-6-phosphate being 
increased by TCA cycle stress, the concentration of several fermentation products or 
intermediates (i.e., lactate, acetate, and acetaldehyde) and the small phosphodonor acetyl-
phosphate (an indicator of overflow metabolism) were also increased (Table 6.1), 
consistent with a change in CcpA-mediated regulation. The repressor CodY also 
contributes to the regulation of overflow metabolism;
54
 however, CodY responds to the 
intracellular concentrations of branched chain amino acids (BCAA).
55
 TCA cycle stress 
did not alter the concentrations of BCAA beyond the 5-fold threshold (Table 6.1), 
suggesting the increase in overflow metabolism was independent of CodY.  
In S. aureus, CcpA enhances biofilm formation and PIA biosynthesis, while 
CodY represses PIA synthesis.
56,57
 In S. epidermidis, ethanol stress, iron-limitation, and 
TCA cycle inactivation enhance biofilm formation and PIA synthesis.
7,13,14,16,24,58
 Based 
on the metabolomic data and published observations, it was reasonable to hypothesize 
that PIA biosynthesis was regulated in response to TCA cycle-associated metabolomic 
changes by a CcpA-dependent and CodY-independent mechanism. To test this 
hypothesis, ccpA and codY deletion mutants were constructed in strains 1457 and 1457-
acnA and the amount of cell-associated PIA was determined after 6 hours of growth 
(Figure 6.6). Consistent with previous observations,
7
 TCA cycle inactivation (strain 
1457-acnA) dramatically increased the accumulation of PIA, while neither CodY nor 
CcpA had a dramatic effect on the post-exponential growth phase amount of PIA. When 
the codY mutation was introduced into an aconitase mutant background, PIA 
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accumulation resembled the response in strain 1457-acnA, suggesting TCA cycle-
associated changes in PIA biosynthesis are independent of CodY. In contrast to the codY-
acnA double mutant, the ccpA-acnA double mutant failed to produce PIA, strongly 
suggesting that some TCA cycle-associated metabolomic changes (i.e., glucose-6-
phosphate) are “sensed” by CcpA, which in turn activates PIA biosynthesis. 
                                                     
Figure 6.6 CcpA is required for PIA synthesis during TCA cycle stress. PIA immunoblot 
assay of strain 1457 and isogenic mutants of acnA, codY, ccpA, codY/acnA, and 
ccpA/acnA grown for 6 h in TSB. The results are representative of 3 independent 
experiments. 
 
6.3.6 TCA cycle stress decreases RNAIII transcription  
In S. aureus, inactivation of the TCA cycle increases the transcription or stability 
of the accessory gene regulator (Agr) system’s riboregulator RNAIII.8,9 Conversely, 
increasing TCA cycle activity decreases the transcription or stability of RNAIII.
59
 The 
causal relationship between TCA cycle activity and RNAIII transcript levels in S. aureus 
led us to examine if disparate environmental conditions would similarly affect RNAIII 
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transcription or message stability in S. epidermidis. In contrast to S. aureus, TCA cycle 
inactivation decreased RNAIII transcription or stability during the exponential and post-
exponential growth phases in S. epidermidis (Figure 6.5). Importantly, ethanol stress and 
iron-limitation decreased RNAIII transcription or stability in a similar manner to TCA 
cycle inactivation (Figure 6.5). In total, these data suggest that environmental stresses act 
through the TCA cycle to elicit transcriptional changes to at least two of the major 
staphylococcal virulence regulators (i.e., CcpA and RNAIII).  
 
6.4 Discussion 
In the life-cycle of S. epidermidis, the transition from a skin-resident, commensal 
state to adhering on implanted biomaterials represents a dramatic environmental change. 
In most pathogenic bacteria, environmental changes are accompanied by changes in the 
transcription of virulence genes; thus, environmental signals (e.g., nutrient replete, iron-
limiting, or oxygen-limiting growth conditions) commonly regulate virulence gene 
transcription.
2,60-64
 Although S. epidermidis has relatively few virulence determinants, 
one of its primary pathogenic effectors is the exopolysaccharide PIA.
65-68
 Previously, we 
demonstrated that PIA biosynthesis is regulated by TCA cycle activity; specifically, 
repression of TCA cycle activity dramatically enhances transcription of PIA biosynthetic 
genes (icaADBC) and PIA accumulation.
7,24,59
 In this study, we demonstrate that 
dissimilar environmental signals decrease TCA cycle activity (Figure 6.1) resulting in 
common metabolomic changes (Figure 6.3 and Tables 6.1 and 6.2; summarized in Figure 
6.7) that alter the activity of metabolite-responsive regulators such as CcpA (Figure 6.7). 
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These data lead us to propose that it is the TCA cycle itself that is “sensing” the 
environmental transition and transducing this information into metabolic signals that 
activate or repress the activity of metabolite-responsive regulators to modulate the 
expression of PIA and other virulence determinants. 
        
Figure 6.7 Summary of post-exponential growth phase metabolic changes associated 
with TCA cycle stress. Metabolites in green represent an increased concentration relative 
to the wild-type strain. Metabolites in red represent a decreased concentration relative to 
the wild-type strain. Metabolites and pathways in black are inferred from the data but 
they are inconclusive. 
 
As S. epidermidis transitions from residing on the skin to being implanted in a 
host, it enters into an environment where free iron is present at a concentration of 10
-18
 M 
61
, a condition antagonistic to TCA cycle activity (Figure 6.1 & 
9,11
). Similarly, this 
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transition dramatically decreases the availability of free oxygen (the partial pressure of 
atmospheric O2 is 159 mmHg at sea level and this decreases to an estimated 3-5 mmHg at 
the host cell level), a condition that is also antagonistic to TCA cycle activity. Taken 
together, this type of environmental transition is accompanied by conditions that are 
inhibitory to TCA cycle activity and stimulatory to PIA biosynthesis.
7,24
 In other words, 
the transition from an external environment to an internal environment represses TCA 
cycle activity and primes S. epidermidis for PIA synthesis, which enhances biofilm 
formation and increases the likelihood of establishing a biomaterial-associated infection.  
The significance of the data presented here is five-fold: First, it establishes a 
mechanism by which well-established regulators (e.g., CcpA) participate in responding to 
environmental stresses. Second, these data suggest how disparate environmental stimuli 
can cause common phenotypic changes (e.g., iron-limitation and ethanol stress both 
increase PIA synthesis and biofilm formation
13,69
). Third, these data suggest a difficulty 
in attributing the effects of an environmental stimulus, such as iron-limitation, to a 
specific regulator like the ferric uptake regulator (Fur),
70
 is that many of the effects are 
due to metabolite-responsive regulators reacting to changes in the metabolome. Fourth, S. 
epidermidis has a second general stress response system that is largely independent of the 
σB-controlled general stress response (Figure 6.3). Finally, in bacteria, three metabolic 
pathways (Embden-Meyerhof-Parnas, pentose phosphate, and TCA cycle) produce the 
thirteen biosynthetic intermediates needed to synthesize all macromolecules in a bacterial 
cell. Therefore, by linking virulence factor synthesis to the TCA cycle, bacteria are 
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connecting virulence to the availability of biosynthetic intermediates needed to synthesize 
virulence determinants.  
 
6.5 Conclusion  
TCA cycle stress alters the intracellular concentrations of metabolites (Tables 6.1 
and 6.2) relative to those of the wild-type strain 1457. If the change in the concentration 
of a metabolite is sufficiently large, then the activity of a regulator that can respond to 
one of those metabolites may be altered. Therefore, these data present an exceptional 
opportunity to identify regulators that coordinate metabolism and virulence in S. 
epidermidis. Although a considerable amount of research needs to be done to determine 
which metabolite-responsive regulators are involved in responding to TCA cycle 
associated metabolomic changes, the work presented here sheds light on how 
environmental signals alter the bacterial metabolic status to regulate adaptation to a new 
environment. 
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CHAPTER 7 
THE INFLUENCE OF IRON AND AERATION ON STAPHYLOCOCCUS 
AUREUS GROWTH, METABOLISM, AND TRANSCRIPTION 
7.1 Introduction 
Staphylococcus aureus is a versatile pathogen capable of infecting almost any 
niche within a human or animal host. As with most bacterial pathogens, successful 
pathogenesis requires that S. aureus gain entry into a host (e.g., through a breach in the 
skin), adhere to a suitable surface, avoid being killed by host’s immune system, acquire 
nutrients, and proliferate. Notably, every step in this pathogenic process involves 
metabolic changes and/or metabolic regulation. Entry into a host is an environmental 
change that dramatically alters the availability of nutrients and co-factors. Similarly, the 
transition from synthesizing adhesins to producing tissue-damaging secreted virulence 
determinants is preceded by changes in the bacterial nutritional status.
1
 To avoid being 
killed by the host’s immune system, S. aureus alters its metabolism to limit damage by 
oxidative and nitrosative stress.
2
 The act of acquiring nutrients is regulated by metabolite-
responsive regulators that respond to changes in the bacterial metabolic status.
3
 Finally, 
proliferation is a carbon and energy intensive undertaking. In short, S. aureus success as a 
pathogen depends on its ability to meet the rapidly changing nutritional and energy 
requirements necessary for survival and proliferation within a host. The ability to meet 
the changing nutritional and energy requirements is complicated by the host, which limits 
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access to enzymatic co-factors such as oxygen and iron by sequestering these in host 
proteins and molecules (e.g., hemoglobin, heme, and transferrin). The limited availability 
of these co-factors creates metabolic blocks that hinder virulence factor synthesis,
4,5
 
which leaves S. aureus vulnerable to the host’s immune system.  
The potential consequences of a metabolic block(s) (i.e., decreased fecundity, 
fitness, and/or death) create selective pressure to maintain a functional metabolic state. 
Over time, this selective pressure has led to the evolution/acquisition of metabolite-
responsive regulators (e.g., CodY, CcpA, RpiRc) that maintain metabolic homeostasis 
when nutritional and environmental conditions are favorable, and that facilitate metabolic 
adaptations when nutritional and environmental conditions change.
6-8
 Specifically, CodY 
responds to changes in branched chain amino acids and GTP concentrations,
9,10
 while 
CcpA indirectly responds to glucose-6-phosphate and fructose-1,6-bisphosphate.
11
 While 
the RpiR regulators all have sugar isomerases binding domains, the metabolites that 
modulate their activities have yet to be determined.
8
 These metabolite-responsive 
regulators, i.e. CodY, CcpA, and RpiRc, coordinate both virulence determinant 
biosynthesis and metabolism in staphylococci.
8,9,12
 In general, the activity of metabolite-
responsive regulators is controlled by intracellular concentrations of numerous 
compounds, such as biosynthetic intermediates,
13
 amino acids,
14
 nucleic acids,
15
 and co-
factors (e.g., iron).
16
 In Staphylococcus epidermidis, the intracellular concentrations of 
metabolites can be altered by environmental stressors, such as antibiotics, ethanol, metal 
ion-limitation, or nutrient-depletion.
3,17,18
 This creates a mechanism by which 
extracellular stress can be transduced into intracellular metabolic signals that elicit 
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regulatory changes via metabolite-responsive regulators. While the transduction of 
external factors into internal metabolic signals has been demonstrated in S. epidermidis, it 
has not been shown in S. aureus. 
Two important enzymatic co-factors that influence S. aureus fitness and that are 
controlled by the host are oxygen and iron. Numerous studies have shown that oxygen- 
and iron-availability can influence growth, antibiotic tolerance, and synthesis of virulence 
factors;
19-23
 however, little regard has been given to the metabolic changes that 
accompany iron- and oxygen-limitation.
24-26
 Where the metabolic effects of iron- or 
oxygen-limitation have been examined, those studies only addressed the metabolic 
effects of a single stress and in a single growth phase/state. The analysis of a single 
growth phase/state overlooks the fact that staphylococci have two very distinct metabolic 
states that correlate with the exponential and post-exponential growth phases.
27
 Because 
pathogenic bacteria rarely encounter a single stress, we chose to examine the combined 
stresses of iron- and oxygen-limitation on the exponential and post-exponential 
metabolomes. In addition, we also assessed the contributions of the single stresses (i.e., 
iron- or oxygen-limitation) to the overall effects of combined stresses (i.e., iron- and 
oxygen-limitation). Lastly, by analyzing the metabolic effects of single stresses, we can 
identify common metabolic signals, similar to what was done in S. epidermidis.
17,18
 In the 
current study, the effects of oxygen- and iron-limitation on the metabolome of S. aureus 
strain SA564 were examined using NMR metabolomics. In addition, a select set of genes 
were examined for transcriptional changes that might be associated with the altered 
growth conditions.  
277 
 
 
 
7.2 Experimental procedures 
7.2.1 Bacterial strains, media, and cultivation conditions  
S. aureus strain SA564 was grown in tryptic soy broth (TSB; BD Biosciences) or 
on tryptic soy agar (TSA). For iron-limitation cultivation conditions, deferrated TSB 
(DTSB) medium was used.
17
 In this study, iron-limited medium was preferred to “iron-
free” medium because iron-free medium requires the addition of adulterants, such as 
deferoxamine mesylate. These adulterants are added to chelate iron; however, they also 
chelate other cations,
28
 which makes comparison between cultivation conditions 
impractical because more than one variable would be changed. To prevent pyrolysis of 
labile metabolites, DTSB and TSB were prepared by filter sterilization. For iron-limiting 
conditions, bacterial cultures were grown overnight in 10 mL of DTSB, harvested by 
centrifugation at 3,795 x g, washed once in 10 mL of DTSB, and suspended in fresh 
DTSB. This culture was used to inoculate (1:100) the starter cultures, which were 
cultivated in 100 mL of DTSB or TSB for 2 h. After 2 h of growth, these cultures were 
used to inoculate the primary cultures to an optical density at 600 nm (O.D.600) of 0.06. 
Each primary culture was cultivated in pre-warmed DTSB or TSB with defined flask-to-
media ratios. All cultures were grown at 37°C with constant aeration (225 rpm) and 
growth (O.D.600) and pH were measured at hourly intervals for 12 h. For the purpose of 
varying culture aeration during growth, flask-to-media ratios (v/v) of 10:8, 10:4, 10:2.5, 
10:1 were used. This approach takes advantage of the poor diffusion coefficient for 
oxygen into water to alter the amount of oxygen available to the bacteria.
29
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7.2.2 Sample preparation for NMR metabolomic analysis 
Bacterial cultures were harvested during the exponential (2 h) and post-
exponential (6 h) growth phases. For one-dimensional (1D) 
1
H NMR experiments, eight 
biological replicates (10 O.D.600 units each) were harvested for each cultivation condition 
and growth phase. For two-dimensional (2D) 
1
H, 
13
C Heteronuclear Single Quantum 
Coherence (HSQC) experiments, four biological replicates (20 O.D.600 units each) were 
harvested for each cultivation condition and growth phase. Bacteria were harvested using 
a sterile 0.45 µm Microfil V filtration system (EMD Millipore Corporation) that had been 
pre-washed with 5 mL of sterile phosphate buffered saline (PBS, pH 7.4). Following 
filtration, bacteria were washed twice with 5 mL of ice-cold PBS, each membrane was 
transferred to a 50 mL conical tube, and quenched in liquid nitrogen. After quenching, 
the conical tubes were placed in ice and bacteria were collected from the filter using ice-
cold 20 mM phosphate buffer (1 mL). The bacterial suspensions were normalized to 
equal O.D.600 units (10 for 1D NMR and 20 for 2D NMR) in a 1 mL total volume, 
transferred to Lysing matrix B tubes, and lysed twice (Speed 6 and 40 s) using a FastPrep 
FP120 instrument (MP Biomedicals). The samples were rested on ice for 5 min between 
lysings. To remove cell debris and glass beads, samples were centrifuged at 17,000 x g 
for 2 min at -9°C and 700 µL of supernatant from each tube was transferred into a new 2 
mL microfuge tube (pre-cooled to -20
o
C). To the residual sample in the lysing matrix B 
tubes, 1 mL of ice-cold phosphate buffer was added, mixed, and centrifuged. After the 
second centrifugation, 900 µL of the supernatant from each tube were pooled with the 
samples from the first centrifugation. Of the 1.6 mL volume for each sample, 100 µL was 
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removed and the protein concentration was determined using a modified Lowry assay kit 
(Thermo Fisher Scientific). The remaining 1.5 mL of each sample was lyophilized and 
600 µL of D2O was added prior to analysis. 50 µM 3-(trimethylsilyl) propionic acid-
2,2,3,3-d4 (TMSP-d4) or 500 µM TMSP-d4 (Sigma-Aldrich) was added to each sample 
as internal standards for 1D 
1
H NMR or 2D 
1
H, 
13
C HSQC experiments, respectively. 
 
7.2.3 Data Collection 
1D data collection was performed as described,
30
 while 2D time zero extrapolated 
1
H, 
13
C HSQC (HSQC0) NMR spectra were processed as described.
31
 For each sample, a 
total of 1024 data points with a spectrum width of 10.00 ppm in the 
1
H dimension, and 64 
data points with a spectrum width of 140.00 ppm in the 
13
C dimension were collected. A 
total of 16 dummy scans and 64 scans with a receiver gain of 9195.2 and a relaxation 
delay of 1.5 seconds were applied for each sample.  
 
7.2.4 Data analysis 
1D 
1
H NMR spectra were processed as described.
18
 2D 
1
H, 
13
C HSQC spectra 
were processed using the NMRPipe software package.
32
 Peak picking and peak matching 
were done using NMRViewJ Version 8.
33
 A table of peaks along with respective 
intensities were recorded and the concentrations of metabolites were calculated using a 
standard curve generated using nine metabolites with known concentrations: [D-glucose-
13
C6, D-fructose-
13
C6, glycine-
13
C2, DL-alanine-3-
13
C, sodium pyruvate-
13
C3, succinic 
acid-
13
C4, sodium acetate-
13
C2, 2-keto-3-(methyl-
13
C)-butyric acid-4-
13
C, sodium salt, 
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and 2-ketobutyric acid-4-
13
C sodium salt hydrate (Sigma-Aldrich)].
31
 A Student’s T-test 
was used to determine the statistical significance (p < 0.05) of metabolite concentration 
changes.  
The principal component analysis (PCA) and Orthogonal Projections to Latent 
Structures-discriminant analysis (OPLS-DA) scores plots and shared and unique structure 
(SUS)-plots were generated using the SIMCA 12.0+ (UMETRICS) statistical package 
(http://www.umetrics.com/). The OPLS-DA models were validated using a modified 
leave-one-out method
34,35
 and CV-ANOVA.
36
 The metabolomics tree diagrams 
(dendrograms) and the ellipses corresponding to the 95% confidence limits from a normal 
distribution for each cluster within the PCA scores plots were generated using our 
PCA/PLS-DA utilities (http://bionmr.unl.edu/pca-utils.php).
37,38
  
 
7.2.5 Data interpretation 
The peaks were assigned to metabolites using chemical shift references from the 
Human Metabolomics Database (HMDB),
39
 Platform for RIKEN Metabolomics 
(PRIMe)
40
 Biological Magnetic Resonance Data Bank (BMRB)
41
 and Chenomx NMR 
Suite 7.6 (Chenomx. Inc., Edmonton, Canada) software. Heat maps were generated in R 
with a gplots package.
42
  
 
7.2.6 ICP-MS analysis of DTSB 
Cultivation of S. aureus strain SA564 was performed as described. For the 
determination of iron concentrations in the culture supernatants, 1 mL of each culture was 
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harvested during the exponential (2 h) or post-exponential (6 h) growth phases by 
centrifugation at 3,795 x g for 5 min at room temperature. To remove any residual 
bacteria, samples were passed through Nalgene 0.2 µm polyethersulfone membrane 
syringe filters (Thermo Fisher Scientific). All samples were diluted 1:20 with a solution 
containing 52.6 ppb 
71
Ga in 0.1% HNO3, which resulted in a 
71
Ga concentration of 50 
ppb that was used as an internal standard. ICP-MS analyses were performed at the 
University of Nebraska-Lincoln Spectroscopy Core Facility using an Agilent 
Technologies ICP-MS 7500cs with an ESI SC-4 high-throughput autosampler (Elemental 
Scientific Inc.). The concentration of metals was calculated using ChemStation for ICP 
software with a calibration curve for 18 elements from serial dilutions of a standard stock 
from Inorganic Ventures.  The instrument was operated with an octopole collision 
reaction cell filled with He at a flow rate of 5.0 mL/min and the following Ar plasma 
conditions:  plasma power, 1500W, plasma gas, 17 L/min, auxiliary gas, 1 L/min., sample 
gas, 0.9-1.1 L/min and makeup gas 0.1-0.2 L/min, sample flow rate, 0.1 mL/min. For 
each sample, three replicates from three independent cultures were analyzed. Statistical 
significance was determined by one-way ANOVA using SigmaPlot 11.2 software (Systat 
Software Inc).  
 
7.2.7 Aconitase activity assay 
Aconitase enzymatic activity was measured as described.
17
 Protein concentrations 
were determined using a Modified Lowry Protein Assay Kit (Thermo Fisher Scientific). 
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7.2.8 Real-time RT-PCR  
Total RNA was isolated from 10 O.D.600 units of bacteria harvested in the 
exponential (2 h) and post-exponential (6 h) growth phases using the FastRNA Pro Blue 
kit (MP Biomedical) and the RNeasy kit (Qiagen) as described.
43
 For mRNA analysis, a 
two-step real-time RT-PCR was performed with a cDNA synthesis from total RNA 
followed by PCR. Ten µg of TURBO DNase (Bio-Rad) treated total RNA for each 
sample was used to prepare cDNA by reverse transcriptase reaction using an iScript 
master mix (Bio-Rad) according to manufacturer’s protocol. The reaction mixtures for 
Real-time PCR contained 10 µL of 2× SsoAdvanced SybrGreen Supermix (Bio-Rad), 7 
pmoles of each primer (Table 1), and 5 μl of 10-fold diluted cDNA, in a total volume of 
20 μl. As an internal reference, primers for 16s rRNA were used in the same reaction 
volume containing 1000-fold diluted cDNA as a template. The RT-PCR cycling 
conditions were: Initial denaturation at 94°C for 3 min, followed by 40 cycles at 94°C for 
15 sec, 60°C for 25 sec, and 72°C for 20 sec. Relative transcript levels were determined 
by the comparative threshold (∆∆CT) method (Bio-Rad). Experimental set-up and data 
analysis were carried out using CFX96 Real-Time PCR Detection System and Bio-rad 
CFX Manager Software version 3.0 (Bio-Rad).  
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Table 7.1 Real-time RT-PCR primers used in this study. 
Primer Mu50 orf* Sequence 
16SrRNA RTF SAVrRNA16 CGTGCTACAATGGACAATACAAA 
16SrRNA RTF SAVrRNA16 ATCTACGATTACTAGCGATTCCA 
citB RTF SAV1350 GCGCAACAGCAACTGATTTA  
citB RTR SAV1350 GTTGTACACCTGGACCAAAGA 
feoB RTF SAV2584 GGAATGACAGCAACACAGTTAC 
feoB RTR SAV2584 GTGCTGACTGACCACCTAAA 
sbnA RTF SAV0116 TTCTGTAGGGCAAACACCTATG  
sbnA RTR SAV0116 GCTGCCTCCAGGATTCATATAC  
sstC RTF SAV0735 GACCTAATGGTGCGGGTAAG 
sstC RTR SAV0735 CAGACATGAGCTGTCCATCTATT 
*Gene designations based on the Staphylococcus aureus strain Mu50 genomic DNA 
sequence
44
 
 
7.2.9 Acetate, glucose and lactate level determination of the media supernatant 
Metabolite concentrations in the culture media were determined using kits 
purchased from R-biopharm, Inc.  
 
7.3 Results 
7.3.1 Growth of S. aureus under iron- and oxygen-limitation 
The transition from an oxygen- and iron-replete environment (e.g., the skin, the 
nares) to an oxygen- and iron-limited environment (e.g., blood) constrains metabolic 
possibilities because many enzymatic reactions require iron and oxygen as co-factors. 
These constraints have fitness consequences; specifically, the ability to place progeny 
into the next generation.
45-47
 To assess the extent of the fitness cost of iron- and oxygen-
limitation on the growth yield, S. aureus strain SA564 was cultivated under iron- and/or 
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oxygen-limited conditions and the growth was monitored (Figure 7.1a & 1b). As 
expected, the growth rates were largely independent of iron- and/or oxygen-limited 
conditions. Consistent with the Pasteur Effect, oxygen-limited growth conditions 
dramatically decreased biomass generation, whereas, iron-limitation did not significantly 
alter the biomass generated per mmol of glucose (Figure 7.1c).
48
 Importantly, these data 
demonstrate the ease with which a batch culture can become microaerobic/anaerobic at 
an atmospheric oxygen concentration of 20.946% and with vigorous agitation at 225 
rpm.
29
 This transition to a microaerobic/anaerobic status is due to two factors: First, the 
poor diffusion coefficient for oxygen into water; and second, the relatively small surface 
area that is exposed to atmospheric oxygen as the volume of medium in a culture flask is 
increased. In contrast to oxygen-limitation, iron-limitation only decreased the growth 
yield of strain SA564 by ~25% relative to growth in iron-replete culture medium (Figure 
7.1a). In S. aureus, the demand for iron is greatest in the post-exponential growth phase  
when the TCA cycle and the electron transport chain are most active; hence, the small 
amount of iron in the culture medium (Figure 7.1b) is sufficient to maintain the 
exponential growth rate but not the growth yield (Figure 7.1a).
5
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 Figure 7.1 Cultivation of S. aureus strain SA564 under aeration- and/or iron-limitation 
conditions. (a) Growth curves. (b) Iron concentrations of un-inoculated media and from 
cultivation media harvested in the exponential and post-exponential growth phases. (c) 
Glucose utilization as a function of growth. (d) pH profiles. (e) Acetate accumulation and 
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depletion in culture media. (f) Lactate accumulation and depletion in the culture media. 
Data are presented as representative of experiments performed at least twice. The data in 
panel B are presented as the mean of 3 independent experiments done in triplicate with 
error bars representing standard deviations. Figure insets: Culture medium: TSB = tryptic 
soy broth, DTSB = deferrated TSB; Flask-to-medium ratio: 10:1 (aerobic), 10:8 
(microaerobic/anaerobic).  
 
S. aureus is a facultative anaerobe and is well-adapted for growth in low-oxygen 
environments when nutrients are abundant. As nutrients become scarce, S. aureus 
catabolize incompletely oxidized carbon compounds (e.g., lactic acid or acetic acid) that 
accumulate in the medium during the exponential growth phase;
27
 hence, the pH of the 
culture medium will alkalinize. As expected, strain SA564 grown under oxygen- and 
iron-replete conditions began to alkalinize the culture medium during the transition from 
the exponential growth phase to the post-exponential growth phase (Figure 7.1d). Iron-
limited growth slightly delayed and decreased the alkalinization of the culture medium, 
while oxygen-limitation severely restricted alkalinization of the medium.  
In contrast to previous speculation, iron-limitation does not lead to the 
acidification of the culture medium.
26
 As stated above, the acidification of the culture 
medium is the result of the inefficient use of carbohydrates during growth in nutrient-rich 
conditions, which occurs irrespective of the availability of iron or oxygen (Figure 7.1c-
1f). The decreased ability of oxygen-limited cultures, and to a lesser extent iron-limited 
cultures, to alkalinize the medium was most likely due to a diminished capacity to 
catabolize organic acids and amino acids. To address this possibility, the concentrations 
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of acetic acid and lactic acid in the culture media were measured throughout the growth 
cycle (Figure 7.1e and 1f). During microaerobic/anaerobic growth (i.e., when the flask-
to-medium ratio is 10:8), pyruvate is largely reduced to lactic acid (Figure 7.1f).
49,50
 In 
contrast, when the flask-to-medium ratio was altered to 10:1, pyruvate was oxidized to 
acetyl-CoA and CO2 by the pyruvate dehydrogenase complex (Figure 7.1e).
51
 In the 
exponential growth phase, acetyl-CoA is used to generate the small phospho-donor 
acetyl-phosphate, which serves as a substrate for acetate kinase in substrate-level 
phosphorylation to generate ATP and acetic acid (Figure 7.1e). During the post-
exponential growth phase, this acetic acid can be used in the synthesis of acetyl-CoA to 
fuel the TCA cycle. When iron was limiting, the catabolism of acetate and the biomass 
generated from that catabolism were reduced (Figure 7.1e). As expected, oxygen-
limitation inhibited the catabolism of acetate; however, it had only a slight effect on 
lactate catabolism (Figure 7.1e and 1f). The latter data were surprising because acetate 
catabolism through the TCA cycle
27
 and lactate catabolism through L-lactate-quinone 
oxidoreductase (Lqo)
52
 both require electron acceptors to balance the redox status.  
 
7.3.2 Iron- and oxygen-limitation create metabolic blocks 
Staphylococci lack a glyoxylate shunt and catabolize acetate through the 
tricarboxylic acid (TCA) cycle;
27,53
 hence, a diminished ability to catabolize acetate 
(Figure 7.1e) suggests the TCA cycle had reduced activity under iron- and oxygen-
limited growth. To test this suggestion, the TCA cycle enzyme aconitase was assayed for 
activity under iron- and oxygen-limited growth conditions (Figure 7.2a & 2b). Since 
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aconitase is an iron-sulfur cluster containing enzyme, iron-limitation would be expected 
to decrease its activity. As expected, growth of S. aureus strain SA564 in iron-limited 
culture medium dramatically decreased post-exponential growth phase aconitase activity 
(Figure 7.2a). As stated earlier, one function of iron is to facilitate electron transfer 
reactions, a process that requires an electron donor (e.g., NADH, NADPH) and acceptor 
(e.g., oxygen). In the presence of iron but the absence of an electron acceptor, reduced 
dinucleotides will accumulate, which should inhibit enzyme activity through a feedback 
mechanism. To test this hypothesis, we limited oxygen availability by varying the flask-
to-medium ratio and assayed for aconitase activity (Figure 7.2b).
29
 As the medium 
volume was increased the surface area available for oxygen diffusion decreased, resulting 
in a post-exponential growth phase decrease in aconitase activity. While aconitase is an 
excellent metabolic sentinel, iron- and oxygen-limitation will affect the activity of many 
enzymes in bacteria. 
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Figure 7.2 Temporal and stress related aconitase activity differences in S. aureus strain 
SA564 in the exponential (2h) and post-exponential (6h) growth phases. (a) Aconitase 
activity during iron-limited growth. (b) Aconitase activity with decreasing aeration flask-
to-medium ratios of 10:8, 10:5, 10:2.5, 10:1. (c) Addition of iron to DTSB medium 
restores aconitase activity. 
 
7.3.3 Iron and/or oxygen limitation alters the S. aureus metabolome 
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Iron- and oxygen-limited growth created a metabolic block at aconitase in the TCA cycle 
(Figure 7.2a & 2b); however, these stresses will also inhibit the activity of many different 
metabolic enzymes and pathways. It is impractical to assay for all enzymes that might be 
affected by iron- and/or oxygen-limited growth, so metabolic changes were assessed 
using NMR metabolomics (Figure 7.3). As expected, principal component analysis (PCA) 
of exponential growth phase metabolomes revealed they were minimally affected by 
iron-limitation; whereas, oxygen-limitation caused modest changes in the metabolomes 
(Figure 7.3a & 3c). The heterogeneity of the exponential growth phase metabolomes is 
easily demonstrated in a PCA shared and unique structure (SUS)-plot, where very few 
shared or inversely shared metabolites were identified (Figure 7.3e). In contrast to the 
exponential growth phase, iron-limitation significantly altered the post-exponential 
growth phase metabolome PCA scores plot (Figure 7.3b, 3d & 3f). Similarly, oxygen-
limitation had a very pronounced effect on the metabolome. Interestingly, strain SA564 
metabolomes from cultures grown in iron-limited medium and with reduced aeration 
clustered nearer to the aeration-limited cultures than they did with the iron-limited 
cultures in a PCA scores plot (Figure 7.3b). In other words, the effect of iron-limitation 
was masked by growth under conditions that limit the diffusion of oxygen into the culture 
medium. This can also be easily seen in the metabolic heat map where the metabolic 
changes in post-exponential growth phase (6 h) cultures grown under aeration-limitation 
are very similar, irrespective of iron-limitation (Figure 7.4). Taken together, these data 
demonstrate the significance of iron-limitation on S. aureus metabolism is largely 
determined by the growth phase and the availability of oxygen.  
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Figure 7.3 Exponential and post-exponential growth phase metabolomic changes 
associated with iron- and/or oxygen-limited cultivation. PCA scores plot of the (a) 
exponential and (b) post-exponential growth phases of iron- and/or oxygen-limited 
cultures of S. aureus strain SA564. The ellipses in the PCA scores plot correspond to the 
95% confidence limits from a normal distribution for each cluster. Metabolic tree 
generated using the PCA scores plot data demonstrating the relationship of iron- and/or 
oxygen-limited cultures in the (c) exponential growth phase and (d) post-exponential 
growth phase. The statistical significance of each node in the metabolic tree is indicated 
by a p-value. Shared and unique structure (SUS)-plots generated from the PCA model of 
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the (e) exponential and (f) post-exponential growth phases that compares the DTSB, 10:1 
and TSB, 10:8 classes to a common reference (TSB, 10:1). The red boxes highlight the 
chemical shift bins with intensity changes that are shared by both models. The blue boxes 
highlight the chemical shift bins with intensity changes that are negatively-shared by both 
models (relative intensity changes are in the opposite direction). The brown boxes 
highlight the chemical shift bins with intensity changes unique to model 1 (TSB, 10:8 vs. 
TSB, 10:1). The green boxes highlight the chemical shift bins with intensity changes 
unique to model 2 (DTSB, 10:1 vs. TSB, 10:1). In the post-exponential growth phase, 73 
bins were found to be present in the shared/inversely shared region of the plot, compared 
to 29 bins to be found in the same regions of the exponential phase. Culture medium: 
TSB = tryptic soy broth, DTSB = deferrated TSB; Flask-to-medium ratio: 10:1 (aerobic), 
10:8 (microaerobic/anaerobic).  
 
To identify metabolites that contributed to the separation of the sample clusters, 
OPLS-DA was employed (Figure 7.4 & 1.5). In contrast to PCA, OPLS-DA is a 
supervised classification analysis where all the variation leading to separation between 
the two groups is aligned in the X-axis (Pp) and all other variation is aligned in the Y-
axis (Po).
54
 To achieve separation based on aeration in an OPLS-DA scoring plot, 
clusters TSB, 10:1 and DTSB, 10:1 were assigned a value of 0 and the clusters of TSB, 
10:8 and DTSB, 10:8 were assigned a value of 1 (Figure 7.4). This model resulted in one 
predictive and two orthogonal (1+2) components with a cross-validated predictive ability 
of Q
2
(Y)=0.883, which indicated the data fit well within the model. The model was 
validated with CV-ANOVA producing a statistically significant p-value of 8.27x10
-12
. 
Based on this model, the perturbations caused by iron-limitation were largely suppressed 
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when aeration was also limiting. As expected, the majority of the metabolic differences 
between aerobic growth and oxygen-limited growth include fermentation products, 
metabolites of pyruvate homeostasis, and amino acids (Figure 7.4). To achieve separation 
based on iron availability in an OPLS-DA scores plot, clusters TSB, 10:1 and TSB, 10:8 
were assigned a value of 0 and the clusters of DTSB, 10:1 and DTSB, 10:8 were assigned 
a value of 1 (Figure 7.5). This model also produced an excellent fit that resulted in one 
predictive and three orthogonal (1+3) components with a cross-validated predictive 
ability of Q
2
(Y)=0.969 (Figure 7.5). This model was also validated with CV-ANOVA 
producing a statistically significant p-value of 1.33x10
-17
. In this model, the four 
metabolomic clusters are largely separated from each other, suggesting that oxygen-
limitation as a stressor cannot be overwhelmed by iron-limitation. Altogether, the 
clustering of metabolomes in both models suggested that the effects of iron-limitation 
were suppressed by oxygen-limitation.  
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Figure 7.4 (a) OPLS-DA scores plot generated from 1D 
1
H NMR spectra of iron- and/or 
aeration-limited cultures of S. aureus strain SA564 in the exponential (2 h) growth phase. 
The ellipses in the PCA scores plot correspond to the 95% confidence limits from a 
normal distribution for each cluster. TSB, 10:1 (▲); DTSB, 10:1 (▲); TSB, 10:8 (▲); 
DTSB, 10:8 (▲).  (b) Metabolic tree generated using the OPLS-DA data demonstrating 
the relationship of iron- and/or oxygen-limited cultures in the post-exponential growth 
phase. (c) S-plot identifies the chemical shift bins that significantly contribute to class 
separation in the OPLS-DA scores plot. (d) OPLS-DA loading plot comparing two 
aeration conditions 10:1 and 10:8 for S. aureus strain SA564 grown on either TSB or 
DTSB media. Negative values indicate a decrease in peak intensity when comparing 10:8 
to 10:1, while positive values indicate an increase in peak intensity. The color scale on 
the right indicates the relative correlation these data to the OPLS-DA model and class 
separation. 
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Figure 7.5 (a) OPLS-DA scores plot generated from 1D 
1
H NMR spectra of iron- and/or 
aeration-limited cultures of S. aureus strain SA564 in the post-exponential (6 h) growth 
phase. The ellipses in the PCA scores plot correspond to the 95% confidence limits from 
a normal distribution for each cluster. TSB, 10:1 (▲); DTSB, 10:1 (▲); TSB, 10:8 (▲); 
DTSB, 10:8 (▲). (b) Metabolic tree generated using the OPLS-DA data demonstrating 
the relationship of iron- and/or oxygen-limited cultures in the post-exponential growth 
phase. (c) S-plot identifies the chemical shift bins that significantly contribute to class 
separation in the OPLS-DA scores plot. (d) OPLS-DA loading plot comparing two 
aeration conditions 10:1 and 10:8 for S. aureus strain SA564 grown on either TSB or 
DTSB media. Negative values indicate a decrease in peak intensity when comparing 
DTSB media to TSB media, while positive values indicate an increase in peak intensity. 
The color scale on the right indicates the relative correlation these data to the OPLS-DA 
model and class separation. 
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7.3.4 Iron-regulated gene transcription varies with oxygen availability 
If oxygen-limitation can mask metabolic changes associated with iron-limitation, 
then it raises the question as to whether iron-dependent transcriptional changes can be 
obscured by oxygen-limitation. To address this question, bacteria were grown under iron- 
and/or oxygen-limited culture conditions and transcriptional changes in genes regulated 
by iron were assessed using qRT-PCR (Figure 7.7). As a positive control, transcription of 
the aconitase gene acnA/citB was assessed and compared to the enzyme activity data 
(Figure 7.2a). Overall, the acnA/citB mRNA levels correlated well (r = 0.83) with the 
enzymatic activity data. Similar to the metabolomics data, oxygen-limitation was able to 
mask the effect of iron-limited growth on some genes. Specifically, oxygen-limitation 
dramatically decreased the exponential  (2 h) and post-exponential (6 h) growth phase 
transcription of the ferrous iron transporter, feoB, and the first gene (i.e., sbnA) of the 
staphyloferrin B biosynthetic locus.
55
 This reduction in transcript levels occurred despite 
the fact that the culture medium was iron-limited (Figure 7.1b). In contrast to feoB and 
sbnA, some genes [e.g., sstC, which codes for an ATP binding cassette in a siderophore 
transporter]
56
 had only minimal changes in mRNA levels under iron- and/or oxygen-
limited growth. These data demonstrate that iron-dependent regulation of transcription in 
S. aureus can be suppressed under conditions of low oxygen-availability. In addition, 
these data highlight the necessity of carefully considering, and reporting, bacterial 
cultivation conditions.
29
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7.4 Discussion 
When cultures of Staphylococcus epidermidis are challenged with ethanol, 
antibiotics, iron-limitation, or high glucose concentrations, these stresses cause common 
phenotypic changes; namely, they favor biofilm formation and/or biosynthesis of 
polysaccharide intercellular adhesin.
57-60
 These same stresses cause the post-exponential 
growth phase metabolomic profiles to resemble that of an S. epidermidis TCA cycle 
mutant.
17,18
 The fact that divergent environmental challenges produce similar metabolic 
and phenotypic alterations suggests that common regulatory changes are occurring to 
produce the similar phenotypic outcomes.
3
 This suggestion was confirmed when it was 
observed that an S. epidermidis ccpA mutant failed to respond to metabolic changes 
associated with TCA cycle stress.
7
 Similar to S. epidermidis, we hypothesize that 
divergent environmental stresses cause common metabolic changes in S. aureus that alter 
the activity of metabolite-responsive regulators. The first step in identifying metabolite-
responsive regulators is to define the common metabolic changes associated with 
environmental stresses (Figure 7.4 & 1.8). The metabolic effects of many of the 
environmental stresses S. aureus encounters have been studied in detail; however, with 
little, or no, deference to the temporal nature and the interconnectedness of metabolic 
changes.
26,61-63
 The intent of the current study was to identify common metabolic changes 
associated with iron- and/or oxygen-limitation that could alter the activity of metabolite-
responsive regulators; the identification of these regulators is an active area of research in 
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our laboratories. As a side benefit, this study reinforces the necessity of carefully 
considering and reporting cultivation conditions.
64
  
While the most prominent metabolomic differences are in the post-exponential 
growth phase, the exponential growth phase changes are greatest under combined iron- 
and oxygen-limited growth (Figure 7.3, 1.4 & 7.8). As an example, both iron- and 
oxygen-limitation redirect carbon into amino sugar biosynthesis (e.g., UDP-N-acetyl-
glucosamine, glucosamine-6-phosphate, acetyl-glucosamine). This redirection of carbon 
appears to be at the expense of the exponential growth phase basal level TCA cycle 
carbon flow because the concentration of succinate is decreased relative to the iron- and 
oxygen-replete growth conditions (Figure 7.4 & 7.8). We observed a similar redirection 
of carbon into amino sugar biosynthesis in S. epidermidis, where TCA cycle stress 
induces the formation of an N-acetyl-glucosamine polymer known as polysaccharide 
intercellular adhesin.
43,65
 Together these data suggest that TCA cycle dependent 
regulation of polysaccharide intercellular adhesin synthesis is common to the 
staphylococci and not just S. epidermidis. While amino sugar biosynthesis was increased 
during oxygen- and iron-limited growth, S. aureus acidified the culture medium 
irrespective of iron or oxygen availability (Figure 7.1d). This latter observation is 
consistent with previous observations on staphylococcal carbohydrate catabolism,
27,66,67
 
yet inconsistent with more recent speculation.
26
  
As stated above, the metabolic perturbations during iron- and/or oxygen-limited 
cultivation are greatest in the post-exponential growth phase (Figure 7.3a & 3b). These 
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differences are primarily a consequence of three factors: 1.) the TCA cycle is catabolite 
repressed during the exponential growth phase;
27
 2.) de-repression of the TCA cycle 
creates a large demand for iron in the post-exponential growth phase [Fig 1F and 
5
]; and 
3.) TCA cycle activity generates reducing potential, which creates a need for an electron 
acceptor, most commonly, oxygen. Once glucose is depleted from the culture medium 
during growth in iron- and oxygen-replete conditions (Figure 7.1b), catabolite repression 
of the TCA cycle genes is relieved and enzymatic activities increase (Figure 7.2a, 2b & 
1.7). In contrast, when S. aureus are cultivated under iron- and/or oxygen-limited 
conditions, transcription of TCA cycle genes and enzymatic activity remain low despite 
the depletion of glucose (Figure 7.1, 2a & 1.7). Though oxygen and iron are both 
important for post-exponential phase growth (Figure 7.1), the availability of oxygen is the 
major determinant of the metabolome (Figure 7.3b & 1.4). The absence of oxygen 
prevents carbon flow through the TCA cycle, decreasing the concentrations of 
biosynthetic intermediates and the amino acids derived from those intermediates (Figure 
7.2a, 2b & 7.3); specifically, citric acid, succinate, and α-ketoglutarate, glutamate, 
glutamine, aspartate, and asparagine are decreased (Figure 7.4 & 7.8). In other words, the 
decreased carbon flow through the TCA cycle results in multiple amino acid auxotrophies. 
In addition, decreased carbon flow through the TCA cycle likely decreased the 
availability of oxaloacetate/PEP for gluconeogenesis, which is essential for growth when 
glucose has been depleted from the medium. When combined, the amino acid 
auxotrophies, a lack of gluconeogenesis, and inhibition of the electron transport chain 
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(i.e., due to the lack of an electron acceptor) result in a decreased growth yield (Figure 
7.1a).  
Inhibition of electron transport forces bacteria to use alternative pathways to 
oxidize dinucleotides; however, these alternatives are strongly dependent upon carbon 
availability. When carbon sources that can generate pyruvate (e.g., glucose and serine) 
are abundant in the medium, bacteria can maintain redox balance by using enzymes like 
lactate dehydrogenase, which leads to the accumulation of lactic acid in the medium 
(Figure 7.1f & 7.4). In addition to lactate dehydrogenase, S. aureus can oxidize 
dinucleotides through alanine dehydrogenase, a result consistent with the post-
exponential growth phase accumulation of D-alanyl-D-alanine and alanine. These data 
suggest that as readily catabolizable carbon sources were being depleted from the 
medium several pathways are used to oxidize dinucleotides, resulting in an accumulation 
of NAD
+ 
(Figure 7.4). While oxidation of dinucloetides is important, it is only one part of 
redox homeostasis, the other being reduction.  
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Figure 7.6 Heat maps showing the changes in metabolites as a function of cultivation 
conditions and growth phase. Culture medium: TSB = tryptic soy broth, DTSB = 
deferrated TSB; Flask-to-medium ratio: 10:1 (aerobic), 10:8 (microaerobic/anaerobic). 
Statistical significance (p < 0.05): ** = both oxygen- and iron-limitation; * = only 
oxygen-limitation; + = only iron-limitation.  
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Table 7.2. Summary of metabolite changes.
a 
Culture 
conditions 
TSB, 
10:8 
DTSB, 
10:1 
DTSB, 
10:8 
Metabol
ite 
Metabolic Pathway 
Growth phase Ex
p 
PE Ex
p 
PE Ex
p 
PE KEGG 
ID 
KEGG ID 
Xanthosine  ↓  ↓ ↓ ↓ C01762 00230, 01065 
Uracil  ↑     C00106 00240,00410,00770 
UDPAcGlcN ↑↑ ↑↑ ↑↑
↑ 
↑↑
↑ 
↑ ↑↑↑ C00043 00520, 00540,00550 
Succinate  ↑↑
↑ 
 ↑↑
↑ 
 ↑↑↑ C00042 00020,00190,00250,00350,00360 ,00630,00650
,02020 
Ribose    ↓  ↓ C00121 00030,02010 
Proline  ↑↑  ↑  ↑↑↑ C00148 00330,00970 ,01230,02010 
NADH  ↓  ↓  ↓ C00004 00190, 01100, 04020 
NAD+ ↑↑ ↑↑    ↑ C00003 00190 
Lysine  ↑↑
↑ 
   ↑ C00047 00300,00310,00780, 00970,01210,01230,02010 
Lactate  ↑↑
↑ 
    C00186 00010,00620,00640 
GPC  ↓ ↓ ↓↓  ↓↓ C00670 00564,00565 
Glyceraldehyde  ↑↑     C00577 00030,00051,00561 
Glutamine    ↑↑
↑ 
 ↑↑↑ C00064 00230,00240,00250,00330,00471,00970,01230,
02010,02020 
Glutamate    ↑↑
↑ 
 ↑↑↑ C00025 00250,00330,00340,00430,00471,00480,00650,
00660,00970,01210,01230,02010,02020 
Glc6P ↑ ↑↑
↑ 
↑   ↑↑↑ C00352 00250,00520,02060 
Dihydroxyaceto
ne 
↑↑ ↑↑
↑ 
   ↑↑↑ C00184 00561,00680 
Betaine ↓↓ ↓↓ ↓  ↓↓ ↓ C00719 00260,02010 
Aspartate ↑↑  ↓ ↑↑  ↑↑↑ C00049 00250,00260,00270,00300,00330,00340,00410,
00770,00970,01210,01230,02010,02020 
Asparagine ↑↑
↑ 
↑↑
↑ 
↓↓
↓ 
 ↓↓
↓ 
↑↑↑ C00152 00250,00970,01230 
Alanyl-alanine  ↑  ↑↑ ↓ ↑↑↑ C00993 00473,00550 
Alanine ↓  ↓↓  ↓↓ ↑↑↑ C00041 00250,00270,00430 ,00473,00970,01230,02010 
Acetyl-
phosphate 
 ↓↓  ↓ ↓ ↓↓ C00227 00430,00620,00680 
Acetyl-
glucosamine 
   ↓  ↓ C00140 00520, 01110,02010,02060 
Acetate  ↑↑  ↓  ↑↑↑ C00033 00010,00430,00440,00534,00620,00660,00680 
4-
Aminobutyrate 
   ↑  ↑ C00334 00250,00330,00410,00650 
2-
Hydroxyglutara
te 
 ↑↑
↑ 
 ↑↑
↑ 
 ↑↑ C00026 00020,00040,00053,00250,00300,00340,00430,
00471,00650,00660,01210,01230 
         
a“↑” indicates an increase; “↓” indicates a decrease. One arrow represents a p≤0.05 
(Student’s T-test), two arrows represents a p≤0.01, three 3 arrows represents a p≤0.001.  
b
Metabolites altered in the exponential (Exp) growth phase in TSB, 10:8, DTSB,10:1 and 
DTSB10:8 relative to the cultures grown in TSB with a 10:1 flask-to-medium ratio.  
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c
Metabolites altered in the post-exponential phase (PE) of growth in TSB, 10:8, 
DTSB,10:1 and DTSB10:8 relative to the cultures grown in TSB with a 10:1 flask-to-
medium ratio. 
d
KEGG (Kyoto Encyclopedia of Genes and Genomes) database identification number for 
the metabolite and the associate metabolic pathways. 
 
When the TCA cycle is inhibited by iron- and/or oxygen-limitation, the ability to 
reduce dinucleotides and restore redox balance is also greatly impaired. This inability to 
reduce dinucleotides is reflected in the decreased concentrations of TCA cycle associated 
α-
ketoglutarate, glutamate, and glutamine. In addition to the TCA cycle, glycerol-3-
phosphate can be used in an electron transfer reaction to reduce NAD
+
 to NADH and 
generate dihydroxyacetone phosphate. This reduction reaction is consistent with the 
oxygen-limited accumulation of dihydroxyacetone (the phosphate is labile and can be lost 
during harvest and sample preparation to generate the more stable dihydroxyacetone) 
(Figure 7.4). When carbon flow through the TCA cycle and pentose phosphate pathway 
is decreased, the ability to generate reducing potential via the NAD(P)H-dependent 
glycerol-3-phosphate dehydrogenase (Figure 7.4) can be important for redox homeostasis 
and biosynthesis. That being said, this metabolic rearrangement is insufficient to offset 
the accumulation of NAD
+
. In summary, the necessity of maintaining redox homeostasis 
explains why the availability of oxygen (i.e., its function as an electron acceptor) has a 
greater influence on the post-exponential growth phase metabolome than does the 
availability of iron (Figure 7.3b). In the absence of an electron acceptor, iron is not 
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needed for electron transport; hence, the demand for iron will be lower. This also 
explains why oxygen availability alters transcription of genes involved in iron-acquisition 
(Figure 7.7). In essence, decreased oxygen availability suppresses the iron-sparing 
response, a phenomenon similar to that seen in Saccharomyces cerevisiae.
68
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Figure 7.7 Oxygen-limitation influences transcription of iron-regulated genes in the 
exponential (2 h) and post-exponential (6 h) growth phases. Relative mRNA levels for 
acnA/citB, sbnA, feoB, and sstC as determined by qRT-PCR. The data are the mean and 
SEM of at least 2 biological replicates each determined in duplicate. Culture medium: 
TSB = tryptic soy broth, DTSB = deferrated TSB; Flask-to-medium ratio: 10:1 (aerobic), 
10:8 (microaerobic/anaerobic). 
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Figure 7.8 Schematic representation of the central metabolic changes associated with 
iron- or oxygen-limitation. The black/blue arrows indicate exponential/post-exponential 
growth phase increased or decreased intracellular concentrations of metabolites in strain 
SA564 cultivated in TSB with a 10:8 flask-to-medium ratio relative to a control culture 
grown in TSB with a flask-to-medium ratio of 10:1. The red/orange arrows indicate 
exponential/post-exponential growth phase increased or decreased intracellular 
concentrations of metabolites in strain SA564 grown in DTSB with a flask-to-medium 
ratio of 10:1 relative to a control culture of S. aureus strain SA564 grown in TSB with a 
flask-to-medium ratio of 10:1. Statistical significance at the 95% confidence level (p< 
0.05) is denoted by asterisks above the arrows. 
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CHAPTER 8 
CCPE IS A LYSR-TYPE REGULATOR CONTROLLING TCA CYCLE 
ACTIVITY IN STAPHYLOCOCCUS AUREUS 
8.1 Introduction 
 Carbon catabolite repression (CCR) in bacteria is a widespread, regulatory 
phenomenon that represses transcription of genes and operons involved in the catabolism 
of non-preferred carbon sources when the preferred carbon source(s) are present. CCR 
has been studied extensively in Bacillus subtilis and serves as the prototype of CCR-
regulated gene expression in Gram-positive bacteria (reviewed in references 1).
1,2
 In B. 
subtilis, the catabolite control protein A (CcpA) acts in concert with the small 
phosphocarrier proteins histidine-containing protein (HPr) and catabolite repression HPr 
(Crh) to regulate transcription in response to carbohydrate availability. In addition, the 
metabolite-activated bifunctional HPr kinase/phosphorylase is involved in CCR through 
its action of phosphorylating and dephosphorylating Hpr.
3,4
 There are several other 
proteins in B. subtilis that contribute to CCR either in cooperation with, or independently 
of CcpA, including CcpC,
5,6
 CcpN,
7
 CitR,
8
 Crh,
9
 CodY,
10
 and GlcU
11
 (reviewed in 
reference 1a).
1
 In Staphylococcus aureus, homologs of CcpA and CodY regulate the 
transcription of numerous metabolic and biosynthetic genes and virulence determinants; 
thereby, linking staphylococcal carbon metabolism with pathogenicity.
12
  
To identify additional CCR elements in S. aureus, we compared the genomes of S. 
aureus strain Newman with that of B. subtilis strain 168 and found that S. aureus had 
uncharacterized homologs of B. subtilis genes that are known to affect the regulation of 
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carbon catabolism. Here we report about the identification of a putative carbon catabolite 
responsive regulator, CcpE (NWMN_0641) that affects central metabolism by regulating 
tricarboxylic acid (TCA) cycle activity via transcriptional control of the aconitase-
encoding gene citB.  
 
8.2 Methods and materials 
8.2.1 Bacterial strains and culture conditions  
 The bacterial strains and plasmids used in this study are listed in Table 8.1. S. 
aureus strains were grown in Luria-Bertani Lennox (LB-L) medium (BD, Heidelberg, 
Germany) and B. subtilis strains were grown in TSS minimal medium supplemented with 
0.2 % (w/v) glutamine and 0.5 % (w/v) glucose (6). All strains were grown at 37°C and 
aerated at 230 rpm with a flask-to-medium volume ratio of 10:1. Antibiotics, when used, 
were added to the medium at the following concentrations (per milliliter): 10 µg 
chloramphenicol, 50 µg kanamycin, and 8 µg tetracycline.  
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Table 8.1 Strains and plasmids used in this study. 
 
Strain or plasmid Relevant genotype or characteristic(s)a Reference or source 
S. aureus 
RN4220 NCTC 8325-4 r- m+ (restriction-negative, modification-positive) (34) 13 
Newman  Clinical isolate (ATCC 25904); CP-5 producer (35)14 
THa RN4220 ∆ccpE::lox66-aphAIII-lox71, Kanr This study 
TH01 Newman ∆ccpE::lox72 This study 
TH01c TH01 harboring plasmid pTH2c cis-integrated at the NWMN_0640 
locus, leading to a duplication of the NWMN_0640 gene, ccpE+, Tcr 
This study 
B. subtilis 
AF21 ΔamyE::Φ(citBp21-lacZ cat), Cmr (43)15 
CJB9 ΔamyE::Φ(citBp21-lacZ cat) ccpC::spc, Cmr, Spcr (3b)6 
E. coli 
 hsdR17(rk
– mk
+) deoR endA1 gyrA96 recA1 relA1  
supE44 thi-1 F– λ–- Δ(lacZYA-argF) U169 φ80 lacZΔM15 
Invitrogen 
SCS110 dam dcm rpsL (Strr) thr leu endA thi-1 lacY galK galT ara tonA tsx 
supE lac-proAB) [F' traD36 proAB lacIqZ  
Stratagene 
Plasmids 
pBT 1.6-kb PCR fragment of the tet(L) gene of pHY300PLK into Alw26I-
digested pBC SK(+) (Stratagene); Tcr 
(37)16 
pBT2-arcA Allelic replacement vector for S. aureus arcA, harboring the lox66-
aphAIII-lox71 cassette; Kanr 
(10)17 
pBT lox-aph pBT with a 1.6 kb lox66-aphAIII-lox71 fragment obtained from pBT2-
arcA cloned into the PstI site of pBT; Kanr, Tcr 
This study 
pBus1 E. coli-S. aureus shuttle plasmid with multicloning site from 
pBluescript II SK (Stratagene) and the rrnT14 terminator sequence 
from pLL2443; Tcr 
(11)18 
pRAB1 cat, bla, PpagA-cre; pBT2 derivative; expression of Cre in 
staphylococci; Cmr 
(10)17 
pT7HMT pET28-based expression vector, allowing a T7 polymerase-driven 
expression of hexahistidine-tagged fusion proteins, Kanr 
(38)19 
pT7HMT-ccpE pT7HMT derivative harboring the ccpE ORF cloned into the SalI and 
NotI sites of the vector, Kanr  
This study 
pTH2 pBT with a 3 kb fragment covering the NWMN_0641 flanking regions 
and the lox66-aphAIII-lox71 resistance cassette fully replacing the 
ccpE  ORF, Tcr 
This study 
pTH2c pBT with a 2 kb fragment covering the ccpE ORF and 1 kb of the 
upstream region including the NWMN_0640 ORF, Tcr 
This study 
pTH3 pBus1 with a 1.7-kb fragment covering the B. subtilis ccpC promoters 
P1/P2 and the ccpC ORF, Tcr 
This study 
pTH4 pBus1 with a 1.7-kb fragment covering the B. subtilis ccpC promoters 
P1/P2 and the ccpE ORF, Tcr 
This study 
a
 Abbreviations: Cm
r
, chloramphenicol resistant; Kan
r
, kanamycin resistant; Spc
r
, 
spectinomycin resistant; Tc
r
, tetracycline resistant; ORF, open reading frame  
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Table 8.2 Primers used in this study. 
Primer Sequence (5’-3’) 
Construction primer 
MBH152 forward GCAAATTGAGCTCTATCTTTAGAGC 
MBH153 reverse gtcgGATCCGAGCATGTTGCAATTGCC 
MBH154 forward gtcggtacCTGGCGTCGCCTAATTGATAGG 
MBH155 reverse gtcctcgaGTATGGCTGCAGCTTGAATTAC 
MBH225 forward gtcggatcCAGAATAGATTTGATGCTTCAGC 
MBH226 reverse gtcggtACCAACTACGTTCAATTTAACCG 
MBH239 forward ggggtcgacACCAACTACGTTCAATTTAACCG 
MBH255 reverse gtcggtaccTGATTTTCAATATCATATGTATCAC 
MBH338 forward GCATGTCFACCTCCTTTTTGTTATCAATAAG 
MBH341 reverse ctgtctAGATCAACGATATAGAGACAGGG 
5’-RACE primer 
5’ RACE-Adapter  GAUAUGCGCGAAUUCCUGUAGAACGAACACUAGAAGAAA 
NWMN_0640-RT TCTACTGTACACGCATTACC 
citB-RT ACGTCATCCATTGCTTTACG 
RACE_PCR_5’ GATATGCGCGAATTCCTGTAGAACG 
NWMN_0640-PCR CGTGACTAAGCCTATAATACCC 
Cit-PCR GTAATACCTTGCTCTTCTACAGC 
Northern probe primer 
MBH279 forward GGTATTATAGGCTTAGTCACG 
MBH280 reverse GCAGTACATGATTTTCTTTTGG 
MBH281 forward AGACGAAACGAAAACGTTACG 
MBH282 reverse GTAACTTTGTAACATCATCTCG 
Real-time RT PCR primer 
Bs ccpC forward TGTGGAAAAGTATCCGAATGCA 
Bs ccpC reverse CTGCTCCACCCGGTTATGA 
ccpE forward CCGCTGATTCGTTCGACAT 
ccpE reverse CAATTGCAACATGCTCGGAT 
citB forward CAAGATCATCAAGTGCCTATTCGT 
citB reverse CGTGATTACCACGTCTTGAACC 
Bs citB forward TAATCGGCGCGCGAAACTTGTC 
Bs citB reverse CAGTAGCTATTGTTCCGTTTGG 
citZ forward CCGTAGGTTCTCTGAAAGGGC 
citZ reverse AACATCGTCATAACTTGTTCGTTTG 
gyrB forward GACTGATGCCGATGTGGA 
gyrB reverse AACGGTGGCTGTGCAATA 
Bs gyrB forward CATTGGCGAAACGGATCATA 
Bs gyrB reverse GGGTCCGGGACAAAATGTG 
EMSA primer 
ccpE forward CAAATAAAGCCTAAGCAATAT 
ccpE reverse AGTAAACGATAGTCTTCAATC 
citBp forward ATCATTTCTGTCCCACTCCCATC 
citBp reverse GTAAGTATAACTTTGGCCATTCAAGTC 
citZp forward ATTGTAAAATTCATGGATTATTCAC 
citZp reverse CTAAACCTCTTTGTAATTCTGCCAT 
NWMN- 
0640P 
forward GTGATCAATGAAGTGGTTTGAAGG 
NWMN- 
0640P 
reverse CTTTTACCTCTGTGTATTCCCTATC 
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8.2.2 Construction of a S. aureus ∆ccpE mutant  
1 kb fragments, containing the flanking regions of the ccpE (NWMN_0641) gene 
were amplified by PCR from chromosomal DNA of S. aureus strain Newman using 
primer-pairs MBH154/MBH155 and MBH152/MBH153, respectively (primer sequences 
are listed in Table 8.1). The PCR products were digested with KpnI/XhoI and 
BamHI/SacI, respectively, and cloned together with the XhoI/BamHI digested lox66-
aphAIII-lox71 resistance cassette (obtained from pBT2-arcA) into suicide vector pBT to 
generate plasmid pTH2. Plasmid pTH2 was electroporated into S. aureus strain RN4220 
to obtain strain THa, in which the ccpE gene was replaced by the lox66-aphAIII-lox71 
cassette by allelic replacement. THa was then used as a donor for transducing the ccpE 
deletion into other S. aureus strains. The marker-free ∆ccpE mutant TH01 of S. aureus 
strain Newman was constructed by treatment with the Cre recombinase expressed from 
the temperature-sensitive vector pRAB1,
17
 which was subsequently removed from TH01 
by culturing the strain at 42°C. The deletion of ccpE in TH01 was confirmed by PCR, 
pulsed-field gel electrophoresis (PFGE) of total genome SmaI digests, and DNA 
sequencing. 
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Figure 8.1 Schematic representation of the ccpE region of S. aureus and the strategies 
used to obtain the ΔccpE mutant TH01 and the cis-complemented derivative TH01c. 1) 
genetic organization of the S. aureus Newman ccpE region. Open reading frames 
(arrowed boxes) and promoters (vertical arrows) are indicated. 2) a 3-kb fragment 
containing the lox66-aphAIII-lox71 resistance cassette and the flanking regions of the 
ccpE gene was cloned into the vector pBT to generate plasmid pTH2. 3) plasmid pTH2 
was electroporated into S. aureus strain RN4220 to obtain THa (RN4220 ΔccpE::lox66-
aphAIII-lox71), which was used as a donor for transducing the aphAIII-tagged ccpE 
deletion into other S. aureus strains. 4) a marker-free ΔccpE mutant of S. aureus strain 
Newman was obtained by treating a ΔccpE::lox66-aphAIII-lox71 positive derivative of 
strain Newman with a Cre recombinase. Dotted lines between 3 and 4 indicate the region 
removed by Cre. 5) a 2-kb fragment covering the ccpE ORF and 1 kb of the upstream 
region including the NWMN_0640 ORF was cloned into the vector pBT to generate 
plasmid pTH2c. 6) a dam- and dcm-methylation free aliquot of plasmid pTH2c was 
directly electroporated into TH01 to obtain Th01c. 
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8.2.3 Construction of the S. aureus ccpE cis-complementation strain TH01c  
For the cis-complementation of the ccpE mutation in strain TH01, a 2 kb fragment 
containing the wild-type ccpE allele and 1 kb of the upstream region including the 
NWMN_0640 open reading frame, was amplified by PCR from chromosomal DNA of S. 
aureus strain Newman using the primer-pair MBH225/MBH226. The resulting PCR 
product was digested with BamHI/KpnI, and subsequently cloned into BamHI/KpnI-
digested vector pBT to generate the suicide plasmid pTH2c. The plasmid was 
transformed into and purified out of the dam- and dcm-negative E. coli strain SCS110 
(Stratagene), and electroporated into S. aureus strain TH01 to obtain the cis-
complementation strain TH01c (TH01∆ccpE::pTH2c). Restoration of the ccpE wild-type 
gene was verified by sequencing of the respective DNA fragment. 
 
8.2.4 Construction of the B. subtilis ccpC promoter - B. subtilis ccpC and B. subtilis ccpC 
promoter - ccpE trans-complementation plasmids  
Nucleotide sequences covering the B. subtilis ccpC promoter and gene were 
amplified by PCR from B. subtilis strain AF21 using the primer pairs MBH341/MBH255 
and cloned into XbaI/KpnI digested shuttle vector pBus1.
18
 Similarly, the ccpE gene from 
S. aureus strain Newman was amplified by PCR using primers MBH239/MBH226 and 
the ccpE fragment was digested with SalI/KpnI and cloned into pBus1 that was digested 
with the same restriction enzymes. The ccpC promoters P1 and P2 were amplified by 
PCR by using primer pair MBH341/MBH338 and B. subtilis strain AF21 DNA. The PCR 
product was digested with XbaI/SalI and cloned into pre-digested pBus1 harboring the S. 
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aureus ccpE open reading frame. The resulting plasmids, pTH3 (Bs ccpC P1/2-ccpC) and 
pTH4 (Bs ccpC P1/2-Sa ccpE fusion), were used to transform competent cells of CJB9 or 
to electroporate RN4220. The resulting derivatives of RN4220 were then used as a donor 
for transducing it into S. aureus strain TH01.  
 
8.2.5 Aconitase activity assay  
Aliquots (2 mL) of bacteria were harvested after 3, 6, 9 and 12 h of growth in LB-
L, and suspended in 850 µL lysis buffer (90 mM Tris pH 8.0 and 100 µM fluorocitrate). 
Bacteria were mechanically disrupted in a Fast Prep instrument (Qbiogene, Heidelberg, 
Germany) at a speed of 6.0 for 30 sec. The lysate was centrifuged for 1 min at 15,000 x g 
and 4°C. Aconitase activity was assayed in the cell-free lysate as described previously.
20
 
One unit of aconitase activity was defined as the amount of enzyme necessary for a ∆A240 
min
-1
 of 0.0033.
21
 Total protein concentrations were determined according to the method 
described by Bradford.
22
 
 
8.2.6 Citrate synthase activity assay  
Citrate synthase activity was determined with the Citrate Synthase Assay Kit 
purchased from Sigma-Aldrich (Taufkirchen, Germany) with slight modifications. 
Aliquots (2 mL) of bacteria were harvested after 3, 6, 9 and 12 h of growth in LB-L and 
suspended in CelLytic M Cell Lysis Reagent. Bacteria were mechanically disrupted in a 
Fast Prep instrument (Qbiogene) at a speed of 6.0 for 30 sec. The lysate was centrifuged 
for 1 min at 15,000 x g at 4°C, and 10 µL of the cell free lysate was mixed at room 
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temperature with 0.1 mM 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) and 0.3 mM 
acetyl coenzyme A (CoA) in 1x Assay buffer (Sigma-Aldrich). The solution was mixed 
gently, and the absorbance of the reaction mixture at 412 nm (A412) was followed for 1.5 
min to obtain a background reading. After the addition of 0.5 mM oxaloacetate (OAA), 
the absorbance of the reaction mixture at A412 was monitored for an additional 1.5 min to 
detect the formation of 5-thio-2-nitrobenzoic acid (TNB). Citrate synthase activity units 
were calculated as micromoles of TNB produced (i.e., CoA-SH released) per minute per 
milligram of total protein (µmol/min/mg). Total protein concentrations were determined 
according to the method described by Bradford.
22
 
  
8.2.7 Determination of citrate by GC/MS 
Lyophilized cell pellets (10 mg dry weight) of Newman, TH01, and TH01c (each 
harvested after 8 h of growth in LB-L) were combined with 0.5 mL glass beads (Roth, 
Karslruhe, Germany; 0.25 – 0.5 mm diameter) and 1 mL of deuterated methanol 
(MeOD4) was added. This mixture was subjected to homogenizer lysis (FastPrep FP120, 
QBiogene, USA; 3 cycles each of 20 s at 6.5 m/s). After cell disruption, the cell debris 
and glass beads were separated by centrifugation (10 min at 5,000 rpm). The supernatant 
(0.5 mL) was dried under a stream of nitrogen. The residue was dissolved in 50 µL of 
methoxyamine hydrochloride (solution of 20 mg per mL pyridine) and reacted at 30°C 
for 90 min. 50 µL of N-methyl-N-(trimethylsilyl) trifluoroacetamide with 1 % 
trimethylclorosilane (Fluka, Germany) were added and the mixture was incubated at 
37°C for 30 min. GC/MS analyses were performed on a GC/MS Shimadzu QP 2010 Plus 
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(Shimadzu, Duisburg, Germany) equipped with a fused silica capillary column (Equity 
TM-5; 30 m × 0.25 mm, 0.25 µm film thickness; SUPELCO, Bellafonte, PA) and a QP-
5000 mass selective detector (Shimadzu, Duisburg, Germany) working with electron 
impact ionization at 70 eV. An aliquot (1 µL) of the solution was injected in 1:10 split 
mode at an interface temperature of 250°C and a helium inlet pressure of 76 kPa. The 
column was developed at 70°C for 5 min and then with a temperature gradient of 
5°C/min to a final temperature of 310°C that was held for 1 min. Data were collected 
using the LabSolutions software (Shimadzu, Duisburg, Germany). Compound peaks were 
assigned by comparison of the resulting mass spectra with those of a spectral library 
(NIST05, Shimadzu) and with data of injected reference samples under the same 
conditions.   
 
8.2.8 Transcriptional analyses  
For Northern blot experiments, overnight cultures of S. aureus were diluted to an 
A600 of 0.05 into fresh pre-warmed LB-L and grown at 37°C and 230 rpm. Samples were 
removed from the culture at the indicated times and centrifuged at 9,000 × g and 4°C for 
2 min, the culture supernatants were discarded, and the cell pellets were snap frozen in 
liquid nitrogen. Total RNAs were isolated according to,
23
 and blotting, hybridization, and 
labeling were performed as described previously.
24
 Primer pairs MBH279/MBH280 and 
MBH281/MBH282 were used to generate digoxigenin-labeled NWMN_0640- and ccpE-
specific probes by PCR labeling, respectively. 
323 
 
 
For the quantification of transcripts by real-time RT-PCR, RNA isolations and 
real-time RT-PCRs were carried out essentially as described in (17).
25
 The obtained 
cDNA was used for real-time amplification with specific primers (Table 8.1) and 20 ng 
of cDNA per reaction. mRNA levels were normalized against the mRNA level of gyrB, 
which is constitutively expressed under the conditions analyzed.
26
 The amounts of 
different transcripts were expressed as the n-fold difference relative to the control gene 
(2
-∆CT
, where ∆CT represents the difference in threshold cycle between the target and 
control genes).  
 
8.2.9 Determination of transcriptional start sites of NMMN_0640 and citB  
Strain Newman TF was grown for 3h as described and the bacteria were harvested 
by centrifugation at 8,000 × g for 10 min. RNA isolation was carried out as described 
above. The transcriptional start points of NMMN_0640 and citB were determined by 
rapid amplification of cDNA ends essentially as described by (19).
27
 The reverse 
transcription of 8.2 µL of the ligated RNA was carried out with NMWN_0640 or citB 
specific primers (Table 8.1) with the High Capacity cDNA Reverse Transcription Kit 
(Life Technologies) according to the manufacturer’s instructions. 2 µL of the cDNA was 
amplified by PCR using a primer complementary to the RNA adapter sequence, and a 
specific primer for NMWN_0640 or citB (Table 8.1) closer to the 5’-end than the primers 
used for the reverse transcription. Finally, the PCR products were sequenced. 
 
8.2.10 Antibody production and Immunoblotting  
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Polyclonal anti-CcpE antibodies were raised by injecting 500 µg of the His-tagged 
recombinant CcpE into rabbits (Eurogentec, Liege, Belgium). The resulting crude 
antisera were purified against the immobilized CcpE antigen. For the determination of 
CcpE, cytoplasmic protein extracts were isolated from S. aureus cell cultures grown for 
3, 6, 9 and 12 h in LB-L at 37°C as described previously,
28
 and protein fractions (20 
µg/lane) were separated using SDS-PAGE, blotted onto a nitrocellulose membrane, and 
subjected to Western blot analysis using the antigen-purified polyclonal anti-CcpE 
antiserum.  
 
8.2.11 Electrophoretic Mobility Shift Assays  
The DNA probes for electrophoretic mobility shift assays (EMSAs) were 
generated by PCR using S. aureus strain Newman chromosomal DNA as a template, and 
primer pairs (listed in Table 8.1) that amplified the DNA regions preceding the ccpE, 
citB, citZ, and NWMN_0640 ORFs. The 5’-ends of the double-stranded PCR products 
were labeled using [ɣ-32P] ATP and T4 polynucleotide kinase. A typical assay mixture 
contained (in 20 µL) 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 
0.1 µg of nonspecific competitor (poly(dI-dC)), 5% (v/v) glycerol, radioactive DNA 
probe (2000 cpm mL
-1
), and various amounts (0, 15, 65, 130, and 200 nM) of purified 
CcpE. After 30 min of incubation at room temperature, 20 µL of this mixture was loaded 
into a native 4% (w/v) polyacrylamide Tris borate-EDTA Ready Gel (Bio-Rad) and 
electrophoresed in 1% Tris borate-EDTA (v/v) buffer for 1 h at 100 V cm
-1
. Radioactive 
species were detected by autoradiography using direct exposure to films. 
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8.2.12 NMR Sample preparation  
S. aureus strains were grown in filter-sterilized Luria-Bertani Lennox (LB-L) 
medium (BD, Heidelberg, Germany) supplemented with 0.1% glucose (Sigma-Aldrich). 
Bacteria from overnight cultures were diluted into pre-warmed medium to an optical 
density at 600 nm (OD600) of 0.05. All bacterial cultures were incubated at 37
o
C under 
aerated conditions at 225 rpm with a flask-to-medium ratio of 10:1. For two-dimensional 
(2D) 
1
H, 
13
C HSQC analysis LB-L medium containing 0.1% 
13
C6-glucose (Cambridge 
Isotope Laboratories) was used for main cultures. NMR samples for intracellular 
metabolite analysis were prepared from independent cultures in exponential (3 h) and 
post-exponential (8 h) growth phase.  The extraction of the metabolome from cell lysates 
followed our previously published protocols.
29,30
  
 
8.2.13 NMR data collection, analysis and interpretation  
Followed as previously published.
29,30
 
 
8.2.14 Statistical analyses  
 Statistical significance was assessed using Student’s t-test or Mann–Whitney U 
test. P values < 0.05 were considered significant. 
 
8.3 Results 
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8.3.1 Identification of potential carbon metabolism-affecting factors in S. aureus strain 
Newman 
A bioinformatic comparison of the genomes of B. subtilis isolate 168 (Genbank 
acc. no. AL009126.3) and S. aureus strain Newman (acc. no. AP009351.1) suggested the 
strain Newman genome might have genes whose products have been associated with 
carbon catabolite repression (CCR) in B. subtilis (reviewed in reference 1). One 
uncharacterized gene was NWMN_0641 (renamed here as ccpE), which shared 61% 
similarity and 35% identity to the B. subtilis citrate-responsive regulator CcpC, and like 
CcpC it was predicted to encode for a putative transcriptional regulator of the LysR 
family. These observations and the fact that CcpC is a regulator of tricarboxylic acid 
(TCA) cycle genes citZ (encoding citrate synthase) and citB (encoding aconitase)
6
, led us 
to examine the function of CcpE in S. aureus.  
 
8.3.2 Transcriptional organization of the ccpE locus in S. aureus strain Newman  
Our microarray analysis of σB-mediated transcriptional changes suggested that 
ccpE might form a bi-cistronic operon with the open reading frame (ORF) 
NWMN_0640.
31
 Further bioinformatic analysis of this region suggested that both genes 
were likely controlled by a promoter located upstream of NWMN_0640. To test this 
suggestion, we assessed the transcription of NWMN_0640 and ccpE by Northern blotting 
(Figure 8.1a). This Northern blot analysis revealed ccpE-specific transcripts with sizes of 
approximately 4.1-, 2.9-, 2.3-, and 1.5-kb. The 2.9- and 1.5-kb transcripts migrated on the 
gel to the same extent as the 16S- and 23S rRNAs; hence, they might represent 
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degradation products of higher molecular weight transcripts. That being said, all 
transcripts were detectable throughout the growth cycle and the transcription profiles of 
ccpE and NWMN_0640 were nearly identical. Based on these results, and on the genetic 
organization of the ccpE locus (Figure 8.1b), we hypothesized that all transcripts 
originate from a single promoter in front of NWMN_0640, which would give rise to a 
NWMN_0640/ccpE encoding 2.3-kb transcript, and a larger NWMN_0640/ccpE 
/NWMN_0642/3 encoding 4.1-kb transcript.  
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Figure 8.2 Transcriptional organization of the ccpE locus of S. aureus Newman  
A, Northern blot of NWMN_0640 and ccpE transcriptions in strains Newman, TH01 
(ΔccpE), and the complemented TH01c during growth in LB-L. Approximate transcript 
sizes are indicated on the left. Ethidium bromide-stained 16 S rRNA are presented to 
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indicate equivalent RNA loading. B, schematic representation of the ccpE region of S. 
aureus. Proposed ORFs, promoters, terminators, and transcripts identified by Northern 
analyses are indicated. ORF notations and nucleotide (nt) numbers correspond to those of 
the respective genomic regions of strain Newman (GenBank accession 
number AP009351.1). C, nucleotide sequence of the region preceding the NWMN_0640 
open reading frame. The transcriptional start point identified by RACE (bent arrow), 
putative −35 and −10 boxes (boxes), terminator sequences (hatched lines), and primers 
used to amplify the NWMN_0640-ccpE promoter fragment used in EMSA (horizontal 
arrows) are indicated. D, binding activity of CcpE to the DNA regions preceding the 
NWMN_0640 and ccpE ORFs. The PCR-amplified DNA fragments were radioactively 
labeled and incubated with the amount of purified CcpE indicated. The results are 
representative of at least two independent experiments. E, Western blot analysis of CcpE 
in cytosolic extracts of strains Newman, TH01, and TH01c cells grown in LB-L to the 
time points indicated. The results are representative of at least two independent 
experiments. 
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Figure 8.3 Growth characteristics of S. aureus strain Newman (black symbols), TH01 
(white symbols), and TH01c (gray symbols). Culture media pH and A600values during 
growth in LB-L medium (A) and LB-L supplemented with 0.1% glucose (B). Time points 
of sampling for downstream applications (enzyme assays, qRT-PCRs) are indicated 
byarrows. The data presented are mean ± S.D. of at least three independent experiments. 
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Student's t test *, p < 0.05; **, p < 0.01. C, glucose, acetate, and ammonia concentrations 
in the culture supernatants of Newman (black bars), TH01 (white bars), and TH01c (gray 
bars) cell cultures grown in LB-L + 0.1% glucose. The data presented are mean ± S.D. of 
at least three independent experiments done in duplicate. Mann-Whitney U test. **, p< 
0.01. 
                               
To identify the transcriptional start point (TSP) of NWMN_0640, we performed a 
5`RACE experiment which identified a TSP 14 bp upstream of the proposed start point of 
the NWMN_0640 open reading frame, and immediately upstream of the putative 
ribosomal binding site of this ORF (Figure 8.1c). The TSP is preceded by the nucleotide 
sequence ATGACA-17-TATAAT that strongly matched with the -35 and -10 hexamers 
identified in the promoters of genes shown to be transcribed by S. aureus σA containing 
RNA-polymerase.
32,33
 
Since many LysR-type of regulators display autocrine regulation of their own 
transcription,
34
 we determined the capacity of CcpE to bind to its own promoter. To do 
this, purified CcpE was used in electrophoretic mobility shift assays with a PCR probe 
covering the genomic region preceding the NWMN_0640 ORF (Figure 8.1d). As 
expected, a clear, dose-dependent shift with CcpE and the radioactive-labeled 
NWMN_0640 promoter probe fragment was observed, suggesting that CcpE affects its 
own transcription. This DNA binding activity was specific, as an EMSA using a DNA 
probe covering the region preceding the ccpE ORF did not cause a mobility shift. Taken 
together, our data suggest that ccpE is transcribed in a bi-cistronic message using a 
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promoter upstream of NWMN_0640, and that this promoter is subjected to autocrine 
regulation by CcpE. 
 
8.3.3 Inactivation of ccpE in S. aureus strain Newman  
Using the cre-lox based deletion system described by Leibig and colleagues,
17
 we 
created a marker-less deletion of ccpE in S. aureus strain Newman, giving rise to strain 
TH01. In addition, a cis-complemented derivative was created by integrating the 
NWMN_0640/ccpE containing suicide plasmid, pTH2c, into the deletion site of strain 
TH01, resulting in strain TH01c. Sequencing of the respective genome regions confirmed 
the mutations occurred as expected. Further, Northern blot analysis qualitatively 
confirmed that strain TH01 did not produce a ccpE-specific transcript, while strain 
TH01c expressed ccpE at a level comparable to that of the wild-type strain (Figure 8.1a). 
Probing total RNA from TH01 and TH01c with a NWMN_0640-specific probe also 
confirmed the deletion of ccpE in TH01, as we detected in strain TH01 NWMN_0640-
specific transcripts of approximately 3.3- and 1.5-kb. These mRNA sizes are consistent 
with the deletion of 800 bp of the ccpE locus in this mutant. Importantly, 
complementation restored all NWMN_0640-specific transcripts found in the wild-type 
strain and also transcripts that were identified in TH01. This latter result was expected 
due to our complementation strategy that created a duplication of the NWMN_0640 gene 
due to the insertion of the suicide plasmid pTH2c in the NWMN_0640 open reading 
frame. Taken together, these data confirmed that the correct gene was inactivated and that 
wild-type transcription profiles could be restored by complementation.     
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To assess the production of CcpE in S. aureus, rabbit polyclonal antibodies were 
generated against CcpE and used in Western blot analyses of cytosolic protein fractions 
from strains Newman, TH01, and TH01c grown in LB-L (Figure 8.2). In these anti-CcpE 
Western blots, 33 kDa bands in both the wild-type strain and complemented strain TH01c 
were observed throughout the growth cycle and, as expected, this band was absent in the 
ccpE mutant strain TH01. These data were consistent with the Northern data (Figure 
8.1a) and indicated that CcpE accumulated in the cytosols of the wild-type and TH01c 
strains during the later stages of growth. 
 
8.3.4 CcpE affects the in vitro growth yield of S. aureus  
To determine if ccpE inactivation affected the physiology of S. aureus, we 
assessed the growth and the culture medium pH profiles of strains Newman, TH01, and 
TH01c in LB-L medium in absence or presence of 0.1% supplemental glucose (Figure 
8.3a). In LB-L medium lacking glucose, strain TH01 displayed a slight decrease in the 
growth yield relative to the wild-type and TH01c strains (Figure 8.3a). Additionally, the 
pH of the culture medium for strain TH01 was less alkaline than for the wild-type and 
TH01c strains, indicating that the ccpE mutant was either impaired in amino acid 
catabolism or that the accumulation or depletion of organic acids has changed. 
Supplementation of LB-L with 0.1% glucose increased the overall growth yields of all 
three strains relative to cultures grown in LB-L, but it did not alter the growth rate 
(Figure 8.3b). The similarity of the growth rates but the differences in growth yields 
suggested that exponential growth phase metabolism was similar but that post-
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exponential growth phase metabolism was altered. Consistent with this suggestion, the 
pH profiles and glucose, acetate, and ammonia accumulation in the medium were nearly 
identical up until the post-exponential growth phase (Figure 8.3). In the post-exponential 
growth phase, the culture medium of strain Newman and TH01c began to alkalinize as 
acetate was extracted from the medium for catabolism via the TCA cycle, and ammonia 
accumulated due to the deamination of amino acids (Figure 8.3c). In contrast to strains 
Newman and TH01c, alkalization of the culture medium from strain TH01 was very 
slow, as both acetate catabolism and ammonia accumulation were repressed. This 
reduced ability to catabolize acetate and amino acids was also reflected in the decreased 
biomass generation and final growth yield. As acetate catabolism and amino acid 
catabolism were repressed, these data suggested that ccpE inactivation 
inhibited/decreased TCA cycle activity. 
 
8.3.5 Deletion of ccpE alters the S. aureus metabolome  
The deletion of ccpE changed the accumulation and depletion of organic acids in 
the culture medium and the pH profile (Figure 8.3), suggesting that ccpE inactivation 
caused significant metabolic changes. To test this hypothesis, strains Newman, TH01, 
and TH01c were grown in LB-L medium containing 0.1% 
13
C-glucose and the 
metabolomes were analyzed by NMR spectroscopy. The metabolomic analysis of strains 
Newman, TH01, and TH01c grown in LB-L medium containing 0.1% 
13
C-glucose 
provided a metabolic snapshot of the exponential (3 h) and post-exponential (8 h) growth 
phases (Figure 8.4). Consistent with growth and pH profiles for the strains (Figure 8.3b), 
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an exponential growth phase PCA plot (Figure 8.4a) revealed no significant differences 
in the metabolomes of strains Newman, TH01, and TH01c. In contrast to the exponential 
growth phase, ccpE inactivation had a major effect on post-exponential growth phase 
metabolism (Figure 8.4b-e). In particular, carbon flow through the TCA cycle was 
reduced as evidenced by the accumulation of citrate and the shunting of pyruvate into 
fermentative pathways. The accumulation of citrate in strain TH01 was also confirmed in 
bacteria cultivated in LB-L without glucose, using gas chromatography-mass 
spectrometry (GC-MS) (Figure 8.5). The metabolic block in the TCA cycle created by 
ccpE inactivation led to a reduction in the intracellular concentrations of glutamate and 
glutamine, which affects the availability of nitrogen donors. The decreased ammonia 
assimilation via glutamate to glutamine may be the cause for an increased concentration 
of asparagine, which is generated by amination of aspartate via asparaginase. In 
summary, we can conclude that CcpE is involved in regulating carbon flow through the 
TCA cycle, independent of glucose or its catabolic products.  
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Figure 8.4 Effect of the ccpE deletion on the metabolome of S. aureus strain 
Newman. Aand B, two-dimensional PCA scores plots generated from the entire one-
dimensional 
1
H NMR spectra of the exponential growth phase (3 h) metabolomes (A), 
and post-exponential growth phase (8 h) metabolomes (B) of strains Newman (black 
triangles), TH01 (red triangles), and TH01c (gray triangles). C, two-dimensional
1
H, 
13
C-
HSQC difference spectrum showing the post-exponential growth phase differences 
between strains Newman (green) and TH01 (red). D, a heat map of six independent 
replicates showing the major differences in metabolites produced in post-exponential 
growth phase by strain TH01 in relationship to strain Newman. Relative concentration 
changes were plotted as outlined under “Experimental Procedures,” using a color-scale 
from −1 (red) to 1 (green). The dendrogram depicts hierarchal clustering of the 
metabolite concentration changes, where metabolites exhibiting the same relative trend 
and magnitude changes across all replicates are clustered together (n = 6). A 
Student's t test was used to determine the statistical significance of each metabolites 
change between the TH01 and Newman strains (*, p < 0.05). 
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Figure 8.5 CcpE-dependent changes in the metabolome of S. aureus. A, a cytoscape 
map showing the changes in the central metabolism associated with ccpE inactivation. B, 
overlays of representative GC/MS profiles of Newman, TH01, and TH01c whole cell 
extracts of 8-h LB-L cultures. The elevated citrate peak observed with TH01 is indicated. 
 
8.3.6 Inactivation of ccpE affects transcription of TCA cycle genes and its activity  
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The CcpE open reading frame in S. aureus was identified based on its homology 
to CcpC in B. subtilis. CcpC is involved in the regulation of the TCA cycle genes citZ 
and citB;
5,6,8
 hence, we hypothesized that CcpE might regulate the same TCA cycle genes 
in S. aureus. To test this assumption, transcription of the TCA cycle genes citZ and citB 
was assessed by qRT-PCR in strains Newman, TH01, and TH01c grown in LB-L 
medium (Figure 8.6). In the wild-type strain Newman, citZ and citB mRNAs were at the 
highest levels just prior to the post-exponential growth phase (Figure 8.6a). Inactivation 
of ccpE decreased transcription of both citB and citZ; however, the effect on citB was 
more dramatic. Complementation of the ccpE mutation restored citZ and citB 
transcription to levels similar to that in the wild-type strain. Thus, in order to determine if 
the differences in citB and citZ transcription were reflected in enzymatic activity changes, 
the activities of citrate synthase and aconitase were measured in the wild-type, TH01, and 
TH01c strains as well (Figure 8.6b). Consistent with the transcriptional data, citrate 
synthase activity was decreased in strain TH01 at 3 h of growth only, while aconitase 
activity was significantly decreased in TH01 cells in all growth phases. Also consistent 
with the transcriptional data, complementation of the ccpE mutation restored citrate 
synthase and aconitase enzymatic activities to those in the wild-type strain, strongly 
suggesting that CcpE is a major positive transcriptional regulator of citB in S. aureus.  
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Figure 8.6 Transcription and activity of citZ and citB in strain Newman and its 
derivatives. A, quantitative transcript analysis of citZ andcitB by qRT-PCR of strains 
Newman (black bars), TH01 (white bars), and TH01c (gray bars) during growth in LB-
L. mRNA levels are expressed relative to gyrase B (in numbers of copies per copy 
of gyrB). The data presented are mean ± S.D. of four independent experiments each 
determined in duplicate. B, enzyme activities of citrate synthase, and aconitase of strains 
Newman (black bars), TH01 (white bars), and TH01c (gray bars) during growth in LB-
L. The data are presented as the mean ± S.D. of three independent experiments done in 
duplicate. Mann-Whitney U test *, p < 0.05; **, p < 0.01. C, EMSA using purified CcpE 
and the DNA probes generated from the citB and citZ promoters. The PCR-amplified 
DNA fragments were radioactively labeled and incubated with the amount of purified 
CcpE indicated. The results are representative of at least two independent experiments. 
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8.3.7 CcpE binds to the citB promoter  
To assess whether CcpE might directly regulate transcription of citB and citZ by 
binding to the respective promoters, we performed EMSAs using the citZ and citB 
promoters as probes (Figure 8.6c). The probe generated from the citB promoter shifted 
with CcpE in a dose-dependent manner; however, the citZ promoter region was not 
shifted by CcpE, suggesting that CcpE directly controls the expression of citB but not 
citZ. The similarity of CcpE to CcpC and the fact that citrate accumulated when ccpE was 
inactivated, led us to determine if citrate would influence CcpE DNA binding activity. In 
contrast to B. subtilis CcpC, the binding activity of CcpE was independent of the 
concentration of citrate in the binding buffer. Similarly, the CcpE binding was 
independent of NAD
+
 and NADH. These data suggest that CcpE is not a functional 
ortholog of CcpC, but a newly described TCA cycle regulator.   
 
8.3.8 CcpE is not a functional homolog of CcpC  
In B. subtilis, CcpC regulates transcription of TCA cycle genes in response to 
changes in citric acid, and inactivation of ccpC increases the exponential growth phase 
transcription of citB.
6
 Although ccpE inactivation decreases citB transcription and its 
DNA binding properties are not altered by citric acid; out of an abundance of caution, we 
assessed whether the S. aureus ccpE gene could complement a B. subtilis ccpC mutant 
and whether the B. subtilis ccpC gene could complement our S. aureus ccpE mutant. To 
do this, plasmids having ccpC under the control of its native promoter (pTH3) and a 
fusion plasmid harboring the B. subtilis ccpC P1 and P2 promoters fused to the S. aureus 
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ccpE ORF (pTH4) were constructed. These plasmids were transformed into TH01 and 
the B. subtilis ccpC mutant CJB9,
6
 respectively, and the final transformants were tested 
for CcpE by Western blotting and citB, ccpC, and ccpE transcription using qRT-PCR 
(Figure 8.7). As expected, citB transcription was increased in the B. subtilis ccpC mutant 
strain CJB9 when grown in TSS minimal medium supplemented with 0.2 % (w/v) 
glutamine and 0.5 % (w/v) glucose. Complementation of strain CJB9 with ccpC under 
the control of its native promoter, plasmid pTH3, restored citB transcription to wild-type 
levels. In contrast, transforming strain CJB9 with plasmid pTH4, harboring the S. aureus 
ccpE under the control of the B. subtilis ccpC P1 and P2 promoters, failed to revert citB 
transcription to wild-type levels. To exclude that the inability of CcpE to restore wild-
type citB mRNA levels was due to the fact that it was not transcribed or translated, we 
assessed the ccpE transcription using qRT-PCR and CcpE translation by Western 
blotting. In strain CJB9 containing plasmid pTH4, ccpE was strongly transcribed and 
CcpE was produced in large quantities (Figure 8.7a), demonstrating that the inability of 
ccpE to complement a ccpC mutation was neither due to a failure of transcription nor 
translation. Similarly, transforming strain TH01 with plasmids pTH3 (containing ccpC) 
or pTH4 (containing ccpE) increased citB transcription to wild-type levels with ccpE but 
not ccpC (Figure 8.7b). Taken together, these data demonstrate that CcpE is not a 
functional homolog of CcpC.   
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Figure 8.7 Trans-complementation ofB. subtilis ccpC and S. aureus ccpE mutants. A, 
Western blot analysis of CcpE in cytosolic extracts of B. subtilis strains AF21, CJB9 
(AF21::ccpC), CJB9 + pTH3 (ccpC under the control of its native promoters), CJB9 + 
pTH4 (ccpC P1/2-ccpE fusion), S. aureus strains Newman, TH01, TH01 + pTH3, and 
TH01 + pTH4 after growth in LB-L for 6 h. The results are representative of at least two 
independent experiments. B, quantitative transcript analyses of ccpC, ccpE, and citB by 
qRT-PCR of B. subtilisderivatives grown in TSS minimal medium supplemented with 
0.2% (w/v) glutamine and 0.5% (w/v) glucose, and S. aureus derivatives grown in LB-L 
to the mid-exponential growth phase. The data presented are mean ± S.D. of four 
independent experiments each determined in duplicate. #, transcripts below detection 
limits. 
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8.4 Discussion 
Central metabolism provides S. aureus with the thirteen biosynthetic 
intermediates from which it derives all macromolecules; hence, central metabolism is 
critically important for growth and survival.
35
 The TCA cycle is one component of 
central metabolism that provides the bacterium with energy, reducing potential and three 
of the thirteen biosynthetic intermediates. When these 13 biosynthetic intermediates, or 
the amino acids, nucleic acids, fatty acids, etc. that these intermediates produce, are 
exogenously available, TCA cycle activity is largely repressed.
36
 In the presence of 
readily catabolizable carbohydrates, such as glucose, transcription of TCA cycle genes is 
repressed by CcpA.
37
 Similarly, transcription of TCA cycle genes is repressed by CodY, 
a highly conserved Gram-positive repressor that responds to intracellular concentrations 
of branched-chain amino acids (BCAA) and GTP.
12
 When nutrients become growth 
limiting, transcription of TCA cycle genes is de-repressed and TCA cycle activity 
dramatically increases, allowing for the utilization of incompletely oxidized organic acids 
that accumulated in the culture medium.
38
 This utilization of organic acids through the 
TCA cycle allows S. aureus to generate biosynthetic intermediates needed for precursor 
and macromolecular synthesis by shunting carbon into gluconeogenesis via PEP. In other 
words, the TCA cycle is an important metabolic pathway that facilitates S. aureus 
adaption to a nutrient-limited environment. The importance of the TCA cycle to the 
success of S. aureus as a pathogen is illustrated by mutagenesis studies that identified 
TCA cycle mutants to be attenuated in different mouse models
39,40
 and a Caenorhabditis 
elegans-killing model.
41,42
 More recently, the significance of TCA cycle activity during 
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the course of infection was also suggested by a study from Chaffin and colleagues,
43
 
where it was observed that citB transcription increased over time in a mouse pneumonia 
model.  
The importance of the TCA cycle in metabolism, survival, and virulence factor 
synthesis, led us to search the S. aureus genomic DNA sequence for TCA cycle 
regulators that are present in B. subtilis. One such regulator that is present in B. subtilis 
but undescribed in S. aureus is CcpC. We identified a homologue of CcpC in the S. 
aureus genome, which we named CcpE. At the amino acid level, CcpE is similar to the B. 
subtilis CcpC; however, the similarities end there. Deletion of ccpE in S. aureus 
dramatically decreased transcription of citB and to a lesser extent citZ. This decreased 
transcription resulted in decreased TCA cycle activity, causing a metabolic block in the 
TCA cycle that increased the intracellular citrate concentration. The increased citrate 
accumulation and the inability to effectively fully oxidize carbohydrates likely caused the 
decreased growth yield. These data are in stark contrast to that of CcpC where 
inactivation of ccpC in B. subtilis de-represses citB and citZ transcription.
6
 Also unlike 
CcpC, the DNA binding activity of CcpE is not dependent upon the concentration of 
citrate. In summary, CcpE is a major positive regulator of TCA cycle activity that binds 
DNA independent of the citrate concentration.  
TCA cycle activity has been also associated with virulence in staphylococci. In S. 
aureus, TCA cycle activity was found to be critical for the elaboration of a capsule.
44
 In 
contrast, TCA cycle activity negatively affects synthesis of polysaccharide intercellular 
adhesin and biofilm formation.
45
 Because CcpE increases TCA cycle activity in S. 
345 
 
 
aureus, it is likely that CcpE activity will affect virulence determinant biosynthesis and 
pathogenesis. Experiments are ongoing to address this question. Moreover, another 
unresolved question is what metabolite/co-factors alter the DNA binding properties of 
CcpE. We know some that do not affect CcpE binding to DNA; namely, citrate and 
NAD
+
/NADH. Lastly, we are in the process of identifying the DNA binding site for 
CcpE.  
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CHAPTER 9 
OVEREXPRESSION AND PURIFICATION OF ISOTOPICALLY LABELED C-
TERMINAL DOMAIN OF RPIRA FOR NMR STUDIES 
9.1 Introduction 
Staphylococcus aureus is a life-threatening human pathogen associated with 
biofilm formation on implantable medical devices.
1
 Biosynthesis of virulence factors that 
can determine the pathogenicity of staphylococci is found to be regulated by tricarboxylic 
acid (TCA) cycle activity.
2
 An interesting observation in Chapter 6 is that the TCA cycle, 
as a component of central metabolism, can interdependently influence the carbon flow of 
glycolysis and the pentose phosphate pathway (PPP).
3
 The fact that intracellular ribose 
concentration increases during TCA cycle suppression indicates the presence of a pentose 
phosphate pathway (PPP)-responsive regulator that can partially mediate TCA cycle-
dependent regulatory effects.
4
 This led us to hypothesize that the ribose phosphate 
isomerase (Rpi) protein is a potential regulator of PPP and TCA cycle.
5-7
  
Ribose can be phosphorylated and uptaken from the growth medium using an Rbs 
transport system or generated from nucleotide degradation.
8
 Ribose 5-phosphate is 
mainly involved in the non-oxidative branch of the pentose phosphate pathway (PPP): 
ribose 5-phosphate, ribulose 5-phosphate and xylubose 5-phosphate are interconverted in 
reactions catalyzed by ribose phosphate isomerase and ribulose-5-phosphate 3-epimerase 
(Figure 9.1).
9
 The family of Rpi naturally occurs in two distinct classes, ribose phosphate 
isomerase A (RpiA; EC 5.3.1.6) and ribose phosphate isomerase B (RpiB; EC 5.3.1.6), 
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and structures of both has been resolved using X-ray crystallography in several 
organisms.
10-12
 In Escherichia coli (E. coli), RpiA is a homodimeric enzyme with an 
α/β/(α/β)/β/α fold where arabinose 5-phosphate was identified as an inhibitor and the 
complex structure was previously determined.
11
 RpiB is unrelated to RpiA in terms of 
protein sequence and structure. RpiB exhibits a Rossmann-type αβα-sandwich fold and 
also forms a dimer in E. coli and Coccidioides immitis (C. immitis).
10,13
 Besides the same 
catalytic function as RpiA, a secondary activity of RpiB is unknown.  
                
Figure 9.1 RpiR family of proteins role in the central metabolism. 
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Members of the RpiR protein family often act as transcriptional regulators of 
sugar catabolism, and RpiR homologues have been identified as repressors and activators 
in both Gram-negative and Gram-positive bacteria, including E. coli, Pseudomonas 
putida, and Bacillus subtilis.
9,14,15
 As sugar-responsive regulators, members of the RpiR 
family of proteins have N-terminal helix-turn-helix DNA binding motifs and C-terminal 
sugar isomerase binding domain.
16
 However, detailed structural information has not been 
reported. There are three known members of the RpiR family: RpiRa, -b, and -c. RpiRb 
and -c positively influence the activity of RpiA while RpiRa works as a downstream 
antagonist of RpiA by binding to a certain dinucleotide (Figure 9.1).
4
 It has also been 
reported that the inactivation of RpiRc altered the temporal transcription of RNAIII, the 
effector molecule of the agr quorum-sensing system.
4
 Thus, central metabolism is 
potentially linked with virulence determinant synthesis through RpiR and PPP.
4
 
Consequently, our initial research goal is the structural determination and functional 
annotation of the S. aureus RpiRa protein (S. aureus subsp. aureus Mu50, UniProt ID: 
Q99WQ9; Gene Symbol SAV0317; Gene ID: 1120275) by NMR.  
NMR spectroscopy is one of the cornerstone techniques for structural studies of 
biological macromolecules. It is the only current technique that can obtain atomic level 
information about both the structure and dynamics of macromolecules such as proteins, 
nucleic acids and their complexes in a solution. The limitations of NMR spectroscopy 
result from the low inherent sensitivity and from the high complexity of NMR spectra. As 
a specific example, a minimal of 10-20 mg/L expression yield is practically required for 
sufficient sensitivity in three and four dimensional NMR experiments. NMR also has a 
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molecular-weight limitation and a routine strategy is to focus the NMR analysis to the 
smallest possible subdomain. Thus, only the ligand binding C-terminal domain (CTD) of 
RpiRa will be studied by multi-dimensional NMR. Two-, three-, and four-dimensional 
NMR experiments are required to disperse the hundreds of NMR resonances from RpiRa 
CTD to avoid spectral overlap and simplify the analysis. Typically, the additional NMR 
dimensions correspond to 
13
C and 
15
N chemical shifts that are correlated with 
1
H 
chemical shifts through large single-bond coupling constants. Heteronuclei like 
15
N, 
13
C 
and 
2
H can be incorporated into proteins by uniform or selective isotopic labelling. As a 
result, the NMR spectra are drastically simplified and the sensitivity of the nitrogen and 
carbon signals is largely increased. In summary, obtaining a well folded protein with a 
minimal molecular-weight that can be overexpressed and purified at a high concentration 
and with isotopic labeling is the first step of using NMR to study a protein structure. 
Several challenging aspects of this process that include overproduction, purification, 
storage and isotopic labeling are addressed in this chapter.   
The optimization of protein expression in a heterogonous system is one of the 
major challenges of structural biology. Many recombinant proteins are expressed in the 
prokaryotic system of E. coli due to its simplicity and high efficiency, but not all proteins 
are expressed equally well in E. coli.
17
 Thus, it is critical to optimize the experimental 
conditions in order to maximize the protein yield. Many different strategies have been 
developed to meet the needs of a variety of proteins, such as E. coli strains supplemented 
with rare codons,
18
 strains with disabled thioredoxin reductase and glutathioine 
reductase,
19
 plasmids with a tunable promoter,
20
 transport or periplasmic spaces,
21
 and 
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co-expression with other proteins.
22
 Despite all these efforts that have successfully 
addressed known mechanisms of low yield, “trial and error” is still a large component of 
most protein expression efforts. 
Another common challenge of a protein structural study is the requirement for a 
highly purified protein sample. In general, a purity level of 90%-95% of the target protein 
is needed. A fusion tag is often used to simplify the purification process.
23
 An affinity tag 
is a recombinant hybrid containing a polypeptide fusion partner which facilitates the 
purification of the target protein.
24
 There are many different types of tags and the choice 
of tag depends on the property of the protein: poly-Arg, FLAG, poly-His, c-myc, S and 
Strep II-tag.
25
 A poly-His tag utilizes an immobilized metal affinity chromatography 
(IMAC) to purify a recombinant protein containing hexa-histidine residues as a short 
affinity-tag. A His-tag has been carried out successfully using a number of expression 
systems including bacteria, yeast, and mammalian cells. It is commercially incorporated 
in the cloning vectors such as pET-28a-c (+), which we used to express RpiRa CTD.  
A purified protein has to be stored in a buffer at an extremely high concentration 
of 1-2 mM for NMR studies. Therefore, another challenge of NMR structural biology is 
the identification of an optimal buffer condition that can stabilize a properly folded 
protein at a high concentration. The buffer should exhibit little or no change in pH with 
temperature, show insignificant penetration through biological membranes, and have 
maximum buffer capacity at the pH where the protein exhibits optimal stability. The 
isoelectric point, hydrophobicity, intermolecular interactions and many other protein 
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properties and NMR requirements significantly impacts and limits buffer choices. There 
is no reliable approach to predict an optimal buffer for a given protein. Some of the most 
commonly used buffer systems include Tris-HCl, sodium/potassium phosphate saline, 
MES, and acetate.
26
 There are other factors to consider that include salt concentration, pH, 
reducing reagents, etc. In short, buffer composition and physical properties can perturb 
protein conformational stability because of a complex interplay between various effects 
rather than through a single mechanism. The goal is to identify an optimal buffer that is 
beneficial to both the protein and the NMR analysis.   
One of the most important techniques for NMR structural studies is isotopic 
labeling. The introduction of uniform 
15
N and 
13
C labeling into a protein provides NMR 
signals that can be sequentially assigned by “walking through” correlated peaks between 
neighboring residues. A two dimensional (2D) 
1
H, 
15
N heteronuclear single quantum 
coherence (HSQC) spectrum is used as a template in which each peak corresponds to the 
amide H-N bond for each amino acid residue in the protein sequence.
27
 Thus, the 2D 
1
H, 
15N HSQC spectrum provides the “root” 1H and 15N chemical shifts for each amino acid 
in the protein. Each root is then connected to additional 
1
H and 
13
C chemical shifts 
through a series of three dimensional NMR spectra. This establishes a complete set of 
peaks per residue (spin system) based on the 2D 
1
H, 
15
N HSQC spectrum.
27
 Sequential 
assignments are then made by identifying spin systems (residues) that have two or more 
chemical shifts in common.  Therefore, the structural analysis of proteins using NMR 
starts with a 2D 
1
H, 
15
N HSQC spectrum. A high quality, well dispersed 2D 
1
H, 
15
N 
HSQC spectrum indicates a properly folded protein. It also identifies the likelihood that 
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the NMR assignments can be completed. The availability of backbone sequential 
assignments and a high-quality 2D 
1
H, 
15
N HSQC spectrum are also important for an 
NMR ligand-affinity screen (FAST-NMR).
28
 So, a 2D 
1
H, 
15
N HSQC spectrum is the 
primary means of evaluating the preparation of a protein sample for NMR.  
Deuterium (
2
H) labeling can simplify an NMR spectrum and sharpen peaks by 
removing pathways that contribution to transverse relaxations. This is critical for 
studying proteins with a high molecular weight because larger molecules tend to have 
broader peaks due to their relatively slower tumbling and complex dipole-dipole 
relaxations. Incorporating 
2
H labeling into a protein sample is difficult and more 
challenging compared to 
15
N or 
13
C isotope labeling protocols. 
2
H doubles the atomic 
weight that leads to significant isotope effects and drastic changes in enzymatic activity. 
As a result, the viability of E. coli is negatively impacted by growing cells in D2O.
29
 If 
D2O is the sole deuterium source, 0–86% of the chemically nonexchangeable hydrogen 
atoms can be deuterated. Higher levels of “perdeuteration” require using deuterated 
glucose because cell growth in higher percentages of D2O is not practical. In addition to 
these uniform labeling strategies, selective labeling methods have also been applied for 
more challengeable systems to further simplify the NMR spectrum.
30
 These isotopic 
approaches complement NMR techniques to explore protein structures. For example, 
transverse relaxation optimized spectroscopy (TROSY) type experiments can be used 
with a high-field magnet NMR to increase the sensitivity of an NMR spectrum by 
selecting the component, from a decoupled spectrum, in which the relaxation 
mechanisms have almost cancelled leading to a single, sharp peak.
31
 TROSY is often 
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combined with the 
2
H labeling.
32,33
 The efforts to optimize the overexpression and 
purification of 
2
H, 
13
C, 
15
N labeled RpiRa CTD, and the use of selective labeling schemes 
along with the application of TROSY-based NMR experiments for the backbone 
sequential assignments of RpiRa CTD are discussed in this chapter. 
 
9.2 Materials and Methods 
9.2.1 Materials  
For the RpiRa CTD79-266 NMR analysis, purified and uniformly 
15
N labeled, 
uniformly 
13
C, 
15
N double labeled, and uniformly 
2
H
 
, 
13
C, 
15
N,  triple labeled proteins 
were expressed in a pET-28a-c(+) cloning plasmid with an N-terminal His-Tag sequence 
in the E.coli BL21 (DE3) strain. N-terminal modification of RpiRa CTD79-266 included 
the addition of the following amino acid sequence: MGSSHHHHHHSSG 
LVPRGSHMAS. 
  Deuterium oxide (99.9% D), 
15
N-NH4Cl (98% 
15
N), 
13
C6-glucose (99% D), 
imidazole, NH4OAc, yeast extract Hy-Yest® 444, kanamycin sulfate salt, DL-
dithiothreitol, sodium azide (99.5%), and glycerol were obtained from Sigma-Aldrich 
(Milwaukee, WI). The 3-(trimethylsilyl) propionic-2, 2, 3, 3-d4 acid sodium salt (98% D) 
was purchased from Cambridge Isotope (Andover, MA). The potassium phosphate 
dibasic salt (anhydrous, 99.1% pure) and sodium chloride (ACS reagent) was purchased 
from Mallinckrodt (Phillipsburg, NJ). The Bacto
Tm
 Agar and Bacto
Tm
 Typtone were 
purchased from BD (Franklin Lakes, NJ). The prestained Protein Marker, Broad Range 
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(7-175 kDa) was purchased from New England BioLabs (Ipswich, MA). The tris (2-
carboxyethyl) phosphine hydrochloride (TCEP) was purchased from Biosynth (Itasca, IL). 
The isopropyl β-D-thiogalactoside (IPTG) was purchased from GOLDBIO®COM (St. 
Louis, MO). All the recipes for the cell culture media and buffers are listed in the 
Appendix B.  
 
9.2.2 Plasmid construction, E coli. strains and glycerol starter 
The three plasmids with three different RpiRa CTD amino acid sequences and the 
corresponding E. coli BL21 (DE3) strains were prepared by Dr. Marat Sadykov, Dr. 
Nagender Ledala and Mckenzie Steger in Dr. Somerville’s lab.    
Selected E. coli BL21 (DE3) colonies from fresh agar plate were inoculated into 3 
mL of Luria-Bertani (LB) media containing 30 µg/mL kanamycin. The cells were 
incubated at 37
o
C overnight with shaking at 220 rpm in a GYROMAX
TM
 incubator 
shaker (Concord, CA). 0.5 mL of glycerol was added to 1 mL of the initial culture, and 
the mixture as the glycerol stock was stored at -80
o
C.  
Same protocol was used to generate D2O adapted cultures. A series of minimal 
media containing 20%, 40%, 60% and 80% of D2O were used sequentially to adapt the 
cell culture to 80% D2O concentration. No antibiotics were added to the minimal media. 
DNA sequencing was performed after this culturing to validate the sequence.   
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9.2.3 Protein expression in M9 medium and high cell density medium 
Selected colonies from fresh agar plate were inoculated into 3 mL of LB media 
containing 30 µg/mL kanamycin. The cells were incubated at 37
o
C overnight with 
shaking at 220 rpm. 1 mL initial culture was diluted into 100 mL M9 minimal media 
containing 30 µg/mL kanamycin. The culture was grown at 37
o
C and 220 rpm until an 
optical density at 600 nm (O.D.600) reached 0.6-0.8 unit. Freshly prepared stock solution 
of IPTG was added to make a final concentration of 0.8 mM. The cells were grown for 
another 3 hours. The cells were harvested by centrifuging at 5000 X g for 20 minutes at 
4°C in a Sorvall RC-5B Refrigerated Superspeed centrifuge (Du Pont Instruments, 
Wilmington, DE) and the pellets were collected for protein extraction. 
Same incubation and centrifugation settings were used for high-cell density 
medium-based protein expression. Selected colonies from fresh agar plate were 
inoculated into 3 mL of LB media containing 30 µg/mL kanamycin. The cells were 
incubated at 37
o
C overnight with shaking at 220 rpm. 1 mL initial culture was diluted 
into 100 mL LB medium containing 30 µg/mL kanamycin. The culture was grown at 
37
o
C and 220 rpm until an O.D.600 reached 2.5-3.0 units. The cells were harvested by 
centrifuging at 4000 X g for 8 minutes. The cell pellets were suspended in high cell 
density medium and inoculated for another 0.5-1 hour until an O.D.600 was increased by 1 
unit. IPTG was added with a final concentration of 1 mM and the cells were grown for 
another 4 hours. The cells were harvested by centrifuging at 5000 X g for 20 minutes at 
4°C and the pellets were collected for protein extraction.  
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9.2.4 Protein extraction and purification 
The cells were re-suspended in the protein extraction buffer (see recipe in the 
Appendix B) of 15-25 mL. Sonication was performed to lyse the cells using a Fisher 
Scientific sonicator probe, Sonic Dismembrator Model 100 (Waltham, MA). A burst 
cycle of 15 seconds on and 45 second off were chosen with 60% power. Nine burst 
cycles were completed before the lysates were spun down at 7,000 X g for 45 min at 4
o
C. 
The sample was kept on ice during this process. 
The extraction was followed by purification. A gravity-flow IMAC column 
packed with HisPur Cobalt beads (Thermo scientific, Rockford, IL) was equilibrated with 
25 mL wash buffer consisting of phosphate buffer saline pH 7.2 with 10 mM imidazole 
(to prevent nonspecific binding of endogenous proteins that have histidine clusters). The 
cell lysate was applied to the column and allowed to bind for 2-3 h during which the 
lysate solution was thoroughly mixed with the beads. The column was repositioned 
vertically and drained to collect the flow-through. The beads were then washed with two 
wash buffers: first with ~200 mL of 10 mM imidazole and second with ~200 mL of 50 
mM imidazole. The bound RpiRa CTD79-266 was eluted by applying ~300 mL elution 
buffer with 150 mM imidazole. The flow rate was 1 mL/min and 1 mL fractions were 
collected. The presence of RpiRa CTD79-266 in the eluted fractions was assayed by 
Ultraviolet-visible (UV-Vis) spectroscopy at a wavelength of 280 nm. All purification 
steps were performed at 4°C.  
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9.2.5 Imidazole removal, protein concentration and NMR sample preparation 
All eluted fractions were collected until UV-Vis absorptive spectral readings 
reached baseline. These fractions were concentrated to 10 mL using 15 mL Amicon 
ultrafiltration cells with a 10 kDa cutoff membrane (EMD Millipore, Billerica, MA). The 
filtration was performed by centrifugation using a Thermo scientific CL10 bench-top 
centrifuge (Rockford, IL) and a swinging bucket rotor at 4000 x g and 25°C. A 10 mL 
Float-A-Lyzer G2 with 8-10 kDa cutoff membrane from Spectrum®Laboratories 
(Rancho Dominguez, CA) was used for dialysis. A total of 2 L NMR buffer was prepared 
and four rounds of dialysis with 200, 200, 600, 1000 mL volume of the buffer were 
performed. The protein was concentrated to 8-10 mL and stored at room temperature. 
The RpiRa CTD79-266 was concentrated to a final volume of 500 µL using a 0.5 mL 
Amicon ultrafiltration cells. 50 µL of a D2O buffer was added to the concentrated RpiRa 
CTD79-266  protein sample to yield an NMR sample consisting of 1.2 mM RpiRa CTD79-
266 in a 91% H2O/9% D2O solution containing 100 mM NaCl, 25 mM  K2HPO4/KH2PO4 
at pH 4.5 (uncorrected). An Eppendorf 5415D Micro Centrifuge (New York, NY) was 
used at 4000 X g at 25
o
C to concentrate the sample. The sample was kept in 5 mm NMR 
tubes (Norell ST500-7, Norell, Inc., Landisville, NJ).  
 
9.2.6 Analytical Apparatus and data analysis 
For the RpiRa CTD79-266 NMR analysis, one dimensional (1D) 
1
H NMR 
experiments were collected at 298 K on a three channel 500 MHz Bruker Avance DRX 
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spectrometer equipped with a triple resonance, Z-axis gradient 5 mm Cryoprobe. A total 
of 8192 data points were collected with a total of 16 dummy scans and 128 acquisition 
scans and a sweep width of 5482.5 Hz. 2D 
1
H, 
15
N HSQC NMR experiments used were 
collected at 298 K on the same instrument. A total of 1024 data points were collected in 
the 
1
H dimension and 128 data points were collected in the 
15
N dimension. The spectrum 
was collected with a total of 256 dummy scans and 64 acquisition scans and a sweep 
width of 7002.8 Hz in the 
1
H dimension and 2027.3 Hz in the 
15
N dimension. TROSY- 
2D 
1
H, 
15
N HSQC
 
was collected at 298 K on a three channel 700 MHz Bruker Avance 
III-HD spectrometer equipped with a triple resonance, Z-axis gradient 5 mm Cryoprobe. 
A total of 2048 data points were collected in the 
1
H dimension and 128 data points were 
collected in the 
15
N dimension. The spectrum was collected with a total of 128 dummy 
scans and 32 acquisition scans and a sweep width of 9803.9 Hz in the 
1
H dimension and 
2838.4Hz in the 
15
N dimension. 1D 
1
H NMR spectra were processed in the ACD/1D 
NMR manager version 12.0 (Advanced Chemistry Development, Inc). 2D 
1
H, 
15
N HSQC 
spectra were processed using the NMRPipe software package.
34
  
UV-Vis spectroscopy was used for protein concentration determination and 
optical density of cells using a PerkinElmer Lambda Bio+ spectrometer (Waltham, MA). 
Circular dichroism (CD) absorption spectra were recorded on a JASCO J-815 
spectropolarimeter (Easton, MD). A wavelength range of 200–240 nm in far-UV region 
was used for probing the secondary structure of RpiRa CTD79-266. Far-UV CD spectra 
were collected with 1 mm path length cuvette on an RpiRa CTD79-266 sample with an 
estimated concentration of 50 μM in 50 mM potassium phosphate buffer, pH 7.4. All CD 
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spectra were acquired at a scan speed of 10 nm/ min. The spectrum was plotted in Excel 
(Microsoft, Redmond, WA).   
SDS–polyacrylamide gel electrophoresis of the proteins in all fractions was 
performed using a 4%-12% PAGE with a Bio-Rad Mini-Protean® 3 Multi-Casting 
Chamber (Hercules, CA). Protein bands were visualized by Coomassie brilliant blue 
staining and photographed. 
 
9.3 Results 
9.3.1 Determination of CTD amino acid region  
        
Scheme 9.1 RpiRa sequence.  
 
                      10                    20                    30                    40                   50                                                                                                                                                                                                                                                                                                                                            
MKFENRVQRY QHLFTKTDKR IVNYIRQNGY SDAFSTINSL AHAIGTSPAT  
                    60                     70                   80                   90                 100                                       
MTRFSHKLDY ENFQDLKFNI QQEMTETVIE NSPIIQRIHK YHQQIIQQTG  
              110                  120                  130                   140                   150                                                         
EFIDNDIIQT FIDKLQSSRH ILFAGLGSSG LSATEFYYRM IRMGLKGNVT  
                 160                   170                   180                 190                  200                                                      
TDSHLMKISA SLLSHSDMFI AMSNSGNTSE LISAAEVAKS HGAYVVAITN  
                  210                  220                  230               240                  250                                                       
FEGSKLTDCA DLVLLTTDQS RNTDHQFINT QIATLFLIDI VSYHLLENTN  
                  260                                                                                               
LSQTYQHTKS IILDNK 
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S. aureus RpiRa has a single polypeptide chain containing 266 amino acid 
residues. The complete protein primary sequence is shown in Scheme 1. A collection of 
database including DomPred,
35
 InterProScan
36
 and DOMAC
37
 were performed and two 
domains were predicted: an N-terminal domain (NTD) of helix-turn-helix-like domain 
and a C-terminal domain (CTD) of sugar isomerase-like domain.  The predicted 
boundaries of the CTD were shown below (Table 9.1). The starting position of CTD was 
predicted with a range of 78-113. A closer look at the secondary structure prediction 
using PsiPred,
35,38
 SWISS-MODEL
39
 and PredictProtein
40
 suggested that the boundary of 
CTD and NTD should be in loop regions of 75-82 or 112-123. So a series of constructs 
were proposed and three were validated experimentally. It turned out that both PsiPred 
provided the closest prediction that residue I79 is the starting amino acid of an α-helix in 
CTD and therefore the secondary prediction based on the same database was used for 
secondary structure prediction.
41
     
Table 9.1 Summary of boundary prediction of RpiR CTD. 
 Beginning Ending E-value 
BLAST  108 240 6.11e-37 
FASTA 112 238 5.1e-105 
InterproScan 111 251 6.8e-13 
DomPred 113 NA NA 
PsiPred 79 266 2e-07 
SWISS-MODEL 78 264 NA 
 
Three forms of RpiRa were constructed to experimentally determine the CTD 
boundaries by residue sequence numbers: 81-259, 79-249 and 79-266 and the 
corresponding proteins were termed as RpiRa CTD81-259, CTD79-249, and CTD79-266. These 
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constructs were amplified by polymerase chain reaction (PCR) and cloned separately into 
plasmid pET-28a (+). The CTD79-266 strain was selected based on its relatively high 
protein expression level. The CTD79-266 strain has the longest sequence of the three 
constructs and contains the seven predicted α-helices, increasing the likelihood of 
obtaining correctly folded protein. There are 188 amino acids in the predicted RpiRa 
CTD79-266 with a molecular weight of 21009.7 kDa. RpiRa CTD79-266 is also predicted to 
have an extension coefficient of 8940 M
-1
 cm
-1
 at 280 nm, assuming all Cys residues are 
reduced. The theoretical isoelectric point (pI) is 5.95. These parameters were calculated 
using ProtParam.
42
 The experimental CD spectrum of RpiRa CTD79-266   predicted that 
RpiRa CTD79-266 is 50.4% α-helical and 15.5% β-stranded (Figure 9.2b). This is also 
comparable with the RpiRa homology modeling results (α-helix%: 51.1; β strand%: 13.3) 
using PsiPred (Figure 9.2a).
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Figure 9.2 a) Secondary structure prediction using PSIPRED 
(http://bioinf.cs.ucl.ac.uk/psipred/). Top matched structure is Vibrio vulnificus NanR 
protein (PDB ID: 4IVN) with a percentage identity of 29%. b) CD spectrum prediction 
using K2D2, a web server to estimate α helix and β strand content of a protein from its 
CD spectrum. (http://k2d2.ogic.ca/). Red line represented the query spectrum, and green 
line represented the target spectrum. The maximum total α and β error of the prediction 
was 0.32. 
 
9.3.2 Protein expression 
The optimization of protein expression was focused on optimizing cell growth 
conditions. M9 and LB media only yielded an O.D. 600 of 1.5-1.8 units. Since the protein 
expression level was also low; the limited amount of cells became a bottleneck for 
providing enough proteins in a standard 1 L culture. Therefore, a high cell density 
medium was used (Appendix B).
43
 Cell mass was increased to four folds compared to 
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normal M9 media. The procedure is outlined in Figure 9.3a. The growth curves (induced 
vs. non-induced) based on medium switch are shown in Figure 9.3b. A large production 
of cells was achieved without wasting unnecessary nutrients. The media switch was also 
beneficial for the introduction of 
13
C glucose and/ or 
15
N ammonium chloride for isotope 
labeling. Bacterial cells in their mid-exponential phase were induced by IPTG and grown 
to a higher O.D.600 of 5-6 units. A comparison between the protein expressions indicates 
that a high cell density growth provided a higher protein yield (Figure 9.3c).   
The protein was also expressed under anaerobic growth and aerobic growth 
conditions. A volume ratio of flask to medium at 2:1 was used to generate an anaerobic 
condition, while the ratio at 8:1 was used for aerobic growth. As shown in Figure 9.2c, 
the expression level was much better under aerobic growth using the high cell density 
growth. These results also agree with previous reports that high cell density media for E. 
coli are generally designed for aerobic cultivations.
44
 A room temperature overnight 
expression and a prolonged time of expression were also tested. Neither approach was 
shown to be beneficial (Figure 9.4) since no increase in expression levels were seen after 
4 hours. Different IPTG concentrations of 0.4, 0.6, 0.8, 1.0 and 1.2 mM were also 
investigated, but no significant changes were observed. An IPTG concentration of 1.0 
mM was used for all subsequent protein sample preparations.   
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Figure 9.3 The overexpression of RpiRa CTD79-266: a) flowchart illustrating the protocols 
for the high-cell-density expression system; b) E. coli growth curve using the high-cell-
density expression system; c) comparison of RpiRa CTD79-266 protein expression levels 
under different growth conditions.  
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Figure 9.4 Impact of pH changes on RpiRa CTD79-266 protein expression levels using 
aerobic growth with high cell density media at 25
o
C. 
 
9.3.3 Protein extraction 
Cell lysis was accomplished using sonication. The cell sample was immersed in 
an ice bath during sonication to prevent any overheating effects. 20-25 mL extraction 
buffer was used and the choice of buffer was mainly dependent on the compatibility of 
the following purification procedures. Therefore 50 mM potassium dihydrogen 
phosphate/ dipotassium hydrogen phosphate buffer (KH2PO4/K2HPO4) was chosen with a 
pH of 7.4. It is advisable to measure the pH during the cell lysis to maintain a neutral or 
mild basic conditions.
45
 5% glycerol was also proved to be useful to prevent damage to 
the protein during the sonication. A burst cycle of 15 seconds on and 45 second off was 
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chosen and sonication powers from 40% to 80% were tested to maximize the efficiency 
of cell lysing. A 60% sonication amplitude was chosen due to its high lysing efficiency 
without generating the appearance of a foam for a 20-25 mL cell suspension. The 
presence of foam indicates denatured or destroyed proteins. As shown in Figure 9.5, 
extending the number of burst cycles increased the amount of RpiRa CTD79-266 being 
released from the cells. Nine burst cycles were chosen because it corresponded to the 
largest increase in RpiRa CTD79-266 with the smallest number of burst cycles.  
 
                   
Figure 9.5 The impact of the number of burst cycles on the efficiency of extracting of 
RpiRa CTD79-266. 
 
9.3.4 Protein purification 
HisPur cobalt IMAC resin can bind more than 10 mg proteins per mL of resin and 
can maximize protein purity compared to nickel resins. The exact protocol was followed. 
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The only variable in regards to the standard protocol was the length of the binding time – 
the time the cell lysate is simply incubated with the resin. Binding times of of 2, 4 and 8 
hours were tested, but 2 hours was chosen since extending the binding time did not 
improve either the relative protein purification or the amount of protein recovered. Figure 
9.5 showed the purified protein band in a denatured SDS-PAGE. The flowthrough sample 
in Lane 2 indicated almost all the target protein was captured and the target protein band 
in Lane 7 showed that the purity of the protein and the correct molecular weight in the 
non-native SDS-PAGE. 
The protein band in the elution buffer as shown in Figure 9.6a was rather pure, 
but an extremely concentrated and overloaded sample (Figure 9.6b) verified the purity of 
RpiRa CTD79-266. After weeks of room-temperature storage, a small amount of 
proteolytic degradation was observed. Therefore, it is advisable to include broad-
spectrum protease inhibitors in the extraction buffer and the NMR sample. Figure 9.6b 
demonstrates that after IPTG induction, not only was RpiRa CTD79-266 overexpressed, but 
the levels of other protein were decreased. So, it appears that under carbon limitation, the 
induction of a protein overexpression also suppress other protein expression. All of these 
results are consistent with our protocol being successful in inducing the expression of 
soluble RpiRa CTD79-266 exclusively and efficiently.  
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Figure 9.6 a) The Co-affinity chromatography purification of RpiRa. Lane 1 is the 
protein ladder, Lane 2 is the flow-through of non-binding proteins, Lane 4 and 6 are two 
concentrated wash buffers containing non-specific bound proteins, Lane 7 is the elution 
buffer containing the target protein. b) The cell lysate, before purification, that compares 
expression and non-expression conditions. An over-loaded gel of RpiRa CTD79-266 was 
also performed to verify the purity of the protein.  
 
9.3.5 Protein buffer conditions 
The pH was chosen to be from 4.5-5.5 so that the pH was at least one unit lower 
from the theoretical pI value of 5.95. A lower pH also benefits the quality of the 2D 
1
H, 
15
N-HSQC spectrum by decreasing backbone amide exchange rates.
27
 A series of 
standard NMR protein buffer were tested that included: Tris buffer, MES buffer, 
NH4OAc, acetate and potassium phosphate buffers (Appendix B). NH4OAc and 
phosphate buffers both yielded higher quality NMR spectra. However, a phosphate buffer 
was chosen for the final NMR sample conditions because of slightly better protein 
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stabilization at higher temperatures. NaCl concentrations of 100 mM, 200, 300, 400, 500 
mM were also tested. The final NMR sample contained 100 mM of NaCl because higher 
ion strengths (>300 mM NaCl) was shown to denature the protein or decrease the 
performance of the cryoprobe without any added benefit to protein stability. Additives 
such as imidazole and glycerol may also improve protein stability, but they can also 
negatively impact the quality of the NMR spectrum.
46
 No obvious benefit was observed 
for including any additive to the RpiRa CTD79-266 NMR sample (Figure 9.7). 
Dithiothreitol (DTT) was also tested over a range of concentrations: 1, 5 and 10 mM.  10 
mM DTT was proved to be necessary to the long-term stability of the RpiRa CTD79-266 
NMR sample. An alternative reducing reagent, TECP-HCl, was shown to similarly 
stabilize the RpiRa CTD79-266 NMR sample at a concentration of 2 mM. A typical 1D 
1
H 
NMR spectrum for RpiRa CTD79-266 in the optimized NMR buffer is shown in Figure 9.8. 
A flash frozen and a slow frozen approach were tested for possible approaches to 
achieve a long-term storage of RpiRa CTD79-266. Unfortunately, RpiRa CTD79-266 was 
shown to be denatured after thawing from either these long-term storage techniques. A 
storage temperature of -20
o
C or -80
o
C was also tested. Again, the protein was denatured 
when thawed from either temperature. Similarly, RpiRa CTD79-266 is not stable to high 
temperature and denatures when exposed to temperatures above 30
o
C for overnight 
(Figure 9.9). RpiRa CTD79-266 is also not stable to lyophilization. Lyophilization of the 
protein from (NH4)2CO3 or a phosphate buffer results in a precipitated protein that will 
not re-dissolve into the original buffer. In practice, RpiRa CTD79-266 was always kept in 
room temperature in the optimized NMR buffer.  
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There are two common methods to perform buffer exchange: dialysis and 
ultrafiltration using a centrifuge. Both float-A-analyzer and traditional dialysis membrane 
tubing were tested and show comparable results. Importantly, a dialysis approach to a 
buffer exchange outperformed Amicon ultrafiltration. Amicon ultrafiltration caused a 
significant amount of protein purification probably because it is a harsh method relative 
to dialysis.   
 
                     
Figure 9.7 The impact of adding stability agents to the RpiRa CTD79-266 NMR buffer. 
Two optimal NMR buffer systems were tested for adding these additives. No observable 
changes in the RpiRa CTD79-266 samples were observed after weeks of storage.  
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Figure 9.8 The 1D 
1
H NMR spectrum of RpiRa CTD79-266. The water peak in the region 
of 4.6-5.2 ppm was removed.  
 
9.3.6 Isotopic labeling of RpiRa CTD 
Uniformly 
15
N and 
13
C labeled RpiRa CTD79-266 was produced using minimal 
medium supplemented with 
15
N NH4Cl and 
13
C glucose. Deuteration of the aromatic and 
aliphatic protons in the protein can be achieved by expressing the protein in D2O.
47
 
Deuteration of the non-exchangeable proton was shown to improve the resolution and 
sensitivity of NMR experiments by reducing the overall relaxation rates of NMR active 
nuclei (Figure 9.10a and 9.10b).
48, 29
 The difficulty of deuterium incorporation was 
demonstrated by the fact that increasing the percentage of D2O in the cell culture media 
dramatically slowed cell growth. 80% D2O was shown to be the highest percentage of 
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D2O that the E. coli strain could tolerate. Although, after adaptation to D2O, the E. coli 
growth was comparable to cell growth in H2O.    
The non-exchangeable and exchangeable protons are both labeled with deuterium 
during the cell culture, so it takes additional effort to exchange deuterated amides back to 
protons to be observable by NMR. It may be particularly challenging to exchange amides 
buried in the core of the protein or involved in secondary structures. Therefore, it may 
require an increase in the temperature to partially unfold the protein in order to expose all 
the amides to the solvent and increase the HD exchange rate. Also, it may simply require 
waiting days or weeks until all of the deuterated amides have effectively changed back to 
protons.  As shown in Figure 9.8, the peaks of the 2D 
1
H, 
15
N HSQC spectrum were 
sharpened after an overnight incubation at 30
o
C in H2O. But a longer incubation time 
leads to the denaturing of RpiRa CTD79-266. An alternative and safer approach was chosen 
in which the protein was placed in a 50 mL buffer at pH 7.4 for 2-4 days at room 
temperature. This was effective in back exchange all of the amides since the amide 
exchange rate is higher at higher pH. After the amide exchange was completed, the 2D 
1
H, 
15
N HSQC spectrum improved and more peaks were observable (Figure 9.10a and b). 
An alternative approach is to increase the sample temperature during NMR data 
collection. The 2D 
1
H, 
15
N HSQC spectrum was collected at 25
o
C, 27
o
C, 29
o
C, and 31
o
C. 
Temperatures higher than 31
o
C caused significant protein precipitation. No improvement 
in the 2D 
1
H, 
15
N HSQC spectrum was observed, so the sample temperature was kept at 
25
o
C for all NMR experiments. Figures 9.10b-c illustrates an interesting phenomenon. 
Over a month time frame, the RpiRa CTD79-266 NMR sample slowly precipitated and then 
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eventually stabilized. This resulted in a higher quality 2D 
1
H, 
15
N HSQC spectrum, 
suggesting that there might be a concentration dependent monomer-dimer transition.  
RpiRa CTD79-266 is a relatively large protein for NMR, so using TROSY 
experiment are expected to improve the spectral quality by generating sharper peaks. As 
shown in Figure 9.10d, the collection of a 2D 
1
H, 
15
N TROSY-HSQC experiment on a 
700 MHz NMR spectrometer resulted in a dramatic improvement in the quality of the 
NMR spectrum compared to the other 2D 
1
H, 
15
N HSQC spectra.  
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Figure 9.9 The overnight incubation of an RpiRa NMR sample at a) 25
o
C; b) 30
o
C; c) 
35
o
C; d) 40
o
C.  
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Figure 9.10 a) 2D 
1
H, 
15
N HSQC spectrum of uniformly 
15
N labeled RpiRa CTD79-266 ; b) 
2D 
1
H, 
15
N HSQC spectrum of uniformly 
2
H (80%), 
15
N labeled RpiRa CTD79-266; c) 2D 
1
H, 
15
N HSQC spectrum of uniformly 
2
H (80%), 
15
N labeled RpiRa CTD79-266  sample  
from (b), but after a month; d) 2D 
1
H, 
15
N TROSY-HSQC spectrum of uniformly 
2
H 
(80%), 
15
N labeled RpiRa CTD79-266. 
 
9.4 Discussion 
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The optimization of experimental conditions for the overexpression, purification 
and storage of RpiRa CTD79-266 was primarily based on “trial and error” due to the 
unpredictable nature of proteins. This initial and essential work was done to achieve an 
RpiRa CTD79-266 sample amenable for future NMR structural biology studies. This effort 
has led to the identification of an appropriate expression system and purification 
protocols, to an optimal buffer condition to maintain protein stability and obtain high 
quality NMR spectra, and an effective isotope labeling strategy to enable the use of 
TROSY-based experiments. Further work in the application of selective labeling and 
non-uniform labeling are still required to improve the likelihood that the NMR backbone 
assignments can be obtained for RpiRa CTD79-266.     
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APPENDIX B: Medium and buffer recipes 
Note: All the buffers and media were prepared in nanopure H2O and autoclaved. 
1. LB media (1 L): 
             10.0 g Tryptone 
              5.0 g Yeast extract 
             10.0 g NaCl 
 
         2. LB media agar plate (1 L): 
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             10.0 g Tryptone 
              5.0 g Yeast extract 
             10.0 g NaCl 
             15.0 g Agar 
 
         3. M9 minimal medium (1 L):  
            A) M9 salt (1 L, 5X) 
            64 g Na2HPO4·7H2O 
            15.0 g KH2PO4      
            2.5g NaCl  
            5.0 g NH4Cl (or 
15
NH4Cl) 
            0.2 mL of 10 mM FeCl3 stock solution 
 
            B) M9 minmal medium (1L)  
            200 mL 5XM9 salt 
            2.0 mL 1M MgSO4 stock solution  
            2.0 mL 1M CaCl2 stock solution 
            2 g glucose  (or 
13
C-glucose)  
 
         4. High-cell-density medium (1 L): 
            13.4 g Na2HPO4·7H2O 
            3.4 g KH2PO4 
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            0.58 g NaCl   
            5 mL 1 M MgSO4 stock solution   
            0.2 CaCl2 stock solution   
            1.0 g NH4Cl (or 
15
NH4Cl) 
            10 g glucose (or 
13
C-glucose)   
 
         5. Extraction buffer (1 L): 
            2.63 g KH2PO4 
            5.34 g K2HPO4 
            17.55 g NaCl 
            50 mL glycerol 
 
         6. Wash buffer (1 L): 
            2.63 g KH2PO4 
            5.34 g K2HPO4 
            680.8 g NaCl 
            680.8 mg imidazole 
 
         7. Elution buffer (1 L):  
            2.63 g KH2PO4 
            5.34 g K2HPO4 
            3.40 g NaCl 
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            3.40 g imidazole (for 50 mM) or 10.2 g imidazole (for 150 mM) 
 
         8. NMR sample buffer (1 L):  
         8.1 Potassium phosphate buffer saline
*
 
            2.72 g KH2PO4  
            5.85 g NaCl 
            1.54 g DTT (or 0.57 g TCEP-HCl) 
            0.20 g NaN3 
            
*
adjust pH to 4.5 
 
         8.2 Ammonium acetate buffer
o
 
             1.54 g NH4OAc  
             5.85 g NaCl 
             1.54 g DTT (or 0.57 g TCEP-HCl) 
             0.20 g NaN3 
             
o
adjust pH to 4.5
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CHAPTER 10 
SUMMARY AND FUTURE DIRECTIONS 
10.1 Summary 
Simplistically, metabolomics can be considered as a continuous array of 
metabolite assays, but it is not feasible to optimize a single experimental condition to 
accurately measure each metabolite in this hypothetical array of assays. Therefore subtle 
differences in experimental procedures may lead to detectable changes in metabolite 
concentrations. This is an inherent challenge of metabolomics, but this issue is also 
significantly diminished by relying on a comparative (instead of an absolute) analysis 
between two of more samples. As long as experimental consistency is maintained 
between all samples, the underlying errors will be constant. Thus, these errors will be 
irrelevant and will “subtract out” when two or more samples are compared to identify 
“differences”. So the first aim of my thesis was to exhaustively evaluate all of the 
experimental factors that may contribute to any sample inconsistency and negatively 
impact the outcome of an NMR-based metabolomics study.  
Maintaining consistency across a dataset of 1D 
1
H NMR spectra is critical for an 
untargeted metabolomics study because multivariate statistical techniques such as PCA or 
OPLS-DA are intrinsically sensitive to all variations in the data, regardless of the origin 
of these differences. Thus, biologically irrelevant variations between classes that are 
introduced by the investigator of by the experimental protocols need to be removed in 
order to avoid misinterpretations and erroneous conclusions. Towards this end, we 
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optimized sample preparation protocols for bacteria and mammalian cell lines to 
maximize reproducibility between replicates, and to achieve complete and efficient 
extraction of the cellular metabolome. These protocols are described in detail in Chapters 
3 and 4. The entire process includes: 1) growing and harvesting bacterial cells, 2) 
extracting the metabolome, 3) NMR data collection, processing and analysis, 4) statistical 
analysis, 5) metabolite identification, and 6) metabolic network generation. Consider, for 
example, the preparation of a metabolomics sample, we were able to identify and correct 
for a number of variables that decrease consistency between replicates. We 
simultaneously use three different normalization schemes to correct for variations in total 
metabolite concentration: the number of cells per sample, protein concentration per 
sample, and Standard Normal Variate (SNV) data preprocessing. We can harvest and 
quench each metabolomics sample in less than 20 seconds using centrifugation or 
filtration. The type of glass beads, the bead beating program, and the temperature used 
for cell lysis were all optimized to obtain complete extraction of the cellular metabolome. 
Similarly, the type of solvent and buffer to obtain complete extraction of the metabolome 
was also optimized. NMR experimental parameters that include the number of scan, 
number of data points, receiver gain settings, water suppression pulse program, spectral 
width, and relaxation time were optimized for each project. These validated experimental 
protocols were successfully applied to all metabolic projects. Based on this exhaustive 
analysis, we have a thorough understanding of the experimental parameters and 
conditions that significantly impact the quality and outcome of a metabolomics study. 
Consequently, in future studies, we only need to focus on these specific steps to 
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successfully optimize the preparation and analysis of metabolomics samples. In return, 
this will help increase the efficiency and consistency of future metabolomics studies.  
The second aim of my thesis was to understand the regulatory role that the TCA 
cycle plays in S. aureus and S. epidermidis biofilm formation. Specifically, how due 
bacteria respond to a disparate set of environmental stress conditions that are all known 
to induce biofilm formation? Iron-depletion, the addition of ethanol, glucose or low-
dosages of antibiotics, temperature, and anaerobic conditions are all known to induce 
biofilm formation. We observed that iron-depletion, the addition of ethanol, glucose,    
low-dose tetracycline, and anaerobic conditions perturbed the metabolome of S. 
epidermidis in a manner similar to an aconitase mutant. A metabolomics network map 
identified the TCA cycle as playing a central role in the proposed signaling pathway that 
also involves the urea cycle, alanine metabolism, glycolysis/gluconeogenesis, amino 
sugar metabolism and other metabolites associated with PIA, which is a major precursor 
to biofilm formation. 
13
C glucose was used to trace carbon flow in S. aureus and S. 
epidermidis under conditions that induce biofilm formation. The observed inactivation 
of the TCA cycle was correlated with an increase in a number of precursors of PIA, 
which indicates PIA biosynthesis is reversely regulated by TCA cycle.
1
 As a result of 
these observations, the TCA cycle can be considered as a metabolic sensor of 
environmental stressors. In summary, the metabolomics study of the role that TCA cycle 
plays in mediating intracellular energy and homeostasis in response to environmental 
stressors significantly enhanced our understanding of a metabolism-dependent 
mechanism of biofilm formation. 
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NMR-based metabolomics was also employed to investigate the impact of TCA 
cycle activity on the S. aureus metabolome with a specific emphasis on the role of CcpE, 
a putative LysR-type of regulator and a predicted activator of the TCA cycle. The 
construction of a metabolic network based on perturbations in CcpE activity indicated 
that changes in the S. aureus metabolome was centered on the TCA cycle. This clearly 
supported our hypothesis that CcpE functions as a positive regulator of the TCA cycle. 
Additionally, our analysis suggested that citB is a target of CcpE. This study combined 
with previous studies of AcnA, CcpA, RpiR and CodY as metabolic regulators, describe 
a group of genes in staphylococci that control the function of TCA cycle. Another 
metabolomic study in S. aureus was focused on the influence of oxygen and iron 
limitation. By decreasing the flask-to-medium ratio, the S. aureus metabolome shifts 
from oxidative to a heterofermentatative metabolism. Similarly, iron-limitation also 
shifted the metabolic profile to a heterofermentative metabolism. Both stressors caused a 
suppression of the TCA cycle, as further evident by the decreased transcription of 
aconitase (citB/acnA). Importantly, the effects of iron-limitation were obscured by the 
oxygen-limitation. Once again, different environmental stressors were shown to have a 
similar effect on the central metabolism in staphylococci, but our results also demonstrate 
that two specific environmental stressors are connected and interdependent.   
The last aim of my thesis was the optimization of experimental conditions for the 
overexpression, purification and storage of RpiRa CTD79-266. This initial and essential 
work was done to achieve an RpiRa CTD79-266 sample amenable for future NMR 
structural biology studies. This effort has led to the identification of an appropriate T7 
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expression system and the selection of the correct sequence for the RpiRa CTD79-266. Four 
different growth strategies were compared and the aerobic growth on high cell density 
medium was chosen to maximize the protein yield. A protein purification protocol and 
NMR sample conditon was also optimized. The optimal buffer condition consisted of a 
phosphate buffer pH 4.5 with 2 mM TCEP-HCl, 100 mM NaCl and 0.02 % NaN3 was 
chosen to maintain protein stability and obtain high quality NMR spectra. An effective 
2
H, 
13
C, 
15
N triple-labeling strategy to enable the use of TROSY-based experiments was also 
implemented.  
 
10.2 Future directions 
The protocol used to extract and prepare a metabolomics sample also influences 
the choice of analytical method (MS vs. NMR) and the corresponding analysis strategy. 
There is a growing consensus that using multiple analytical techniques is a preferred 
approach to thoroughly characterize the metabolome. This, in turn, requires the 
integration of different methods in terms of sample handling, instrumental analysis, and 
data process. In regards to NMR-based metabolomics, additional experimental techniques 
for selective detection and suppression should also be considered. For example, 
31
P NMR 
and 
15
N NMR can be used to highlight groups of metabolite such as phosphorylated 
sugars and amino acids.
2
 
31
P and 
15
N isotopic labeling coupled with monitoring the flow 
of nitrogen and phosphorus throughout the metabolome may yield interesting insights 
about metabolic pathways not observed using 
13
C-labeled metabolites. Analyzing a 
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subset of metabolites based on prior knowledge of biological relevance is a unique 
feature of NMR. Investigating a smaller set of metabolites would also simplify metabolite 
identification since the corresponding NMR spectra are greatly simplified and peak 
overlap is significantly diminished. This addresses a major bottleneck of NMR 
metabolomics – the manual peak assignments. Currently, metabolite identification is 
based on the manual analysis of NMR spectra that requires using the entirety of the 
spectral information combined with cross-validation using multiple database, all available 
biological information, the experience of the investigator, and an iterative analysis that 
relies on informed and educated guesses. Ideally, this process should be automated by 
using a combination of new software and a series of NMR experiments such as 2D 
COSY, TOCSY, HSQC, HMBC, and HSQC-TOCSY. 
Staphylococcus epidermidis and Staphylococcus aureus are the leading causes of 
hospital-associated infections.
3
 The only remaining treatment for most staphylococci is 
glycopeptide antibiotic vancomycin, although a vancomycin resistant strain has been 
found.
4
 Poor antibiotic penetration, nutrient limitation, slow growth, adaptive stress 
responses, and formation of persister cells are all hypothesized to constitute a defense 
system.
5
 Many of these mechanisms are metabolism associated. A critical fact is that 
although the type and severity of the virulence produced, or level of drug resistance by 
these bacteria can vary, the metabolic pathways that they utilize are very similar. 
Staphylococcal species can synthesize all their virulence factors based on 13 small 
molecules derived from central metabolic pathways.
6
 A study showed that over 90% of 
the enzymes, metabolic reactions and metabolites were common to all strains.
7
 A 
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common mechanism of their drug-resistance is biofilm-related infectious manifestations 
associated with implanted biomaterials and biofilm formation can be largely influenced 
by central metabolism.
8
 It is appealing to study the common feature of the metabolism so 
as to not only understand their pathogenesis development, but also to search for next 
generation antibiotics.
6,1
   
In the structural characterization of RpiRa CTD, the most important and long term 
goal is to solve its three dimensional NMR structure. Other aspects of interests include: (i) 
different labeling strategies that highlight selected residues to simplify the NMR 
assignments, (ii) implementation of non-uniform sampling to increase spectrum quality to 
enable determining the NMR structure, (iii) ligand screening (FAST-NMR) that identifies 
small molecules potentially related to the function of RpiRa and the identification of the 
functionally relevant ligand binding site, and (vi) additional molecular and cellular 
biology experiments to understand the regulation mechanism of RpiRa and its role in the 
pentose phosphate pathway. 
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